

Champion Health Plan of Nevada

Renal Payer Solutions, Inc.

Formulario 2026 (Lista de medicamentos cubiertos)

POR FAVOR, LEA: ESTE DOCUMENTO CONTIENE INFORMACIÓN
ACERCA DE LOS MEDICAMENTOS QUE CUBRIMOS EN ESTE PLAN

Formulario 00026365, número de versión 10

Este formulario se actualizó el 1 de abril de 2026. Para obtener información más reciente o si tiene pregunta, comuníquese con Servicios para Miembros de Champion Health Plan al 1-844-282-5341 (los usuarios de TTY deben llamar al 711), de 8:00 a. m. a 8:00 p. m., los 7 días de la semana, desde el 1 de octubre hasta el 31 de marzo. Desde el 1 de abril hasta el 30 de septiembre, el horario es de 8:00 a. m. a 8:00 p. m., de lunes a Viernes (los mensajes recibidos en días festivos y fuera del horario de atención se responderán en el plazo de un día hábil). También puede visitar www.championhmo.com.

Nota a los miembros existentes: Esta lista de medicamentos es diferente al del año anterior. Por favor revise este documento para asegurarse de que todavía contenga los medicamentos que usted toma.

Cuando esta lista de medicamentos (formulario) se refiere a “nosotros” o a “nuestro”, se estará refiriendo a Champion. Cuando se refiere al “plan” o a “nuestro plan”, significa Champion.

Este documento incluye una lista de los medicamentos (formulario) de nuestro plan, que entrará en vigencia el 1 de abril de 2026. Para obtener un formulario actualizado, por favor póngase en contacto con nosotros. Nuestra información de contacto, junto con la fecha en la que se actualizó el formulario por última vez, aparecen en la portada y contraportada.

De forma general debe usar las farmacias de la red para utilizar su beneficio de medicamentos controlados. Los beneficios, el formulario, la red de farmacias, y/o los copagos/coaseguros pueden cambiar el 1 de enero de 2026, y también de vez en cuando durante el año.

¿Qué es el Formulario de Champion?

Un formulario es una lista de medicamentos seleccionados que están cubiertos por Champion en consulta con un equipo de proveedores de atención médica, que representa los medicamentos controlados que se cree son una parte necesaria de un programa de tratamiento de calidad. Por lo general, Champion cubrirá los medicamentos descritos en nuestro formulario siempre que el medicamento sea médicamente necesario, y la receta se surta en una farmacia de la red y se cumplan otras reglas del plan. Para obtener más información sobre cómo surtir sus recetas, favor de revisar la Evidencia de Cobertura.

¿Puede cambiar el formulario (la lista de medicamentos)?

La mayoría de los cambios en la cobertura de medicamentos ocurren el 1 de enero, pero Champion puede agregar o eliminar medicamentos de la Lista de medicamentos durante el año, moverlos a diferentes niveles de costo compartido o agregar nuevas restricciones. Debemos seguir las reglas de Medicare al hacer estos cambios.

Cambios que pueden afectarlo este año: En los siguientes casos, usted se verá afectado por cambios de cobertura durante el año:

- **Nuevos medicamentos genéricos.** Podemos eliminar inmediatamente un medicamento de marca de nuestra Lista de medicamentos si lo reemplazamos por un nuevo medicamento genérico que aparecerá en el mismo nivel de costo compartido o en un nivel más bajo y con las mismas o menos restricciones. Además, cuando agregamos el nuevo medicamento genérico, podemos decidir mantener el medicamento de marca en nuestra Lista de medicamentos, pero inmediatamente lo movemos a otro nivel de costo compartido o agregamos nuevas restricciones. Si actualmente toma el medicamento de marca, es posible que no le informemos con anticipación antes de hacer ese cambio, pero posteriormente le proporcionaremos información sobre los cambios específicos que hayamos hecho.
 - Si hacemos dicho cambio, usted o su recetador pueden solicitarnos que hagamos una excepción y que continuemos cubriendo el medicamento de marca para usted. El aviso que le proporcionamos también incluye información sobre cómo solicitar una excepción, y puede encontrar información en la siguiente sección titulada “¿Cómo solicito una excepción al Formulario de Champion?”

Medicamentos retirados del mercado. Si la Administración de Alimentos y Medicamentos (FDA por sus siglas en inglés) considera que alguno de los medicamento de nuestro formulario es inseguro o si el fabricante del mismo lo retira del mercado, inmediatamente retiraremos el medicamento de nuestro formulario y daremos aviso a los miembros que toman dicho medicamento.

- **Otros cambios.** Podríamos hacer otros cambios que afecten a los miembros que actualmente toman un medicamento. Por ejemplo, podemos agregar un nuevo medicamento genérico para reemplazar un medicamento de marca que se encuentra actualmente en el formulario o agregar nuevas restricciones al medicamento de marca o moverlo a otro nivel de costo compartido, o las dos cosas. O bien, podemos hacer cambios con base en nuevos lineamientos clínicos. Si quitamos medicamentos de nuestro formulario [o] agregamos una autorización previa, o límites de cantidad y/o restricciones de

tratamiento por pasos de algún medicamento o si movemos un medicamento a un nivel más alto de costo compartido, debemos notificarle a los miembros afectados sobre dicho cambio al menos 30 días antes de que el cambio sea efectivo, o en el momento en que el miembro solicite una reposición del medicamento, en cuyo caso el miembro recibirá un suministro de 30 días del medicamento.

- Si hacemos estos u otros cambios, usted o su recetador pueden solicitarnos que hagamos una excepción y que continuemos cubriendo el medicamento de marca para usted. El aviso que le proporcionamos también incluye información sobre cómo solicitar una excepción, y también puede encontrar información en la siguiente sección titulada “¿Cómo solicito una excepción al Formulario de Champion?”

Cambios que no lo afectarán si toma actualmente el medicamento. Por lo general, si está tomando un medicamento de nuestro formulario 2026 que estaba cubierto a principios de año, no interrumpiremos ni reduciremos la cobertura del medicamento durante el año de cobertura 2026, excepto en las condiciones descritas anteriormente. Esto significa que estos medicamentos permanecerán disponibles al mismo costo compartido y sin nuevas restricciones para aquellos miembros que los toman por el resto del año de cobertura. No recibirá una notificación directa este año sobre los cambios que no le afecten. Sin embargo, el 1 de enero del próximo año, dichos cambios le afectarán y es importante que revise la Lista de medicamentos para el nuevo año de beneficios para conocer cualquier cambio en los medicamentos.

El formulario adjunto está actualizado a partir el 1 de enero de 2026. Para obtener información actualizada acerca de los medicamentos cubiertos por Champion, póngase en contacto con nosotros. Nuestra información de contacto aparece en la portada y contraportada.

¿Cómo puedo utilizar el formulario?

Existen dos maneras de encontrar su medicamento dentro del formulario:

Padecimiento médico

El formulario comienza en la página 1. Los medicamentos de este formulario se agrupan en categorías según el tipo de padecimiento médico que tratan. Por ejemplo, los medicamentos utilizados para tratar una afección del corazón aparecen bajo la categoría de Agentes cardiovasculares. Si sabe para qué se utiliza su medicamento, busque el nombre de la categoría en la lista que comienza en la página 1. Luego, busque en la categoría el nombre de su medicamento.

Lista alfabética

Si no está seguro de en qué categoría buscar, busque su medicamento en el Índice. El índice proporciona una lista alfabética de todos los medicamentos incluidos en este documento. Ambos medicamentos, tanto de marca como genéricos, están enlistados en el índice. Busque en el Índice y encuentre su medicamento. Al lado de su medicamento, verá el número de la página donde podrá encontrar la información de cobertura. Vaya a la página que aparece en el Índice y encuentre el nombre de su medicamento en la primera columna de la lista.

¿Qué son los medicamentos genéricos?

Champion cubre medicamentos de marca y medicamentos genéricos. Un medicamento genérico está aprobado por la Administración de Alimentos y Medicamentos (FDA por sus siglas en inglés), ya que contiene el mismo ingrediente activo que el medicamento de marca. Por lo general, los medicamentos

genéricos cuestan menos que los medicamentos de marca.

¿Existen restricciones en mi cobertura?

Algunos medicamentos cubiertos pueden tener requisitos adicionales o límites de cobertura. Estos requisitos y límites pueden incluir:

- **Autorización previa:** Champion requiere que usted [o su médico] obtenga una autorización previa para ciertos medicamentos. Esto significa que deberá obtener la aprobación de Champion antes de surtir sus recetas. Si no obtiene la aprobación, Champion podría no cubrir el medicamento.
- **Límites de cantidad:** Para ciertos medicamentos, Champion limita la cantidad del medicamento que Champion cubrirá. Por ejemplo, nuestro Plan proporciona 18 comprimidos de succinato de sumatriptán oral por receta para 28 días. Esto puede ser adicional al suministro estándar para un mes o tres meses.
- **Tratamiento por pasos:** En algunos casos, Champion requiere que primero pruebe ciertos medicamentos para tratar su afección médica antes de cubrir otro medicamento para dicha afección. Por ejemplo, si tanto el medicamento A como el medicamento B tratan su afección médica, Champion podría no cubrir el medicamento B a menos que primero pruebe el medicamento A. Si el medicamento A no funciona para usted, Champion cubrirá el medicamento B.

Para averiguar si su medicamento tiene requisitos o límites adicionales, revise el formulario que comienza en la página 1. También puede obtener más información sobre las restricciones que se aplican a medicamentos específicos cubiertos si visita nuestro sitio web. Hemos publicado documentos en línea que explican nuestras restricciones en cuanto a autorizaciones previas y tratamiento por pasos. También puede solicitar que le enviemos una copia. Nuestra información de contacto, junto con la fecha en la que se actualizó el formulario por última vez, aparecen en la portada y contraportada.

Puede solicitarle a Champion una excepción a estas restricciones o límites, o una lista de otros medicamentos similares, que pudieran tratar la misma afección médica. Consulte la sección “¿Cómo solicito una excepción al Formulario de Champion?” en la página 1 para obtener información sobre cómo solicitar una excepción.

¿Qué sucede si mi medicamento no está en el Formulario?

Si su medicamento no está incluido en este formulario (lista de medicamentos cubiertos), primero debe comunicarse con el Servicio a Miembros y preguntar si su medicamento está cubierto. Para obtener más información, comuníquese con nosotros. Nuestra información de contacto, junto con la fecha en la que se actualizó el formulario por última vez, aparecen en la portada y contraportada.

Si Champion no cubre su medicamento, usted tiene dos opciones:

- Puede solicitar a Servicio a Miembros una lista de medicamentos similares que estén cubiertos por Champion. Cuando usted reciba la lista, muéstresela a su médico y pídale que le recete un

medicamento similar que esté cubierto por Champion.

- Usted puede solicitarle a Champion que haga una excepción y cubra su medicamento. Consulte lo siguiente para obtener información sobre cómo solicitar una excepción.

¿Cómo solicito una excepción al formulario de Champion?

Usted puede solicitarle a Champion que haga una excepción a nuestras reglas de cobertura. Existen varios tipos de excepciones que puede solicitarnos.

- Puede pedirnos que cubramos un medicamento incluso si no está en nuestro formulario. Si se aprueba, este medicamento estará cubierto a un nivel predeterminado de costo compartido, y usted no podría pedirnos que suministremos el medicamento a un nivel inferior de costo compartido.
- Puede pedirnos que cubramos un medicamento del formulario a un nivel inferior de costo compartido, a menos que el medicamento esté en el nivel de especialidades. Si se aprueba, esto disminuiría la cantidad que usted debe pagar por su medicamento.
- Puede solicitarnos que exoneremos las restricciones de cobertura o los límites de su medicamento. Por ejemplo, para algunos medicamentos, Champion limita la cantidad del medicamento que cubriremos. Si su medicamento tiene un límite de cantidad, puede solicitarnos que exoneremos el límite y cubramos una cantidad mayor.

Por lo general, Champion solo aprobará su solicitud de excepción si los medicamentos alternativos incluidos en el formulario del plan, el medicamento de costo compartido inferior o las restricciones adicionales de uso pudieran no ser tan efectivos para tratar su afección o pudieran provocarle efectos médicos adversos.

Debe contactarnos para solicitarnos una decisión inicial de cobertura con respecto a alguna excepción del formulario o restricción de uso. **Cuando solicite alguna excepción al formulario o a alguna restricción de uso, deberá ingresar una declaración de quién se lo haya recetado o de su médico quien apoya su solicitud.** Por lo general, debemos emitir una decisión dentro de las siguientes 72 horas a partir de recibir la declaración de apoyo de su médico. Puede solicitar una excepción expedita (rápida) si usted o su médico consideran que su salud podría verse seriamente comprometida si espera hasta 72 horas para obtener una decisión. Si se autoriza su solicitud expedita, debemos proporcionarle una decisión a más tardar 24 horas después de haber recibido la declaración de apoyo de su médico u otra persona autorizada para recetar.

Qué debo hacer antes de que pueda hablar con mi médico sobre un cambio en mis medicamentos o de solicitar una excepción?

Como un miembro nuevo o uno que continua en nuestro plan, es posible que esté tomando medicamentos que no se encuentren en nuestro formulario. O bien, es posible que esté tomando un medicamento que no esté en nuestro formulario, pero su capacidad para obtenerlo sea limitada. Por ejemplo, puede ser que necesite una autorización previa de nuestra parte antes de poder surtir su receta médica. Usted deberá hablar con su médico para decidir si deben cambiar a un medicamento apropiado que sí cubramos o solicitar una excepción al formulario para que cubramos el medicamento que toma. En el transcurso antes de hablar con su médico para determinar el curso correcto de acción para usted, podemos cubrir su medicamento en ciertos casos durante los primeros 90 días a partir de que se afilie a nuestro plan.

Para cada uno de sus medicamentos que no estén incluidos en nuestro formulario, o si su capacidad de obtener los medicamentos es limitada, cubriremos un suministro temporal para 30 días. Si su receta está escrita para menos días, permitiremos resurtidos para proporcionar hasta un suministro máximo para 30 días del medicamento. Después de su primer suministro de 30 días, no pagaremos por dichos medicamentos, incluso si usted lleva menos de 90 días siendo miembro del plan.

Si usted es residente de un centro de cuidados a largo plazo y necesita un medicamento que no esté incluido en nuestro formulario, o si su capacidad de obtener los medicamentos es limitada, pero usted lleva más de 90 días afiliado a nuestro plan, cubriremos un suministro de emergencia de 31 días de ese medicamento mientras tramita una excepción al formulario.

Los miembros que cambian de lugar de tratamiento debido a cambios en el nivel de atención también se consideran en transición. Estos miembros recibirán un resurtido de transición adecuado.

Para obtener más información

Para obtener información más detallada acerca de su cobertura de medicamentos controlados por Champion, consulte su Evidencia de Cobertura y otros materiales del plan.

Si tiene preguntas sobre Champion, comuníquese con nosotros. Nuestra información de contacto, junto con la fecha en la que se actualizó el formulario por última vez, aparecen en la portada y contraportada.

Si tiene preguntas generales sobre la cobertura de medicamentos controlados por Medicare, llame a Medicare al 1-800-MEDICARE (1-800-633-4227) 24 horas del día / 7 días de la semana. Los usuarios de TTY deben llamar al 1-877-486-2048. O visite <http://www.medicare.gov>.

Formulario de Champion

El formulario proporciona información de cobertura sobre los medicamentos cubiertos por Champion. Si tiene problemas para encontrar su medicamento en la lista, consulte el Índice que comienza en la página 107.

La primera columna del cuadro muestra el nombre del medicamento. Los medicamentos de marca están en mayúsculas (por ej., HUMIRA) y los medicamentos genéricos están escritos en minúsculas en bastarda (p. ej., *atorvastatina*).

La información en la columna de Requisitos/Límites indica si Champion tiene algún requisito especial para la cobertura de su medicamento. La siguiente es una lista de abreviaturas que pueden aparecer en las siguientes páginas en la columna de Requisitos/Límites para indicarle si su medicamento está sujeto a algún requisito especial de cobertura.

Lista de Abreviaciones

B/D PA: Este medicamento recetado podría estar cubierto bajo Medicare Parte B o Parte D, dependiendo de las circunstancias. Puede ser necesario que se presente información que describa la utilización y las circunstancias en las que se administrará el medicamento, para que se pueda tomar una determinación.

EX: Medicamento excluido. Este medicamento recetado no se cubre normalmente bajo un plan de medicamentos recetados Medicare. La cantidad que usted paga cuando se surte una receta de este medicamento no se imputa al costo total de sus medicamentos (es decir, la cantidad que pague no le ayudará a calificar para recibir cobertura catastrófica). Además, si recibe asistencia suplementaria para pagar sus medicamentos recetados, no recibirá asistencia suplementaria para pagar este medicamento.

LA: Disponibilidad limitada. Esta receta puede estar disponible solo en ciertas farmacias. Para obtener más información, llame al Servicio de atención al cliente de Express Scripts.

MO: Medicamento obtenido por correo. Este medicamento recetado está disponible a través de nuestro servicio de pedido por correo, así como en las farmacias minoristas de nuestra red. Considere utilizar el servicio de farmacia por correo para obtener sus medicamentos de uso continuo, o de mantenimiento (por ejemplo, los medicamentos para la presión sanguínea elevada). Las farmacias minoristas de la red pueden ser más adecuadas para obtener medicamentos de uso a corto plazo (por ejemplo, los antibióticos).

NDS: Medicamentos con Suministro de Día No Extendido. Este medicamento solo está disponible como suministro de 30 días o menos.

NSO: No Disponible para Pedidos por Correo. Esto indica que ciertos medicamentos no son elegibles para entrega por correo y deben obtenerse en persona en una farmacia.

PA: Autorización Previa. El Plan requiere que usted o su médico obtengan autorización previa para obtener ciertos medicamentos. Esto significa que deberá obtener aprobación antes de que se surtan sus recetas. Si no obtiene aprobación, podríamos no cubrir el medicamento.

PA HRM: Autorización Previa para Medicamentos de Alto Riesgo. Ciertos medicamentos se consideran de alto riesgo, especialmente para adultos mayores (generalmente para adultos de 65 años o más). Estos medicamentos pueden tener un alto potencial de causar efectos secundarios graves y requieren autorización previa para su uso.

QL: Límite de cantidad. En el caso de ciertos medicamentos, el Plan limita la cantidad del medicamento que cubriremos.

ST: Terapia de paso. En algunos casos, el Plan requiere que primero pruebe ciertos medicamentos para el tratamiento de su afección médica antes de que podamos cubrir otro medicamento para tratar esa afección. Por ejemplo, si puede utilizarse tanto un medicamento A como un medicamento B en el tratamiento de la misma afección médica, es posible que no cubramos el medicamento B a menos que usted pruebe primero el medicamento A. Si el medicamento A no le produce mejoras, cubriremos el medicamento B.

V: Esta vacuna se suministra a los adultos sin costo alguno cuando se usa según las recomendaciones del Comité Asesor sobre Prácticas de Inmunización (ACIP) de los Centros para el Control y la Prevención de Enfermedades (CDC).

Tabla de Contenido

| | |
|---|-----|
| Agentes Anti Cáncer | 3 |
| Agentes Anti-Adicción/De Tratamiento De Abuso De Sustancias | 23 |
| Agentes Antiansiedad | 24 |
| Agentes Antidemencia | 25 |
| Agentes Antidiabetico | 26 |
| Agentes Antigota | 31 |
| Agentes Antimigraña | 32 |
| Agentes Antinausea | 33 |
| Agentes Antiparasitarios | 34 |
| Agentes Antiparkinson | 35 |
| Agentes Antipsicóticos | 37 |
| Agentes Calóricos | 44 |
| Agentes Cardiovasculares | 44 |
| Agentes De Enfermedad Intestinal Inflamatoria | 55 |
| Agentes De Enfermedad Ósea Metabólica | 56 |
| Agentes De Trastorno De Sueño | 57 |
| Agentes Del Sistema Nervioso Central | 58 |
| Agentes Del Tracto Respiratorio | 61 |
| Agentes Dentales Y Orales | 66 |
| Agentes Dermatológicos | 67 |
| Agentes Gastrointestinales | 71 |
| Agentes Genitourinarios | 74 |
| Agentes Hormonales, Estimulante/Reemplazo/Modificador | 75 |
| Agentes Inmunológicos | 80 |
| Agentes Oftálmicos | 93 |
| Agentes Para Los Ojos, Oídos, Nariz, Garganta | 94 |
| Agentes Terapeuticos Misceláneos | 98 |
| Agentes Vasodilatadores | 100 |
| Analgésicos | 100 |
| Anestésicos | 104 |
| Antagonistas De Metales Pesados | 105 |
| Anti Infecciosos (Membrana Cutánea Y Mucosa) | 105 |
| Antibacterianos | 105 |
| Anticonceptivos | 113 |
| Anticonvulsivos | 121 |
| Antidepresivos | 127 |
| Antifúngicos | 130 |
| Antihistamínicos | 132 |

| | |
|---|-----|
| Antimicrobacteriales..... | 133 |
| Antivirales (Sistémico)..... | 133 |
| Cofactores Enzimáticos/Otros..... | 140 |
| Dispositivos..... | 140 |
| Preparaciones De Reemplazo..... | 188 |
| Productos Para La Tos Y Resfriado..... | 189 |
| Productos Sanguíneos/Modificadores/Expansores De Volumen..... | 189 |
| Reemplazo/Modificadores De Enzima..... | 192 |
| Relajantes Musculares Esqueléticos..... | 193 |
| Vitaminas Y Minerales..... | 194 |

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|---------------------------------------|
| Agentes Anti Cáncer | | |
| Agentes Anti Cáncer | | |
| <i>abiraterone oral tablet 250 mg</i> (Abirtega) | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| <i>abiraterone oral tablet 500 mg</i> (Zytiga) | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| <i>abiraterone, submicronized oral tablet 125 mg</i> (Yonsa) | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| <i>abirtega oral tablet 250 mg</i> (abiraterone) | 2 | PA NSO; QL (120 per 30 days) |
| <i>adrucil intravenous solution 2.5 gram/50 ml</i> (fluorouracil) | 2 | PA BvD |
| AKEEGA ORAL TABLET 100-500 MG, 50-500 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| ALECENSA ORAL CAPSULE 150 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| ALUNBRIG ORAL TABLET 180 MG, 90 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| ALUNBRIG ORAL TABLET 30 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| ALUNBRIG ORAL TABLETS,DOSE PACK 90 MG (7)-180 MG (23) | 5 | PA NSO; NM; NDS |
| <i>anastrozole oral tablet 1 mg</i> (Arimidex) | 1 | |
| ANKTIVA INTRAVESICAL SOLUTION 400 MCG/0.4 ML | 5 | PA NSO; NM; NDS; QL (1.6 per 28 days) |
| AUGTYRO ORAL CAPSULE 160 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| AUGTYRO ORAL CAPSULE 40 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| AVMAPKI ORAL CAPSULE 0.8 MG | 5 | PA NSO; NM; NDS; QL (24 per 28 days) |
| AVMAPKI-FAKZYNJA ORAL COMBO PACK 0.8-200 MG | 5 | PA NSO; NM; NDS; QL (66 per 28 days) |
| AXTLE INTRAVENOUS RECON SOLN 100 MG, 500 MG | 5 | NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|---------------------------------------|
| AYVAKIT ORAL TABLET 100 MG, 200 MG, 25 MG, 300 MG, 50 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>azacitidine injection recon soln 100 mg</i> (Vidaza) | 5 | NM; NDS |
| BALVERSA ORAL TABLET 3 MG | 5 | PA NSO; NM; NDS; QL (84 per 28 days) |
| BALVERSA ORAL TABLET 4 MG | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| BALVERSA ORAL TABLET 5 MG | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| <i>bendamustine intravenous recon soln 100 mg, 25 mg</i> (Treanda) | 5 | PA NSO; NM; NDS |
| BENDAMUSTINE INTRAVENOUS SOLUTION 25 MG/ML (Bendeka) | 5 | PA NSO; NM; NDS |
| BENDEKA INTRAVENOUS SOLUTION 25 MG/ML (bendamustine) | 5 | PA NSO; NM; NDS |
| <i>bexarotene oral capsule 75 mg</i> (Targretin) | 5 | PA NSO; NM; NDS |
| <i>bexarotene topical gel 1 %</i> (Targretin) | 5 | PA NSO; NM; NDS |
| <i>bicalutamide oral tablet 50 mg</i> (Casodex) | 2 | |
| BIZENGRI INTRAVENOUS SOLUTION 375 MG/18.75 ML (20 MG/ML) | 5 | PA NSO; NM; NDS; QL (75 per 28 days) |
| <i>bleomycin injection recon soln 15 unit, 30 unit</i> | 2 | |
| <i>bortezomib injection recon soln 1 mg, 2.5 mg</i> | 4 | PA NSO |
| <i>bortezomib injection recon soln 3.5 mg</i> (Velcade) | 5 | PA NSO; NM; NDS |
| BORUZU INJECTION SOLUTION 2.5 MG/ML | 4 | PA NSO |
| BOSULIF ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| BOSULIF ORAL CAPSULE 50 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|--|
| BOSULIF ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| BOSULIF ORAL TABLET 400 MG, 500 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| BRAFTOVI ORAL CAPSULE 75 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| BRUKINSA ORAL CAPSULE 80 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| BRUKINSA ORAL TABLET 160 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| CABOMETYX ORAL TABLET 20 MG, 60 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| CABOMETYX ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| CALQUENCE (ACALABRUTINIB MAL) ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| CALQUENCE ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| CAMCEVI (6 MONTH) SUBCUTANEOUS SYRINGE 42 MG | 4 | PA NSO |
| CAPRELSA ORAL TABLET 100 (vandetanib) MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| CAPRELSA ORAL TABLET 300 (vandetanib) MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| COMETRIQ ORAL CAPSULE 100 MG/DAY(80 MG X1-20 MG X1), 60 MG/DAY (20 MG X 3/DAY) | 5 | PA NSO; NM; NDS |
| COMETRIQ ORAL CAPSULE 140 MG/DAY(80 MG X1-20 MG X3) | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| COPIKTRA ORAL CAPSULE 15 MG, 25 MG | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| COTELLIC ORAL TABLET 20 MG | 5 | PA NSO; NM; LA; NDS; QL (63 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|---------------------------------------|
| <i>cyclophosphamide intravenous recon soln 1 gram, 2 gram, 500 mg</i> | 5 | PA BvD; NM; NDS |
| <i>cyclophosphamide intravenous solution 100 mg/ml, 200 mg/ml</i> | 5 | PA BvD; NM; NDS |
| <i>cyclophosphamide intravenous solution 500 mg/ml</i> (Frindovyx) | 5 | PA BvD; NM; NDS |
| <i>cyclophosphamide oral capsule 25 mg, 50 mg</i> | 2 | PA BvD; ST |
| <i>cyclophosphamide oral tablet 25 mg, 50 mg</i> | 3 | PA BvD; ST |
| DANYELZA INTRAVENOUS SOLUTION 4 MG/ML | 5 | PA NSO; NM; NDS; QL (120 per 28 days) |
| DANZITEN ORAL TABLET 71 MG, 95 MG | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| <i>dasatinib oral tablet 100 mg, 140 mg, 50 mg, 70 mg, 80 mg</i> (Sprycel) | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>dasatinib oral tablet 20 mg</i> (Sprycel) | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| DATROWAY INTRAVENOUS RECON SOLN 100 MG | 5 | PA NSO; NM; NDS |
| DAURISMO ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| DAURISMO ORAL TABLET 25 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| <i>decitabine intravenous recon soln 50 mg</i> | 5 | NM; NDS |
| <i>doxorubicin, peg-liposomal intravenous suspension 2 mg/ml</i> (Caelyx) | 5 | PA BvD; NM; NDS |
| ELAHERE INTRAVENOUS SOLUTION 5 MG/ML | 5 | PA NSO; NM; NDS |
| ELIGARD (3 MONTH) SUBCUTANEOUS SYRINGE 22.5 MG | 4 | PA NSO |
| ELIGARD (4 MONTH) SUBCUTANEOUS SYRINGE 30 MG | 4 | PA NSO |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|--|
| ELIGARD (6 MONTH) SUBCUTANEOUS SYRINGE 45 MG | 4 | PA NSO |
| ELIGARD SUBCUTANEOUS SYRINGE 7.5 MG (1 MONTH) | 4 | PA NSO |
| ELREXFIO 44 MG/1.1 ML VIAL INNER, SUV, P/F 40 MG/ML | 5 | PA NSO; NM; NDS |
| ELREXFIO SUBCUTANEOUS SOLUTION 40 MG/ML | 5 | PA NSO; NM; NDS; QL (9.5 per 28 days) |
| EMCYT ORAL CAPSULE 140 MG | 5 | NM; NDS |
| EMRELIS INTRAVENOUS RECON SOLN 100 MG, 20 MG | 5 | PA NSO; NM; NDS |
| ENSACOVE ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| ENSACOVE ORAL CAPSULE 25 MG | 5 | PA NSO; NM; NDS; QL (270 per 30 days) |
| EPKINLY SUBCUTANEOUS SOLUTION 4 MG/0.8 ML, 48 MG/0.8 ML | 5 | PA NSO; NM; NDS |
| ERBITUX INTRAVENOUS SOLUTION 100 MG/50 ML, 200 MG/100 ML | 5 | PA NSO; NM; NDS |
| ERIVEDGE ORAL CAPSULE 150 MG | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| ERLEADA ORAL TABLET 240 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| ERLEADA ORAL TABLET 60 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| <i>erlotinib oral tablet 100 mg, 25 mg</i> | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| <i>erlotinib oral tablet 150 mg</i> | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| ETOPOPHOS INTRAVENOUS RECON SOLN 100 MG | 4 | |
| <i>etoposide intravenous solution 20 mg/ml</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|---------------------------------------|
| EULEXIN ORAL CAPSULE 125 MG (flutamide) | 5 | NM; NDS |
| <i>everolimus (antineoplastic) oral tablet 10 mg</i> (Torpenz) | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| <i>everolimus (antineoplastic) oral tablet 2.5 mg</i> (Torpenz) | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| <i>everolimus (antineoplastic) oral tablet 5 mg</i> (Torpenz) | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>everolimus (antineoplastic) oral tablet 7.5 mg</i> (Torpenz) | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| <i>everolimus (antineoplastic) oral tablet for suspension 2 mg, 3 mg, 5 mg</i> (Afinitor Disperz) | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| <i>exemestane oral tablet 25 mg</i> (Aromasin) | 2 | |
| FAKZYNJA ORAL TABLET 200 MG | 5 | PA NSO; NM; NDS; QL (42 per 28 days) |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 120 MG | 5 | PA BvD; NM; NDS |
| FIRMAGON KIT W DILUENT SYRINGE SUBCUTANEOUS RECON SOLN 80 MG | 3 | PA BvD |
| <i>floxuridine injection recon soln 0.5 gram</i> | 2 | PA BvD |
| <i>fluorouracil intravenous solution 1 gram/20 ml, 5 gram/100 ml, 500 mg/10 ml</i> | 2 | PA BvD |
| <i>flutamide oral capsule 125 mg</i> (Eulexin) | 2 | |
| FOTIVDA ORAL CAPSULE 0.89 MG, 1.34 MG | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| FRUZAQLA ORAL CAPSULE 1 MG | 5 | PA NSO; NM; NDS; QL (84 per 28 days) |
| FRUZAQLA ORAL CAPSULE 5 MG | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| <i>fulvestrant intramuscular syringe 250 mg/5 ml</i> (Faslodex) | 5 | NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|---------------------------------------|
| FYARRO INTRAVENOUS SUSPENSION FOR RECONSTITUTION 100 MG | 5 | PA NSO; NM; NDS |
| GAVRETO ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| <i>gefitinib oral tablet 250 mg</i> (Iressa) | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| GILOTRIF ORAL TABLET 20 MG, 30 MG, 40 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| GOMEKLI ORAL CAPSULE 1 MG | 5 | PA NSO; NM; NDS; QL (224 per 28 days) |
| GOMEKLI ORAL CAPSULE 2 MG | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| GOMEKLI ORAL TABLET FOR SUSPENSION 1 MG | 5 | PA NSO; NM; NDS; QL (224 per 28 days) |
| HERCEPTIN HYLECTA SUBCUTANEOUS SOLUTION 600 MG-10,000 UNIT/5 ML | 5 | PA NSO; NM; NDS; QL (5 per 21 days) |
| HERNEXEOS ORAL TABLET 60 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| <i>hydroxyurea oral capsule 500 mg</i> (Hydrea) | 2 | |
| HYRNUO ORAL TABLET 10 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| IBRANCE ORAL CAPSULE 100 MG, 125 MG, 75 MG | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| IBRANCE ORAL TABLET 100 MG, 125 MG, 75 MG | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| IBTROZI ORAL CAPSULE 200 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| ICLUSIG ORAL TABLET 10 MG, 15 MG, 30 MG, 45 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| IDHIFA ORAL TABLET 100 MG, 50 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>ifosfamide intravenous recon soln 1 gram</i> (Ifex) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|---------------------------------------|
| <i>ifosfamide intravenous solution 1 gram/20 ml, 3 gram/60 ml</i> | 2 | |
| <i>imatinib oral tablet 100 mg</i> (Gleevec) | 2 | PA NSO; QL (180 per 30 days) |
| <i>imatinib oral tablet 400 mg</i> (Gleevec) | 2 | PA NSO; QL (60 per 30 days) |
| IMBRUVICA ORAL CAPSULE 140 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| IMBRUVICA ORAL CAPSULE 70 MG | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| IMBRUVICA ORAL SUSPENSION 70 MG/ML | 5 | PA NSO; NM; NDS; QL (216 per 30 days) |
| IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG, 560 MG | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| IMDELLTRA INTRAVENOUS RECON SOLN 1 MG, 10 MG | 5 | PA NSO; NM; NDS |
| IMJUDO INTRAVENOUS SOLUTION 20 MG/ML | 5 | PA NSO; NM; NDS |
| IMKELDI ORAL SOLUTION 80 MG/ML | 5 | PA NSO; NM; NDS; QL (280 per 28 days) |
| INLEXZO INTRAVESICAL IMPLANT 225 MG | 5 | PA BvD; NM; NDS |
| INLURIYO ORAL TABLET 200 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| INLYTA ORAL TABLET 1 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| INLYTA ORAL TABLET 5 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| INQOVI ORAL TABLET 35-100 MG | 5 | PA NSO; NM; NDS; QL (5 per 28 days) |
| INREBIC ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| ITOVEBI ORAL TABLET 3 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| ITOVEBI ORAL TABLET 9 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|--|
| IWILFIN ORAL TABLET 192 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| JAKAFI ORAL TABLET 10 MG, 15 MG, 20 MG, 25 MG, 5 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| JAYPIRCA ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| JAYPIRCA ORAL TABLET 50 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| JEMPERLI INTRAVENOUS SOLUTION 50 MG/ML | 5 | PA NSO; NM; NDS |
| JYLAMVO ORAL SOLUTION 2 MG/ML | 4 | PA BvD; ST |
| KEYTRUDA INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NM; NDS |
| KEYTRUDA QLEX SUBCUTANEOUS SOLUTION 395 MG-4,800 UNIT/2.4 ML, 790 MG-9,600 UNIT/4.8 ML | 5 | PA NSO; NM; NDS |
| KIMMTRAK INTRAVENOUS SOLUTION 100 MCG/0.5 ML | 5 | PA NSO; NM; NDS; QL (2 per 28 days) |
| KISQALI 200 MG DAILY DOSE 200 MG/DAY (200 MG X 1) | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 200 MG/DAY(200 MG X 1)-2.5 MG | 5 | PA NSO; NM; NDS; QL (49 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 400 MG/DAY(200 MG X 2)-2.5 MG | 5 | PA NSO; NM; NDS; QL (70 per 28 days) |
| KISQALI FEMARA CO-PACK ORAL TABLET 600 MG/DAY(200 MG X 3)-2.5 MG | 5 | PA NSO; NM; NDS; QL (91 per 28 days) |
| KISQALI ORAL TABLET 200 MG/DAY (200 MG X 1) | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| KISQALI ORAL TABLET 400 MG/DAY (200 MG X 2) | 5 | PA NSO; NM; NDS; QL (42 per 28 days) |
| KISQALI ORAL TABLET 600 MG/DAY (200 MG X 3) | 5 | PA NSO; NM; NDS; QL (63 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|---------------------------------------|
| KOMZIFTI ORAL CAPSULE 200 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| KOSELUGO ORAL CAPSULE 10 MG | 5 | PA NSO; NM; NDS; QL (300 per 30 days) |
| KOSELUGO ORAL CAPSULE 25 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| KOSELUGO ORAL CAPSULE, SPRINKLE 5 MG | 5 | PA NSO; NM; NDS; QL (600 per 30 days) |
| KOSELUGO ORAL CAPSULE, SPRINKLE 7.5 MG | 5 | PA NSO; NM; NDS; QL (390 per 30 days) |
| KRAZATI ORAL TABLET 200 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>lapatinib oral tablet 250 mg</i> (Tykerb) | 5 | PA NSO; NM; NDS |
| LAZCLUZE ORAL TABLET 240 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| LAZCLUZE ORAL TABLET 80 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| <i>lenalidomide oral capsule 10 mg, 15 mg, 2.5 mg, 20 mg, 25 mg, 5 mg</i> (Revlimid) | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| LENVIMA ORAL CAPSULE 10 MG/DAY (10 MG X 1), 12 MG/DAY (4 MG X 3), 14 MG/DAY(10 MG X 1-4 MG X 1), 18 MG/DAY (10 MG X 1-4 MG X2), 20 MG/DAY (10 MG X 2), 24 MG/DAY(10 MG X 2-4 MG X 1), 4 MG, 8 MG/DAY (4 MG X 2) | 5 | PA NSO; NM; NDS |
| <i>letrozole oral tablet 2.5 mg</i> (Femara) | 2 | |
| LEUKERAN ORAL TABLET 2 MG | 5 | NM; NDS |
| <i>leuprolide acetate (3 month) intramuscular suspension for reconstitution 22.5 mg</i> (Lutrate Depot (3 month)) | 4 | PA NSO |
| <i>leuprolide subcutaneous kit 1 mg/0.2 ml</i> | 2 | PA NSO |
| <i>lomustine oral capsule 10 mg</i> (Gleostine) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|---------------------------------------|
| <i>lomustine oral capsule 100 mg, 40 mg</i> (Gleostine) | 5 | NM; NDS |
| LONSURF ORAL TABLET 15-6.14 MG | 5 | PA NSO; NM; NDS; QL (100 per 28 days) |
| LONSURF ORAL TABLET 20-8.19 MG | 5 | PA NSO; NM; NDS; QL (80 per 28 days) |
| LOQTORZI INTRAVENOUS SOLUTION 240 MG/6 ML (40 MG/ML) | 5 | PA NSO; NM; NDS |
| LORBRENA ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| LORBRENA ORAL TABLET 25 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| LUMAKRAS ORAL TABLET 120 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| LUMAKRAS ORAL TABLET 240 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| LUMAKRAS ORAL TABLET 320 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| LUNSUMIO INTRAVENOUS SOLUTION 1 MG/ML | 5 | PA NSO; NM; NDS |
| LUNSUMIO VELO SUBCUTANEOUS SOLUTION 45 MG/ML, 5 MG/0.5 ML | 5 | PA NSO; NM; NDS |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 22.5 MG | 5 | PA NSO; NM; NDS |
| LUPRON DEPOT (4 MONTH) INTRAMUSCULAR SYRINGE KIT 30 MG | 5 | PA NSO; NM; NDS |
| LUPRON DEPOT (6 MONTH) INTRAMUSCULAR SYRINGE KIT 45 MG | 5 | PA NSO; NM; NDS |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 7.5 MG | 5 | PA NSO; NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|--|
| LUTRATE DEPOT (3 MONTH) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 22.5 MG (leuprolide acetate (3 month)) | 4 | PA NSO |
| LYNOZYFIC INTRAVENOUS SOLUTION 2 MG/ML | 5 | PA NSO; NM; NDS; QL (15 per 8 days) |
| LYNOZYFIC INTRAVENOUS SOLUTION 20 MG/ML | 5 | PA NSO; NM; NDS; QL (40 per 28 days) |
| LYNPARZA ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| LYSODREN ORAL TABLET 500 MG | 5 | NM; NDS |
| LYTGOBI ORAL TABLET 12 MG/DAY (4 MG X 3), 16 MG/DAY (4 MG X 4), 20 MG/DAY (4 MG X 5) | 5 | PA NSO; NM; NDS; QL (140 per 28 days) |
| MARGENZA INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NM; NDS |
| MATULANE ORAL CAPSULE 50 MG | 5 | NM; NDS |
| <i>megestrol oral tablet 20 mg, 40 mg</i> | 2 | PA NSO-HRM; AGE (Max 64 Years) |
| MEKINIST ORAL RECON SOLN 0.05 MG/ML | 5 | PA NSO; NM; NDS; QL (1260 per 30 days) |
| MEKINIST ORAL TABLET 0.5 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| MEKINIST ORAL TABLET 2 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| MEKTOVI ORAL TABLET 15 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>mercaptopurine oral suspension 20 mg/ml</i> (Purixan) | 5 | NM; NDS |
| <i>mercaptopurine oral tablet 50 mg</i> | 2 | |
| <i>methotrexate sodium (pf) injection recon soln 1 gram</i> | 2 | |
| <i>methotrexate sodium (pf) injection solution 25 mg/ml</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|---------------------------------------|
| <i>methotrexate sodium injection solution 25 mg/ml</i> | 2 | |
| <i>methotrexate sodium oral tablet 2.5 mg</i> | 2 | PA BvD; ST |
| <i>mitoxantrone intravenous concentrate 2 mg/ml</i> | 2 | |
| MODEYSO ORAL CAPSULE 125 MG | 5 | PA NSO; NM; NDS; QL (20 per 28 days) |
| NERLYNX ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>nilutamide oral tablet 150 mg</i> | 5 | NM; NDS |
| NINLARO ORAL CAPSULE 2.3 MG, 3 MG, 4 MG | 5 | PA NSO; NM; NDS; QL (3 per 28 days) |
| NUBEQA ORAL TABLET 300 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| ODOMZO ORAL CAPSULE 200 MG | 5 | PA NSO; NM; LA; NDS |
| OGIVRI INTRAVENOUS RECON SOLN 150 MG, 420 MG | 5 | PA NSO; NM; NDS |
| OGSIVEO ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| OGSIVEO ORAL TABLET 50 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| OJEMDA ORAL SUSPENSION FOR RECONSTITUTION 25 MG/ML | 5 | PA NSO; NM; NDS; QL (96 per 28 days) |
| OJEMDA ORAL TABLET 400 MG/WEEK (100 MG X 4), 500 MG/WEEK (100 MG X 5), 600 MG/WEEK (100 MG X 6) | 5 | PA NSO; NM; NDS; QL (24 per 28 days) |
| OJJAARA ORAL TABLET 100 MG, 150 MG, 200 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| ONUREG ORAL TABLET 200 MG, 300 MG | 5 | PA NSO; NM; NDS; QL (14 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|---------------------------------------|
| OPDIVO INTRAVENOUS SOLUTION 100 MG/10 ML, 120 MG/12 ML, 240 MG/24 ML, 40 MG/4 ML | 5 | PA NSO; NM; NDS |
| OPDIVO QVANTIG SUBCUTANEOUS SOLUTION 300 MG-5,000 UNIT/2.5 ML, 600 MG-10,000 UNIT/5 ML | 5 | PA NSO; NM; NDS |
| OPDUALAG INTRAVENOUS SOLUTION 240-80 MG/20 ML | 5 | PA NSO; NM; NDS |
| ORSERDU ORAL TABLET 345 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| ORSERDU ORAL TABLET 86 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| <i>paclitaxel protein-bound intravenous suspension for reconstitution 100 mg</i> (Abraxane) | 5 | PA BvD; NM; NDS |
| <i>pazopanib oral tablet 200 mg</i> (Votrient) | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| <i>pazopanib oral tablet 400 mg</i> | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| PEMAZYRE ORAL TABLET 13.5 MG, 4.5 MG, 9 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>pemetrexed disodium intravenous recon soln 1,000 mg, 750 mg</i> | 5 | NM; NDS |
| <i>pemetrexed disodium intravenous recon soln 100 mg, 500 mg</i> (Alimta) | 5 | NM; NDS |
| <i>pemetrexed disodium intravenous solution 25 mg/ml</i> | 5 | NM; NDS |
| PEMRYDI RTU INTRAVENOUS SOLUTION 10 MG/ML | 5 | NM; NDS |
| PIQRAY ORAL TABLET 200 MG/DAY (200 MG X 1) | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| PIQRAY ORAL TABLET 250 MG/DAY (200 MG X1-50 MG X1), 300 MG/DAY (150 MG X 2) | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| <i>pomalidomide oral capsule 1 mg, 2 mg, 3 mg, 4 mg</i> (Pomalyst) | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|---------------------------------------|
| POMALYST ORAL CAPSULE 1 MG, 2 MG, 3 MG, 4 MG (pomalidomide) | 5 | PA NSO; NM; NDS; QL (21 per 28 days) |
| QINLOCK ORAL TABLET 50 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| RETEVMO ORAL CAPSULE 40 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| RETEVMO ORAL CAPSULE 80 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| RETEVMO ORAL TABLET 120 MG, 160 MG, 80 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| RETEVMO ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| REVUFORJ ORAL TABLET 110 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| REVUFORJ ORAL TABLET 160 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| REVUFORJ ORAL TABLET 25 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| REZLIDHIA ORAL CAPSULE 150 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| RITUXAN HYCELA SUBCUTANEOUS SOLUTION 1400 MG/11.7 ML (120 MG/ML), 1600 MG/13.4 ML (120 MG/ML) | 5 | PA NSO; NM; NDS |
| ROMVIMZA ORAL CAPSULE 14 MG, 20 MG, 30 MG | 5 | PA NSO; NM; NDS; QL (8 per 28 days) |
| ROZLYTREK ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| ROZLYTREK ORAL CAPSULE 200 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| ROZLYTREK ORAL PELLETS IN PACKET 50 MG | 5 | PA NSO; NM; NDS; QL (360 per 30 days) |
| RUBRACA ORAL TABLET 200 MG, 250 MG, 300 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|--|
| RYBREVANT FASPRO SUBCUTANEOUS SOLUTION 1,600 MG-20,000 UNIT/10 ML, 2,240 MG-28,000 UNIT/14 ML, 2,400 MG-30,000 UNIT/15 ML, 3,520 MG-44,000 UNIT/22 ML | 5 | PA NSO; NM; NDS |
| RYBREVANT INTRAVENOUS SOLUTION 50 MG/ML | 5 | PA NSO; NM; NDS |
| RYDAPT ORAL CAPSULE 25 MG | 5 | PA NSO; NM; NDS; QL (224 per 28 days) |
| RYTELO INTRAVENOUS RECON SOLN 188 MG, 47 MG | 5 | PA NSO; NM; NDS |
| SCEMBLIX ORAL TABLET 100 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| SCEMBLIX ORAL TABLET 20 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| SCEMBLIX ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (300 per 30 days) |
| SOLTAMOX ORAL SOLUTION 20 MG/10 ML | 5 | NM; NDS |
| <i>sorafenib oral tablet 200 mg</i> (Nexavar) | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| STIVARGA ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (84 per 28 days) |
| <i>sunitinib malate oral capsule 12.5 mg, 25 mg, 37.5 mg, 50 mg</i> (Sutent) | 5 | PA NSO; NM; NDS; QL (28 per 28 days) |
| SYNRIBO SUBCUTANEOUS RECON SOLN 3.5 MG | 5 | PA NSO; NM; NDS |
| TABLOID ORAL TABLET 40 MG (thioguanine) | 5 | NM; NDS |
| TABRECTA ORAL TABLET 150 MG, 200 MG | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| TAFINLAR ORAL CAPSULE 50 MG, 75 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| TAFINLAR ORAL TABLET FOR SUSPENSION 10 MG | 5 | PA NSO; NM; NDS; QL (900 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|--|
| TAGRISO ORAL TABLET 40 MG, 80 MG | 5 | PA NSO; NM; LA; NDS; QL (30 per 30 days) |
| TALVEY SUBCUTANEOUS SOLUTION 2 MG/ML, 40 MG/ML | 5 | PA NSO; NM; NDS |
| TALZENNA ORAL CAPSULE 0.1 MG, 0.25 MG, 0.35 MG, 0.5 MG, 0.75 MG, 1 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>tamoxifen oral tablet 10 mg, 20 mg</i> | 2 | |
| TASIGNA ORAL CAPSULE 150 MG, 200 MG (nilotinib hcl) | 5 | PA NSO; NM; NDS; QL (112 per 28 days) |
| TASIGNA ORAL CAPSULE 50 MG (nilotinib hcl) | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| TAZVERIK ORAL TABLET 200 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| TECVAYLI SUBCUTANEOUS SOLUTION 10 MG/ML, 90 MG/ML | 5 | PA NSO; NM; NDS |
| TEPMETKO ORAL TABLET 225 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| TEVIMBRA INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA NSO; NM; NDS |
| TIBSOVO ORAL TABLET 250 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| TICE BCG INTRAVESICAL SUSPENSION FOR RECONSTITUTION 50 MG | 4 | |
| TIVDAK INTRAVENOUS RECON SOLN 40 MG | 5 | PA NSO; NM; NDS; QL (5 per 21 days) |
| <i>toposar intravenous solution 20 mg/ml</i> (etoposide) | 2 | |
| <i>toremifene oral tablet 60 mg</i> (Fareston) | 5 | NM; NDS |
| <i>torpenz oral tablet 10 mg</i> (everolimus (antineoplastic)) | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| <i>torpenz oral tablet 2.5 mg, 5 mg, 7.5 mg</i> (everolimus (antineoplastic)) | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|---|
| TRELSTAR INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 11.25 MG, 22.5 MG, 3.75 MG | 4 | PA NSO |
| <i>tretinoin (antineoplastic) oral capsule 10 mg</i> | 5 | NM; NDS |
| TRUQAP ORAL TABLET 160 MG, 200 MG | 5 | PA NSO; NM; NDS; QL (64 per 28 days) |
| TRUXIMA INTRAVENOUS SOLUTION 10 MG/ML | 5 | PA NSO; NM; NDS |
| TUKYSA ORAL TABLET 150 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| TUKYSA ORAL TABLET 50 MG | 5 | PA NSO; NM; NDS; QL (300 per 30 days) |
| TURALIO ORAL CAPSULE 125 MG, 200 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| VANFLYTA ORAL TABLET 17.7 MG, 26.5 MG | 5 | PA NSO; NM; NDS |
| VENCLEXTA ORAL TABLET 10 MG | 3 | PA NSO; LA; QL (60 per 30 days) |
| VENCLEXTA ORAL TABLET 100 MG | 5 | PA NSO; NM; LA; NDS; QL (180 per 30 days) |
| VENCLEXTA ORAL TABLET 50 MG | 5 | PA NSO; NM; LA; NDS; QL (30 per 30 days) |
| VENCLEXTA STARTING PACK ORAL TABLETS,DOSE PACK 10 MG-50 MG- 100 MG | 5 | PA NSO; NM; LA; NDS |
| VERZENIO ORAL TABLET 100 MG, 150 MG, 200 MG, 50 MG | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| <i>vinorelbine intravenous solution 10 mg/ml, 50 mg/5 ml</i> | 2 | |
| VITRAKVI ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| VITRAKVI ORAL CAPSULE 25 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|---------------------------------------|
| VITRAKVI ORAL SOLUTION 20 MG/ML | 5 | PA NSO; NM; NDS; QL (300 per 30 days) |
| VIVIMUSTA INTRAVENOUS SOLUTION 25 MG/ML (bendamustine) | 5 | PA NSO; NM; NDS |
| VIZIMPRO ORAL TABLET 15 MG, 30 MG, 45 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| VONJO ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| VORANIGO ORAL TABLET 10 MG, 40 MG | 5 | PA NSO; NM; NDS |
| VYLOY INTRAVENOUS RECON SOLN 100 MG, 300 MG | 5 | PA NSO; NM; NDS |
| WELIREG ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| XALKORI ORAL CAPSULE 200 MG, 250 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| XALKORI ORAL PELLETT 150 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| XALKORI ORAL PELLETT 20 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| XALKORI ORAL PELLETT 50 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| XATMEP ORAL SOLUTION 2.5 MG/ML | 4 | PA BvD; ST |
| XOSPATA ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| XPOVIO ORAL TABLET 100 MG/WEEK (50 MG X 2), 40MG TWICE WEEK (40 MG X 2), 80 MG/WEEK (40 MG X 2), 80 MG/WEEK (80 MG X 1) | 5 | PA NSO; NM; NDS; QL (8 per 28 days) |
| XPOVIO ORAL TABLET 40 MG/WEEK (10 MG X 4) | 5 | PA NSO; NM; NDS; QL (16 per 28 days) |
| XPOVIO ORAL TABLET 40 MG/WEEK (40 MG X 1), 60 MG/WEEK (60 MG X 1) | 5 | PA NSO; NM; NDS; QL (4 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|--|
| XPOVIO ORAL TABLET 60MG TWICE WEEK (120 MG/WEEK) | 5 | PA NSO; NM; NDS; QL (24 per 28 days) |
| XPOVIO ORAL TABLET 80MG TWICE WEEK (160 MG/WEEK) | 5 | PA NSO; NM; NDS; QL (32 per 28 days) |
| XTANDI ORAL CAPSULE 40 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| XTANDI ORAL TABLET 40 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| XTANDI ORAL TABLET 80 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| YERVOY INTRAVENOUS SOLUTION 200 MG/40 ML (5 MG/ML), 50 MG/10 ML (5 MG/ML) | 5 | PA NSO; NM; NDS |
| YONSA ORAL TABLET 125 MG (abiraterone, submicronized) | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| ZEJULA ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (90 per 30 days) |
| ZEJULA ORAL TABLET 100 MG, 200 MG, 300 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| ZELBORAF ORAL TABLET 240 MG | 5 | PA NSO; NM; NDS; QL (240 per 30 days) |
| ZIIHERA INTRAVENOUS RECON SOLN 300 MG | 5 | PA NSO; NM; NDS |
| ZIRABEV INTRAVENOUS SOLUTION 25 MG/ML | 5 | PA NSO; NM; NDS |
| ZOLADEX SUBCUTANEOUS IMPLANT 10.8 MG, 3.6 MG | 4 | PA NSO |
| ZOLINZA ORAL CAPSULE 100 MG | 5 | NM; NDS |
| ZYDELIG ORAL TABLET 100 MG, 150 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| ZYKADIA ORAL TABLET 150 MG | 5 | PA NSO; NM; NDS; QL (84 per 28 days) |
| ZYNLONTA INTRAVENOUS RECON SOLN 10 MG | 5 | PA NSO; NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|--------------------------------------|
| ZYNYZ INTRAVENOUS SOLUTION 500 MG/20 ML | 5 | PA NSO; NM; NDS; QL (20 per 28 days) |
| Agentes Anti-Adicción/De Tratamiento De Abuso De Sustancias | | |
| Agentes Anti-Adicción/De Tratamiento De Abuso De Sustancias | | |
| <i>acamprosate oral tablet, delayed release (dr/ec) 333 mg</i> | 2 | |
| <i>buprenorphine hcl sublingual tablet 2 mg, 8 mg</i> | 2 | |
| <i>buprenorphine-naloxone sublingual film 12-3 mg, 2-0.5 mg, 4-1 mg, 8-2 mg</i> (Suboxone) | 2 | |
| <i>buprenorphine-naloxone sublingual tablet 2-0.5 mg, 8-2 mg</i> | 2 | |
| <i>bupropion hcl (smoking deter) oral tablet extended release 12 hr 150 mg</i> | 2 | |
| <i>disulfiram oral tablet 250 mg, 500 mg</i> | 2 | |
| KLOXXADO NASAL SPRAY, NON-AEROSOL 8 MG/ACTUATION | 3 | QL (4 per 30 days) |
| <i>naloxone injection solution 0.4 mg/ml</i> | 2 | |
| <i>naloxone injection syringe 0.4 mg/ml, 0.4 mg/ml (prefilled syringe), 1 mg/ml</i> | 2 | |
| <i>naloxone nasal spray, non-aerosol 4 mg/actuation</i> (Narcan) | 2 | QL (4 per 30 days) |
| <i>naltrexone oral tablet 50 mg</i> | 2 | |
| NICOTROL NS NASAL SPRAY, NON-AEROSOL 10 MG/ML | 4 | ST; QL (240 per 180 days) |
| <i>varenicline tartrate oral tablet 0.5 mg, 1 mg</i> (Chantix) | 2 | QL (336 per 365 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>varenicline tartrate oral tablet 1 mg (56 pack)</i> | 2 | QL (336 per 365 days) |
| <i>varenicline tartrate oral tablets, dose pack 0.5 mg (11)- 1 mg (42)</i> (Chantix Starting Month Box) | 2 | |
| Agentes Antiansiedad | | |
| Benzodiacepinas | | |
| <i>alprazolam oral tablet 0.25 mg, 0.5 mg, 1 mg</i> (Xanax) | 1 | NM; QL (120 per 30 days) |
| <i>alprazolam oral tablet 2 mg</i> (Xanax) | 1 | NM; QL (150 per 30 days) |
| <i>chlordiazepoxide hcl oral capsule 10 mg, 25 mg, 5 mg</i> | 2 | NM; QL (120 per 30 days) |
| <i>clonazepam oral tablet 0.5 mg, 1 mg</i> (Klonopin) | 1 | QL (90 per 30 days) |
| <i>clonazepam oral tablet 2 mg</i> (Klonopin) | 1 | QL (300 per 30 days) |
| <i>clonazepam oral tablet, disintegrating 0.125 mg, 0.25 mg, 0.5 mg, 1 mg</i> | 2 | QL (90 per 30 days) |
| <i>clonazepam oral tablet, disintegrating 2 mg</i> | 2 | QL (300 per 30 days) |
| <i>clorazepate dipotassium oral tablet 15 mg, 3.75 mg, 7.5 mg</i> | 2 | QL (180 per 30 days) |
| <i>diazepam injection solution 5 mg/ml</i> | 2 | QL (10 per 28 days) |
| <i>diazepam injection syringe 5 mg/ml</i> | 2 | |
| <i>diazepam intensol oral concentrate 5 mg/ml</i> (diazepam) | 2 | QL (1200 per 30 days) |
| <i>diazepam oral solution 5 mg/5 ml (1 mg/ml)</i> | 2 | QL (1200 per 30 days) |
| <i>diazepam oral tablet 10 mg, 2 mg, 5 mg</i> (Valium) | 1 | QL (120 per 30 days) |
| <i>lorazepam 2 mg/ml oral concent</i> (Lorazepam Intensol) | 2 | NM; QL (150 per 30 days) |
| <i>lorazepam 4 mg/ml vial inner</i> (Ativan) | 1 | QL (2 per 30 days) |
| <i>lorazepam injection solution 2 mg/ml</i> (Ativan) | 1 | QL (2 per 30 days) |
| <i>lorazepam injection solution 4 mg/ml</i> (Ativan) | 4 | QL (2 per 30 days) |
| <i>lorazepam injection syringe 2 mg/ml</i> | 1 | QL (2 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| <i>lorazepam intensol oral concentrate</i> (lorazepam) 2 mg/ml | 2 | NM; QL (150 per 30 days) |
| <i>lorazepam oral tablet 0.5 mg, 1 mg</i> (Ativan) | 1 | NM; QL (90 per 30 days) |
| <i>lorazepam oral tablet 2 mg</i> (Ativan) | 1 | NM; QL (150 per 30 days) |
| <i>temazepam oral capsule 15 mg, 30 mg</i> (Restoril) | 1 | NM; QL (30 per 30 days) |
| <i>temazepam oral capsule 22.5 mg</i> (Restoril) | 2 | NM; QL (30 per 30 days) |
| <i>temazepam oral capsule 7.5 mg</i> (Restoril) | 2 | NM; QL (120 per 30 days) |
| Agentes Antidemencia | | |
| Agentes Antidemencia | | |
| <i>donepezil oral tablet 10 mg, 5 mg</i> (Aricept) | 1 | QL (30 per 30 days) |
| <i>donepezil oral tablet 23 mg</i> (Aricept) | 2 | QL (30 per 30 days) |
| <i>donepezil oral tablet, disintegrating 10 mg</i> | 2 | |
| <i>donepezil oral tablet, disintegrating 5 mg</i> | 2 | QL (30 per 30 days) |
| <i>ergoloid oral tablet 1 mg</i> | 2 | |
| <i>galantamine oral capsule, ext rel. pellets 24 hr 16 mg, 24 mg, 8 mg</i> | 2 | QL (30 per 30 days) |
| <i>galantamine oral solution 4 mg/ml</i> | 2 | QL (200 per 30 days) |
| <i>galantamine oral tablet 12 mg, 4 mg, 8 mg</i> | 2 | QL (60 per 30 days) |
| <i>memantine oral capsule, sprinkle, er 24hr 14 mg, 21 mg, 28 mg</i> | 2 | ST; QL (30 per 30 days) |
| <i>memantine oral capsule, sprinkle, er 24hr 7 mg</i> (Namenda XR) | 2 | ST; QL (30 per 30 days) |
| <i>memantine oral solution 2 mg/ml</i> | 2 | QL (300 per 30 days) |
| <i>memantine oral tablet 10 mg, 5 mg</i> | 2 | QL (60 per 30 days) |
| <i>rivastigmine tartrate oral capsule 1.5 mg, 3 mg, 4.5 mg, 6 mg</i> | 2 | |
| <i>rivastigmine transdermal patch 24 hour 13.3 mg/24 hour, 4.6 mg/24 hour, 9.5 mg/24 hour</i> (Exelon Patch) | 2 | QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| Agentes Antidiabetico | | |
| Agentes Antidiabeticos, Varios | | |
| <i>acarbose oral tablet 100 mg, 25 mg, 50 mg</i> (Precose) | 2 | |
| <i>dapagliflozin propanediol oral tablet 10 mg, 5 mg</i> (Farxiga) | 3 | QL (30 per 30 days) |
| FARXIGA ORAL TABLET 10 MG, 5 MG (dapagliflozin propanediol) | 3 | QL (30 per 30 days) |
| GLYXAMBI ORAL TABLET 10-5 MG, 25-5 MG | 3 | QL (30 per 30 days) |
| JANUMET ORAL TABLET 50-1,000 MG, 50-500 MG | 3 | QL (60 per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 100-1,000 MG | 3 | QL (30 per 30 days) |
| JANUMET XR ORAL TABLET, ER MULTIPHASE 24 HR 50-1,000 MG, 50-500 MG | 3 | QL (60 per 30 days) |
| JANUVIA ORAL TABLET 100 MG, 25 MG | 3 | QL (30 per 30 days) |
| JANUVIA ORAL TABLET 50 MG | 3 | QL (30 per 30 days) |
| JARDIANCE ORAL TABLET 10 MG, 25 MG | 3 | QL (30 per 30 days) |
| JENTADUETO ORAL TABLET 2.5-1,000 MG, 2.5-500 MG, 2.5-850 MG (linagliptin-metformin) | 3 | QL (60 per 30 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG | 3 | QL (60 per 30 days) |
| JENTADUETO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG | 3 | QL (30 per 30 days) |
| <i>metformin oral solution 500 mg/5 ml</i> (Riomet) | 2 | QL (765 per 30 days) |
| <i>metformin oral tablet 1,000 mg</i> | 6 | QL (75 per 30 days) |
| <i>metformin oral tablet 500 mg</i> | 6 | QL (150 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>metformin oral tablet 750 mg, 850 mg</i> | 6 | QL (90 per 30 days) |
| <i>metformin oral tablet extended release 24 hr 500 mg</i> | 6 | QL (120 per 30 days) |
| <i>metformin oral tablet extended release 24 hr 750 mg</i> | 6 | QL (60 per 30 days) |
| <i>mifepristone oral tablet 300 mg</i> (Korlym) | 5 | PA; NM; NDS; QL (112 per 28 days) |
| MOUNJARO SUBCUTANEOUS PEN INJECTOR 10 MG/0.5 ML, 12.5 MG/0.5 ML, 15 MG/0.5 ML, 2.5 MG/0.5 ML, 5 MG/0.5 ML, 7.5 MG/0.5 ML | 3 | PA; QL (2 per 28 days) |
| <i>nateglinide oral tablet 120 mg, 60 mg</i> | 6 | QL (90 per 30 days) |
| OZEMPIC SUBCUTANEOUS PEN INJECTOR 0.25 MG OR 0.5 MG (2 MG/3 ML), 0.25 MG OR 0.5 MG(2 MG/1.5 ML), 1 MG/DOSE (4 MG/3 ML), 2 MG/DOSE (8 MG/3 ML) | 3 | PA; QL (3 per 28 days) |
| <i>pioglitazone oral tablet 15 mg, 30 mg, 45 mg</i> (Actos) | 6 | QL (30 per 30 days) |
| <i>pioglitazone-metformin oral tablet 15-500 mg</i> | 6 | QL (90 per 30 days) |
| <i>pioglitazone-metformin oral tablet 15-850 mg</i> (Actoplus MET) | 6 | QL (90 per 30 days) |
| <i>repaglinide oral tablet 0.5 mg, 1 mg</i> | 6 | QL (120 per 30 days) |
| <i>repaglinide oral tablet 2 mg</i> | 6 | QL (240 per 30 days) |
| RYBELSUS ORAL TABLET 1.5 MG, 14 MG, 3 MG, 4 MG, 7 MG, 9 MG | 3 | PA; QL (30 per 30 days) |
| SYNJARDY ORAL TABLET 12.5-1,000 MG, 12.5-500 MG, 5-1,000 MG, 5-500 MG | 3 | QL (60 per 30 days) |
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG, 25-1,000 MG | 3 | QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|--|
| SYNJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-1,000 MG, 5-1,000 MG | 3 | QL (60 per 30 days) |
| TRADJENTA ORAL TABLET 5 MG (linagliptin) | 3 | QL (30 per 30 days) |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-5-1,000 MG, 25-5-1,000 MG | 3 | QL (30 per 30 days) |
| TRIJARDY XR ORAL TABLET, IR - ER, BIPHASIC 24HR 12.5-2.5-1,000 MG, 5-2.5-1,000 MG | 3 | QL (60 per 30 days) |
| TRULICITY SUBCUTANEOUS PEN INJECTOR 0.75 MG/0.5 ML, 1.5 MG/0.5 ML, 3 MG/0.5 ML, 4.5 MG/0.5 ML | 3 | PA; QL (2 per 28 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-1,000 MG (dapaglifloz propaned-metformin) | 3 | QL (30 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 10-500 MG | 3 | QL (30 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 2.5-1,000 MG, 5-500 MG | 3 | QL (60 per 30 days) |
| XIGDUO XR ORAL TABLET, IR - ER, BIPHASIC 24HR 5-1,000 MG (dapaglifloz propaned-metformin) | 3 | QL (60 per 30 days) |
| Insulinas | | |
| FIASP FLEXTOUCH U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| FIASP PENFILL U-100 INSULIN SUBCUTANEOUS CARTRIDGE 100 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| FIASP PUMPCART SUBCUTANEOUS CARTRIDGE 100 UNIT/ML (1.6 ML) | 3 | max \$35 copay per month supply |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|--|
| FIASP U-100 INSULIN SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| HUMULIN R U-500 (CONC) INSULIN SUBCUTANEOUS SOLUTION 500 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| HUMULIN R U-500 (CONC) KWIKPEN SUBCUTANEOUS INSULIN PEN 500 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (24 per 28 days) |
| <i>insulin asp prt-insulin aspart subcutaneous insulin pen 100 unit/ml (70-30)</i> | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin asp prt-insulin aspart subcutaneous solution 100 unit/ml (70-30)</i> | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| <i>insulin aspart u-100 subcutaneous cartridge 100 unit/ml</i> | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin aspart u-100 subcutaneous insulin pen 100 unit/ml (3 ml)</i> | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin aspart u-100 subcutaneous solution 100 unit/ml</i> | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| <i>insulin glargine-yfgn subcutaneous insulin pen 100 unit/ml (3 ml)</i> | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| <i>insulin glargine-yfgn subcutaneous solution 100 unit/ml</i> | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| <i>insulin lispro subcutaneous solution 100 unit/ml</i> | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| LANTUS SOLOSTAR U-100 INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|--|
| LANTUS U-100 INSULIN (insulin glargine) SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN 70/30 U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML (70-30) | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN 70-30 FLEXPEN U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN N FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN N NPH U-100 INSULIN SUBCUTANEOUS SUSPENSION 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLIN R FLEXPEN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLIN R REGULAR U100 INSULIN INJECTION SOLUTION 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLOG FLEXPEN U-100 (insulin aspart u-100) INSULIN SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (3 ML) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLOG MIX 70-30 U-100 (insulin asp prt-insulin aspart) INSULN SUBCUTANEOUS SOLUTION 100 UNIT/ML (70-30) | 3 | max \$35 copay per month supply; QL (40 per 28 days) |
| NOVOLOG MIX 70-30FLEXPEN (insulin asp prt-insulin aspart) U-100 SUBCUTANEOUS INSULIN PEN 100 UNIT/ML (70-30) | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLOG PENFILL U-100 (insulin aspart u-100) INSULIN SUBCUTANEOUS CARTRIDGE 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (30 per 28 days) |
| NOVOLOG U-100 INSULIN (insulin aspart u-100) ASPART SUBCUTANEOUS SOLUTION 100 UNIT/ML | 3 | max \$35 copay per month supply; QL (40 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|---------------------------------------|--|
| SOLQUA 100/33 SUBCUTANEOUS INSULIN PEN 100 UNIT-33 MCG/ML | 3 | max \$35 copay per month supply; QL (30 per 30 days) |
| TOUJEO MAX U-300 SOLOSTAR SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (3 ML) | (insulin glargine u-300 conc) 3 | max \$35 copay per month supply; QL (18 per 28 days) |
| TOUJEO SOLOSTAR U-300 INSULIN SUBCUTANEOUS INSULIN PEN 300 UNIT/ML (1.5 ML) | (insulin glargine u-300 conc) 3 | max \$35 copay per month supply; QL (13.5 per 28 days) |
| XULTOPHY 100/3.6 SUBCUTANEOUS INSULIN PEN 100 UNIT-3.6 MG /ML (3 ML) | 3 | max \$35 copay per month supply; QL (15 per 28 days) |
| Sulfonilureas | | |
| <i>glimepiride oral tablet 1 mg, 2 mg</i> | 6 | QL (30 per 30 days) |
| <i>glimepiride oral tablet 4 mg</i> | 6 | QL (60 per 30 days) |
| <i>glipizide oral tablet 10 mg</i> | 6 | QL (120 per 30 days) |
| <i>glipizide oral tablet 2.5 mg</i> | 6 | QL (90 per 30 days) |
| <i>glipizide oral tablet 5 mg</i> | 6 | QL (240 per 30 days) |
| <i>glipizide oral tablet extended release 24hr 10 mg</i> | 6 | QL (60 per 30 days) |
| <i>glipizide oral tablet extended release 24hr 2.5 mg, 5 mg</i> | 6 | QL (30 per 30 days) |
| <i>glipizide-metformin oral tablet 2.5- 250 mg</i> | 6 | QL (240 per 30 days) |
| <i>glipizide-metformin oral tablet 2.5- 500 mg, 5-500 mg</i> | 6 | QL (120 per 30 days) |
| <i>glyburide micronized oral tablet 1.5 mg, 3 mg, 6 mg</i> | 6 | PA-HRM; AGE (Max 64 Years) |
| <i>glyburide oral tablet 1.25 mg, 2.5 mg, 5 mg</i> | 6 | PA-HRM; AGE (Max 64 Years) |
| <i>glyburide-metformin oral tablet 1.25- 250 mg, 2.5-500 mg, 5-500 mg</i> | 6 | PA-HRM; AGE (Max 64 Years) |
| Agentes Antigota | | |
| Agentes Antigota, Otros | | |
| <i>allopurinol oral tablet 100 mg</i> | (Zyloprim) 1 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|------------------------------------|
| <i>allopurinol oral tablet 300 mg</i> | 1 | |
| <i>colchicine oral capsule 0.6 mg</i> (Mitigare) | 2 | QL (60 per 30 days) |
| <i>colchicine oral tablet 0.6 mg</i> (Colcryst) | 2 | QL (120 per 30 days) |
| <i>febuxostat oral tablet 40 mg, 80 mg</i> (Uloric) | 2 | QL (30 per 30 days) |
| <i>probenecid oral tablet 500 mg</i> | 2 | |
| <i>probenecid-colchicine oral tablet 500-0.5 mg</i> | 2 | |
| Agentes Antimigraña | | |
| Agentes Antimigraña | | |
| AIMOVIG AUTOINJECTOR SUBCUTANEOUS AUTO- INJECTOR 140 MG/ML, 70 MG/ML | 3 | PA; QL (1 per 30 days) |
| <i>dihydroergotamine nasal spray, non- aerosol 0.5 mg/pump act. (4 mg/ml)</i> (Migranal) | 5 | ST; NM; NDS; QL (8 per 28 days) |
| EMGALITY PEN SUBCUTANEOUS PEN INJECTOR 120 MG/ML | 3 | PA; QL (2 per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 120 MG/ML | 3 | PA; QL (2 per 30 days) |
| EMGALITY SYRINGE SUBCUTANEOUS SYRINGE 300 MG/3 ML (100 MG/ML X 3) | 3 | PA; QL (3 per 30 days) |
| <i>naratriptan oral tablet 1 mg, 2.5 mg</i> | 2 | QL (18 per 30 days) |
| NURTEC ODT ORAL TABLET, DISINTEGRATING 75 MG | 3 | PA; QL (18 per 30 days) |
| QULIPTA ORAL TABLET 10 MG, 30 MG, 60 MG | 3 | PA; QL (30 per 30 days) |
| <i>rizatriptan oral tablet 10 mg</i> (Maxalt) | 2 | QL (18 per 30 days) |
| <i>rizatriptan oral tablet 5 mg</i> | 2 | QL (18 per 30 days) |
| <i>rizatriptan oral tablet, disintegrating 10 mg</i> (Maxalt-MLT) | 2 | QL (18 per 30 days) |
| <i>rizatriptan oral tablet, disintegrating 5 mg</i> | 2 | QL (18 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>sumatriptan 4 mg/0.5 ml inject outer, suv</i> (Imitrex STATdose Pen) | 2 | QL (4 per 28 days) |
| <i>sumatriptan 6 mg/0.5 ml autoinj suv</i> (Imitrex STATdose Pen) | 4 | QL (4 per 28 days) |
| <i>sumatriptan nasal spray, non-aerosol 20 mg/actuation, 5 mg/actuation</i> | 2 | QL (12 per 30 days) |
| <i>sumatriptan succinate oral tablet 100 mg</i> (Imitrex) | 2 | QL (9 per 30 days) |
| <i>sumatriptan succinate oral tablet 25 mg, 50 mg</i> (Imitrex) | 2 | QL (18 per 30 days) |
| <i>sumatriptan succinate subcutaneous pen injector 4 mg/0.5 ml</i> (Imitrex STATdose Pen) | 4 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous pen injector 6 mg/0.5 ml</i> (Imitrex STATdose Pen) | 2 | QL (4 per 28 days) |
| <i>sumatriptan succinate subcutaneous solution 6 mg/0.5 ml</i> | 2 | QL (5 per 28 days) |
| UBRELVY ORAL TABLET 100 MG, 50 MG | 3 | PA; QL (16 per 30 days) |

Agentes Antinausea

Agentes Antinausea

| | | |
|---|---|----------------------------|
| <i>aprepitant oral capsule 125 mg</i> | 2 | PA BvD; QL (2 per 28 days) |
| <i>aprepitant oral capsule 40 mg</i> | 2 | PA BvD; QL (1 per 28 days) |
| <i>aprepitant oral capsule 80 mg</i> (Emend) | 2 | PA BvD; QL (4 per 28 days) |
| <i>aprepitant oral capsule, dose pack 125 mg (1)- 80 mg (2)</i> (Emend) | 2 | PA BvD |
| <i>compro rectal suppository 25 mg</i> (prochlorperazine) | 2 | |
| <i>dronabinol oral capsule 10 mg, 2.5 mg, 5 mg</i> (Marinol) | 2 | PA; QL (60 per 30 days) |
| <i>meclizine oral tablet 12.5 mg</i> | 1 | |
| <i>meclizine oral tablet 25 mg</i> (Dramamine (meclizine)) | 1 | |
| <i>ondansetron hcl oral tablet 4 mg, 8 mg</i> | 2 | PA BvD |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|---|
| <i>ondansetron oral tablet, disintegrating 4 mg, 8 mg</i> | 2 | PA BvD |
| <i>prochlorperazine edisylate injection solution 10 mg/2 ml (5 mg/ml)</i> | 2 | |
| <i>prochlorperazine maleate oral tablet 10 mg, 5 mg</i> (Compazine) | 2 | |
| <i>prochlorperazine rectal suppository 25 mg</i> (Compro) | 2 | |
| <i>promethazine injection solution 25 mg/ml</i> (Phenergan) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>promethazine oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | PA-HRM; AGE (Max 64 Years) |
| <i>promethazine rectal suppository 25 mg</i> (Promethegan) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>promethegan rectal suppository 12.5 mg, 25 mg</i> (promethazine) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>scopolamine base transdermal patch 3 day 1 mg over 3 days</i> (Transderm-Scop) | 2 | PA-HRM; QL (10 per 30 days); AGE (Max 64 Years) |
| Agentes Antiparasitarios | | |
| Agentes Antiparasitarios | | |
| <i>albendazole oral tablet 200 mg</i> | 2 | |
| <i>atovaquone oral suspension 750 mg/5 ml</i> (Mepron) | 2 | |
| <i>atovaquone-proguanil oral tablet 250-100 mg</i> (Malarone) | 2 | |
| <i>atovaquone-proguanil oral tablet 62.5-25 mg</i> (Malarone Pediatric) | 2 | |
| <i>chloroquine phosphate oral tablet 250 mg, 500 mg</i> | 2 | |
| COARTEM ORAL TABLET 20-120 MG | 4 | |
| <i>hydroxychloroquine oral tablet 100 mg</i> | 2 | QL (180 per 30 days) |
| <i>hydroxychloroquine oral tablet 200 mg</i> (Plaquenil) | 2 | QL (90 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>hydroxychloroquine oral tablet 300 mg</i> (Sovuna) | 2 | QL (60 per 30 days) |
| <i>hydroxychloroquine oral tablet 400 mg</i> | 2 | QL (60 per 30 days) |
| IMPAVIDO ORAL CAPSULE 50 MG | 5 | PA; NM; NDS; QL (84 per 28 days) |
| <i>ivermectin oral tablet 3 mg</i> (Stromectol) | 2 | |
| <i>ivermectin oral tablet 6 mg</i> | 2 | |
| <i>mefloquine oral tablet 250 mg</i> | 2 | |
| <i>nitazoxanide oral tablet 500 mg</i> (Alinia) | 5 | NM; NDS; QL (60 per 30 days) |
| <i>pentamidine inhalation recon soln 300 mg</i> (Nebupent) | 2 | PA BvD |
| <i>pentamidine injection recon soln 300 mg</i> (Pentam) | 2 | |
| <i>praziquantel oral tablet 600 mg</i> (Biltricide) | 2 | |
| PRIMAQUINE ORAL TABLET 26.3 MG (15 MG BASE) | 4 | |
| <i>pyrimethamine oral tablet 25 mg</i> (Daraprim) | 5 | PA; NM; NDS |
| <i>quinine sulfate oral capsule 324 mg</i> (Qualaquin) | 2 | PA |
| <i>tinidazole oral tablet 250 mg, 500 mg</i> | 2 | |
| Agentes Antiparkinson | | |
| Agentes Antiparkinson | | |
| <i>amantadine hcl oral capsule 100 mg</i> | 2 | |
| <i>amantadine hcl oral solution 50 mg/5 ml</i> | 2 | |
| <i>amantadine hcl oral tablet 100 mg</i> | 2 | |
| <i>benztropine oral tablet 0.5 mg, 1 mg</i> | 2 | |
| <i>benztropine oral tablet 2 mg</i> | 2 | |
| <i>bromocriptine oral tablet 2.5 mg</i> | 2 | |
| <i>cabergoline oral tablet 0.5 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet 10-100 mg</i> (Sinemet) | 2 | |
| <i>carbidopa-levodopa oral tablet 25-100 mg</i> (Dhivy) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>carbidopa-levodopa oral tablet 25-250 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet extended release 25-100 mg, 50-200 mg</i> | 2 | |
| <i>carbidopa-levodopa oral tablet, disintegrating 10-100 mg, 25-100 mg, 25-250 mg</i> | 2 | |
| <i>entacapone oral tablet 200 mg</i> | 2 | |
| KYNMOBI SUBLINGUAL FILM 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; NM; NDS; QL (150 per 30 days) |
| KYNMOBI SUBLINGUAL FILM 10-15-20-25-30 MG | 5 | PA; NM; NDS |
| ONAPGO SUBCUTANEOUS CARTRIDGE 4.9 MG/ ML | 5 | PA; NM; NDS; QL (600 per 30 days) |
| <i>pramipexole oral tablet 0.125 mg, 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.5 mg</i> | 2 | |
| <i>rasagiline oral tablet 0.5 mg, 1 mg</i> (Azilect) | 2 | |
| <i>ropinirole oral tablet 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 5 mg</i> | 2 | |
| <i>ropinirole oral tablet extended release 24 hr 2 mg, 4 mg</i> | 2 | |
| <i>selegiline hcl oral capsule 5 mg</i> | 2 | |
| <i>selegiline hcl oral tablet 5 mg</i> | 2 | |
| <i>trihexyphenidyl oral tablet 2 mg, 5 mg</i> | 2 | |
| VYALEV CONTIN. SUBCUTANEOUS INFUSION SOLUTION 12-240 MG/ML | 5 | PA; NM; NDS; QL (560 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|-----------------------------------|
| Agentes Antipsicóticos | | |
| Agentes Antipsicóticos | | |
| ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 720 MG/2.4 ML | 5 | NM; NDS; QL (2.4 per 42 days) |
| ABILIFY ASIMTUFII INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 960 MG/3.2 ML | 5 | NM; NDS; QL (3.2 per 42 days) |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL RECON 300 MG, 400 MG | 5 | NM; NDS; QL (2 per 28 days) |
| ABILIFY MAINTENA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 300 MG, 400 MG | 5 | NM; NDS; QL (2 per 28 days) |
| <i>aripiprazole oral solution 1 mg/ml</i> | 2 | |
| <i>aripiprazole oral tablet 10 mg, 15 mg, 2 mg, 20 mg, 30 mg, 5 mg</i> (Abilify) | 2 | |
| <i>aripiprazole oral tablet,disintegrating 10 mg</i> | 2 | ST; QL (90 per 30 days) |
| <i>aripiprazole oral tablet,disintegrating 15 mg</i> | 2 | ST; QL (60 per 30 days) |
| ARISTADA INITIO INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 675 MG/2.4 ML | 5 | NM; NDS; QL (4.8 per 365 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 1,064 MG/3.9 ML | 5 | NM; NDS; QL (3.9 per 14 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 441 MG/1.6 ML | 5 | NM; NDS; QL (1.6 per 14 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|-------------------------------------|
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 662 MG/2.4 ML | 5 | NM; NDS; QL (2.4 per 14 days) |
| ARISTADA INTRAMUSCULAR SUSPENSION,EXTENDED REL SYRING 882 MG/3.2 ML | 5 | NM; NDS; QL (3.2 per 14 days) |
| <i>asenapine maleate sublingual tablet</i> (Saphris) <i>10 mg, 2.5 mg, 5 mg</i> | 2 | QL (60 per 30 days) |
| CAPLYTA ORAL CAPSULE 10.5 MG, 21 MG, 42 MG | 5 | ST; NM; NDS; QL (30 per 30 days) |
| <i>chlorpromazine injection solution 25 mg/ml</i> | 2 | |
| <i>chlorpromazine oral concentrate 100 mg/ml, 30 mg/ml</i> | 2 | |
| <i>chlorpromazine oral tablet 10 mg, 100 mg, 200 mg, 25 mg, 50 mg</i> | 2 | |
| <i>clozapine oral tablet 100 mg, 200</i> (Clozaril) <i>mg, 25 mg, 50 mg</i> | 2 | |
| <i>clozapine oral tablet,disintegrating 100 mg, 12.5 mg, 25 mg</i> | 2 | ST; QL (90 per 30 days) |
| <i>clozapine oral tablet,disintegrating 150 mg</i> | 2 | ST; QL (180 per 30 days) |
| <i>clozapine oral tablet,disintegrating 200 mg</i> | 2 | ST; QL (120 per 30 days) |
| COBENFY ORAL CAPSULE 100- 20 MG, 125-30 MG, 50-20 MG | 5 | ST; NM; NDS; QL (60 per 30 days) |
| COBENFY STARTER PACK ORAL CAPSULE,DOSE PACK 50 MG-20 MG /100 MG-20 MG | 5 | ST; NM; NDS |
| ERZOFRI INTRAMUSCULAR SYRINGE 117 MG/0.75 ML | 5 | NM; NDS; QL (0.75 per 21 days) |
| ERZOFRI INTRAMUSCULAR SYRINGE 156 MG/ML | 5 | NM; NDS; QL (1 per 21 days) |
| ERZOFRI INTRAMUSCULAR SYRINGE 234 MG/1.5 ML | 5 | NM; NDS; QL (1.5 per 21 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| ERZOFRI INTRAMUSCULAR SYRINGE 351 MG/2.25 ML | 5 | NM; NDS; QL (2.25 per 21 days) |
| ERZOFRI INTRAMUSCULAR SYRINGE 39 MG/0.25 ML | 5 | NM; NDS; QL (0.25 per 21 days) |
| ERZOFRI INTRAMUSCULAR SYRINGE 78 MG/0.5 ML | 5 | NM; NDS; QL (0.5 per 21 days) |
| FANAPT ORAL TABLET 1 MG, 10 MG, 12 MG, 2 MG, 4 MG, 6 MG, 8 MG | 5 | ST; NM; NDS; QL (60 per 30 days) |
| FANAPT TITRATION PACK A ORAL TABLETS,DOSE PACK 1MG(2)-2MG(2)- 4MG(2)-6MG(2) | 4 | ST |
| FANAPT TITRATION PACK B ORAL TABLETS,DOSE PACK 1 MG(6)-2MG(2)- 6 MG(2)-8 MG(2) | 4 | ST |
| FANAPT TITRATION PACK C ORAL TABLETS,DOSE PACK 1 MG(4)-2 MG(2) -6 MG (2) | 4 | ST |
| <i>fluphenazine decanoate injection solution 25 mg/ml</i> | 2 | |
| <i>fluphenazine hcl injection solution 2.5 mg/ml</i> | 2 | |
| <i>fluphenazine hcl oral concentrate 5 mg/ml</i> | 2 | |
| <i>fluphenazine hcl oral elixir 2.5 mg/5 ml</i> | 2 | |
| <i>fluphenazine hcl oral tablet 1 mg, 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>haloperidol decanoate intramuscular solution 100 mg/ml, 100 mg/ml (1 ml), 50 mg/ml, 50 mg/ml(1ml)</i> | 2 | |
| <i>haloperidol lactate injection solution 5 mg/ml</i> | 2 | |
| <i>haloperidol lactate intramuscular syringe 5 mg/ml</i> | 2 | |
| <i>haloperidol lactate oral concentrate 2 mg/ml</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>haloperidol oral tablet 0.5 mg, 1 mg, 10 mg, 2 mg, 20 mg, 5 mg</i> | 2 | |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,092 MG/3.5 ML | 5 | NM; NDS; QL (3.5 per 166 days) |
| INVEGA HAFYERA INTRAMUSCULAR SYRINGE 1,560 MG/5 ML | 5 | NM; NDS; QL (5 per 166 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 117 MG/0.75 ML | 5 | NM; NDS; QL (0.75 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 156 MG/ML | 5 | NM; NDS; QL (1 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 234 MG/1.5 ML | 5 | NM; NDS; QL (1.5 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 39 MG/0.25 ML | 3 | QL (0.25 per 21 days) |
| INVEGA SUSTENNA INTRAMUSCULAR SYRINGE 78 MG/0.5 ML | 5 | NM; NDS; QL (0.5 per 21 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 273 MG/0.88 ML | 5 | NM; NDS; QL (0.88 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 410 MG/1.32 ML | 5 | NM; NDS; QL (1.32 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 546 MG/1.75 ML | 5 | NM; NDS; QL (1.75 per 70 days) |
| INVEGA TRINZA INTRAMUSCULAR SYRINGE 819 MG/2.63 ML | 5 | NM; NDS; QL (2.63 per 70 days) |
| <i>loxapine succinate oral capsule 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|--------------------------------------|
| <i>lurasidone oral tablet 120 mg, 20 mg, 40 mg, 60 mg</i> (Latuda) | 2 | QL (30 per 30 days) |
| <i>lurasidone oral tablet 80 mg</i> (Latuda) | 2 | QL (60 per 30 days) |
| LYBALVI ORAL TABLET 10-10 MG, 15-10 MG, 20-10 MG, 5-10 MG | 5 | NM; NDS; QL (30 per 30 days) |
| <i>molindone oral tablet 10 mg</i> | 2 | QL (240 per 30 days) |
| <i>molindone oral tablet 25 mg</i> | 2 | QL (270 per 30 days) |
| <i>molindone oral tablet 5 mg</i> | 5 | NM; NDS; QL (120 per 30 days) |
| NUPLAZID ORAL CAPSULE 34 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| NUPLAZID ORAL TABLET 10 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| <i>olanzapine intramuscular recon soln 10 mg</i> (Zyprexa) | 2 | QL (30 per 30 days) |
| <i>olanzapine oral tablet 10 mg, 15 mg, 7.5 mg</i> | 2 | |
| <i>olanzapine oral tablet 2.5 mg, 20 mg, 5 mg</i> (Zyprexa) | 2 | |
| <i>olanzapine oral tablet, disintegrating 10 mg, 15 mg, 20 mg, 5 mg</i> | 2 | |
| OPIPZA ORAL FILM 10 MG, 2 MG, 5 MG | 5 | ST; NM; NDS |
| <i>paliperidone oral tablet extended release 24hr 1.5 mg</i> | 2 | QL (30 per 30 days) |
| <i>paliperidone oral tablet extended release 24hr 3 mg, 9 mg</i> (Invega) | 2 | QL (30 per 30 days) |
| <i>paliperidone oral tablet extended release 24hr 6 mg</i> (Invega) | 2 | QL (60 per 30 days) |
| <i>perphenazine oral tablet 16 mg, 2 mg, 4 mg, 8 mg</i> | 2 | |
| PERSERIS SUBCUTANEOUS SUSPENSION, EXTENDED REL SYRING 120 MG, 90 MG | 5 | NM; NDS; QL (1 per 30 days) |
| <i>pimozide oral tablet 1 mg, 2 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>prochlorperazine 10 mg/2 ml vial inner 10 mg/2 ml (5 mg/ml)</i> | 2 | |
| <i>quetiapine oral tablet 100 mg, 200 mg, 25 mg, 300 mg, 400 mg, 50 mg</i> (Seroquel) | 2 | |
| <i>quetiapine oral tablet 150 mg</i> | 2 | QL (30 per 30 days) |
| <i>quetiapine oral tablet extended release 24 hr 150 mg, 200 mg, 300 mg, 400 mg, 50 mg</i> (Seroquel XR) | 2 | |
| REXULTI ORAL TABLET 0.25 MG, 0.5 MG, 1 MG, 2 MG, 3 MG, 4 MG | 5 | NM; NDS; QL (30 per 30 days) |
| <i>risperidone microspheres intramuscular suspension, extended rel recon 12.5 mg/2 ml</i> (Risperdal Consta) | 2 | QL (2 per 28 days) |
| <i>risperidone microspheres intramuscular suspension, extended rel recon 25 mg/2 ml</i> (Rykindo) | 2 | QL (2 per 28 days) |
| <i>risperidone microspheres intramuscular suspension, extended rel recon 37.5 mg/2 ml, 50 mg/2 ml</i> (Rykindo) | 5 | NM; NDS; QL (2 per 28 days) |
| <i>risperidone oral solution 1 mg/ml</i> (Risperdal) | 2 | |
| <i>risperidone oral tablet 0.25 mg</i> | 2 | |
| <i>risperidone oral tablet 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> (Risperdal) | 2 | |
| <i>risperidone oral tablet, disintegrating 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg</i> | 2 | |
| RYKINDO INTRAMUSCULAR SUSPENSION, EXTENDED REL RECON 25 MG/2 ML, 37.5 MG/2 ML, 50 MG/2 ML (risperidone microspheres) | 5 | NM; NDS; QL (2 per 28 days) |
| SECUADO TRANSDERMAL PATCH 24 HOUR 3.8 MG/24 HOUR, 5.7 MG/24 HOUR, 7.6 MG/24 HOUR | 5 | ST; NM; NDS; QL (30 per 30 days) |
| <i>thioridazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>thiothixene oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | |
| <i>trifluoperazine oral tablet 1 mg, 10 mg, 2 mg, 5 mg</i> | 2 | |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 100 MG/0.28 ML | 5 | NM; NDS; QL (0.28 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 125 MG/0.35 ML | 5 | NM; NDS; QL (0.35 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 150 MG/0.42 ML | 5 | NM; NDS; QL (0.42 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 200 MG/0.56 ML | 5 | NM; NDS; QL (0.56 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 250 MG/0.7 ML | 5 | NM; NDS; QL (0.7 per 56 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 50 MG/0.14 ML | 5 | NM; NDS; QL (0.14 per 28 days) |
| UZEDY SUBCUTANEOUS SUSPENSION,EXTENDED REL SYRING 75 MG/0.21 ML | 5 | NM; NDS; QL (0.21 per 28 days) |
| VERSACLOZ ORAL SUSPENSION 50 MG/ML | 5 | ST; NM; NDS; QL (540 per 30 days) |
| VRAYLAR ORAL CAPSULE 0.5 MG, 0.75 MG, 1.5 MG, 3 MG, 4.5 MG, 6 MG | 5 | ST; NM; NDS; QL (30 per 30 days) |
| VRAYLAR ORAL CAPSULE,DOSE PACK 1.5 MG (1)- 3 MG (6) | 4 | ST |
| <i>ziprasidone hcl oral capsule 20 mg, 40 mg, 60 mg, 80 mg</i> (Geodon) | 2 | |
| <i>ziprasidone mesylate intramuscular recon soln 20 mg/ml (final conc.)</i> (Geodon) | 2 | QL (6 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|-----------------------------|
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 210 MG | 4 | QL (2 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 300 MG | 5 | NM; NDS; QL (2 per 28 days) |
| ZYPREXA RELPREVV INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 405 MG | 5 | NM; NDS; QL (1 per 28 days) |
| Agentes Calóricos | | |
| Agentes Calóricos | | |
| CLINIMIX 6%-D5W (SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 6-5 % | 4 | PA BvD |
| CLINIMIX 8%-D10W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 8-10 % | 4 | PA BvD |
| CLINIMIX 8%-D14W(SULFITE-FREE) INTRAVENOUS PARENTERAL SOLUTION 8-14 % | 4 | PA BvD |
| CLINIMIX E 8%-D10W SULFITEFREE INTRAVENOUS PARENTERAL SOLUTION 8-10 % | 4 | PA BvD |
| CLINIMIX E 8%-D14W SULFITEFREE INTRAVENOUS PARENTERAL SOLUTION 8-14 % | 4 | PA BvD |
| <i>dextrose 5 % in water (d5w) intravenous parenteral solution</i> | 2 | |
| Agentes Cardiovasculares | | |
| Agentes Alfa-Adrenérgicos | | |
| <i>clonidine hcl oral tablet 0.1 mg, 0.2 mg, 0.3 mg</i> | 1 | |
| <i>clonidine transdermal patch weekly 0.1 mg/24 hr</i> (Catapres-TTS-1) | 2 | |
| <i>clonidine transdermal patch weekly 0.2 mg/24 hr</i> (Catapres-TTS-2) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>clonidine transdermal patch weekly 0.3 mg/24 hr</i> (Catapres-TTS-3) | 2 | |
| <i>doxazosin oral tablet 1 mg, 2 mg, 4 mg, 8 mg</i> (Cardura) | 1 | |
| <i>droxidopa oral capsule 100 mg</i> (Northera) | 2 | PA; QL (180 per 30 days) |
| <i>droxidopa oral capsule 200 mg, 300 mg</i> (Northera) | 5 | PA; NM; NDS; QL (180 per 30 days) |
| <i>guanfacine oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>midodrine oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>prazosin oral capsule 1 mg, 2 mg, 5 mg</i> | 2 | |
| Agentes Antiarrítmicos | | |
| <i>amiodarone oral tablet 100 mg, 200 mg</i> (Pacerone) | 2 | |
| <i>amiodarone oral tablet 400 mg</i> | 2 | |
| <i>dofetilide oral capsule 125 mcg, 250 mcg, 500 mcg</i> (Tikosyn) | 2 | |
| <i>flecainide oral tablet 100 mg, 150 mg, 50 mg</i> | 2 | |
| MULTAQ ORAL TABLET 400 MG | 3 | |
| <i>pacerone oral tablet 100 mg, 200 mg, 400 mg</i> (amiodarone) | 2 | |
| <i>propafenone oral capsule, extended release 12 hr 225 mg, 325 mg, 425 mg</i> | 2 | |
| <i>propafenone oral tablet 150 mg, 225 mg, 300 mg</i> | 2 | |
| <i>quinidine sulfate oral tablet 200 mg, 300 mg</i> | 2 | |
| Agentes Bloqueadores Beta-Adrenérgicos | | |
| <i>acebutolol oral capsule 200 mg, 400 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>atenolol oral tablet 100 mg, 25 mg, 50 mg</i> (Tenormin) | 1 | |
| <i>atenolol-chlorthalidone oral tablet 100-25 mg</i> (Tenoretic 100) | 2 | |
| <i>atenolol-chlorthalidone oral tablet 50-25 mg</i> (Tenoretic 50) | 2 | |
| <i>bisoprolol fumarate oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>bisoprolol-hydrochlorothiazide oral tablet 10-6.25 mg, 2.5-6.25 mg, 5-6.25 mg</i> | 2 | |
| <i>carvedilol oral tablet 12.5 mg, 25 mg, 3.125 mg, 6.25 mg</i> (Coreg) | 1 | |
| <i>labetalol oral tablet 100 mg, 200 mg, 300 mg</i> | 2 | |
| <i>metoprolol succinate oral tablet extended release 24 hr 100 mg, 200 mg, 25 mg, 50 mg</i> (Toprol XL) | 1 | |
| <i>metoprolol ta-hydrochlorothiaz oral tablet 50-25 mg</i> | 2 | |
| <i>metoprolol tartrate oral tablet 100 mg, 50 mg</i> (Lopressor) | 1 | |
| <i>metoprolol tartrate oral tablet 25 mg, 37.5 mg, 75 mg</i> | 1 | |
| <i>nebivolol oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> (Bystolic) | 2 | |
| <i>propranolol oral capsule, extended release 24 hr 120 mg, 160 mg, 60 mg, 80 mg</i> (Inderal LA) | 2 | |
| <i>propranolol oral tablet 10 mg, 20 mg, 40 mg, 60 mg, 80 mg</i> | 2 | |
| <i>sorine oral tablet 120 mg, 160 mg, 240 mg, 80 mg</i> (sotalol) | 2 | |
| <i>sotalol af oral tablet 120 mg, 160 mg, 80 mg</i> (sotalol) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| <i>sotalol oral tablet 120 mg, 160 mg, 80 mg</i> (Sotalol AF) | 2 | |
| <i>sotalol oral tablet 240 mg</i> (Betapace) | 2 | |
| <i>timolol maleate oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | |
| Agentes Bloqueadores Da Canal De Calcio | | |
| <i>cartia xt oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> (diltiazem hcl) | 2 | |
| <i>diltiazem 24hr er 360 mg cap once-a-day dosage</i> (Tiadylt ER) | 2 | |
| <i>diltiazem 24hr er 420 mg cap</i> (Tiadylt ER) | 2 | |
| <i>diltiazem hcl oral capsule,extended release 12 hr 120 mg, 60 mg, 90 mg</i> | 2 | |
| <i>diltiazem hcl oral capsule,extended release 24 hr 180 mg, 360 mg, 420 mg</i> (Tiadylt ER) | 2 | |
| <i>diltiazem hcl oral capsule,extended release 24hr 120 mg, 180 mg, 240 mg, 300 mg</i> (Cartia XT) | 2 | |
| <i>diltiazem hcl oral tablet 120 mg, 30 mg, 60 mg</i> (Cardizem) | 2 | |
| <i>diltiazem hcl oral tablet 90 mg</i> | 2 | |
| <i>dilt-xr oral capsule,ext.rel 24h degradable 120 mg, 180 mg, 240 mg</i> (diltiazem hcl) | 2 | |
| <i>taztia xt oral capsule,extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg</i> (diltiazem hcl) | 2 | |
| <i>tiadylt er oral capsule,extended release 24 hr 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg</i> (diltiazem hcl) | 2 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 120 mg, 180 mg, 240 mg</i> | 2 | |
| <i>verapamil oral capsule,ext rel. pellets 24 hr 360 mg</i> | 4 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>verapamil oral tablet 120 mg, 40 mg, 80 mg</i> | 1 | |
| <i>verapamil oral tablet extended release 120 mg, 180 mg, 240 mg</i> | 2 | |
| Agentes Cardiovasculares, Varios | | |
| ATTRUBY ORAL TABLET 356 MG | 5 | PA; NM; NDS; QL (112 per 28 days) |
| CAMZYOS ORAL CAPSULE 10 MG, 15 MG, 2.5 MG, 5 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| CORLANOR ORAL SOLUTION 5 MG/5 ML | 4 | QL (600 per 30 days) |
| <i>digoxin injection syringe 250 mcg/ml (0.25 mg/ml)</i> | 2 | |
| <i>digoxin oral tablet 125 mcg (0.125 mg), 250 mcg (0.25 mg)</i> (Digitek) | 2 | |
| <i>epinephrine injection auto-injector 0.15 mg/0.15 ml</i> (Auvi-Q) | 3 | QL (4 per 30 days) |
| <i>epinephrine injection auto-injector 0.15 mg/0.3 ml</i> (EpiPen Jr) | 2 | QL (4 per 30 days) |
| <i>epinephrine injection auto-injector 0.3 mg/0.3 ml</i> | 3 | QL (4 per 30 days) |
| <i>epinephrine injection auto-injector 0.3 mg/0.3 ml</i> (Auvi-Q) | 2 | QL (4 per 30 days) |
| <i>hydralazine oral tablet 10 mg, 100 mg, 25 mg, 50 mg</i> | 1 | |
| <i>icatibant subcutaneous syringe 30 mg/3 ml</i> (Firazyr) | 5 | PA; NM; NDS; QL (18 per 30 days) |
| <i>ivabradine oral tablet 5 mg, 7.5 mg</i> (Corlanor) | 3 | QL (60 per 30 days) |
| <i>metyrosine oral capsule 250 mg</i> | 5 | PA; NM; NDS |
| <i>ranolazine oral tablet extended release 12 hr 1,000 mg</i> | 2 | QL (60 per 30 days) |
| <i>ranolazine oral tablet extended release 12 hr 500 mg</i> | 2 | QL (120 per 30 days) |
| VERQUVO ORAL TABLET 10 MG, 2.5 MG, 5 MG | 4 | PA; QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------------|
| VYNDAMAX ORAL CAPSULE 61 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| Antagonistas De Receptores De Angiotensina II | | |
| <i>candesartan oral tablet 16 mg, 32 mg, 4 mg, 8 mg</i> (Atacand) | 6 | |
| <i>candesartan-hydrochlorothiazid oral tablet 16-12.5 mg, 32-12.5 mg, 32-25 mg</i> (Atacand HCT) | 6 | |
| ENTRESTO ORAL TABLET 24-26 MG, 49-51 MG, 97-103 MG (sacubitril-valsartan) | 3 | QL (60 per 30 days) |
| ENTRESTO SPRINKLE ORAL PELLETT 15-16 MG, 6-6 MG | 3 | QL (240 per 30 days) |
| <i>irbesartan oral tablet 150 mg, 300 mg</i> (Avapro) | 6 | |
| <i>irbesartan oral tablet 75 mg</i> | 6 | |
| <i>irbesartan-hydrochlorothiazide oral tablet 150-12.5 mg, 300-12.5 mg</i> (Avalide) | 6 | |
| <i>losartan oral tablet 100 mg, 25 mg, 50 mg</i> (Cozaar) | 6 | |
| <i>losartan-hydrochlorothiazide oral tablet 100-12.5 mg, 100-25 mg, 50-12.5 mg</i> (Hyzaar) | 6 | |
| <i>olmesartan oral tablet 20 mg, 40 mg, 5 mg</i> (Benicar) | 6 | |
| <i>olmesartan-amlodipin-hctiazid oral tablet 20-5-12.5 mg, 40-10-12.5 mg, 40-10-25 mg, 40-5-12.5 mg, 40-5-25 mg</i> (Tribenzor) | 6 | |
| <i>olmesartan-hydrochlorothiazide oral tablet 20-12.5 mg, 40-12.5 mg, 40-25 mg</i> (Benicar HCT) | 6 | |
| <i>sacubitril-valsartan oral tablet 24-26 mg, 49-51 mg, 97-103 mg</i> (Entresto) | 2 | QL (60 per 30 days) |
| <i>telmisartan oral tablet 20 mg</i> | 6 | |
| <i>telmisartan oral tablet 40 mg, 80 mg</i> (Micardis) | 6 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>telmisartan-hydrochlorothiazid oral tablet 40-12.5 mg, 80-12.5 mg, 80-25 mg</i> (Micardis HCT) | 6 | |
| <i>valsartan oral tablet 160 mg, 320 mg, 40 mg, 80 mg</i> (Diovan) | 6 | |
| <i>valsartan-hydrochlorothiazide oral tablet 160-12.5 mg, 160-25 mg, 320-12.5 mg, 320-25 mg, 80-12.5 mg</i> (Diovan HCT) | 6 | |
| Dihidropiridinas | | |
| <i>amlodipine oral tablet 10 mg, 2.5 mg, 5 mg</i> (Norvasc) | 1 | |
| <i>amlodipine-benazepril oral capsule 10-20 mg, 10-40 mg, 5-10 mg, 5-20 mg</i> (Lotrel) | 6 | |
| <i>amlodipine-benazepril oral capsule 2.5-10 mg, 5-40 mg</i> | 6 | |
| <i>amlodipine-olmesartan oral tablet 10-20 mg, 10-40 mg, 5-20 mg, 5-40 mg</i> (Azor) | 6 | |
| <i>amlodipine-valsartan oral tablet 10-160 mg, 10-320 mg, 5-160 mg, 5-320 mg</i> (Exforge) | 6 | |
| <i>amlodipine-valsartan-hcthiazyd oral tablet 10-160-12.5 mg, 10-160-25 mg, 10-320-25 mg, 5-160-12.5 mg, 5-160-25 mg</i> (Exforge HCT) | 2 | |
| <i>felodipine oral tablet extended release 24 hr 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>nifedipine oral tablet extended release 24hr 30 mg, 60 mg</i> (Procardia XL) | 2 | |
| <i>nifedipine oral tablet extended release 24hr 90 mg</i> | 2 | |
| <i>nifedipine oral tablet extended release 30 mg, 60 mg, 90 mg</i> | 2 | |
| Dislipidémicos | | |
| <i>amlodipine-atorvastatin oral tablet 10-10 mg, 5-10 mg</i> (Caduet) | 6 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>amlodipine-atorvastatin oral tablet</i> (Caduet) 10-20 mg, 10-40 mg, 10-80 mg, 5-20 mg, 5-40 mg, 5-80 mg | 6 | QL (30 per 30 days) |
| <i>amlodipine-atorvastatin oral tablet</i> 2.5-10 mg, 2.5-20 mg, 2.5-40 mg | 6 | |
| <i>atorvastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> (Lipitor) | 6 | |
| <i>cholestyramine light oral powder in packet 4 gram</i> (cholestyramine) | 2 | |
| <i>cholestyramine oral powder in packet 4 gram</i> (Cholestyramine Light) | 2 | |
| <i>colesevelam oral powder in packet 3.75 gram</i> (WelChol) | 2 | |
| <i>colesevelam oral tablet 625 mg</i> (WelChol) | 2 | |
| <i>colestipol oral packet 5 gram</i> | 2 | |
| <i>colestipol oral tablet 1 gram</i> (Colestid) | 2 | |
| <i>ezetimibe oral tablet 10 mg</i> (Zetia) | 2 | QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-10 mg</i> (Vytorin 10-10) | 6 | QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-20 mg</i> (Vytorin 10-20) | 6 | QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-40 mg</i> (Vytorin 10-40) | 6 | QL (30 per 30 days) |
| <i>ezetimibe-simvastatin oral tablet 10-80 mg</i> (Vytorin 10-80) | 6 | QL (30 per 30 days) |
| <i>fenofibrate micronized oral capsule 134 mg, 200 mg, 67 mg</i> | 2 | |
| <i>fenofibrate nanocrystallized oral tablet 145 mg</i> (Tricor) | 2 | |
| <i>fenofibrate nanocrystallized oral tablet 48 mg</i> | 2 | |
| <i>fenofibrate oral tablet 160 mg, 54 mg</i> | 2 | |
| <i>fluvastatin oral capsule 20 mg, 40 mg</i> | 6 | QL (60 per 30 days) |
| <i>fluvastatin oral tablet extended release 24 hr 80 mg</i> (Lescol XL) | 6 | |
| <i>gemfibrozil oral tablet 600 mg</i> (Lopid) | 1 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>icosapent ethyl oral capsule 0.5 gram</i> (Vascepa) | 2 | QL (240 per 30 days) |
| <i>icosapent ethyl oral capsule 1 gram</i> (Vascepa) | 2 | QL (120 per 30 days) |
| <i>lovastatin oral tablet 10 mg, 20 mg, 40 mg</i> | 6 | |
| NEXLETOL ORAL TABLET 180 MG | 3 | ST; QL (30 per 30 days) |
| NEXLIZET ORAL TABLET 180-10 MG | 3 | ST; QL (30 per 30 days) |
| <i>niacin oral tablet extended release 24 hr 1,000 mg, 500 mg, 750 mg</i> | 2 | |
| <i>omega-3 acid ethyl esters oral capsule 1 gram</i> (Lovaza) | 2 | ST; QL (120 per 30 days) |
| <i>pitavastatin calcium oral tablet 1 mg, 2 mg, 4 mg</i> (Livalo) | 2 | QL (30 per 30 days) |
| <i>pravastatin oral tablet 10 mg, 20 mg, 40 mg, 80 mg</i> | 6 | |
| <i>prevalite oral powder in packet 4 gram</i> (cholestyramine) | 2 | |
| REPATHA PUSHTRONEX SUBCUTANEOUS WEARABLE INJECTOR 420 MG/3.5 ML | 3 | ST; QL (7 per 28 days) |
| REPATHA SURECLICK SUBCUTANEOUS PEN INJECTOR 140 MG/ML | 3 | ST; QL (6 per 28 days) |
| REPATHA SYRINGE SUBCUTANEOUS SYRINGE 140 MG/ML | 3 | ST; QL (6 per 28 days) |
| <i>rosuvastatin oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> (Crestor) | 6 | |
| <i>simvastatin oral tablet 10 mg, 20 mg, 40 mg</i> (Zocor) | 6 | |
| <i>simvastatin oral tablet 5 mg, 80 mg</i> | 6 | |
| Diuréticos | | |
| <i>amiloride oral tablet 5 mg</i> | 1 | |
| <i>amiloride-hydrochlorothiazide oral tablet 5-50 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|-----------------------------------|
| <i>bumetanide oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | |
| <i>chlorthalidone oral tablet 25 mg, 50 mg</i> | 2 | |
| <i>furosemide injection solution 10 mg/ml</i> | 1 | |
| <i>furosemide injection syringe 10 mg/ml</i> | 1 | |
| <i>furosemide oral solution 10 mg/ml, 40 mg/5 ml (8 mg/ml)</i> | 2 | |
| <i>furosemide oral tablet 20 mg, 40 mg, 80 mg</i> (Lasix) | 1 | |
| <i>hydrochlorothiazide oral capsule 12.5 mg</i> | 1 | |
| <i>hydrochlorothiazide oral tablet 12.5 mg, 25 mg, 50 mg</i> | 1 | |
| <i>indapamide oral tablet 1.25 mg, 2.5 mg</i> | 1 | |
| JYNARQUE ORAL TABLET 15 MG, 30 MG (tolvaptan (polycystic kidney dis)) | 5 | PA; NM; NDS; QL (120 per 30 days) |
| <i>metolazone oral tablet 10 mg, 2.5 mg, 5 mg</i> | 2 | |
| <i>spironolactone oral tablet 100 mg, 25 mg, 50 mg</i> (Aldactone) | 1 | |
| <i>spironolacton-hydrochlorothiazid oral tablet 25-25 mg</i> | 2 | |
| <i>tolvaptan (polycystic kidney dis) oral tablets, sequential 15 mg (am)/ 15 mg (pm), 30 mg (am)/ 15 mg (pm), 45 mg (am)/ 15 mg (pm), 60 mg (am)/ 30 mg (pm), 90 mg (am)/ 30 mg (pm)</i> (Jynarque) | 5 | PA; NM; NDS; QL (56 per 28 days) |
| <i>torseamide oral tablet 10 mg, 100 mg, 20 mg, 5 mg</i> | 1 | |
| <i>triamterene-hydrochlorothiazid oral capsule 37.5-25 mg</i> | 1 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>triamterene-hydrochlorothiazid oral tablet 37.5-25 mg, 75-50 mg</i> | 1 | |
| Inhibidores De Enzima Convertidoras De Angiotensina | | |
| <i>benazepril oral tablet 10 mg, 20 mg, 40 mg</i> (Lotensin) | 6 | |
| <i>benazepril oral tablet 5 mg</i> | 6 | |
| <i>benazepril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> (Lotensin HCT) | 6 | |
| <i>benazepril-hydrochlorothiazide oral tablet 5-6.25 mg</i> | 6 | |
| <i>captopril oral tablet 100 mg, 12.5 mg, 25 mg, 50 mg</i> | 6 | |
| <i>enalapril maleate oral tablet 10 mg, 2.5 mg, 20 mg, 5 mg</i> (Vasotec) | 6 | |
| <i>enalapril-hydrochlorothiazide oral tablet 10-25 mg</i> (Vaseretic) | 6 | |
| <i>enalapril-hydrochlorothiazide oral tablet 5-12.5 mg</i> | 6 | |
| <i>fosinopril oral tablet 10 mg, 20 mg, 40 mg</i> | 6 | |
| <i>fosinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg</i> | 6 | |
| <i>lisinopril oral tablet 10 mg, 2.5 mg, 20 mg, 30 mg, 40 mg, 5 mg</i> (Zestril) | 6 | |
| <i>lisinopril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> (Zestoretic) | 6 | |
| <i>moexipril oral tablet 15 mg, 7.5 mg</i> | 6 | |
| <i>perindopril erbumine oral tablet 2 mg, 4 mg, 8 mg</i> | 6 | |
| <i>quinapril oral tablet 10 mg, 20 mg, 40 mg, 5 mg</i> | 6 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>quinapril-hydrochlorothiazide oral tablet 10-12.5 mg, 20-12.5 mg, 20-25 mg</i> | 6 | |
| <i>ramipril oral capsule 1.25 mg, 2.5 mg, 5 mg</i> (Altace) | 6 | |
| <i>ramipril oral capsule 10 mg</i> | 6 | |
| <i>trandolapril oral tablet 1 mg, 2 mg, 4 mg</i> | 6 | |
| Inhibidores Del Sistema De Renina-Angiotensina-Aldosterona | | |
| <i>aliskiren oral tablet 150 mg, 300 mg</i> (Tekturna) | 2 | |
| <i>eplerenone oral tablet 25 mg</i> (Inspra) | 2 | |
| <i>eplerenone oral tablet 50 mg</i> | 2 | |
| KERENDIA ORAL TABLET 10 MG, 20 MG, 40 MG | 3 | PA; QL (30 per 30 days) |
| Vasodilatadores | | |
| <i>isosorbide dinitrate oral tablet 10 mg, 20 mg, 30 mg</i> | 2 | |
| <i>isosorbide dinitrate oral tablet 5 mg</i> (Isordil Titradoso) | 2 | |
| <i>isosorbide mononitrate oral tablet 10 mg, 20 mg</i> | 2 | |
| <i>isosorbide mononitrate oral tablet extended release 24 hr 120 mg, 30 mg, 60 mg</i> | 1 | |
| <i>minoxidil oral tablet 10 mg, 2.5 mg</i> | 2 | |
| <i>nitroglycerin sublingual tablet 0.3 mg, 0.4 mg, 0.6 mg</i> (Nitrostat) | 2 | |
| <i>nitroglycerin transdermal patch 24 hour 0.1 mg/hr, 0.2 mg/hr, 0.4 mg/hr, 0.6 mg/hr</i> (Nitro-Dur) | 2 | |
| Agentes De Enfermedad Intestinal Inflamatoria | | |
| Agentes De Enfermedad Intestinal Inflamatoria | | |
| <i>alosetron oral tablet 0.5 mg</i> (Lotronex) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>alose tron oral tablet 1 mg</i> (Lotronex) | 5 | NM; NDS |
| <i>balsalazide oral capsule 750 mg</i> (Colazal) | 2 | |
| <i>budesonide oral capsule, delayed, extend. release 3 mg</i> | 2 | |
| <i>budesonide rectal foam 2 mg/actuation</i> (Uceris) | 2 | |
| <i>hydrocortisone rectal enema 100 mg/60 ml</i> (Cortenema) | 2 | |
| <i>mesalamine oral capsule, extended release 500 mg</i> (Pentasa) | 2 | |
| <i>mesalamine oral capsule, extended release 24hr 0.375 gram</i> (Apriso) | 2 | |
| <i>mesalamine oral tablet, delayed release (dr/ec) 1.2 gram</i> (Lialda) | 2 | QL (120 per 30 days) |
| <i>sulfasalazine oral tablet 500 mg</i> (Azulfidine) | 2 | |
| <i>sulfasalazine oral tablet, delayed release (dr/ec) 500 mg</i> (Azulfidine EN-tabs) | 4 | |
| Agentes De Enfermedad Ósea Metabólica | | |
| Agentes De Enfermedad Ósea Metabólica | | |
| <i>alendronate oral solution 70 mg/75 ml</i> | 2 | QL (300 per 28 days) |
| <i>alendronate oral tablet 10 mg</i> | 1 | QL (30 per 30 days) |
| <i>alendronate oral tablet 35 mg</i> | 1 | QL (4 per 28 days) |
| <i>alendronate oral tablet 70 mg</i> (Fosamax) | 1 | QL (4 per 28 days) |
| <i>calcitonin (salmon) nasal spray, non-aerosol 200 unit/actuation</i> | 2 | |
| <i>calcitriol oral capsule 0.25 mcg, 0.5 mcg</i> | 2 | |
| <i>cinacalcet oral tablet 30 mg, 60 mg</i> (Sensipar) | 2 | QL (60 per 30 days) |
| <i>cinacalcet oral tablet 90 mg</i> (Sensipar) | 2 | QL (120 per 30 days) |
| <i>ibandronate oral tablet 150 mg</i> | 2 | QL (1 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|--|
| NATPARA SUBCUTANEOUS CARTRIDGE 100 MCG/DOSE, 25 MCG/DOSE, 50 MCG/DOSE, 75 MCG/DOSE | 5 | PA; NM; NDS; QL (2 per 28 days) |
| OSENVELT SUBCUTANEOUS SOLUTION 120 MG/1.7 ML (70 MG/ML) | 5 | PA; NM; NDS |
| <i>paricalcitol oral capsule 1 mcg, 2 mcg</i> (Zemplar) | 2 | |
| <i>paricalcitol oral capsule 4 mcg</i> | 2 | |
| RAYALDEE ORAL CAPSULE,EXTENDED RELEASE 24 HR 30 MCG | 5 | NM; NDS; QL (60 per 30 days) |
| STOBOCLO SUBCUTANEOUS SYRINGE 60 MG/ML | 3 | QL (1 per 180 days) |
| <i>teriparatide subcutaneous pen injector 20 mcg/dose (560mcg/2.24ml)</i> (Bonsity) | 5 | PA; NM; NDS; QL (2.24 per 28 days) |
| TYMLOS SUBCUTANEOUS PEN INJECTOR 80 MCG (3,120 MCG/1.56 ML) | 5 | PA; NM; NDS; QL (1.56 per 30 days) |
| Agentes De Trastorno De Sueño | | |
| Agentes De Trastorno De Sueño | | |
| <i>armodafinil oral tablet 150 mg, 200 mg, 250 mg, 50 mg</i> (Nuvigil) | 2 | PA; QL (30 per 30 days) |
| BELSOMRA ORAL TABLET 10 MG, 15 MG, 20 MG, 5 MG | 3 | QL (30 per 30 days) |
| <i>doxepin oral tablet 3 mg, 6 mg</i> (Silenor) | 2 | QL (30 per 30 days) |
| <i>eszopiclone oral tablet 1 mg, 2 mg, 3 mg</i> (Lunesta) | 2 | QL (30 per 30 days) |
| <i>modafinil oral tablet 100 mg</i> (Provigil) | 2 | PA; QL (30 per 30 days) |
| <i>modafinil oral tablet 200 mg</i> (Provigil) | 2 | PA; QL (60 per 30 days) |
| <i>sodium oxybate oral solution 500 mg/ml</i> (Xyrem) | 5 | PA; NM; LA; NDS; QL (540 per 30 days) |
| <i>zaleplon oral capsule 10 mg, 5 mg</i> | 2 | QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|-----------------------------------|
| <i>zolpidem oral tablet 10 mg, 5 mg</i> (Ambien) | 1 | QL (30 per 30 days) |
| Agentes Del Sistema Nervioso Central | | |
| Agentes Del Sistema Nervioso Central | | |
| <i>atomoxetine oral capsule 10 mg, 18 mg, 25 mg, 40 mg</i> | 2 | QL (60 per 30 days) |
| <i>atomoxetine oral capsule 100 mg, 60 mg, 80 mg</i> | 2 | QL (30 per 30 days) |
| AUSTEDO ORAL TABLET 12 MG, 9 MG | 5 | PA; NM; NDS; QL (120 per 30 days) |
| AUSTEDO ORAL TABLET 6 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 12 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 18 MG, 24 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 30 MG, 36 MG, 42 MG, 48 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HR 6 MG | 5 | PA; NM; NDS; QL (210 per 30 days) |
| AUSTEDO XR TITRATION KT(WK1-4) ORAL TABLET, EXT REL 24HR DOSE PACK 12-18-24-30 MG, 6 MG (14)-12 MG (14)-24 MG (14) | 5 | PA; NM; NDS |
| AVONEX INTRAMUSCULAR PEN INJECTOR KIT 30 MCG/0.5 ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| AVONEX INTRAMUSCULAR SYRINGE KIT 30 MCG/0.5 ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| BETASERON SUBCUTANEOUS KIT 0.3 MG | 5 | PA; NM; NDS; QL (15 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>dalfampridine oral tablet extended release 12 hr 10 mg</i> (Ampyra) | 2 | PA; QL (60 per 30 days) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr 10 mg, 15 mg, 5 mg</i> (Adderall XR) | 2 | QL (30 per 30 days) |
| <i>dextroamphetamine-amphetamine oral capsule, extended release 24hr 20 mg, 25 mg, 30 mg</i> (Adderall XR) | 2 | QL (60 per 30 days) |
| <i>dextroamphetamine-amphetamine oral tablet 10 mg, 12.5 mg, 15 mg, 20 mg, 30 mg, 5 mg, 7.5 mg</i> (Adderall) | 2 | QL (60 per 30 days) |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg</i> (Tecfidera) | 2 | PA; QL (14 per 7 days) |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 120 mg (14)- 240 mg (46)</i> (Tecfidera) | 2 | PA |
| <i>dimethyl fumarate oral capsule, delayed release(dr/ec) 240 mg</i> (Tecfidera) | 5 | PA; NM; NDS; QL (60 per 30 days) |
| <i>fingolimod oral capsule 0.5 mg</i> (Gilenya) | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>glatiramer subcutaneous syringe 20 mg/ml</i> (Glatopa) | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>glatiramer subcutaneous syringe 40 mg/ml</i> (Glatopa) | 5 | PA; NM; NDS; QL (12 per 28 days) |
| <i>glatopa subcutaneous syringe 20 mg/ml</i> (glatiramer) | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>glatopa subcutaneous syringe 40 mg/ml</i> (glatiramer) | 5 | PA; NM; NDS; QL (12 per 28 days) |
| <i>guanfacine oral tablet extended release 24 hr 1 mg, 2 mg, 3 mg, 4 mg</i> (Intuniv ER) | 2 | |
| INGREZZA INITIATION PK(TARDIV) ORAL CAPSULE,DOSE PACK 40 MG (7)- 80 MG (21) | 5 | PA; NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| INGREZZA ORAL CAPSULE 40 MG, 60 MG, 80 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| INGREZZA SPRINKLE ORAL CAPSULE, SPRINKLE 40 MG, 60 MG, 80 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| KESIMPTA PEN SUBCUTANEOUS PEN INJECTOR 20 MG/0.4 ML | 5 | PA; NM; NDS; QL (1.2 per 28 days) |
| <i>lithium carbonate oral capsule 150 mg, 300 mg, 600 mg</i> | 1 | |
| <i>lithium carbonate oral tablet 300 mg</i> | 1 | |
| <i>lithium carbonate oral tablet extended release 300 mg</i> (Lithobid) | 2 | |
| <i>lithium carbonate oral tablet extended release 450 mg</i> | 2 | |
| <i>lithium citrate oral solution 8 meq/5 ml</i> | 2 | |
| MAVENCLAD (10 TABLET PACK) ORAL TABLET 10 MG (cladribine(multiple sclerosis)) | 5 | PA; NM; NDS |
| MAVENCLAD (4 TABLET PACK) ORAL TABLET 10 MG (cladribine(multiple sclerosis)) | 5 | PA; NM; NDS |
| MAVENCLAD (5 TABLET PACK) ORAL TABLET 10 MG (cladribine(multiple sclerosis)) | 5 | PA; NM; NDS |
| MAVENCLAD (6 TABLET PACK) ORAL TABLET 10 MG (cladribine(multiple sclerosis)) | 5 | PA; NM; NDS |
| MAVENCLAD (7 TABLET PACK) ORAL TABLET 10 MG (cladribine(multiple sclerosis)) | 5 | PA; NM; NDS |
| MAVENCLAD (8 TABLET PACK) ORAL TABLET 10 MG (cladribine(multiple sclerosis)) | 5 | PA; NM; NDS |
| MAVENCLAD (9 TABLET PACK) ORAL TABLET 10 MG (cladribine(multiple sclerosis)) | 5 | PA; NM; NDS |
| MAYZENT ORAL TABLET 0.25 MG | 5 | PA; NM; NDS; QL (112 per 28 days) |
| MAYZENT ORAL TABLET 1 MG, 2 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| MAYZENT STARTER(FOR 1MG MAINT) ORAL TABLETS,DOSE PACK 0.25 MG (7 TABS) | 3 | PA |
| MAYZENT STARTER(FOR 2MG MAINT) ORAL TABLETS,DOSE PACK 0.25 MG (12 TABS) | 5 | PA; NM; NDS |
| <i>methylphenidate hcl oral solution 10 mg/5 ml, 5 mg/5 ml</i> (Methylin) | 2 | QL (900 per 30 days) |
| <i>methylphenidate hcl oral tablet 10 mg, 20 mg, 5 mg</i> (Ritalin) | 2 | QL (90 per 30 days) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 125 MCG/0.5 ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| PLEGRIDY SUBCUTANEOUS PEN INJECTOR 63 MCG/0.5 ML- 94 MCG/0.5 ML | 5 | PA; NM; NDS |
| PLEGRIDY SUBCUTANEOUS SYRINGE 125 MCG/0.5 ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| PLEGRIDY SUBCUTANEOUS SYRINGE 63 MCG/0.5 ML- 94 MCG/0.5 ML | 5 | PA; NM; NDS |
| <i>riluzole oral tablet 50 mg</i> | 2 | |
| <i>tetrabenazine oral tablet 12.5 mg</i> (Xenazine) | 2 | PA; QL (112 per 28 days) |
| <i>tetrabenazine oral tablet 25 mg</i> (Xenazine) | 5 | PA; NM; NDS; QL (112 per 28 days) |
| VUMERITY ORAL CAPSULE,DELAYED RELEASE(DR/EC) 231 MG | 5 | PA; NM; NDS; QL (120 per 30 days) |
| Agentes Del Tracto Respiratorio | | |
| Agentes Del Tracto Respiratorio, Otros | | |
| <i>acetylcysteine solution 100 mg/ml (10 %), 200 mg/ml (20 %)</i> | 2 | PA BvD |
| ALYFTREK ORAL TABLET 10-50-125 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|---------------------------------------|
| ALYFTREK ORAL TABLET 4-20-50 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| BRONCHITOL INHALATION CAPSULE, W/INHALATION DEVICE 40 MG | 5 | NM; NDS; QL (560 per 28 days) |
| <i>cromolyn inhalation solution for nebulization 20 mg/2 ml</i> | 2 | PA BvD |
| FASENRA PEN SUBCUTANEOUS AUTO-INJECTOR 30 MG/ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| FASENRA SUBCUTANEOUS SYRINGE 10 MG/0.5 ML, 30 MG/ML | 5 | PA; NM; NDS; QL (1 per 28 days) |
| KALYDECO ORAL GRANULES IN PACKET 13.4 MG, 25 MG, 5.8 MG, 50 MG, 75 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| KALYDECO ORAL TABLET 150 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| NUCALA SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML | 5 | PA; NM; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS RECON SOLN 100 MG | 5 | PA; NM; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 100 MG/ML | 5 | PA; NM; LA; NDS; QL (3 per 28 days) |
| NUCALA SUBCUTANEOUS SYRINGE 40 MG/0.4 ML | 5 | PA; NM; LA; NDS; QL (0.4 per 28 days) |
| OFEV ORAL CAPSULE 100 MG, 150 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| ORKAMBI ORAL TABLET 100-125 MG, 200-125 MG | 5 | PA; NM; NDS; QL (112 per 28 days) |
| <i>pirfenidone oral capsule 267 mg</i> | 5 | PA; NM; NDS; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 267 mg</i> (Esbriet) | 5 | PA; NM; NDS; QL (270 per 30 days) |
| <i>pirfenidone oral tablet 534 mg</i> | 5 | PA; NM; NDS; QL (90 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------------|
| <i>pirfenidone oral tablet 801 mg</i> (Esbriet) | 5 | PA; NM; NDS; QL (90 per 30 days) |
| PROLASTIN-C INTRAVENOUS SOLUTION 1,000 MG (+/-)/20 ML | 5 | PA BvD; NM; NDS |
| <i>roflumilast oral tablet 250 mcg</i> (Daliresp) | 2 | QL (28 per 28 days) |
| <i>roflumilast oral tablet 500 mcg</i> (Daliresp) | 2 | QL (30 per 30 days) |
| TRIKAFTA ORAL GRANULES IN PACKET, SEQUENTIAL 100-50-75MG (D) /75 MG (N), 80-40-60 MG (D) /59.5 MG (N) | 5 | PA; NM; NDS; QL (56 per 28 days) |
| TRIKAFTA ORAL TABLETS, SEQUENTIAL 100-50-75 MG(D) /150 MG (N), 50-25-37.5 MG (D)/75 MG (N) | 5 | PA; NM; NDS; QL (84 per 28 days) |
| WINREVAIR SUBCUTANEOUS KIT 120 MG (60 MG X 2), 45 MG, 60 MG, 90 MG (45 MG X 2) | 5 | PA; NM; NDS; QL (1 per 21 days) |
| XOLAIR SUBCUTANEOUS AUTO-INJECTOR 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML | 5 | PA; NM; NDS |
| XOLAIR SUBCUTANEOUS RECON SOLN 150 MG | 5 | PA; NM; NDS |
| XOLAIR SUBCUTANEOUS SYRINGE 150 MG/ML, 300 MG/2 ML, 75 MG/0.5 ML | 5 | PA; NM; NDS |
| Antiinflamatorios, Corticoesteroides | | |
| Inhalados | | |
| ADVAIR HFA INHALATION HFA AEROSOL INHALER 115-21 MCG/ACTUATION, 230-21 MCG/ACTUATION, 45-21 MCG/ACTUATION (fluticasone propion-salmeterol) | 3 | QL (12 per 30 days) |
| AIRSUPRA 90-80 MCG INHALER 90-80 MCG/ACTUATION | 3 | QL (32.1 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|---------------------------------|
| ARNUITY ELLIPTA (fluticasone furoate) INHALATION BLISTER WITH DEVICE 100 MCG/ACTUATION, 200 MCG/ACTUATION, 50 MCG/ACTUATION | 3 | QL (30 per 30 days) |
| BREO ELLIPTA INHALATION (fluticasone furoate- BLISTER WITH DEVICE 100-25 vilanterol) MCG/DOSE, 200-25 MCG/DOSE | 3 | QL (60 per 30 days) |
| BREO ELLIPTA INHALATION BLISTER WITH DEVICE 50-25 MCG/DOSE | 3 | QL (60 per 30 days) |
| <i>breyina inhalation hfa aerosol inhaler</i> (budesonide-formoterol) <i>160-4.5 mcg/actuation, 80-4.5 mcg/actuation</i> | 2 | QL (30.9 per 30 days) |
| <i>budesonide inhalation suspension for</i> (Pulmicort) <i>nebulization 0.25 mg/2 ml, 0.5 mg/2 ml, 1 mg/2 ml</i> | 2 | PA BvD; QL (120 per 30 days) |
| <i>budesonide-formoterol inhalation hfa</i> (Breyna) <i>aerosol inhaler 160-4.5 mcg/actuation, 80-4.5 mcg/actuation</i> | 2 | QL (30.6 per 30 days) |
| <i>fluticasone propionate inhalation hfa</i> <i>aerosol inhaler 110 mcg/actuation</i> | 2 | QL (12 per 30 days) |
| <i>fluticasone propionate inhalation hfa</i> <i>aerosol inhaler 220 mcg/actuation</i> | 2 | QL (24 per 30 days) |
| <i>fluticasone propionate inhalation hfa</i> <i>aerosol inhaler 44 mcg/actuation</i> | 2 | QL (21.2 per 30 days) |
| <i>fluticasone propion-salmeterol</i> (Wixela Inhub) <i>inhalation blister with device 100-50 mcg/dose, 250-50 mcg/dose, 500-50 mcg/dose</i> | 2 | QL (60 per 30 days) |
| <i>wixela inhub inhalation blister with</i> (fluticasone propion- <i>device 100-50 mcg/dose, 250-50 salmeterol)</i> <i>mcg/dose, 500-50 mcg/dose</i> | 2 | QL (60 per 30 days) |
| Antileucotrinicos | | |
| <i>montelukast oral tablet 10 mg</i> (Singulair) | 1 | |
| <i>montelukast oral tablet, chewable 4</i> (Singulair) <i>mg, 5 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|------------------------------|
| <i>zafirlukast oral tablet 10 mg, 20 mg</i> (Accolate) | 2 | |
| Broncodilatadores | | |
| AIRSUPRA INHALATION HFA AEROSOL INHALER 90-80 MCG/ACTUATION | 3 | QL (32.1 per 30 days) |
| <i>albuterol sulfate inhalation hfa</i> (Ventolin HFA) <i>aerosol inhaler 90 mcg/actuation</i> | 2 | QL (17 per 30 days) |
| <i>albuterol sulfate inhalation hfa</i> <i>aerosol inhaler 90 mcg/actuation</i> (nda020503) | 2 | QL (13.4 per 30 days) |
| <i>albuterol sulfate inhalation hfa</i> <i>aerosol inhaler 90 mcg/actuation</i> (nda020983) | 2 | QL (36 per 30 days) |
| <i>albuterol sulfate inhalation solution</i> <i>for nebulization 0.63 mg/3 ml, 1.25</i> <i>mg/3 ml, 2.5 mg /3 ml (0.083 %), 2.5</i> <i>mg/0.5 ml</i> | 2 | PA BvD |
| ANORO ELLIPTA INHALATION BLISTER WITH DEVICE 62.5-25 MCG/ACTUATION (umeclidinium- vilanterol) | 3 | QL (60 per 30 days) |
| ATROVENT HFA INHALATION HFA AEROSOL INHALER 17 MCG/ACTUATION | 4 | QL (25.8 per 28 days) |
| BREZTRI AEROSPHERE INHALATION HFA AEROSOL INHALER 160-9-4.8 MCG/ACTUATION | 3 | QL (10.7 per 30 days) |
| COMBIVENT RESPIMAT INHALATION MIST 20-100 MCG/ACTUATION | 3 | QL (8 per 30 days) |
| <i>ipratropium bromide inhalation</i> <i>solution 0.02 %</i> | 2 | PA BvD |
| <i>ipratropium-albuterol inhalation</i> <i>solution for nebulization 0.5 mg-3</i> <i>mg(2.5 mg base)/3 ml</i> | 2 | PA BvD; QL (540 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| SEREVENT DISKUS INHALATION BLISTER WITH DEVICE 50 MCG/DOSE | 3 | QL (60 per 30 days) |
| SPIRIVA RESPIMAT INHALATION MIST 1.25 MCG/ACTUATION | 3 | QL (4 per 30 days) |
| SPIRIVA RESPIMAT INHALATION MIST 2.5 MCG/ACTUATION | 3 | QL (4 per 30 days) |
| STIOLTO RESPIMAT INHALATION MIST 2.5-2.5 MCG/ACTUATION | 3 | QL (4 per 30 days) |
| STRIVERDI RESPIMAT INHALATION MIST 2.5 MCG/ACTUATION | 3 | QL (4 per 28 days) |
| <i>theophylline oral solution 80 mg/15 ml</i> | 2 | |
| <i>theophylline oral tablet extended release 12 hr 100 mg, 200 mg, 300 mg, 450 mg</i> | 2 | |
| <i>theophylline oral tablet extended release 24 hr 400 mg, 600 mg</i> | 2 | |
| <i>tiotropium bromide inhalation capsule, w/inhalation device 18 mcg</i> (Spiriva with HandiHaler) | 2 | QL (30 per 30 days) |
| TRELEGY ELLIPTA INHALATION BLISTER WITH DEVICE 100-62.5-25 MCG, 200- 62.5-25 MCG | 3 | QL (60 per 30 days) |
| Agentes Dentales Y Orales | | |
| Agentes Dentales Y Orales | | |
| <i>cevimeline oral capsule 30 mg</i> (Evoxac) | 2 | |
| <i>chlorhexidine gluconate mucous membrane mouthwash 0.12 %</i> | 1 | |
| <i>denta 5000 plus dental cream 1.1 %</i> (fluoride (sodium)) | 1 | |
| <i>dentagel dental gel 1.1 %</i> (fluoride (sodium)) | 1 | |
| <i>fluoride (sodium) dental gel 1.1 %</i> (DentaGel) | 1 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>fluoride (sodium) dental solution 0.2 %</i> (PreviDent) | 1 | |
| <i>periogard mucous membrane mouthwash 0.12 %</i> (chlorhexidine gluconate) | 1 | |
| <i>pilocarpine hcl oral tablet 5 mg, 7.5 mg</i> (Salagen (pilocarpine)) | 2 | |
| <i>sf 5000 plus dental cream 1.1 %</i> (fluoride (sodium)) | 1 | |
| <i>sodium fluoride-pot nitrate dental paste 1.1-5 %</i> (Denta 5000 Plus Sensitive) | 1 | |
| <i>triamcinolone acetonide dental paste 0.1 %</i> (Kourzeq) | 2 | |
| Agentes Dermatológicos | | |
| Agentes Antiinflamatorios Dermatológicos | | |
| <i>ala-cort topical cream 1 %</i> (hydrocortisone) | 2 | |
| <i>betamethasone dipropionate topical cream 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate topical lotion 0.05 %</i> | 2 | |
| <i>betamethasone dipropionate topical ointment 0.05 %</i> | 2 | |
| <i>betamethasone valerate topical cream 0.1 %</i> | 2 | |
| <i>betamethasone valerate topical lotion 0.1 %</i> | 2 | |
| <i>betamethasone valerate topical ointment 0.1 %</i> | 2 | |
| <i>betamethasone, augmented topical cream 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical gel 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical lotion 0.05 %</i> | 2 | |
| <i>betamethasone, augmented topical ointment 0.05 %</i> (Diprolene (augmented)) | 2 | |
| <i>clobetasol scalp solution 0.05 %</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>clobetasol topical cream 0.05 %</i> | 2 | |
| <i>clobetasol topical gel 0.05 %</i> | 2 | |
| <i>clobetasol topical lotion 0.05 %</i> (Clobex) | 2 | |
| <i>clobetasol topical ointment 0.05 %</i> | 2 | |
| <i>clobetasol topical shampoo 0.05 %</i> (Clobex) | 2 | |
| <i>clobetasol-emollient topical cream 0.05 %</i> | 2 | |
| <i>clobetasol-emollient topical foam 0.05 %</i> (Olux-E) | 2 | |
| EUCRISA TOPICAL OINTMENT 2 % | 3 | |
| <i>fluocinolone topical cream 0.01 %</i> | 2 | |
| <i>fluocinolone topical cream 0.025 %</i> (Synalar) | 2 | |
| <i>fluocinolone topical ointment 0.025 %</i> (Synalar) | 2 | |
| <i>fluocinonide topical cream 0.05 %</i> | 2 | |
| <i>fluocinonide topical gel 0.05 %</i> | 2 | |
| <i>fluocinonide topical ointment 0.05 %</i> | 2 | |
| <i>fluocinonide topical solution 0.05 %</i> | 2 | |
| <i>fluticasone propionate topical cream 0.05 %</i> | 2 | |
| <i>halobetasol propionate topical cream 0.05 %</i> | 2 | |
| <i>halobetasol propionate topical ointment 0.05 %</i> | 2 | |
| <i>hydrocortisone 2.5% cream</i> | 2 | |
| <i>hydrocortisone topical cream 1 %</i> (Ala-Cort) | 2 | |
| <i>hydrocortisone topical cream with perineal applicator 2.5 %</i> (Procto-Med HC) | 2 | |
| <i>hydrocortisone topical lotion 2.5 %</i> | 2 | |
| <i>hydrocortisone topical ointment 1 %</i> (Anti-Itch (HC)) | 1 | |
| <i>hydrocortisone topical ointment 2.5 %</i> | 1 | |
| <i>hydrocortisone valerate topical cream 0.2 %</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>mometasone topical cream 0.1 %</i> | 2 | |
| <i>mometasone topical ointment 0.1 %</i> | 2 | |
| <i>mometasone topical solution 0.1 %</i> | 2 | |
| <i>pimecrolimus topical cream 1 %</i> | 2 | QL (100 per 30 days) |
| <i>procto-med hc topical cream with perineal applicator 2.5 %</i> (hydrocortisone) | 2 | |
| <i>proctosol hc topical cream with perineal applicator 2.5 %</i> (hydrocortisone) | 2 | |
| <i>proctozone-hc topical cream with perineal applicator 2.5 %</i> (hydrocortisone) | 2 | |
| <i>tacrolimus topical ointment 0.03 %, 0.1 %</i> | 2 | QL (100 per 30 days) |
| <i>triamcinolone acetonide topical cream 0.025 %, 0.1 %</i> | 1 | |
| <i>triamcinolone acetonide topical cream 0.5 %</i> (Triderm) | 1 | |
| <i>triamcinolone acetonide topical lotion 0.025 %, 0.1 %</i> | 2 | |
| <i>triamcinolone acetonide topical ointment 0.025 %, 0.1 %, 0.5 %</i> | 2 | |
| Agentes Dermatológicos, Otros | | |
| <i>acitretin oral capsule 10 mg, 17.5 mg, 25 mg</i> | 2 | |
| <i>acyclovir topical ointment 5 %</i> (Zovirax) | 2 | QL (30 per 30 days) |
| <i>ammonium lactate topical cream 12 %</i> | 2 | |
| <i>ammonium lactate topical lotion 12 %</i> (AmLactin) | 2 | |
| <i>calcipotriene scalp solution 0.005 %</i> | 2 | QL (120 per 30 days) |
| <i>calcipotriene topical cream 0.005 %</i> | 2 | QL (120 per 30 days) |
| <i>calcipotriene topical ointment 0.005 %</i> | 2 | QL (120 per 30 days) |
| <i>fluorouracil topical cream 5 %</i> (Efudex) | 2 | |
| <i>fluorouracil topical solution 2 %, 5 %</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>imiquimod topical cream in packet 5 %</i> | 2 | QL (24 per 30 days) |
| KLISYRI (250 MG) TOPICAL OINTMENT IN PACKET 1 % | 5 | ST; NM; NDS; QL (5 per 5 days) |
| <i>methoxsalen oral capsule, liqd-filled, rapid rel 10 mg</i> | 5 | NM; NDS |
| PANRETIN TOPICAL GEL 0.1 % | 5 | NM; NDS; QL (60 per 28 days) |
| <i>podofilox topical solution 0.5 %</i> | 2 | |
| SANTYL TOPICAL OINTMENT 250 UNIT/GRAM | 4 | QL (180 per 30 days) |
| VALCHLOR TOPICAL GEL 0.016 % | 5 | PA NSO; NM; NDS |
| <i>zenatane oral capsule 10 mg, 20 mg, 30 mg, 40 mg</i> (isotretinoin) | 2 | |
| Antibacterianos Dermatológicos | | |
| <i>clindamycin phosphate topical solution 1 %</i> | 2 | QL (180 per 30 days) |
| <i>clindamycin phosphate topical swab 1 %</i> (Clindacin ETZ) | 2 | |
| <i>clindamycin-benzoyl peroxide topical gel 1-5 %</i> | 2 | |
| <i>erythromycin with ethanol topical solution 2 %</i> | 2 | |
| <i>gentamicin topical cream 0.1 %</i> | 2 | QL (90 per 30 days) |
| <i>gentamicin topical ointment 0.1 %</i> | 2 | QL (120 per 30 days) |
| <i>metronidazole topical cream 0.75 %</i> (Rosadan) | 2 | |
| <i>metronidazole topical gel 0.75 %</i> (Rosadan) | 2 | |
| <i>metronidazole topical gel 1 %</i> (Metrogel) | 2 | |
| <i>mupirocin topical ointment 2 %</i> (Centany) | 1 | QL (220 per 30 days) |
| <i>rosadan topical cream 0.75 %</i> (metronidazole) | 2 | |
| <i>selenium sulfide topical lotion 2.5 %</i> | 2 | |
| <i>silver sulfadiazine topical cream 1 %</i> (SSD) | 2 | |
| <i>ssd topical cream 1 %</i> (silver sulfadiazine) | 4 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| Escabicidas Y Pediculicidas | | |
| <i>malathion topical lotion 0.5 %</i> (Ovide) | 2 | |
| <i>permethrin topical cream 5 %</i> | 2 | QL (60 per 30 days) |
| Retinoides Dermatológicos | | |
| <i>adapalene topical cream 0.1 %</i> (Differin) | 2 | |
| ALTRENO TOPICAL LOTION 0.05 % | 4 | PA |
| <i>tazarotene topical cream 0.1 %</i> (Tazorac) | 2 | |
| <i>tretinoin topical cream 0.025 %</i> (Avita) | 2 | PA |
| <i>tretinoin topical cream 0.05 %, 0.1 %</i> (Retin-A) | 2 | PA |
| Agentes Gastrointestinales | | |
| Agentes Antiúlceras Y Supresores De Ácidos | | |
| <i>amoxicil-clarithromy-lansopraz oral combo pack 500-500-30 mg</i> | 2 | |
| <i>cimetidine hcl oral solution 300 mg/5 ml</i> | 2 | |
| <i>esomeprazole magnesium oral capsule, delayed release(dr/ec) 20 mg</i> (Acid Reducer (esomeprazole)) | 2 | QL (30 per 30 days) |
| <i>esomeprazole magnesium oral capsule, delayed release(dr/ec) 40 mg</i> (Nexium) | 2 | QL (60 per 30 days) |
| <i>esomeprazole magnesium oral granules dr for susp in packet 10 mg, 20 mg</i> (Nexium Packet) | 2 | ST; QL (30 per 30 days) |
| <i>esomeprazole magnesium oral granules dr for susp in packet 40 mg</i> (Nexium Packet) | 2 | ST; QL (60 per 30 days) |
| <i>famotidine oral tablet 20 mg</i> (Acid Controller) | 1 | |
| <i>famotidine oral tablet 40 mg</i> (Pepcid) | 1 | |
| <i>lansoprazole oral capsule, delayed release(dr/ec) 15 mg</i> (Acid Reducer (lansoprazole)) | 2 | QL (30 per 30 days) |
| <i>lansoprazole oral capsule, delayed release(dr/ec) 30 mg</i> (Prevacid) | 2 | QL (60 per 30 days) |
| <i>misoprostol oral tablet 100 mcg, 200 mcg</i> (Cytotec) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| <i>omeprazole oral capsule, delayed release(dr/ec) 10 mg, 20 mg, 40 mg</i> | 1 | |
| <i>pantoprazole oral tablet, delayed release (dr/ec) 20 mg</i> (Protonix) | 1 | QL (30 per 30 days) |
| <i>pantoprazole oral tablet, delayed release (dr/ec) 40 mg</i> (Protonix) | 1 | QL (60 per 30 days) |
| <i>rabeprazole oral tablet, delayed release (dr/ec) 20 mg</i> (AcipHex) | 2 | QL (30 per 30 days) |
| <i>sucralfate oral tablet 1 gram</i> (Carafate) | 2 | |
| VOQUEZNA ORAL TABLET 10 MG, 20 MG | 4 | PA |
| Agentes Gastrointestinales, Otros | | |
| <i>carglumic acid oral tablet, dispersible 200 mg</i> (Carbaglu) | 5 | PA; NM; NDS |
| <i>constulose oral solution 10 gram/15 ml</i> (lactulose) | 2 | |
| <i>cromolyn oral concentrate 100 mg/5 ml</i> (Gastrocrom) | 2 | |
| <i>dicyclomine oral capsule 10 mg</i> | 2 | |
| <i>dicyclomine oral solution 10 mg/5 ml</i> | 2 | |
| <i>dicyclomine oral tablet 20 mg</i> | 2 | |
| <i>diphenoxylate-atropine oral tablet 2.5-0.025 mg</i> (Lomotil) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>enulose oral solution 10 gram/15 ml</i> (lactulose) | 2 | |
| <i>generlac oral solution 10 gram/15 ml</i> (lactulose) | 2 | |
| <i>glycopyrrolate oral tablet 1 mg</i> (Robinul) | 2 | |
| <i>glycopyrrolate oral tablet 2 mg</i> (Robinul Forte) | 2 | |
| <i>kionex (with sorbitol) oral suspension 15-20 gram/60 ml</i> | 2 | |
| <i>lactulose oral solution 10 gram/15 ml</i> (Constulose) | 2 | |
| LINZESS ORAL CAPSULE 145 MCG, 290 MCG, 72 MCG | 3 | QL (30 per 30 days) |
| LOKELMA ORAL POWDER IN PACKET 10 GRAM, 5 GRAM | 3 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------------|
| <i>loperamide oral capsule 2 mg</i> (Anti-Diarrheal (loperamide)) | 2 | |
| <i>lubiprostone oral capsule 24 mcg</i> (Amitiza) | 2 | QL (60 per 30 days) |
| <i>lubiprostone oral capsule 8 mcg</i> (Amitiza) | 2 | QL (120 per 30 days) |
| <i>metoclopramide hcl oral solution 5 mg/5 ml</i> | 2 | |
| <i>metoclopramide hcl oral tablet 10 mg, 5 mg</i> (Reglan) | 1 | |
| MOVANTIK ORAL TABLET 12.5 MG, 25 MG | 3 | QL (30 per 30 days) |
| <i>sodium polystyrene sulfonate oral powder 15 gram</i> | 2 | |
| <i>sodium polystyrene sulfonate oral suspension 15 gram/60 ml</i> | 2 | |
| <i>sps (with sorbitol) oral suspension 15-20 gram/60 ml</i> | 2 | |
| TRULANCE ORAL TABLET 3 MG | 3 | QL (30 per 30 days) |
| <i>ursodiol oral capsule 200 mg, 400 mg</i> (Reltone) | 5 | NM; NDS |
| <i>ursodiol oral capsule 300 mg</i> | 2 | |
| <i>ursodiol oral tablet 250 mg</i> | 2 | |
| <i>ursodiol oral tablet 500 mg</i> (URSO Forte) | 2 | |
| VELTASSA ORAL POWDER IN PACKET 1 GRAM, 16.8 GRAM, 25.2 GRAM, 8.4 GRAM | 3 | |
| XERMELO ORAL TABLET 250 MG | 5 | PA; NM; NDS; QL (84 per 28 days) |
| Enlaces De Fosfato | | |
| <i>calcium acetate(phosphat bind) oral capsule 667 mg</i> | 2 | |
| <i>calcium acetate(phosphat bind) oral tablet 667 mg</i> | 2 | |
| <i>sevelamer carbonate oral powder in packet 0.8 gram, 2.4 gram</i> (Renvela) | 2 | |
| <i>sevelamer carbonate oral tablet 800 mg</i> (Renvela) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>sevelamer hcl oral tablet 400 mg, 800 mg</i> | 2 | |
| Laxantes | | |
| <i>gavilyte-c oral recon soln 240-22.72-6.72 -5.84 gram</i> (peg 3350-electrolytes) | 2 | |
| <i>gavilyte-g oral recon soln 236-22.74-6.74 -5.86 gram</i> (peg 3350-electrolytes) | 2 | |
| <i>gavilyte-n oral recon soln 420 gram</i> (peg-electrolyte soln) | 2 | |
| <i>peg 3350-electrolytes oral recon soln 236-22.74-6.74 -5.86 gram</i> (GaviLyte-G) | 2 | |
| <i>peg-electrolyte soln oral recon soln 420 gram</i> (GaviLyte-N) | 2 | |
| <i>sodium,potassium,mag sulfates oral recon soln 17.5-3.13-1.6 gram</i> (Suprep Bowel Prep Kit) | 2 | |
| <i>sodium,potassium,mag sulfates oral recon soln 17.5-3.13-1.6 gram 2 pack (480ml)</i> | 2 | |
| Agentes Genitourinarios | | |
| Agentes Genitourinarios, Varios | | |
| <i>alfuzosin oral tablet extended release 24 hr 10 mg</i> (Uroxatral) | 2 | QL (30 per 30 days) |
| <i>dutasteride oral capsule 0.5 mg</i> (Avodart) | 2 | |
| <i>finasteride oral tablet 5 mg</i> (Proscar) | 1 | |
| <i>tamsulosin oral capsule 0.4 mg</i> | 1 | |
| <i>terazosin oral capsule 1 mg, 10 mg, 2 mg, 5 mg</i> | 1 | |
| Antiespasmódicos, Urinario | | |
| <i>bethanechol chloride oral tablet 10 mg, 25 mg, 5 mg, 50 mg</i> | 2 | |
| <i>fesoterodine oral tablet extended release 24 hr 4 mg, 8 mg</i> (Toviaz) | 2 | |
| <i>flavoxate oral tablet 100 mg</i> | 2 | |
| MYRBETRIQ ORAL TABLET EXTENDED RELEASE 24 HR 25 MG, 50 MG (mirabegron) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>oxybutynin chloride oral syrup 5 mg/5 ml</i> | 2 | |
| <i>oxybutynin chloride oral tablet 5 mg</i> | 2 | |
| <i>oxybutynin chloride oral tablet extended release 24hr 10 mg, 15 mg, 5 mg</i> | 2 | |
| <i>solifenacin oral tablet 10 mg, 5 mg</i> (Vesicare) | 2 | |
| <i>tolterodine oral capsule, extended release 24hr 2 mg, 4 mg</i> | 2 | |
| <i>tolterodine oral tablet 1 mg, 2 mg</i> | 2 | |
| <i>trospium oral tablet 20 mg</i> | 2 | |
| Agentes Hormonales, Estimulante/Reemplazo/Modificador | | |
| Agentes Tiroideos Y Antitiroideos | | |
| <i>levothyroxine oral tablet 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg, 200 mcg, 25 mcg, 50 mcg, 75 mcg, 88 mcg</i> (Euthyrox) | 1 | |
| <i>levothyroxine oral tablet 300 mcg</i> (Levo-T) | 1 | |
| <i>liomny oral tablet 25 mcg, 5 mcg, 50 mcg</i> (liothyronine) | 2 | |
| <i>liothyronine oral tablet 25 mcg, 5 mcg, 50 mcg</i> (Liomny) | 2 | |
| <i>methimazole oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>propylthiouracil oral tablet 50 mg</i> | 2 | |
| REZDIFFRA ORAL TABLET 100 MG, 60 MG, 80 MG | 5 | PA; NM; NDS |
| Andrógenos | | |
| <i>danazol oral capsule 100 mg, 200 mg, 50 mg</i> | 2 | |
| <i>oxandrolone oral tablet 10 mg, 2.5 mg</i> | 2 | PA |
| <i>testosterone cypionate intramuscular oil 100 mg/ml, 200 mg/ml</i> (Depo-Testosterone) | 2 | PA |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>testosterone cypionate intramuscular oil 200 mg/ml (1 ml)</i> | 2 | PA |
| <i>testosterone enanthate intramuscular oil 200 mg/ml</i> | 2 | PA; QL (5 per 28 days) |
| <i>testosterone transdermal gel in metered-dose pump 12.5 mg/ 1.25 gram (1 %)</i> (Vogelxo) | 2 | PA; QL (300 per 30 days) |
| <i>testosterone transdermal gel in metered-dose pump 20.25 mg/1.25 gram (1.62 %)</i> (AndroGel) | 2 | PA; QL (150 per 30 days) |
| <i>testosterone transdermal gel in packet 1 % (25 mg/2.5gram)</i> | 2 | PA; QL (300 per 30 days) |
| <i>testosterone transdermal gel in packet 1 % (50 mg/5 gram)</i> (Vogelxo) | 2 | PA; QL (300 per 30 days) |
| Estrógenos Y Antiestrógenos | | |
| <i>abigale lo oral tablet 0.5-0.1 mg</i> (estradiol-norethindrone acet) | 1 | |
| <i>abigale oral tablet 1-0.5 mg</i> (estradiol-norethindrone acet) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>conjugated estrogens oral tablet 0.3 mg, 0.45 mg, 0.625 mg, 0.9 mg, 1.25 mg</i> (Premarin) | 2 | |
| <i>estradiol oral tablet 0.5 mg, 1 mg, 2 mg</i> | 1 | |
| <i>estradiol transdermal patch semiweekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> (Dotti) | 2 | QL (8 per 28 days) |
| <i>estradiol transdermal patch weekly 0.025 mg/24 hr, 0.0375 mg/24 hr, 0.05 mg/24 hr, 0.06 mg/24 hr, 0.075 mg/24 hr, 0.1 mg/24 hr</i> (Climara) | 2 | QL (4 per 28 days) |
| <i>estradiol vaginal cream 0.01 % (0.1 mg/gram)</i> (Estrace) | 2 | |
| <i>estradiol vaginal tablet 10 mcg</i> (Yuvafem) | 2 | QL (18 per 28 days) |
| <i>estradiol-norethindrone acet oral tablet 0.5-0.1 mg</i> (Abigale Lo) | 2 | PA-HRM; AGE (Max 64 Years) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| <i>estradiol-norethindrone acet oral tablet 1-0.5 mg</i> (Abigale) | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>mimvey oral tablet 1-0.5 mg</i> (estradiol-norethindrone acet) | 2 | PA-HRM; AGE (Max 64 Years) |
| PREMARIN VAGINAL CREAM 0.625 MG/GRAM | 3 | |
| PREMPHASE ORAL TABLET 0.625 MG (14)/ 0.625MG-5MG(14) | 3 | PA-HRM; AGE (Max 64 Years) |
| PREMPRO ORAL TABLET 0.3-1.5 MG, 0.45-1.5 MG, 0.625-2.5 MG, 0.625-5 MG | 3 | PA-HRM; AGE (Max 64 Years) |
| <i>raloxifene oral tablet 60 mg</i> (Evista) | 2 | |
| <i>yuvafem vaginal tablet 10 mcg</i> (estradiol) | 2 | QL (18 per 28 days) |
| Glucocorticoides/Mineralocorticoides | | |
| <i>dexamethasone oral solution 0.5 mg/5 ml</i> | 2 | |
| <i>dexamethasone oral tablet 0.5 mg, 0.75 mg, 1 mg, 1.5 mg, 2 mg, 4 mg, 6 mg</i> | 2 | |
| <i>dexamethasone sodium phosphate injection solution 10 mg/ml, 4 mg/ml</i> | 1 | |
| <i>fludrocortisone oral tablet 0.1 mg</i> | 2 | |
| <i>hydrocortisone oral tablet 10 mg, 20 mg, 5 mg</i> (Cortef) | 2 | |
| <i>methylprednisolone acetate injection suspension 40 mg/ml</i> (Depo-Medrol) | 2 | |
| <i>methylprednisolone oral tablet 16 mg, 4 mg, 8 mg</i> (Medrol) | 2 | |
| <i>methylprednisolone oral tablet 32 mg</i> | 2 | |
| <i>methylprednisolone oral tablets, dose pack 4 mg</i> (Medrol (Pak)) | 1 | |
| <i>prednisolone 15 mg/5 ml soln d/f 15 mg/5 ml (3 mg/ml)</i> | 2 | PA BvD |
| <i>prednisolone oral solution 15 mg/5 ml</i> | 2 | PA BvD |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|---------------------------------------|
| <i>prednisolone sodium phosphate oral solution 25 mg/5 ml (5 mg/ml), 5 mg base/5 ml (6.7 mg/5 ml)</i> | 2 | PA BvD |
| <i>prednisone oral solution 5 mg/5 ml</i> | 2 | PA BvD |
| <i>prednisone oral tablet 1 mg, 10 mg, 2.5 mg, 20 mg, 5 mg, 50 mg</i> | 1 | PA BvD |
| <i>prednisone oral tablets, dose pack 10 mg, 10 mg (48 pack), 5 mg, 5 mg (48 pack)</i> | 2 | |
| <i>triamcinolone acetonide injection suspension 40 mg/ml</i> (Kenalog) | 2 | |
| Pituitario | | |
| CORTROPHIN GEL INJECTION GEL 80 UNIT/ML | 5 | PA; NM; NDS; QL (35 per 28 days) |
| <i>desmopressin 10 mcg/0.1 ml spr 10 mcg/spray (0.1 ml)</i> | 2 | |
| <i>desmopressin nasal spray, non-aerosol 10 mcg/spray (0.1 ml)</i> | 2 | |
| <i>desmopressin oral tablet 0.1 mg, 0.2 mg</i> (DDAVP) | 2 | |
| INCRELEX SUBCUTANEOUS SOLUTION 10 MG/ML | 5 | PA; NM; NDS |
| <i>lanreotide subcutaneous syringe 120 mg/0.5 ml</i> (Somatuline Depot) | 5 | PA NSO; NM; NDS; QL (0.5 per 28 days) |
| LUPRON DEPOT (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG | 5 | PA NSO; NM; NDS |
| LUPRON DEPOT INTRAMUSCULAR SYRINGE KIT 3.75 MG | 5 | PA NSO; NM; NDS |
| LUPRON DEPOT-PED (3 MONTH) INTRAMUSCULAR SYRINGE KIT 11.25 MG, 30 MG | 5 | PA; NM; NDS |
| LUPRON DEPOT-PED INTRAMUSCULAR SYRINGE KIT 45 MG | 5 | PA; NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|--|
| NORDITROPIN FLEXPRO SUBCUTANEOUS PEN INJECTOR 10 MG/1.5 ML (6.7 MG/ML), 15 MG/1.5 ML (10 MG/ML), 30 MG/3 ML (10 MG/ML), 5 MG/1.5 ML (3.3 MG/ML) | 5 | PA; NM; NDS |
| <i>octreotide acetate injection solution 1,000 mcg/ml</i> | 5 | NM; NDS |
| <i>octreotide acetate injection solution</i> (Sandostatin) <i>100 mcg/ml, 50 mcg/ml, 500 mcg/ml</i> | 2 | |
| <i>octreotide acetate injection solution 200 mcg/ml</i> | 2 | |
| ORGOVYX ORAL TABLET 120 MG | 5 | PA NSO; NM; NDS |
| ORILISSA ORAL TABLET 150 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| ORILISSA ORAL TABLET 200 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| SEROSTIM SUBCUTANEOUS RECON SOLN 4 MG, 5 MG, 6 MG | 5 | PA; NM; NDS |
| SIGNIFOR SUBCUTANEOUS SOLUTION 0.3 MG/ML (1 ML), 0.6 MG/ML (1 ML), 0.9 MG/ML (1 ML) | 5 | PA; NM; NDS; QL (60 per 30 days) |
| SOMATULINE DEPOT (lanreotide) SUBCUTANEOUS SYRINGE 60 MG/0.2 ML | 5 | PA NSO; NM; NDS; QL (0.2 per 28 days) |
| SOMATULINE DEPOT (lanreotide) SUBCUTANEOUS SYRINGE 90 MG/0.3 ML | 5 | PA NSO; NM; NDS; QL (0.3 per 28 days) |
| SOMAVERT SUBCUTANEOUS RECON SOLN 10 MG, 15 MG, 20 MG, 25 MG, 30 MG | 5 | PA; NM; NDS |
| Progestinas | | |
| DEPO-SUBQ PROVERA 104 SUBCUTANEOUS SYRINGE 104 MG/0.65 ML | 3 | QL (0.65 per 84 days) |
| <i>gallifrey oral tablet 5 mg</i> (norethindrone acetate) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|-------------------------------------|
| <i>medroxyprogesterone intramuscular suspension 150 mg/ml</i> (Depo-Provera) | 2 | |
| <i>medroxyprogesterone intramuscular syringe 150 mg/ml</i> (Depo-Provera) | 2 | |
| <i>medroxyprogesterone oral tablet 10 mg, 2.5 mg, 5 mg</i> (Provera) | 1 | |
| <i>megestrol oral suspension 400 mg/10 ml (40 mg/ml), 625 mg/5 ml (125 mg/ml)</i> | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>norethindrone acetate oral tablet 5 mg</i> (Gallifrey) | 2 | |
| <i>progesterone micronized oral capsule 100 mg, 200 mg</i> (Prometrium) | 2 | |
| Agentes Inmunológicos | | |
| Agentes Inmunológicos | | |
| ARCALYST SUBCUTANEOUS RECON SOLN 220 MG | 5 | PA; NM; NDS |
| ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 0.5 MG, 1 MG (tacrolimus) | 4 | PA BvD |
| ASTAGRAF XL ORAL CAPSULE,EXTENDED RELEASE 24HR 5 MG (tacrolimus) | 5 | PA BvD; NM; NDS |
| <i>azathioprine oral tablet 50 mg</i> (Imuran) | 2 | PA BvD |
| <i>azathioprine sodium injection recon soln 100 mg</i> | 2 | PA BvD |
| BENLYSTA SUBCUTANEOUS AUTO-INJECTOR 200 MG/ML | 5 | PA; NM; NDS; QL (8 per 28 days) |
| BENLYSTA SUBCUTANEOUS SYRINGE 200 MG/ML | 5 | PA; NM; NDS; QL (8 per 28 days) |
| BESREMI SUBCUTANEOUS SYRINGE 500 MCG/ML | 5 | PA NSO; NM; NDS; QL (2 per 28 days) |
| CIMZIA 200 MG/ML SYRINGE KIT | 5 | PA; NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| CIMZIA POWDER FOR RECONST SUBCUTANEOUS KIT 400 MG (200 MG X 2 VIALS) | 5 | PA; NM; NDS |
| CIMZIA STARTER KIT SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) | 5 | PA; NM; NDS |
| CIMZIA SUBCUTANEOUS SYRINGE KIT 400 MG/2 ML (200 MG/ML X 2) | 5 | PA; NM; NDS |
| COSENTYX (2 SYRINGES) SUBCUTANEOUS SYRINGE 150 MG/ML | 5 | PA; NM; NDS |
| COSENTYX PEN (2 PENS) SUBCUTANEOUS PEN INJECTOR 150 MG/ML | 5 | PA; NM; NDS |
| COSENTYX SUBCUTANEOUS SYRINGE 75 MG/0.5 ML | 5 | PA; NM; NDS |
| COSENTYX UNOREADY PEN SUBCUTANEOUS PEN INJECTOR 300 MG/2 ML | 5 | PA; NM; NDS |
| <i>cyclosporine intravenous solution</i> (Sandimmune) <i>250 mg/5 ml</i> | 2 | PA BvD |
| <i>cyclosporine modified oral capsule</i> (Gengraf) <i>100 mg, 25 mg</i> | 2 | PA BvD |
| <i>cyclosporine modified oral capsule</i> <i>50 mg</i> | 2 | PA BvD |
| <i>cyclosporine modified oral solution</i> (Gengraf) <i>100 mg/ml</i> | 2 | PA BvD |
| <i>cyclosporine oral capsule 100 mg, 25</i> (Sandimmune) <i>mg</i> | 2 | PA BvD |
| CYLTEZO(CF) PEN CROHN'S-UC- (adalimumab-adbm) HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML | 5 | PA; NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| CYLTEZO(CF) PEN PSORIASIS-UV SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML (adalimumab-adbm) | 5 | PA; NM; NDS |
| CYLTEZO(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 40 MG/0.8 ML (adalimumab-adbm) | 5 | PA; NM; NDS |
| CYLTEZO(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.2 ML, 20 MG/0.4 ML, 40 MG/0.4 ML, 40 MG/0.8 ML (adalimumab-adbm) | 5 | PA; NM; NDS |
| DUPIXENT PEN SUBCUTANEOUS PEN INJECTOR 200 MG/1.14 ML, 300 MG/2 ML | 5 | PA; NM; NDS |
| DUPIXENT SYRINGE SUBCUTANEOUS SYRINGE 100 MG/0.67 ML, 200 MG/1.14 ML, 300 MG/2 ML | 5 | PA; NM; NDS |
| ENBREL MINI SUBCUTANEOUS CARTRIDGE 50 MG/ML (1 ML) | 5 | PA; NM; NDS |
| ENBREL SUBCUTANEOUS RECON SOLN 25 MG (1 ML) | 5 | PA; NM; NDS |
| ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5 ML | 5 | PA; NM; NDS |
| ENBREL SUBCUTANEOUS SYRINGE 25 MG/0.5 ML (0.5), 50 MG/ML (1 ML) | 5 | PA; NM; NDS |
| ENBREL SURECLICK SUBCUTANEOUS PEN INJECTOR 50 MG/ML (1 ML) | 5 | PA; NM; NDS |
| <i>everolimus (immunosuppressive) oral (Zortress) tablet 0.25 mg</i> | 2 | PA BvD |
| <i>everolimus (immunosuppressive) oral (Zortress) tablet 0.5 mg, 0.75 mg, 1 mg</i> | 5 | PA BvD; NM; NDS |
| GAMUNEX-C INJECTION SOLUTION 1 GRAM/10 ML (10 %) | 5 | PA BvD; NM; NDS |
| <i>gengraf oral capsule 100 mg, 25 mg (cyclosporine modified)</i> | 2 | PA BvD |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|--|
| <i>gengraf oral solution 100 mg/ml</i> (cyclosporine modified) | 2 | PA BvD |
| HUMIRA PEN CROHNS-UC-HS START SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA PEN PSOR-UVEITS- ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.8 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA SUBCUTANEOUS SYRINGE KIT 40 MG/0.8 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEDI CROHNS STARTER SUBCUTANEOUS SYRINGE KIT 80 MG/0.8 ML, 80 MG/0.8 ML-40 MG/0.4 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEN CROHNS-UC- HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEN PEDIATRIC UC SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEN PSOR-UV- ADOL HS SUBCUTANEOUS PEN INJECTOR KIT 80 MG/0.8 ML-40 MG/0.4 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) PEN SUBCUTANEOUS PEN INJECTOR KIT 40 MG/0.4 ML, 80 MG/0.8 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| HUMIRA(CF) SUBCUTANEOUS SYRINGE KIT 10 MG/0.1 ML, 20 MG/0.2 ML, 40 MG/0.4 ML | 5 | PA; NM; NDS; Only NDCs starting with 00074 |
| <i>infliximab intravenous recon soln</i> (Remicade) <i>100 mg</i> | 5 | PA; NM; NDS |
| KINERET SUBCUTANEOUS SYRINGE 100 MG/0.67 ML | 5 | PA; NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>leflunomide oral tablet 10 mg, 20 mg</i> (Arava) | 2 | |
| <i>mycophenolate mofetil (hcl) intravenous recon soln 500 mg</i> (CellCept Intravenous) | 2 | PA BvD |
| <i>mycophenolate mofetil oral capsule 250 mg</i> (CellCept) | 2 | PA BvD |
| <i>mycophenolate mofetil oral suspension for reconstitution 200 mg/ml</i> (CellCept) | 5 | PA BvD; NM; NDS |
| <i>mycophenolate mofetil oral tablet 500 mg</i> (CellCept) | 2 | PA BvD |
| <i>mycophenolate sodium oral tablet, delayed release (dr/ec) 180 mg, 360 mg</i> (Myfortic) | 2 | PA BvD |
| NIKTIMVO INTRAVENOUS SOLUTION 50 MG/ML | 5 | PA NSO; NM; NDS |
| NULOJIX INTRAVENOUS RECON SOLN 250 MG | 5 | PA BvD; NM; NDS |
| ORENCIA (WITH MALTOSE) INTRAVENOUS RECON SOLN 250 MG | 5 | PA; NM; NDS |
| ORENCIA CLICKJECT SUBCUTANEOUS AUTO-INJECTOR 125 MG/ML | 5 | PA; NM; NDS |
| ORENCIA SUBCUTANEOUS SYRINGE 125 MG/ML, 50 MG/0.4 ML, 87.5 MG/0.7 ML | 5 | PA; NM; NDS |
| OTEZLA ORAL TABLET 20 MG, 30 MG | 5 | PA; NM; NDS |
| OTEZLA STARTER ORAL TABLETS, DOSE PACK 10 MG (4)-20 MG (51), 10 MG (4)-20 MG (4)-30 MG (47), 10 MG (4)-20 MG (4)-30 MG(19) | 5 | PA; NM; NDS |
| OTEZLA XR INITIATION ORAL TABLET AND TABLET ER DOSE PACK 10-20-30-75 MG | 5 | PA; NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|--------------------------------------|
| OTEZLA XR ORAL TABLET EXTENDED RELEASE 24 HR 75 MG | 5 | PA; NM; NDS |
| PROGRAF INTRAVENOUS (tacrolimus) SOLUTION 5 MG/ML | 4 | PA BvD |
| PROGRAF ORAL GRANULES IN PACKET 0.2 MG, 1 MG | 4 | PA BvD |
| RASUVO (PF) SUBCUTANEOUS AUTO-INJECTOR 10 MG/0.2 ML, 12.5 MG/0.25 ML, 15 MG/0.3 ML, 17.5 MG/0.35 ML, 20 MG/0.4 ML, 22.5 MG/0.45 ML, 25 MG/0.5 ML, 30 MG/0.6 ML, 7.5 MG/0.15 ML | 4 | ST |
| REZUROCK ORAL TABLET 200 MG | 5 | PA NSO; NM; NDS |
| RINVOQ LQ ORAL SOLUTION 1 MG/ML | 5 | PA; NM; NDS; QL (360 per 30 days) |
| RINVOQ ORAL TABLET EXTENDED RELEASE 24 HR 15 MG, 30 MG, 45 MG | 5 | PA; NM; NDS |
| SELARSDI INTRAVENOUS SOLUTION 130 MG/26 ML | 5 | PA; NM; NDS |
| SELARSDI SUBCUTANEOUS SOLUTION 45 MG/0.5 ML | 3 | PA |
| SELARSDI SUBCUTANEOUS (ustekinumab-aekn) SYRINGE 45 MG/0.5 ML | 3 | PA |
| SELARSDI SUBCUTANEOUS (ustekinumab-aekn) SYRINGE 90 MG/ML | 5 | PA; NM; NDS |
| <i>sirolimus oral solution 1 mg/ml</i> | 2 | PA BvD |
| <i>sirolimus oral tablet 0.5 mg, 1 mg, 2 mg</i> | 2 | PA BvD |
| SKYRIZI INTRAVENOUS SOLUTION 60 MG/ML | 5 | PA; NM; NDS |
| SKYRIZI SUBCUTANEOUS PEN INJECTOR 150 MG/ML | 5 | PA; NM; NDS |
| SKYRIZI SUBCUTANEOUS SYRINGE 150 MG/ML | 5 | PA; NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|-----------------------------------|
| SKYRIZI SUBCUTANEOUS WEARABLE INJECTOR 180 MG/1.2 ML (150 MG/ML), 360 MG/2.4 ML (150 MG/ML) | 5 | PA; NM; NDS |
| <i>tacrolimus oral capsule 0.5 mg, 1 mg, 5 mg</i> (Prograf) | 2 | PA BvD |
| TAVNEOS ORAL CAPSULE 10 MG | 5 | PA; NM; NDS; QL (180 per 30 days) |
| TREMIFYA INTRAVENOUS SOLUTION 200 MG/20 ML (10 MG/ML) | 5 | PA; NM; NDS |
| TREMIFYA ONE-PRESS SUBCUTANEOUS AUTO-INJECTOR 100 MG/ML | 5 | PA; NM; NDS |
| TREMIFYA PEN INDUCTION PK(2PEN) SUBCUTANEOUS PEN INJECTOR 200 MG/2 ML | 5 | PA; NM; NDS |
| TREMIFYA PEN SUBCUTANEOUS PEN INJECTOR 200 MG/2 ML | 5 | PA; NM; NDS |
| TREMIFYA SUBCUTANEOUS SYRINGE 100 MG/ML, 200 MG/2 ML | 5 | PA; NM; NDS |
| TYENNE AUTOINJECTOR SUBCUTANEOUS PEN INJECTOR 162 MG/0.9 ML | 5 | PA; NM; NDS |
| TYENNE INTRAVENOUS SOLUTION 200 MG/10 ML (20 MG/ML), 400 MG/20 ML (20 MG/ML), 80 MG/4 ML (20 MG/ML) | 5 | PA; NM; NDS |
| TYENNE SUBCUTANEOUS SYRINGE 162 MG/0.9 ML | 5 | PA; NM; NDS |
| <i>ustekinumab-aauz subcutaneous syringe 45 mg/0.5 ml, 90 mg/ml</i> (Otulfi) | 3 | PA |
| XELJANZ ORAL SOLUTION 1 MG/ML | 5 | PA; NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| XELJANZ ORAL TABLET 10 MG, 5 MG | 5 | PA; NM; NDS |
| XELJANZ XR ORAL TABLET EXTENDED RELEASE 24 HR 11 MG, 22 MG | 5 | PA; NM; NDS |
| YESINTEK INTRAVENOUS SOLUTION 130 MG/26 ML | 5 | PA; NM; NDS |
| YESINTEK SUBCUTANEOUS SOLUTION 45 MG/0.5 ML | 3 | PA |
| YESINTEK SUBCUTANEOUS SYRINGE 45 MG/0.5 ML | 3 | PA |
| YESINTEK SUBCUTANEOUS SYRINGE 90 MG/ML | 5 | PA; NM; NDS |
| YUFLYMA(CF) AI CROHN'S-UC- (adalimumab-aaty) HS SUBCUTANEOUS AUTO- INJECTOR, KIT 80 MG/0.8 ML | 5 | PA; NM; NDS |
| YUFLYMA(CF) AUTOINJECTOR (adalimumab-aaty) SUBCUTANEOUS AUTO- INJECTOR, KIT 40 MG/0.4 ML, 80 MG/0.8 ML | 5 | PA; NM; NDS |
| YUFLYMA(CF) SUBCUTANEOUS (adalimumab-aaty) SYRINGE KIT 20 MG/0.2 ML, 40 MG/0.4 ML | 5 | PA; NM; NDS |
| Vacunas | | |
| ABRYSVO (PF) INTRAMUSCULAR RECON SOLN 120 MCG/0.5 ML | 3 | \$0 copay |
| ACTHIB (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 3 | |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SUSPENSION 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 3 | \$0 copay |
| ADACEL(TDAP ADOLESN/ADULT)(PF) INTRAMUSCULAR SYRINGE 2 LF-(2.5-5-3-5 MCG)-5LF/0.5 ML | 3 | \$0 copay |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| AREXVY (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 120 MCG/0.5 ML | 3 | \$0 copay |
| BCG VACCINE, LIVE (PF) PERCUTANEOUS SUSPENSION FOR RECONSTITUTION 50 MG | 3 | \$0 copay |
| BEXSERO INTRAMUSCULAR SYRINGE 50-50-50-25 MCG/0.5 ML | 3 | \$0 copay |
| BOOSTRIX TDAP INTRAMUSCULAR SUSPENSION 2.5-8-5 LF-MCG-LF/0.5ML | 3 | \$0 copay |
| BOOSTRIX TDAP INTRAMUSCULAR SYRINGE 2.5-8-5 LF-MCG-LF/0.5ML | 3 | \$0 copay |
| DAPTACEL (DTAP PEDIATRIC) (PF) INTRAMUSCULAR SUSPENSION 15-10-5 LF-MCG-LF/0.5ML | 3 | |
| DENGVAXIA (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP4.5-6 CCID50/0.5 ML | 3 | QL (3 per 365 days) |
| ENGERIX-B (PF) INTRAMUSCULAR SUSPENSION 20 MCG/ML | 3 | PA BvD; \$0 copay |
| ENGERIX-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/ML | 3 | PA BvD; \$0 copay |
| ENGERIX-B PEDIATRIC (PF) INTRAMUSCULAR SYRINGE 10 MCG/0.5 ML | 3 | PA BvD; \$0 copay |
| GARDASIL 9 (PF) INTRAMUSCULAR SUSPENSION 0.5 ML | 3 | \$0 copay |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| GARDASIL 9 (PF) INTRAMUSCULAR SYRINGE 0.5 ML | 3 | \$0 copay |
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 1,440 ELISA UNIT/ML | 3 | \$0 copay |
| HAVRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT/0.5 ML | 3 | |
| HEPLISAV-B (PF) INTRAMUSCULAR SYRINGE 20 MCG/0.5 ML | 3 | PA BvD; \$0 copay |
| HIBERIX (PF) INTRAMUSCULAR RECON SOLN 10 MCG/0.5 ML | 3 | |
| IMOVAX RABIES VACCINE (PF) INTRAMUSCULAR RECON SOLN 2.5 UNIT | 3 | PA BvD; \$0 copay |
| INFANRIX (DTAP) (PF) INTRAMUSCULAR SYRINGE 25- 58-10 LF-MCG-LF/0.5ML | 3 | |
| IPOLE INJECTION SUSPENSION 40-8-32 UNIT/0.5 ML | 3 | \$0 copay |
| IXIARO (PF) INTRAMUSCULAR SYRINGE 6 MCG/0.5 ML | 3 | \$0 copay |
| JYNNEOS (PF) SUBCUTANEOUS SUSPENSION 0.5X TO 3.95X 10EXP8 UNIT/0.5 | 3 | \$0 copay |
| KINRIX (PF) INTRAMUSCULAR SYRINGE 25 LF-58 MCG-10 LF/0.5 ML | 3 | |
| MENACTRA (PF) INTRAMUSCULAR SOLUTION 4 MCG/0.5 ML | 3 | \$0 copay |
| MENQUADFI (PF) INTRAMUSCULAR SOLUTION 10 MCG/0.5 ML | 3 | \$0 copay |
| MENVEO A-C-Y-W-135-DIP (PF) INTRAMUSCULAR KIT 10-5 MCG/0.5 ML | 3 | \$0 copay |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| M-M-R II (PF) SUBCUTANEOUS RECON SOLN 1,000-12,500 TCID50/0.5 ML | 3 | \$0 copay |
| MRESVIA (PF) INTRAMUSCULAR SYRINGE 50 MCG/0.5 ML | 3 | \$0 copay |
| PEDIARIX (PF) INTRAMUSCULAR SYRINGE 10 MCG-25LF-25 MCG-10LF/0.5 ML | 3 | |
| PEDVAX HIB (PF) INTRAMUSCULAR SOLUTION 7.5 MCG/0.5 ML | 3 | |
| PENBRAYA (PF) INTRAMUSCULAR KIT 5-120 MCG/0.5 ML | 3 | \$0 copay |
| PENBRAYA MENACWY COMPONENT(PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 5 MCG/0.5 ML | 3 | \$0 copay |
| PENBRAYA MENB COMPONENT (PF) INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML | 3 | \$0 copay |
| PENMENVY MEN A-B-C-W-Y (PF) INTRAMUSCULAR KIT 0.5 ML | 3 | \$0 copay |
| PENMENVY MENACWY COMPONENT(PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 10-5 MCG | 3 | \$0 copay |
| PENMENVY MENB COMPONENT (PF) INTRAMUSCULAR SYRINGE 50-50-50-25 MCG/0.5 ML | 3 | \$0 copay |
| PENTACEL (PF) INTRAMUSCULAR KIT 15LF- 20MCG-5LF- 62 DU/0.5 ML | 3 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| PRIORIX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3.4-4.2- 3.3CCID50/0.5ML | 3 | \$0 copay |
| PROQUAD (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10EXP3-4.3-3- 3.99 TCID50/0.5 | 3 | |
| QUADRACEL (PF) INTRAMUSCULAR SUSPENSION 15 LF-48 MCG- 5 LF UNIT/0.5ML | 3 | |
| QUADRACEL (PF) INTRAMUSCULAR SYRINGE 15 LF-48 MCG- 5 LF UNIT/0.5ML | 3 | |
| RABAVERT (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 2.5 UNIT | 3 | PA BvD; \$0 copay |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SUSPENSION 10 MCG/ML, 40 MCG/ML, 5 MCG/0.5 ML | 3 | PA BvD; \$0 copay |
| RECOMBIVAX HB (PF) INTRAMUSCULAR SYRINGE 10 MCG/ML, 5 MCG/0.5 ML | 3 | PA BvD; \$0 copay |
| ROTARIX ORAL SUSPENSION 10EXP6 CCID50 /1.5 ML | 3 | |
| ROTARIX ORAL SUSPENSION FOR RECONSTITUTION 10EXP6 CCID50/ML | 3 | |
| ROTATEQ VACCINE ORAL SOLUTION 2 ML | 3 | |
| SHINGRIX (PF) INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 50 MCG/0.5 ML | 3 | \$0 copay; QL (2 per 365 days) |
| SHINGRIX (PF) INTRAMUSCULAR SYRINGE 50 MCG/0.5 ML | 3 | \$0 copay; QL (2 per 365 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites | |
|--|-----------------------------------|------------------------------------|-----------|
| TDVAX INTRAMUSCULAR SUSPENSION 2-2 LF UNIT/0.5 ML | 3 | \$0 copay | |
| TENIVAC (PF) INTRAMUSCULAR SUSPENSION 5 LF UNIT- 2 LF UNIT/0.5ML | 3 | \$0 copay | |
| TENIVAC (PF) INTRAMUSCULAR SYRINGE 5-2 LF UNIT/0.5 ML | 3 | \$0 copay | |
| TICOVAC INTRAMUSCULAR SYRINGE 1.2 MCG/0.25 ML | 3 | | |
| TICOVAC INTRAMUSCULAR SYRINGE 2.4 MCG/0.5 ML | 3 | \$0 copay | |
| TRUMENBA INTRAMUSCULAR SYRINGE 120 MCG/0.5 ML | 3 | \$0 copay | |
| TWINRIX (PF) INTRAMUSCULAR SYRINGE 720 ELISA UNIT- 20 MCG/ML | 3 | \$0 copay | |
| TYPHIM VI INTRAMUSCULAR SOLUTION 25 MCG/0.5 ML | 3 | \$0 copay | |
| TYPHIM VI INTRAMUSCULAR SYRINGE 25 MCG/0.5 ML | (typhoid vi polysacch vaccine) | 3 | \$0 copay |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 25 UNIT/0.5 ML | 3 | | |
| VAQTA (PF) INTRAMUSCULAR SUSPENSION 50 UNIT/ML | 3 | \$0 copay | |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 25 UNIT/0.5 ML | 3 | | |
| VAQTA (PF) INTRAMUSCULAR SYRINGE 50 UNIT/ML | 3 | \$0 copay | |
| VARIVAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 1,350 UNIT/0.5 ML | 3 | \$0 copay | |
| VAXCHORA VACCINE ORAL SUSPENSION FOR RECONSTITUTION 4X10EXP8 TO 2X 10EXP9 CF UNIT | 3 | \$0 copay | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| VIMKUNYA INTRAMUSCULAR SYRINGE 40 MCG/0.8 ML | 3 | \$0 copay |
| VIVOTIF ORAL CAPSULE,DELAYED RELEASE(DR/EC) 2 BILLION UNIT | 3 | \$0 copay |
| YF-VAX (PF) SUBCUTANEOUS SUSPENSION FOR RECONSTITUTION 10 EXP4.74 UNIT/0.5 ML, 10 EXP4.74 UNIT/0.5 ML(2.5 ML IN 1 VIAL) | 3 | \$0 copay |
| Agentes Oftálmicos | | |
| Agentes Antiglaucoma | | |
| <i>acetazolamide oral capsule, extended release 500 mg</i> | 2 | |
| <i>acetazolamide oral tablet 125 mg, 250 mg</i> | 2 | |
| <i>acetazolamide sodium injection recon soln 500 mg</i> | 2 | |
| <i>betaxolol ophthalmic (eye) drops 0.5 %</i> | 2 | |
| <i>brimonidine ophthalmic (eye) drops (Alphagan P) 0.1 %, 0.15 %</i> | 2 | |
| <i>brimonidine ophthalmic (eye) drops 0.2 %</i> | 2 | |
| <i>brimonidine-timolol ophthalmic (eye) (Combigan) drops 0.2-0.5 %</i> | 2 | |
| <i>brinzolamide ophthalmic (eye) (Azopt) drops,suspension 1 %</i> | 2 | |
| <i>carteolol ophthalmic (eye) drops 1 %</i> | 2 | |
| <i>dorzolamide ophthalmic (eye) drops 2 %</i> | 2 | |
| <i>dorzolamide-timolol ophthalmic (eye) (Cosopt) drops 22.3-6.8 mg/ml</i> | 2 | |
| <i>latanoprost ophthalmic (eye) drops (Xalatan) 0.005 %</i> | 1 | QL (2.5 per 25 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>levobunolol ophthalmic (eye) drops 0.5 %</i> | 2 | |
| LUMIGAN OPHTHALMIC (EYE) DROPS 0.01 % | 3 | QL (2.5 per 25 days) |
| <i>methazolamide oral tablet 25 mg, 50 mg</i> | 2 | |
| <i>pilocarpine hcl ophthalmic (eye) drops 1 %, 2 %, 4 %</i> | 2 | |
| RHOPRESSA OPHTHALMIC (EYE) DROPS 0.02 % | 3 | QL (2.5 per 25 days) |
| ROCKLATAN OPHTHALMIC (EYE) DROPS 0.02-0.005 % | 3 | QL (2.5 per 25 days) |
| SIMBRINZA OPHTHALMIC (EYE) DROPS,SUSPENSION 1-0.2 % | 3 | |
| <i>timolol maleate ophthalmic (eye) drops 0.25 %, 0.5 %</i> | 1 | |
| <i>timolol ophthalmic (eye) drops 0.5 %</i> (Betimol) | 1 | |
| <i>travoprost ophthalmic (eye) drops 0.004 %</i> (Travatan Z) | 2 | QL (2.5 per 25 days) |
| VYZULTA OPHTHALMIC (EYE) DROPS 0.024 % | 4 | QL (5 per 30 days) |
| Agentes Para Los Ojos, Oídos, Nariz, Garganta | | |
| Agentes Antiinfecciosos De Ojos, Oídos, Nariz Y Garganta | | |
| <i>acetic acid otic (ear) solution 2 %</i> | 2 | |
| <i>bacitracin ophthalmic (eye) ointment 500 unit/gram</i> | 2 | |
| <i>bacitracin-polymyxin b ophthalmic (eye) ointment 500-10,000 unit/gram</i> (Polycin) | 2 | |
| <i>ciprofloxacin hcl ophthalmic (eye) drops 0.3 %</i> | 2 | |
| <i>ciprofloxacin-dexamethasone otic (ear) drops,suspension 0.3-0.1 %</i> | 2 | QL (7.5 per 7 days) |
| <i>erythromycin ophthalmic (eye) ointment 5 mg/gram (0.5 %)</i> | 2 | QL (3.5 per 4 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>gentak ophthalmic (eye) ointment 0.3 % (3 mg/gram)</i> | 2 | |
| <i>gentamicin ophthalmic (eye) drops 0.3 %</i> | 2 | |
| <i>hydrocortisone-acetic acid otic (ear) drops 1-2 %</i> | 2 | |
| <i>moxifloxacin ophthalmic (eye) drops 0.5 %</i> (Vigamox) | 2 | |
| NATACYN OPHTHALMIC (EYE) DROPS,SUSPENSION 5 % | 4 | |
| <i>neomycin-bacitracin-poly-hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> (Neo-Polycin HC) | 2 | |
| <i>neomycin-bacitracin-polymyxin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> (Neo-Polycin) | 2 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) drops,suspension 3.5mg/ml-10,000 unit/ml-0.1 %</i> (Maxitrol) | 2 | |
| <i>neomycin-polymyxin b-dexameth ophthalmic (eye) ointment 3.5 mg/g-10,000 unit/g-0.1 %</i> | 2 | |
| <i>neomycin-polymyxin-gramicidin ophthalmic (eye) drops 1.75 mg-10,000 unit-0.025mg/ml</i> | 2 | |
| <i>neomycin-polymyxin-hc otic (ear) drops,suspension 3.5-10,000-1 mg/ml-unit/ml-%</i> | 2 | |
| <i>neomycin-polymyxin-hc otic (ear) solution 3.5-10,000-1 mg/ml-unit/ml-%</i> | 2 | |
| <i>neo-polycin hc ophthalmic (eye) ointment 3.5-400-10,000 mg-unit/g-1%</i> (neomycin-bacitracin-poly-hc) | 2 | |
| <i>neo-polycin ophthalmic (eye) ointment 3.5-400-10,000 mg-unit-unit/g</i> (neomycin-bacitracin-polymyxin) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>ofloxacin ophthalmic (eye) drops 0.3 %</i> (Ocuflox) | 2 | |
| <i>ofloxacin otic (ear) drops 0.3 %</i> | 2 | |
| <i>polycin ophthalmic (eye) ointment 500-10,000 unit/gram</i> (bacitracin-polymyxin b) | 2 | |
| <i>polymyxin b sulf-trimethoprim ophthalmic (eye) drops 10,000 unit- 1 mg/ml</i> | 1 | |
| <i>sulfacetamide sodium ophthalmic (eye) drops 10 %</i> | 2 | |
| <i>sulfacetamide sodium ophthalmic (eye) ointment 10 %</i> | 2 | |
| <i>sulfacetamide-prednisolone ophthalmic (eye) drops 10 %-0.23 % (0.25 %)</i> | 2 | |
| <i>tobramycin ophthalmic (eye) drops 0.3 %</i> | 1 | |
| <i>tobramycin-dexamethasone ophthalmic (eye) drops,suspension 0.3-0.1 %</i> | 2 | |
| <i>trifluridine ophthalmic (eye) drops 1 %</i> | 2 | |
| XDEMVIY OPTHALMIC (EYE) DROPS 0.25 % | 5 | PA; NM; NDS; QL (10 per 42 days) |
| ZIRGAN OPTHALMIC (EYE) GEL 0.15 % | 4 | |
| ZYLET OPTHALMIC (EYE) DROPS,SUSPENSION 0.3-0.5 % (tobramycin-lotepred) | 3 | |
| Agentes Antiinflamatorios De Ojos, Oídos, Nariz Y Garganta | | |
| <i>bromfenac ophthalmic (eye) drops 0.07 %</i> (Prolensa) | 2 | |
| <i>cyclosporine ophthalmic (eye) dropperette 0.05 %</i> (Restasis) | 2 | QL (60 per 30 days) |
| <i>dexamethasone sodium phosphate ophthalmic (eye) drops 0.1 %</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>diclofenac sodium ophthalmic (eye) drops 0.1 %</i> | 2 | |
| <i>difluprednate ophthalmic (eye) drops 0.05 %</i> (Durezol) | 2 | |
| EYSUVIS OPHTHALMIC (EYE) DROPS,SUSPENSION 0.25 % | 3 | QL (8.3 per 14 days) |
| <i>flunisolide nasal spray,non-aerosol 25 mcg (0.025 %)</i> | 2 | QL (50 per 25 days) |
| <i>fluocinolone acetate oil otic (ear) drops 0.01 %</i> (DermOtic Oil) | 2 | |
| <i>fluorometholone ophthalmic (eye) drops,suspension 0.1 %</i> (FML Liquifilm) | 2 | |
| <i>flurbiprofen sodium ophthalmic (eye) drops 0.03 %</i> | 2 | |
| <i>fluticasone propionate nasal spray,suspension 50 mcg/actuation</i> (24 Hour Allergy Relief) | 1 | QL (16 per 30 days) |
| ILEVRO OPHTHALMIC (EYE) DROPS,SUSPENSION 0.3 % | 3 | |
| INVELTYS OPHTHALMIC (EYE) DROPS,SUSPENSION 1 % | 3 | QL (5.6 per 14 days) |
| <i>ketorolac ophthalmic (eye) drops 0.5 %</i> (Acular) | 2 | QL (10 per 25 days) |
| LOTEMAX OPHTHALMIC (EYE) OINTMENT 0.5 % | 3 | QL (3.5 per 14 days) |
| LOTEMAX SM OPHTHALMIC (EYE) DROPS,GEL 0.38 % | 3 | QL (5 per 16 days) |
| <i>loteprednol etabonate ophthalmic (eye) drops,gel 0.5 %</i> (Lotemax) | 2 | QL (10 per 14 days) |
| <i>loteprednol etabonate ophthalmic (eye) drops,suspension 0.2 %</i> (Alrex) | 2 | ST |
| <i>loteprednol etabonate ophthalmic (eye) drops,suspension 0.5 %</i> | 2 | QL (15 per 19 days) |
| <i>mometasone nasal spray,non-aerosol 50 mcg/actuation</i> (Allergy Nasal (mometasone)) | 2 | QL (34 per 30 days) |
| <i>prednisolone acetate ophthalmic (eye) drops,suspension 1 %</i> (Pred Forte) | 4 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| XIIDRA OPHTHALMIC (EYE) DROPPERETTE 5 % | 3 | QL (60 per 30 days) |
| Agentes De Ojos, Oídos, Nariz Y Garganta, Varios | | |
| <i>atropine ophthalmic (eye) drops 1 %</i> | 2 | |
| <i>azelastine nasal spray,non-aerosol 137 mcg (0.1 %)</i> | 2 | QL (60 per 30 days) |
| <i>azelastine nasal spray,non-aerosol 205.5 mcg (0.15 %)</i> (Astepro Allergy) | 2 | QL (30 per 25 days) |
| <i>azelastine ophthalmic (eye) drops 0.05 %</i> | 2 | |
| <i>cromolyn ophthalmic (eye) drops 4 %</i> | 2 | |
| <i>epinastine ophthalmic (eye) drops 0.05 %</i> | 2 | |
| <i>ipratropium bromide nasal spray,non-aerosol 21 mcg (0.03 %)</i> | 2 | QL (30 per 28 days) |
| <i>ipratropium bromide nasal spray,non-aerosol 42 mcg (0.06 %)</i> | 2 | QL (15 per 10 days) |
| MIEBO (PF) OPHTHALMIC (EYE) DROPS 100 % | 3 | QL (12 per 28 days) |
| <i>olopatadine ophthalmic (eye) drops 0.1 %</i> (Eye Allergy Itch-Redness Rlf) | 2 | |
| <i>olopatadine ophthalmic (eye) drops 0.2 %</i> (Advanced Eye Relief (olopatad)) | 2 | |
| Agentes Terapeuticos Misceláneos | | |
| Agentes Terapeuticos Misceláneos | | |
| ACTIMMUNE SUBCUTANEOUS SOLUTION 100 MCG/0.5 ML | 5 | PA; NM; NDS |
| BAQSIMI NASAL SPRAY, NON-AEROSOL 3 MG/ACTUATION | 3 | |
| <i>betaine oral powder 1 gram/scoop</i> (Cystadane) | 5 | PA; NM; NDS |
| <i>bupirone oral tablet 10 mg, 15 mg, 30 mg, 5 mg, 7.5 mg</i> | 1 | |
| <i>diazoxide oral suspension 50 mg/ml</i> (Proglycem) | 5 | NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|---------------------------------------|
| <i>glucagon emergency kit (human) injection recon soln 1 mg</i> | 3 | |
| <i>glutamine (sickle cell) oral powder in packet 5 gram</i> (Endari) | 5 | PA; NM; NDS; QL (180 per 30 days) |
| GVOKE HYPOPEN 2-PACK SUBCUTANEOUS AUTO-INJECTOR 0.5 MG/0.1 ML, 1 MG/0.2 ML | 3 | |
| GVOKE PFS 1-PACK SYRINGE SUBCUTANEOUS SYRINGE 0.5 MG/0.1 ML, 1 MG/0.2 ML | 3 | |
| GVOKE SUBCUTANEOUS SOLUTION 1 MG/0.2 ML | 3 | |
| <i>hydroxyzine pamoate oral capsule 100 mg</i> | 2 | |
| <i>hydroxyzine pamoate oral capsule 25 mg, 50 mg</i> | 1 | |
| <i>leucovorin calcium oral tablet 10 mg, 15 mg, 25 mg, 5 mg</i> | 2 | |
| <i>mesna oral tablet 400 mg</i> (Mesnex) | 5 | NM; NDS |
| <i>nitroglycerin rectal ointment 0.4 % (w/w)</i> (Rectiv) | 2 | QL (30 per 30 days) |
| <i>pyridostigmine bromide oral tablet 60 mg</i> (Mestinon) | 2 | |
| THALOMID ORAL CAPSULE 100 MG | 5 | PA NSO; NM; NDS; QL (120 per 30 days) |
| THALOMID ORAL CAPSULE 150 MG, 200 MG | 5 | PA NSO; NM; NDS; QL (56 per 28 days) |
| THALOMID ORAL CAPSULE 50 MG | 5 | PA NSO; NM; NDS; QL (224 per 28 days) |
| TYBOST ORAL TABLET 150 MG | 3 | QL (30 per 30 days) |
| VEOZAH ORAL TABLET 45 MG | 4 | PA; QL (30 per 30 days) |
| VOWST ORAL CAPSULE 1 X 10EXP6 TO 3 X 10EXP7 CELL | 5 | PA; NM; NDS; QL (12 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|--------------------------------------|
| Agentes Vasodilatadores | | |
| Agentes Vasodilatadores | | |
| ADEMPAS ORAL TABLET 0.5 MG, 1 MG, 1.5 MG, 2 MG, 2.5 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| <i>alyq oral tablet 20 mg</i> (tadalafil (pulm. hypertension)) | 2 | PA; QL (60 per 30 days) |
| <i>bosentan oral tablet 125 mg, 62.5 mg</i> (Tracleer) | 5 | PA; NM; LA; NDS; QL (60 per 30 days) |
| OPSUMIT ORAL TABLET 10 MG | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>sildenafil (pulm.hypertension) oral tablet 20 mg</i> (Revatio) | 2 | PA; QL (360 per 30 days) |
| <i>sildenafil oral tablet 100 mg, 25 mg, 50 mg</i> (Viagra) | 1 | EX; CB (6 EA per 30 days) |
| <i>tadalafil oral tablet 2.5 mg</i> | 2 | PA; QL (30 per 30 days) |
| <i>tadalafil oral tablet 5 mg</i> (Cialis) | 2 | PA; QL (30 per 30 days) |
| UPTRAVI ORAL TABLET 1,000 MCG, 1,200 MCG, 1,400 MCG, 1,600 MCG, 400 MCG, 600 MCG, 800 MCG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| UPTRAVI ORAL TABLET 200 MCG | 5 | PA; NM; NDS; QL (240 per 30 days) |
| UPTRAVI ORAL TABLETS,DOSE PACK 200 MCG (140)- 800 MCG (60) | 5 | PA; NM; NDS |
| Analgésicos | | |
| Agentes Antiinflamatorios No Esteroides | | |
| <i>celecoxib oral capsule 100 mg, 200 mg, 400 mg, 50 mg</i> (Celebrex) | 2 | QL (60 per 30 days) |
| <i>diclofenac epolamine transdermal patch 12 hour 1.3 %</i> (Flector) | 4 | PA; QL (60 per 30 days) |
| <i>diclofenac potassium oral tablet 50 mg</i> | 2 | QL (120 per 30 days) |
| <i>diclofenac sodium oral tablet extended release 24 hr 100 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|---|
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 25 mg</i> | 2 | |
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 50 mg</i> | 2 | QL (120 per 30 days) |
| <i>diclofenac sodium oral tablet, delayed release (dr/ec) 75 mg</i> | 2 | QL (60 per 30 days) |
| <i>diclofenac sodium topical drops 1.5 %</i> | 2 | QL (300 per 30 days) |
| <i>diclofenac sodium topical solution in metered-dose pump 20 mg/gram /actuation(2 %)</i> | 5 | PA; NM; NDS; QL (224 per 28 days) |
| <i>diclofenac-misoprostol oral tablet, ir, delayed rel, biphasic 50-200 mg-mcg</i> (Arthrotec 50) | 2 | |
| <i>diclofenac-misoprostol oral tablet, ir, delayed rel, biphasic 75-200 mg-mcg</i> (Arthrotec 75) | 2 | |
| <i>etodolac oral capsule 200 mg, 300 mg</i> | 2 | |
| <i>etodolac oral tablet 400 mg</i> (Lodine) | 2 | |
| <i>etodolac oral tablet 500 mg</i> | 2 | |
| <i>flurbiprofen oral tablet 100 mg</i> (Lurbiro) | 2 | |
| <i>ibu oral tablet 400 mg</i> (ibuprofen) | 1 | QL (240 per 30 days) |
| <i>ibu oral tablet 600 mg, 800 mg</i> (ibuprofen) | 1 | |
| <i>ibuprofen oral tablet 400 mg</i> (IBU) | 1 | QL (240 per 30 days) |
| <i>ibuprofen oral tablet 600 mg, 800 mg</i> (IBU) | 1 | |
| <i>indomethacin oral capsule 25 mg, 50 mg</i> | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>ketorolac oral tablet 10 mg</i> | 2 | PA-HRM; QL (20 per 30 days); AGE (Max 64 Years) |
| <i>meloxicam oral tablet 15 mg, 7.5 mg</i> | 1 | |
| <i>nabumetone oral tablet 500 mg, 750 mg</i> | 2 | |
| <i>naproxen oral tablet 250 mg, 375 mg</i> | 1 | |
| <i>naproxen oral tablet 500 mg</i> (Naprosyn) | 1 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|--|
| <i>naproxen oral tablet, delayed release</i> (EC-Naprosyn) <i>(dr/ec) 375 mg</i> | 2 | |
| <i>sulindac oral tablet 150 mg, 200 mg</i> | 2 | |
| Analgésicos, Varios | | |
| <i>acetaminophen-codeine 300-30 mg/12.5 ml cup inner 300 mg-30 mg /12.5 ml</i> | 1 | NM; QL (4500 per 30 days) |
| <i>acetaminophen-codeine oral solution 120-12 mg/5 ml</i> | 1 | NM; QL (4500 per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-15 mg, 300-30 mg</i> | 2 | NM; QL (360 per 30 days) |
| <i>acetaminophen-codeine oral tablet 300-60 mg</i> | 2 | NM; QL (180 per 30 days) |
| <i>buprenorphine transdermal patch</i> (Butrans) <i>weekly 10 mcg/hour, 15 mcg/hour, 20 mcg/hour, 5 mcg/hour, 7.5 mcg/hour</i> | 2 | NM; QL (4 per 28 days) |
| <i>butalbital-acetaminop-caf-cod oral capsule 50-325-40-30 mg</i> | 2 | PA-HRM; NM; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>butalbital-acetaminophen-caff oral capsule 50-300-40 mg</i> (Fioricet) | 2 | PA-HRM; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>butalbital-acetaminophen-caff oral capsule 50-325-40 mg</i> | 2 | PA-HRM; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>butalbital-acetaminophen-caff oral tablet 50-325-40 mg</i> | 2 | PA-HRM; QL (180 per 30 days); AGE (Max 64 Years) |
| <i>endocet oral tablet 10-325 mg</i> (oxycodone-acetaminophen) | 2 | NM; QL (180 per 30 days) |
| <i>endocet oral tablet 2.5-325 mg, 5-325 mg</i> (oxycodone-acetaminophen) | 2 | NM; QL (360 per 30 days) |
| <i>endocet oral tablet 7.5-325 mg</i> (oxycodone-acetaminophen) | 2 | NM; QL (240 per 30 days) |
| <i>fentanyl citrate buccal lozenge on a handle 1,200 mcg, 1,600 mcg, 400 mcg, 600 mcg, 800 mcg</i> | 5 | PA; NM; NDS; NM; QL (120 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>fentanyl citrate buccal lozenge on a handle 200 mcg</i> | 2 | PA; NM; QL (120 per 30 days) |
| <i>fentanyl transdermal patch 72 hour 100 mcg/hr, 12 mcg/hr, 25 mcg/hr, 50 mcg/hr, 75 mcg/hr</i> | 2 | NM; QL (10 per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 10-300 mg/15 ml</i> | 2 | QL (2700 per 30 days) |
| <i>hydrocodone-acetaminophen oral solution 10-325 mg/15 ml, 7.5-325 mg/15 ml</i> | 2 | NM; QL (2700 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 10-325 mg, 7.5-325 mg</i> | 2 | NM; QL (180 per 30 days) |
| <i>hydrocodone-acetaminophen oral tablet 5-325 mg</i> | 2 | NM; QL (240 per 30 days) |
| <i>hydromorphone oral tablet 2 mg, 4 mg, 8 mg</i> (Dilaudid) | 2 | NM; QL (180 per 30 days) |
| <i>methadone oral tablet 10 mg</i> | 2 | NM; QL (120 per 30 days) |
| <i>methadone oral tablet 5 mg</i> | 2 | NM; QL (180 per 30 days) |
| <i>morphine concentrate oral solution 100 mg/5 ml (20 mg/ml)</i> | 2 | PA; NM; QL (180 per 30 days) |
| <i>morphine oral solution 10 mg/5 ml</i> | 2 | NM; QL (700 per 30 days) |
| <i>morphine oral solution 20 mg/5 ml (4 mg/ml)</i> | 2 | NM; QL (300 per 30 days) |
| MORPHINE ORAL TABLET 15 MG | 4 | NM; QL (180 per 30 days) |
| MORPHINE ORAL TABLET 30 MG | 4 | NM; QL (120 per 30 days) |
| <i>morphine oral tablet extended release 100 mg, 200 mg</i> | 2 | NM; QL (60 per 30 days) |
| <i>morphine oral tablet extended release 15 mg, 30 mg</i> (MS Contin) | 2 | NM; QL (90 per 30 days) |
| <i>morphine oral tablet extended release 60 mg</i> (MS Contin) | 2 | NM; QL (60 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>oxycodone oral capsule 5 mg</i> | 2 | NM; QL (180 per 30 days) |
| <i>oxycodone oral tablet 10 mg, 5 mg</i> | 2 | NM; QL (180 per 30 days) |
| <i>oxycodone oral tablet 15 mg, 30 mg</i> (Roxicodone) | 2 | NM; QL (120 per 30 days) |
| <i>oxycodone oral tablet 20 mg</i> | 2 | NM; QL (120 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet</i> (Endocet) <i>10-325 mg</i> | 2 | NM; QL (180 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet</i> (Endocet) <i>2.5-325 mg, 5-325 mg</i> | 2 | NM; QL (360 per 30 days) |
| <i>oxycodone-acetaminophen oral tablet</i> (Endocet) <i>7.5-325 mg</i> | 2 | NM; QL (240 per 30 days) |
| <i>tramadol oral tablet 50 mg</i> | 1 | NM; QL (240 per 30 days) |
| <i>tramadol-acetaminophen oral tablet</i> <i>37.5-325 mg</i> | 2 | NM; QL (300 per 30 days) |

Anestésicos

Anestesia Local

| | | |
|--|---|--------------------------|
| <i>dermacinrx lidocan 5% patch outer</i> (lidocaine) | 2 | PA; QL (90 per 30 days) |
| <i>glydo mucous membrane jelly in applicator 2 %</i> (lidocaine hcl) | 2 | QL (30 per 30 days) |
| <i>lidocaine hcl mucous membrane jelly in applicator 2 %</i> (Glydo) | 2 | QL (30 per 30 days) |
| <i>lidocaine topical adhesive patch,medicated 5 %</i> (DermacinRx Lidocan) | 2 | PA; QL (90 per 30 days) |
| <i>lidocaine topical ointment 5 %</i> | 2 | PA; QL (240 per 30 days) |
| <i>lidocaine viscous mucous membrane solution 2 %</i> (lidocaine hcl) | 2 | |
| <i>lidocaine-prilocaine topical cream 2.5-2.5 %</i> | 2 | PA; QL (30 per 30 days) |
| <i>lidocan iii topical adhesive patch,medicated 5 %</i> (lidocaine) | 2 | PA; QL (90 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|-------------------------------------|
| <i>tridacaine ii topical adhesive patch,medicated 5 %</i> (lidocaine) | 2 | PA; QL (90 per 30 days) |
| ZTLIDO TOPICAL ADHESIVE PATCH,MEDICATED 1.8 % | 3 | PA; QL (90 per 30 days) |
| Antagonistas De Metales Pesados | | |
| Antagonistas De Metales Pesados | | |
| <i>deferasirox oral granules in packet 180 mg, 360 mg, 90 mg</i> (Jadenu Sprinkle) | 5 | PA; NM; NDS |
| <i>deferasirox oral tablet 180 mg, 360 mg, 90 mg</i> (Jadenu) | 2 | PA |
| <i>penicillamine oral tablet 250 mg</i> (Depen Titratabs) | 5 | PA; NM; NDS |
| <i>trientine oral capsule 250 mg</i> (Syprine) | 5 | PA; NM; NDS; QL (240 per 30 days) |
| Anti Infecciosos (Membrana Cutánea Y Mucosa) | | |
| Anti Infecciosos (Membrana Cutánea Y Mucosa) | | |
| <i>clindamycin phosphate vaginal cream 2 %</i> (Cleocin) | 2 | |
| <i>metronidazole vaginal gel 0.75 % (37.5mg/5 gram)</i> (Vandazole) | 2 | |
| <i>terconazole vaginal cream 0.4 %, 0.8 %</i> | 2 | |
| <i>terconazole vaginal suppository 80 mg</i> | 2 | |
| Antibacterianos | | |
| Aminoglicósidos | | |
| <i>amikacin injection solution 500 mg/2 ml</i> | 2 | |
| ARIKAYCE INHALATION SUSPENSION FOR NEBULIZATION 590 MG/8.4 ML | 5 | PA; NM; NDS; QL (235.2 per 28 days) |
| <i>gentamicin injection solution 40 mg/ml</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>gentamicin sulfate (ped) (pf) injection solution 20 mg/2 ml</i> | 2 | |
| <i>gentamicin sulfate (pf) intravenous solution 100 mg/10 ml, 60 mg/6 ml</i> | 2 | |
| <i>neomycin oral tablet 500 mg</i> | 2 | |
| <i>streptomycin intramuscular recon soln 1 gram</i> | 5 | NM; NDS |
| TOBI PODHALER INHALATION CAPSULE, W/INHALATION DEVICE 28 MG | 5 | NM; NDS; QL (224 per 28 days) |
| <i>tobramycin in 0.225 % nacl inhalation solution for nebulization 300 mg/5 ml</i> (Tobi) | 5 | PA BvD; NM; NDS |
| <i>tobramycin sulfate injection solution 10 mg/ml, 40 mg/ml</i> | 2 | |
| Antibacteriales, Misceláneos | | |
| <i>clindamycin hcl oral capsule 150 mg, 300 mg, 75 mg</i> (Cleocin HCl) | 2 | |
| <i>clindamycin phosphate injection solution 150 (mg/ml) (4 ml), 150 (mg/ml) (6 ml)</i> | 2 | |
| <i>clindamycin phosphate injection solution 150 mg/ml</i> (Cleocin) | 2 | |
| <i>colistin (colistimethate na) injection recon soln 150 mg</i> (Coly-Mycin M Parenteral) | 5 | NM; NDS |
| <i>daptomycin intravenous recon soln 350 mg, 500 mg</i> | 5 | NM; NDS |
| <i>fosfomycin tromethamine oral packet 3 gram</i> | 2 | |
| <i>linezolid in dextrose 5% intravenous piggyback 600 mg/300 ml</i> (Zyvox) | 2 | |
| <i>linezolid oral suspension for reconstitution 100 mg/5 ml</i> (Zyvox) | 5 | NM; NDS |
| <i>linezolid oral tablet 600 mg</i> | 2 | |
| <i>methenamine hippurate oral tablet 1 gram</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>metronidazole in nacl (iso-os)</i> (Metro I.V.) <i>intravenous piggyback 500 mg/100 ml</i> | 2 | |
| <i>metronidazole oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>nitrofurantoin macrocrystal oral capsule 100 mg, 50 mg</i> | 2 | QL (120 per 30 days) |
| <i>nitrofurantoin monohyd/m-cryst oral capsule 100 mg</i> (Macrobid) | 2 | QL (60 per 30 days) |
| <i>trimethoprim oral tablet 100 mg</i> | 2 | |
| <i>vancomycin intravenous recon soln 1,000 mg, 1.25 gram, 10 gram, 5 gram, 500 mg, 750 mg</i> | 2 | |
| <i>vancomycin oral capsule 125 mg</i> (Vancocin) | 2 | QL (56 per 14 days) |
| <i>vancomycin oral capsule 250 mg</i> (Vancocin) | 2 | QL (112 per 14 days) |
| XIFAXAN ORAL TABLET 200 MG | 3 | PA; QL (9 per 30 days) |
| XIFAXAN ORAL TABLET 550 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| Antibióticos B-Lactam Misceláneos | | |
| <i>aztreonam injection recon soln 1 gram, 2 gram</i> (Azactam) | 2 | |
| CAYSTON INHALATION SOLUTION FOR NEBULIZATION 75 MG/ML | 5 | PA; NM; LA; NDS |
| <i>ertapenem injection recon soln 1 gram</i> | 2 | |
| <i>imipenem-cilastatin intravenous recon soln 250 mg</i> | 2 | |
| <i>imipenem-cilastatin intravenous recon soln 500 mg</i> (Primaxin IV) | 2 | |
| <i>meropenem intravenous recon soln 1 gram, 500 mg</i> | 2 | |
| <i>meropenem intravenous recon soln 2 gram</i> | 4 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| Cefalosporinas | | |
| <i>cefactor oral capsule 250 mg, 500 mg</i> | 2 | |
| <i>cefadroxil oral capsule 500 mg</i> | 2 | |
| <i>cefadroxil oral suspension for reconstitution 250 mg/5 ml, 500 mg/5 ml</i> | 2 | |
| <i>cefazolin injection recon soln 1 gram, 500 mg</i> | 2 | |
| <i>cefazolin intravenous recon soln 10 gram</i> | 2 | |
| <i>cefdinir oral capsule 300 mg</i> | 2 | |
| <i>cefdinir oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>cefepime injection recon soln 1 gram, 2 gram</i> | 2 | |
| <i>cefixime oral capsule 400 mg</i> | 2 | |
| <i>cefixime oral tablet 400 mg</i> | 2 | |
| <i>cefoxitin intravenous recon soln 1 gram, 10 gram, 2 gram</i> | 2 | |
| <i>cefpodoxime oral tablet 100 mg, 200 mg</i> | 2 | |
| <i>cefprozil oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>ceftaroline fosamil intravenous recon soln 400 mg, 600 mg</i> (Teflaro) | 5 | NM; NDS |
| <i>ceftazidime injection recon soln 1 gram, 2 gram, 6 gram</i> (Tazicef) | 2 | |
| <i>ceftriaxone injection recon soln 1 gram, 10 gram, 2 gram, 250 mg, 500 mg</i> | 2 | |
| <i>cefuroxime axetil oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>cefuroxime sodium injection recon soln 750 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>cefuroxime sodium intravenous recon soln 1.5 gram, 7.5 gram</i> | 2 | |
| <i>cephalexin oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>cephalexin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>tazicef injection recon soln 1 gram, 2 gram, 6 gram</i> (ceftazidime) | 2 | |
| TEFLARO INTRAVENOUS RECON SOLN 400 MG, 600 MG (ceftaroline fosamil) | 5 | NM; NDS |
| Macrólidos | | |
| <i>azithromycin intravenous recon soln 500 mg</i> (Zithromax) | 2 | |
| <i>azithromycin oral suspension for reconstitution 100 mg/5 ml</i> | 2 | |
| <i>azithromycin oral suspension for reconstitution 200 mg/5 ml</i> (Zithromax) | 2 | |
| <i>azithromycin oral tablet 250 mg (6 pack), 500 mg (3 pack), 600 mg</i> | 1 | |
| <i>azithromycin oral tablet 250 mg, 500 mg</i> (Zithromax) | 1 | |
| <i>clarithromycin oral suspension for reconstitution 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>clarithromycin oral tablet 250 mg, 500 mg</i> | 2 | |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 200 mg/5 ml</i> (E.E.S. Granules) | 2 | |
| <i>erythromycin ethylsuccinate oral suspension for reconstitution 400 mg/5 ml</i> (EryPed 400) | 2 | |
| <i>erythromycin oral tablet 250 mg, 500 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|------------------------------|
| <i>fidaxomicin oral tablet 200 mg</i> (Dificid) | 5 | NM; NDS; QL (20 per 10 days) |
| Penicilinas | | |
| <i>amoxicillin oral capsule 250 mg, 500 mg</i> | 1 | |
| <i>amoxicillin oral suspension for reconstitution 125 mg/5 ml, 200 mg/5 ml, 250 mg/5 ml, 400 mg/5 ml</i> | 1 | |
| <i>amoxicillin oral tablet 500 mg, 875 mg</i> | 1 | |
| <i>amoxicillin oral tablet, chewable 125 mg, 250 mg</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 200-28.5 mg/5 ml, 400-57 mg/5 ml</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 250-62.5 mg/5 ml</i> (Augmentin) | 2 | |
| <i>amoxicillin-pot clavulanate oral suspension for reconstitution 600-42.9 mg/5 ml</i> (Augmentin ES-600) | 2 | |
| <i>amoxicillin-pot clavulanate oral tablet 250-125 mg, 875-125 mg</i> | 2 | |
| <i>amoxicillin-pot clavulanate oral tablet 500-125 mg</i> (Augmentin) | 2 | |
| <i>amoxicillin-pot clavulanate oral tablet, chewable 200-28.5 mg, 400-57 mg</i> | 2 | |
| <i>ampicillin oral capsule 500 mg</i> | 2 | |
| <i>ampicillin sodium injection recon soln 1 gram, 10 gram, 125 mg</i> | 2 | |
| <i>ampicillin-sulbactam injection recon soln 1.5 gram, 15 gram, 3 gram</i> (Unasyn) | 2 | |
| BICILLIN L-A INTRAMUSCULAR SYRINGE 1,200,000 UNIT/2 ML, 2,400,000 UNIT/4 ML, 600,000 UNIT/ML | 4 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>dicloxacillin oral capsule 250 mg, 500 mg</i> | 2 | |
| EXTENCILLINE INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 1.2 MILLION UNIT, 2.4 MILLION UNIT | 4 | |
| LENTOCILIN S INTRAMUSCULAR SUSPENSION FOR RECONSTITUTION 1.2 MILLION UNIT | 4 | |
| <i>nafcillin injection recon soln 1 gram, 10 gram, 2 gram</i> | 2 | |
| <i>penicillin g potassium injection recon (Pfizerpen-G) soln 20 million unit</i> | 2 | |
| <i>penicillin g procaine intramuscular syringe 1.2 million unit/2 ml, 600,000 unit/ml</i> | 2 | |
| <i>penicillin v potassium oral recon soln 125 mg/5 ml, 250 mg/5 ml</i> | 2 | |
| <i>penicillin v potassium oral tablet 250 mg, 500 mg</i> | 1 | |
| <i>piperacillin-tazobactam intravenous recon soln 2.25 gram, 3.375 gram, 4.5 gram, 40.5 gram</i> | 2 | |
| Quinolonas | | |
| <i>ciprofloxacin hcl oral tablet 250 mg, 500 mg (Cipro)</i> | 1 | |
| <i>ciprofloxacin hcl oral tablet 750 mg</i> | 1 | |
| <i>ciprofloxacin in 5 % dextrose intravenous piggyback 200 mg/100 ml, 400 mg/200 ml</i> | 2 | |
| <i>levofloxacin in d5w intravenous piggyback 250 mg/50 ml, 500 mg/100 ml, 750 mg/150 ml</i> | 2 | |
| <i>levofloxacin oral solution 250 mg/10 ml</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>levofloxacin oral tablet 250 mg, 500 mg, 750 mg</i> | 1 | |
| <i>moxifloxacin 400 mg/250 ml bag sub, p/f, inner</i> | 2 | |
| <i>moxifloxacin oral tablet 400 mg</i> | 2 | |
| <i>moxifloxacin-sod.chloride(iso) intravenous piggyback 400 mg/250 ml</i> (Avelox in NaCl (iso-osmotic)) | 2 | |
| Sulfonamidas | | |
| <i>sulfadiazine oral tablet 500 mg</i> | 2 | |
| <i>sulfamethoxazole-trimethoprim oral suspension 200-40 mg/5 ml</i> (Sulfatrim) | 2 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 400-80 mg</i> (Bactrim) | 1 | |
| <i>sulfamethoxazole-trimethoprim oral tablet 800-160 mg</i> (Bactrim DS) | 1 | |
| Tetraciclinas | | |
| <i>demeclocycline oral tablet 150 mg, 300 mg</i> | 2 | |
| <i>doxy-100 intravenous recon soln 100 mg</i> (doxycycline hyclate) | 2 | |
| <i>doxycycline hyclate intravenous recon soln 100 mg</i> (Doxy-100) | 2 | |
| <i>doxycycline hyclate oral capsule 100 mg</i> | 2 | |
| <i>doxycycline hyclate oral capsule 50 mg</i> (Morgidox) | 2 | |
| <i>doxycycline hyclate oral tablet 100 mg, 20 mg</i> | 2 | |
| <i>doxycycline monohydrate oral capsule 100 mg</i> (Mondoxyne NL) | 2 | |
| <i>doxycycline monohydrate oral capsule 50 mg</i> | 2 | |
| <i>doxycycline monohydrate oral suspension for reconstitution 25 mg/5 ml</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| <i>doxycycline monohydrate oral tablet 100 mg</i> (Avidoxy) | 2 | |
| <i>doxycycline monohydrate oral tablet 50 mg</i> | 2 | |
| <i>minocycline oral capsule 100 mg, 50 mg, 75 mg</i> | 2 | |
| <i>tetracycline oral capsule 250 mg, 500 mg</i> | 2 | |
| <i>tigecycline intravenous recon soln 50 mg</i> (Tygacil) | 2 | |
| Anticonceptivos | | |
| Anticonceptivos | | |
| <i>afirmelle oral tablet 0.1-20 mg-mcg</i> (levonorgestrel-ethinyl estrad) | 2 | |
| <i>altavera (28) oral tablet 0.15-0.03 mg</i> (levonorgestrel-ethinyl estrad) | 2 | |
| <i>alyacen 1/35 (28) oral tablet 1-35 mg-mcg</i> (norethindrone-ethin estradiol) | 2 | |
| <i>alyacen 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | 2 | |
| <i>amethyst (28) oral tablet 90-20 mcg (28)</i> (levonorgestrel-ethinyl estrad) | 2 | |
| <i>apri oral tablet 0.15-0.03 mg</i> (desogestrel-ethinyl estradiol) | 2 | |
| <i>aubra eq oral tablet 0.1-20 mg-mcg</i> (levonorgestrel-ethinyl estrad) | 2 | |
| <i>aurovela 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> (norethindrone ac-eth estradiol) | 2 | |
| <i>aurovela 1/20 (21) oral tablet 1-20 mg-mcg</i> (norethindrone ac-eth estradiol) | 2 | |
| <i>aurovela 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> (norethindrone-e.estradiol-iron) | 2 | |
| <i>aurovela fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> (norethindrone-e.estradiol-iron) | 2 | |
| <i>aurovela fe 1-20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> (norethindrone-e.estradiol-iron) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|----------------------------------|------------------------------|------------------------------------|
| <i>aviane oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>ayuna oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>azurette (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |
| <i>blisovi 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>blisovi fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>blisovi fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>camila oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>chateal eq (28) oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>cryselle (28) oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| <i>cyred eq oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>dasetta 1/35 (28) oral tablet 1-35 mg-mcg</i> | (norethindrone-ethin estradiol) | 2 | |
| <i>dasetta 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | | 2 | |
| <i>deblitane oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>desog-e.estradiol/e.estradiol oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (Azurette (28)) | 2 | |
| <i>desogestrel-ethinyl estradiol oral tablet 0.15-0.03 mg</i> | (Apri) | 2 | |
| <i>dolishale oral tablet 90-20 mcg (28)</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>elinest oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| <i>eluryng vaginal ring 0.12-0.015 mg/24 hr</i> | (etonogestrel-ethinyl estradiol) | 2 | QL (1 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|--|----------------------------------|------------------------------|--------------------------------|
| <i>emzahh oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>enilloring vaginal ring 0.12-0.015 mg/24 hr</i> | (etonogestrel-ethinyl estradiol) | 2 | QL (1 per 28 days) |
| <i>enpresse oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (levonorg-eth estrad triphasic) | 2 | |
| <i>enskyce oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>errin oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>estarylla oral tablet 0.25-0.035 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>ethynodiol diac-eth estradiol oral tablet 1-35 mg-mcg</i> | (Kelnor 1/35 (28)) | 2 | |
| <i>ethynodiol diac-eth estradiol oral tablet 1-50 mg-mcg</i> | (Valtya) | 2 | |
| <i>etonogestrel-ethinyl estradiol vaginal ring 0.12-0.015 mg/24 hr</i> | (EluRyng) | 2 | QL (1 per 28 days) |
| <i>falmina (28) oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>feirza oral tablet 1 mg-20 mcg (21)/75 mg (7), 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>femynor oral tablet 0.25-35 mg-mcg</i> | (norgestimate-ethinyl estradiol) | 1 | |
| <i>hailey 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>hailey fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>hailey fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>haloette vaginal ring 0.12-0.015 mg/24 hr</i> | (etonogestrel-ethinyl estradiol) | 2 | QL (1 per 28 days) |
| <i>heather oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|--|----------------------------------|------------------------------|------------------------------------|
| <i>iclevia oral tablets, dose pack, 3 month 0.15 mg-30 mcg (91)</i> | (levonorgestrel-ethinyl estrad) | 2 | QL (91 per 84 days) |
| <i>incassia oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>introvale oral tablets, dose pack, 3 month 0.15 mg-30 mcg (91)</i> | (levonorgestrel-ethinyl estrad) | 2 | QL (91 per 84 days) |
| <i>isibloom oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>jencycla oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 1 | |
| <i>jolessa oral tablets, dose pack, 3 month 0.15 mg-30 mcg (91)</i> | (levonorgestrel-ethinyl estrad) | 4 | QL (91 per 84 days) |
| <i>juleber oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>junel 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>junel 1/20 (21) oral tablet 1-20 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>junel fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>junel fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>junel fe 24 oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>kariva (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |
| <i>kelnor 1/35 (28) oral tablet 1-35 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>kelnor 1/50 (28) oral tablet 1-50 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>kurvelo (28) oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| KYLEENA INTRAUTERINE INTRAUTERINE DEVICE 17.5 MCG/24 HR (5 YRS) 19.5 MG | | 4 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|----------------------------------|------------------------------|------------------------------------|
| <i>larin 1.5/30 (21) oral tablet 1.5-30 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>larin 1/20 (21) oral tablet 1-20 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |
| <i>larin 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>larin fe 1.5/30 (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>larin fe 1/20 (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>lessina oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>levonest (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (levonorg-eth estrad triphasic) | 2 | |
| <i>levonorgest-eth.estradiol-iron oral tablet 0.1 mg-0.02 mg (21)/iron (7)</i> | (Balcoltra) | 4 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.1-20 mg-mcg</i> | (Afirmelle) | 2 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 0.15-0.03 mg</i> | (Altavera (28)) | 2 | |
| <i>levonorgestrel-ethinyl estrad oral tablet 90-20 mcg (28)</i> | (Amethyst (28)) | 2 | |
| <i>levonorgestrel-ethinyl estrad oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | (Iclevia) | 2 | QL (91 per 84 days) |
| <i>levonorg-eth estrad triphasic oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (Enpresse) | 2 | |
| <i>levora-28 oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| LILETTA INTRAUTERINE INTRAUTERINE DEVICE 20.4 MCG/24 HR (8 YRS) 52 MG | | 3 | |
| <i>low-ogestrel (28) oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| <i>luizza oral tablet 1-20 mg-mcg, 1.5-30 mg-mcg</i> | (norethindrone ac-eth estradiol) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>luta</i> (28) oral tablet 0.1-20 mg-mcg (levonorgestrel-ethinyl estrad) | 2 | |
| <i>lyleq</i> oral tablet 0.35 mg (norethindrone (contraceptive)) | 2 | |
| <i>lyza</i> oral tablet 0.35 mg (norethindrone (contraceptive)) | 2 | |
| <i>marlissa</i> (28) oral tablet 0.15-0.03 mg (levonorgestrel-ethinyl estrad) | 2 | |
| <i>meleya</i> oral tablet 0.35 mg (norethindrone (contraceptive)) | 2 | |
| <i>microgestin 1.5/30</i> (21) oral tablet 1.5-30 mg-mcg (norethindrone ac-eth estradiol) | 2 | |
| <i>microgestin 1/20</i> (21) oral tablet 1-20 mg-mcg (norethindrone ac-eth estradiol) | 2 | |
| <i>microgestin 24 fe</i> oral tablet 1 mg-20 mcg (24)/75 mg (4) (norethindrone-e.estradiol-iron) | 2 | |
| <i>microgestin fe 1.5/30</i> (28) oral tablet 1.5 mg-30 mcg (21)/75 mg (7) (norethindrone-e.estradiol-iron) | 2 | |
| <i>microgestin fe 1/20</i> (28) oral tablet 1 mg-20 mcg (21)/75 mg (7) (norethindrone-e.estradiol-iron) | 2 | |
| <i>mili</i> oral tablet 0.25-0.035 mg (norgestimate-ethinyl estradiol) | 2 | |
| MIRENA INTRAUTERINE INTRAUTERINE DEVICE 21 MCG/24HR (UP TO 8 YRS) 52 MG | 4 | |
| <i>mono-linyah</i> oral tablet 0.25-0.035 mg (norgestimate-ethinyl estradiol) | 1 | |
| NEXPLANON SUBDERMAL IMPLANT 68 MG | 3 | |
| <i>norelgestromin-ethin.estradiol transdermal patch weekly</i> 150-35 mcg/24 hr (Xulane) | 2 | QL (3 per 28 days) |
| <i>norethindrone (contraceptive) oral tablet</i> 0.35 mg (Jencycla) | 2 | |
| <i>norethindrone-e.estradiol-iron oral tablet</i> 1 mg-20 mcg (21)/75 mg (7) (Aurovela Fe 1-20 (28)) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|----------------------------------|------------------------------|--------------------------------|
| <i>norethindrone-e.estradiol-iron oral tablet 1.5 mg-30 mcg (21)/75 mg (7)</i> | (Aurovela Fe 1.5/30 (28)) | 2 | |
| <i>norethindrone-e.estradiol-iron oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | (Tilia Fe) | 2 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> | (Tri-Lo-Estarylla) | 2 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> | (Tri-Estarylla) | 2 | |
| <i>norgestimate-ethinyl estradiol oral tablet 0.25-0.035 mg</i> | (Mono-Linyah) | 2 | |
| <i>nortrel 1/35 (21) oral tablet 1-35 mg-mcg (21)</i> | | 2 | |
| <i>nortrel 1/35 (28) oral tablet 1-35 mg-mcg</i> | (norethindrone-ethin estradiol) | 2 | |
| <i>nortrel 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | | 2 | |
| <i>nylia 1/35 (28) oral tablet 1-35 mg-mcg</i> | (norethindrone-ethin estradiol) | 2 | |
| <i>nylia 7/7/7 (28) oral tablet 0.5/0.75/1 mg- 35 mcg</i> | | 2 | |
| <i>nymyo oral tablet 0.25-35 mg-mcg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>orquidea oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |
| <i>pimtrea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |
| <i>portia 28 oral tablet 0.15-0.03 mg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>reclipsen (28) oral tablet 0.15-0.03 mg</i> | (desogestrel-ethinyl estradiol) | 2 | |
| <i>setlakin oral tablets,dose pack,3 month 0.15 mg-30 mcg (91)</i> | (levonorgestrel-ethinyl estrad) | 2 | QL (91 per 84 days) |
| <i>sharobel oral tablet 0.35 mg</i> | (norethindrone (contraceptive)) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>simliya (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> (desog-e.estradiol/e.estradiol) | 2 | |
| SKYLA INTRAUTERINE INTRAUTERINE DEVICE 14 MCG/24 HR (3 YRS) 13.5 MG | 4 | |
| <i>sprintec (28) oral tablet 0.25-0.035 mg</i> (norgestimate-ethinyl estradiol) | 2 | |
| <i>sronyx oral tablet 0.1-20 mg-mcg</i> (levonorgestrel-ethinyl estrad) | 2 | |
| <i>tarina 24 fe oral tablet 1 mg-20 mcg (24)/75 mg (4)</i> (norethindrone-e.estradiol-iron) | 2 | |
| <i>tarina fe 1-20 eq (28) oral tablet 1 mg-20 mcg (21)/75 mg (7)</i> (norethindrone-e.estradiol-iron) | 2 | |
| <i>tilia fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> (norethindrone-e.estradiol-iron) | 2 | |
| <i>tri-estarylla oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-legest fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> (norethindrone-e.estradiol-iron) | 2 | |
| <i>tri-linyah oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-lo-estarylla oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-lo-marzia oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-lo-mili oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-lo-sprintec oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-mili oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-nymyo oral tablet 0.18/0.215/0.25 mg-35 mcg (28)</i> (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-sprintec (28) oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> (norgestimate-ethinyl estradiol) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|--|----------------------------------|-----------------------|----------------------------|
| <i>trivora (28) oral tablet 50-30 (6)/75-40 (5)/125-30(10)</i> | (levonorg-eth estrad triphasic) | 2 | |
| <i>tri-vylibra lo oral tablet 0.18/0.215/0.25 mg-0.025 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>tri-vylibra oral tablet 0.18/0.215/0.25 mg-0.035mg (28)</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>turqoz (28) oral tablet 0.3-30 mg-mcg</i> | (norgestrel-ethinyl estradiol) | 2 | |
| <i>valtya oral tablet 1-35 mg-mcg, 1-50 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>vienva oral tablet 0.1-20 mg-mcg</i> | (levonorgestrel-ethinyl estrad) | 2 | |
| <i>viorele (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |
| <i>volnea (28) oral tablet 0.15-0.02 mgx21 /0.01 mg x 5</i> | (desog-e.estradiol/e.estradiol) | 2 | |
| <i>vylibra oral tablet 0.25-0.035 mg</i> | (norgestimate-ethinyl estradiol) | 2 | |
| <i>xarah fe oral tablet 1-20(5)/1-30(7) /1mg-35mcg (9)</i> | (norethindrone-e.estradiol-iron) | 2 | |
| <i>xulane transdermal patch weekly 150-35 mcg/24 hr</i> | (norelgestromin-ethin.estradiol) | 2 | QL (3 per 28 days) |
| <i>zafemy transdermal patch weekly 150-35 mcg/24 hr</i> | (norelgestromin-ethin.estradiol) | 2 | QL (3 per 28 days) |
| <i>zovia 1/35e (28) oral tablet 1-35 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |
| <i>zovia 1-35 (28) oral tablet 1-35 mg-mcg</i> | (ethynodiol diac-eth estradiol) | 2 | |

Anticonvulsivos

Anticonvulsivos

| | | | |
|---|----------------|---|-------------------------------|
| BRIVIACT INTRAVENOUS SOLUTION 50 MG/5 ML | (brivaracetam) | 5 | NM; NDS; QL (80 per 30 days) |
| BRIVIACT ORAL SOLUTION 10 MG/ML | (brivaracetam) | 5 | NM; NDS; QL (600 per 30 days) |
| BRIVIACT ORAL TABLET 10 MG, 100 MG, 25 MG, 50 MG, 75 MG | (brivaracetam) | 5 | NM; NDS; QL (60 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|--|
| <i>carbamazepine 100 mg/5 ml cup outer 100 mg/5 ml (5 ml)</i> | 2 | |
| <i>carbamazepine oral capsule, er multiphase 12 hr 100 mg, 200 mg, 300 mg</i> (Carbatrol) | 2 | |
| <i>carbamazepine oral suspension 100 mg/5 ml</i> (Tegretol) | 2 | |
| <i>carbamazepine oral tablet 200 mg</i> (Tegretol) | 2 | |
| <i>carbamazepine oral tablet extended release 12 hr 100 mg, 200 mg, 400 mg</i> (Tegretol XR) | 2 | |
| <i>carbamazepine oral tablet, chewable 100 mg, 200 mg</i> | 2 | |
| <i>clobazam oral suspension 2.5 mg/ml</i> (Onfi) | 2 | QL (480 per 30 days) |
| <i>clobazam oral tablet 10 mg, 20 mg</i> (Onfi) | 2 | QL (60 per 30 days) |
| DIACOMIT ORAL CAPSULE 250 MG | 5 | PA NSO; NM; NDS; QL (360 per 30 days) |
| DIACOMIT ORAL CAPSULE 500 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| DIACOMIT ORAL POWDER IN PACKET 250 MG | 5 | PA NSO; NM; NDS; QL (360 per 30 days) |
| DIACOMIT ORAL POWDER IN PACKET 500 MG | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>diazepam rectal kit 12.5-15-17.5-20 mg, 5-7.5-10 mg</i> | 2 | |
| <i>diazepam rectal kit 2.5 mg</i> | 4 | |
| DILANTIN ORAL CAPSULE 30 MG | 4 | |
| <i>divalproex oral capsule, delayed rel sprinkle 125 mg</i> (Depakote Sprinkles) | 2 | |
| <i>divalproex oral tablet extended release 24 hr 250 mg, 500 mg</i> (Depakote ER) | 2 | |
| <i>divalproex oral tablet, delayed release (dr/ec) 125 mg, 250 mg, 500 mg</i> (Depakote) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|-------------------------------------|
| ELEPSIA XR ORAL TABLET EXTENDED RELEASE 24 HR 1,000 MG | 5 | ST; NM; NDS; QL (90 per 30 days) |
| ELEPSIA XR ORAL TABLET EXTENDED RELEASE 24 HR 1,500 MG | 5 | ST; NM; NDS; QL (60 per 30 days) |
| EPIDIOLEX ORAL SOLUTION 100 MG/ML | 5 | PA NSO; NM; NDS |
| <i>epitol oral tablet 200 mg</i> (carbamazepine) | 2 | |
| <i>eslicarbazepine oral tablet 200 mg, 400 mg</i> (Aptiom) | 5 | ST; NM; NDS; QL (30 per 30 days) |
| <i>eslicarbazepine oral tablet 600 mg, 800 mg</i> (Aptiom) | 5 | ST; NM; NDS; QL (60 per 30 days) |
| <i>ethosuximide oral capsule 250 mg</i> (Zarontin) | 2 | |
| <i>ethosuximide oral solution 250 mg/5 ml</i> (Zarontin) | 2 | |
| <i>felbamate oral suspension 600 mg/5 ml</i> | 2 | |
| <i>felbamate oral tablet 400 mg, 600 mg</i> (Felbatol) | 2 | |
| FINTEPLA ORAL SOLUTION 2.2 MG/ML | 5 | PA NSO; NM; NDS |
| <i>fosphenytoin injection solution 100 mg pe/2 ml, 500 mg pe/10 ml</i> (Cerebyx) | 2 | |
| <i>gabapentin oral capsule 100 mg, 300 mg</i> (Neurontin) | 2 | QL (360 per 30 days) |
| <i>gabapentin oral capsule 400 mg</i> (Neurontin) | 2 | QL (270 per 30 days) |
| <i>gabapentin oral solution 250 mg/5 ml</i> (Neurontin) | 2 | QL (2160 per 30 days) |
| <i>gabapentin oral tablet 600 mg</i> (Neurontin) | 2 | QL (180 per 30 days) |
| <i>gabapentin oral tablet 800 mg</i> (Neurontin) | 2 | QL (120 per 30 days) |
| <i>lacosamide intravenous solution 200 mg/20 ml</i> (Vimpat) | 2 | QL (200 per 5 days) |
| <i>lacosamide oral solution 10 mg/ml</i> (Vimpat) | 2 | QL (1200 per 30 days) |
| <i>lacosamide oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> (Vimpat) | 2 | QL (60 per 30 days) |
| <i>lamotrigine oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> (Subvenite) | 1 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>lamotrigine oral tablet, chewable dispersible 25 mg, 5 mg</i> (Lamictal) | 2 | |
| <i>lamotrigine oral tablet, disintegrating 100 mg, 200 mg, 25 mg, 50 mg</i> (Lamictal ODT) | 2 | |
| <i>levetiracetam intravenous solution 500 mg/5 ml</i> (Keppra) | 2 | |
| <i>levetiracetam oral solution 100 mg/ml</i> (Keppra) | 2 | |
| <i>levetiracetam oral tablet 1,000 mg, 250 mg, 500 mg, 750 mg</i> (Keppra) | 2 | |
| <i>levetiracetam oral tablet extended release 24 hr 500 mg, 750 mg</i> (Keppra XR) | 2 | |
| <i>levetiracetam oral tablet for suspension 250 mg</i> (Spritam) | 2 | ST |
| <i>levetiracetam oral tablet for suspension 500 mg</i> (Spritam) | 4 | ST |
| LIBERVANT BUCCAL FILM 10 MG, 12.5 MG, 15 MG, 5 MG, 7.5 MG | 4 | QL (10 per 30 days) |
| <i>methsuximide oral capsule 300 mg</i> (Celontin) | 2 | |
| NAYZILAM NASAL SPRAY, NON-AEROSOL 5 MG/SPRAY (0.1 ML) | 4 | QL (10 per 30 days) |
| <i>oxcarbazepine oral suspension 300 mg/5 ml (60 mg/ml)</i> (Trileptal) | 2 | |
| <i>oxcarbazepine oral tablet 150 mg, 300 mg, 600 mg</i> (Trileptal) | 2 | |
| <i>perampanel oral suspension 0.5 mg/ml</i> (Fycompa) | 5 | ST; NM; NDS; QL (720 per 30 days) |
| <i>perampanel oral tablet 10 mg, 12 mg, 8 mg</i> (Fycompa) | 5 | ST; NM; NDS; QL (30 per 30 days) |
| <i>perampanel oral tablet 2 mg</i> (Fycompa) | 2 | ST; QL (30 per 30 days) |
| <i>perampanel oral tablet 4 mg, 6 mg</i> (Fycompa) | 5 | ST; NM; NDS; QL (60 per 30 days) |
| <i>phenobarbital oral elixir 20 mg/5 ml (4 mg/ml)</i> | 2 | PA NSO-HRM; AGE (Max 64 Years) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>phenobarbital oral tablet 100 mg, 15 mg, 16.2 mg, 30 mg, 32.4 mg, 60 mg, 64.8 mg, 97.2 mg</i> | 2 | PA NSO-HRM; AGE (Max 64 Years) |
| <i>phenytek oral capsule 200 mg, 300 mg</i> (phenytoin sodium extended) | 2 | |
| <i>phenytoin oral suspension 125 mg/5 ml</i> (Dilantin-125) | 2 | |
| <i>phenytoin oral tablet, chewable 50 mg</i> (Dilantin Infatabs) | 2 | |
| <i>phenytoin sodium extended oral capsule 100 mg</i> (Dilantin Extended) | 2 | |
| <i>phenytoin sodium extended oral capsule 200 mg, 300 mg</i> (Phenytek) | 2 | |
| <i>phenytoin sodium intravenous solution 50 mg/ml</i> | 2 | |
| <i>phenytoin sodium intravenous syringe 50 mg/ml</i> | 2 | |
| <i>pregabalin oral capsule 100 mg, 150 mg, 200 mg, 25 mg, 50 mg, 75 mg</i> (Lyrica) | 2 | QL (90 per 30 days) |
| <i>pregabalin oral capsule 225 mg, 300 mg</i> (Lyrica) | 2 | QL (60 per 30 days) |
| <i>pregabalin oral solution 20 mg/ml</i> (Lyrica) | 2 | QL (900 per 30 days) |
| <i>primidone oral tablet 125 mg</i> | 2 | |
| <i>primidone oral tablet 250 mg, 50 mg</i> (Mysoline) | 2 | |
| <i>rufinamide oral suspension 40 mg/ml</i> (Banzel) | 5 | ST; NM; NDS |
| <i>rufinamide oral tablet 200 mg</i> (Banzel) | 2 | ST |
| <i>rufinamide oral tablet 400 mg</i> (Banzel) | 5 | ST; NM; NDS |
| SEZABY INTRAVENOUS RECON SOLN 100 MG | 5 | PA BvD; NM; NDS |
| SPRITAM ORAL TABLET FOR SUSPENSION 1,000 MG, 750 MG | 4 | ST |
| SPRITAM ORAL TABLET FOR SUSPENSION 250 MG, 500 MG (levetiracetam) | 4 | ST |
| SUBVENITE ORAL SUSPENSION 10 MG/ML | 4 | PA NSO |
| <i>subvenite oral tablet 100 mg, 150 mg, 200 mg, 25 mg</i> (lamotrigine) | 1 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|--|
| SYMPAZAN ORAL FILM 10 MG, 20 MG, 5 MG | 5 | PA NSO; NM; NDS; QL (60 per 30 days) |
| <i>tiagabine oral tablet 12 mg, 16 mg, 2 mg, 4 mg</i> | 2 | |
| <i>topiramate oral capsule, sprinkle 15 mg, 25 mg</i> (Topamax) | 2 | |
| <i>topiramate oral capsule, sprinkle 50 mg</i> | 2 | |
| <i>topiramate oral solution 25 mg/ml</i> (Eprontia) | 2 | ST |
| <i>topiramate oral tablet 100 mg, 200 mg, 25 mg, 50 mg</i> (Topamax) | 1 | |
| <i>valproate sodium intravenous solution 500 mg/5 ml (100 mg/ml)</i> | 2 | |
| <i>valproic acid (as sodium salt) oral solution 250 mg/5 ml</i> | 2 | |
| <i>valproic acid oral capsule 250 mg</i> | 2 | |
| VALTOCO NASAL SPRAY, NON- AEROSOL 10 MG/SPRAY (0.1 ML), 15 MG/2 SPRAY (7.5/0.1ML X 2), 20 MG/2 SPRAY (10MG/0.1ML X2), 5 MG/SPRAY (0.1 ML) | 5 | NM; NDS; QL (10 per 30 days) |
| <i>vigabatrin oral powder in packet 500 mg</i> (Vigadrone) | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>vigabatrin oral tablet 500 mg</i> (Vigadrone) | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>vigadrone oral powder in packet 500 mg</i> (vigabatrin) | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>vigadrone oral tablet 500 mg</i> (vigabatrin) | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| <i>vigpoder oral powder in packet 500 mg</i> (vigabatrin) | 5 | PA NSO; NM; NDS; QL (180 per 30 days) |
| XCOPRI MAINTENANCE PACK ORAL TABLET 250MG/DAY(150 MG X1-100MG X1), 350 MG/DAY (200 MG X1-150MG X1) | 5 | NM; NDS; QL (56 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|--|
| XCOPRI ORAL TABLET 100 MG, 25 MG, 50 MG | 5 | NM; NDS; QL (30 per 30 days) |
| XCOPRI ORAL TABLET 150 MG, 200 MG | 5 | NM; NDS; QL (60 per 30 days) |
| XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 12.5 MG (14)- 25 MG (14) | 4 | |
| XCOPRI TITRATION PACK ORAL TABLETS,DOSE PACK 150 MG (14)- 200 MG (14), 50 MG (14)- 100 MG (14) | 5 | NM; NDS |
| ZONISADE ORAL SUSPENSION 100 MG/5 ML | 4 | |
| <i>zonisamide oral capsule 100 mg, 25 mg</i> (Zonegran) | 2 | |
| <i>zonisamide oral capsule 50 mg</i> | 2 | |
| ZTALMY ORAL SUSPENSION 50 MG/ML | 5 | PA NSO; NM; NDS; QL (1080 per 30 days) |
| Antidepresivos | | |
| Antidepresivos | | |
| <i>amitriptyline oral tablet 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | |
| <i>amoxapine oral tablet 100 mg, 150 mg, 25 mg, 50 mg</i> | 2 | |
| AUVELITY ORAL TABLET, IR AND ER, BIPHASIC 45-105 MG | 5 | ST; NM; NDS |
| <i>bupropion hcl oral tablet 100 mg, 75 mg</i> | 2 | |
| <i>bupropion hcl oral tablet extended release 24 hr 150 mg, 300 mg</i> (Wellbutrin XL) | 2 | |
| <i>bupropion hcl oral tablet sustained-release 12 hr 100 mg, 150 mg, 200 mg</i> (Wellbutrin SR) | 2 | |
| <i>citalopram oral solution 10 mg/5 ml</i> | 2 | |
| <i>citalopram oral tablet 10 mg</i> (Celexa) | 1 | QL (120 per 30 days) |
| <i>citalopram oral tablet 20 mg, 40 mg</i> (Celexa) | 1 | QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|--------------------------------------|
| <i>clomipramine oral capsule 25 mg, 50 mg, 75 mg</i> (Anafranil) | 2 | |
| <i>desipramine oral tablet 10 mg, 25 mg</i> (Norpramin) | 2 | |
| <i>desipramine oral tablet 100 mg, 150 mg, 50 mg, 75 mg</i> | 2 | |
| <i>desvenlafaxine succinate oral tablet extended release 24 hr 100 mg, 25 mg, 50 mg</i> (Pristiq) | 2 | QL (30 per 30 days) |
| <i>doxepin oral capsule 10 mg, 100 mg, 150 mg, 25 mg, 50 mg, 75 mg</i> | 2 | |
| <i>doxepin oral concentrate 10 mg/ml</i> | 2 | |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 20 MG, 30 MG, 60 MG | 4 | ST; QL (60 per 30 days) |
| DRIZALMA SPRINKLE ORAL CAPSULE, DELAYED REL SPRINKLE 40 MG | 4 | ST; QL (30 per 30 days) |
| <i>duloxetine oral capsule, delayed release(dr/ec) 20 mg, 30 mg, 60 mg</i> | 2 | QL (60 per 30 days) |
| EMSAM TRANSDERMAL PATCH 24 HOUR 12 MG/24 HR, 6 MG/24 HR, 9 MG/24 HR | 5 | ST; NM; NDS; QL (30 per 30 days) |
| <i>escitalopram oxalate oral solution 5 mg/5 ml</i> | 2 | |
| <i>escitalopram oxalate oral tablet 10 mg, 20 mg, 5 mg</i> (Lexapro) | 1 | |
| EXXUA ORAL TABLET EXTENDED RELEASE 24 HR 18.2 MG, 36.3 MG, 54.5 MG, 72.6 MG | 5 | PA NSO; NM; NDS; QL (30 per 30 days) |
| EXXUA ORAL TABLET, EXT REL 24HR DOSE PACK 18.2 MG (32 TABS) | 5 | PA NSO; NM; NDS |
| FETZIMA ORAL CAPSULE,EXT REL 24HR DOSE PACK 20 MG (2)- 40 MG (26) | 4 | ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| FETZIMA ORAL CAPSULE,EXTENDED RELEASE 24 HR 120 MG, 20 MG, 40 MG, 80 MG | 4 | ST; QL (30 per 30 days) |
| <i>fluoxetine oral capsule 10 mg, 20 mg</i> (Prozac) | 1 | |
| <i>fluoxetine oral capsule 40 mg</i> | 1 | |
| <i>fluoxetine oral solution 20 mg/5 ml (4 mg/ml)</i> | 2 | |
| <i>fluvoxamine oral tablet 100 mg, 25 mg, 50 mg</i> | 2 | |
| <i>imipramine hcl oral tablet 10 mg, 25 mg, 50 mg</i> | 2 | |
| MARPLAN ORAL TABLET 10 MG | 4 | |
| <i>mirtazapine oral tablet 15 mg, 30 mg</i> (Remeron) | 2 | |
| <i>mirtazapine oral tablet 45 mg, 7.5 mg</i> | 2 | |
| <i>mirtazapine oral tablet,disintegrating</i> (Remeron SolTab) <i>15 mg, 30 mg, 45 mg</i> | 2 | |
| <i>nefazodone oral tablet 100 mg, 150 mg, 200 mg, 250 mg, 50 mg</i> | 2 | |
| <i>nortriptyline oral capsule 10 mg, 25</i> (Pamelor) <i>mg, 50 mg, 75 mg</i> | 1 | |
| <i>nortriptyline oral solution 10 mg/5 ml</i> | 2 | |
| <i>paroxetine hcl oral suspension 10</i> (Paxil) <i>mg/5 ml</i> | 2 | PA NSO-HRM; AGE (Max 64 Years) |
| <i>paroxetine hcl oral tablet 10 mg, 20</i> (Paxil) <i>mg, 30 mg, 40 mg</i> | 1 | PA NSO-HRM; AGE (Max 64 Years) |
| <i>paroxetine hcl oral tablet extended</i> (Paxil CR) <i>release 24 hr 12.5 mg, 25 mg, 37.5 mg</i> | 2 | PA NSO-HRM; AGE (Max 64 Years) |
| <i>perphenazine-amitriptyline oral tablet 2-10 mg, 2-25 mg, 4-10 mg, 4- 25 mg, 4-50 mg</i> | 2 | |
| <i>phenelzine oral tablet 15 mg</i> (Nardil) | 2 | |
| <i>protriptyline oral tablet 10 mg, 5 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|--|
| RALDESY ORAL SOLUTION 10 MG/ML | 5 | PA NSO; NM; NDS; QL (1200 per 30 days) |
| <i>sertraline oral concentrate 20 mg/ml</i> (Zoloft) | 2 | |
| <i>sertraline oral tablet 100 mg, 25 mg, 50 mg</i> (Zoloft) | 1 | |
| SPRAVATO NASAL SPRAY, NON-AEROSOL 28 MG, 56 MG (28 MG X 2), 84 MG (28 MG X 3) | 5 | PA NSO; NM; NDS |
| <i>tranylcypromine oral tablet 10 mg</i> (Parnate) | 2 | |
| <i>trazodone oral tablet 100 mg, 150 mg, 300 mg, 50 mg</i> | 1 | |
| <i>trimipramine oral capsule 100 mg, 25 mg, 50 mg</i> | 2 | |
| TRINTELLIX ORAL TABLET 10 MG, 20 MG, 5 MG | 3 | QL (30 per 30 days) |
| <i>venlafaxine oral capsule, extended release 24hr 150 mg</i> (Effexor XR) | 2 | QL (30 per 30 days) |
| <i>venlafaxine oral capsule, extended release 24hr 37.5 mg, 75 mg</i> (Effexor XR) | 2 | QL (90 per 30 days) |
| <i>venlafaxine oral tablet 100 mg, 25 mg, 37.5 mg, 50 mg, 75 mg</i> | 2 | |
| <i>vilazodone oral tablet 10 mg, 20 mg, 40 mg</i> (Viibryd) | 2 | QL (30 per 30 days) |
| ZURZUVAE ORAL CAPSULE 20 MG, 25 MG | 5 | PA NSO; NM; NDS; QL (28 per 14 days) |
| ZURZUVAE ORAL CAPSULE 30 MG | 5 | PA NSO; NM; NDS; QL (14 per 14 days) |
| Antifúngicos | | |
| Antifúngicos | | |
| ABELCET INTRAVENOUS SUSPENSION 5 MG/ML | 4 | PA BvD |
| <i>amphotericin b injection recon soln 50 mg</i> | 2 | PA BvD |
| <i>amphotericin b liposome intravenous suspension for reconstitution 50 mg</i> (AmBisome) | 5 | PA BvD; NM; NDS |
| <i>ciclopirox topical cream 0.77 %</i> (Ciclodan) | 2 | QL (180 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>ciclopirox topical solution 8 %</i> (Ciclodan) | 2 | QL (19.8 per 30 days) |
| <i>ciclopirox topical suspension 0.77 %</i> (Loprox (as olamine)) | 2 | QL (180 per 30 days) |
| <i>clotrimazole mucous membrane troche 10 mg</i> | 2 | |
| <i>clotrimazole topical cream 1 %</i> (Antifungal (clotrimazole)) | 2 | |
| <i>clotrimazole topical solution 1 %</i> (Athlete's Foot (clotrimazole)) | 2 | |
| <i>clotrimazole-betamethasone topical cream 1-0.05 %</i> | 2 | QL (90 per 30 days) |
| CRESEMBA INTRAVENOUS RECON SOLN 372 MG | 5 | NM; NDS |
| CRESEMBA ORAL CAPSULE 186 MG, 74.5 MG | 5 | PA; NM; NDS |
| <i>econazole nitrate topical cream 1 %</i> | 2 | QL (170 per 30 days) |
| <i>fluconazole in nacl (iso-osm) intravenous piggyback 200 mg/100 ml, 400 mg/200 ml</i> | 2 | |
| <i>fluconazole oral suspension for reconstitution 10 mg/ml</i> | 2 | |
| <i>fluconazole oral suspension for reconstitution 40 mg/ml</i> (Diflucan) | 2 | |
| <i>fluconazole oral tablet 100 mg, 150 mg, 200 mg, 50 mg</i> | 2 | |
| <i>flucytosine oral capsule 250 mg, 500 mg</i> (Ancobon) | 5 | NM; NDS |
| <i>griseofulvin microsize oral suspension 125 mg/5 ml</i> | 2 | |
| <i>griseofulvin microsize oral tablet 500 mg</i> | 2 | |
| <i>griseofulvin ultramicrosize oral tablet 125 mg, 165 mg, 250 mg</i> | 2 | |
| <i>itraconazole oral capsule 100 mg</i> (Sporanox) | 2 | |
| <i>ketoconazole oral tablet 200 mg</i> | 2 | |
| <i>ketoconazole topical cream 2 %</i> | 2 | QL (180 per 30 days) |
| <i>ketoconazole topical shampoo 2 %</i> | 2 | QL (360 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>micafungin intravenous recon soln</i> 100 mg, 50 mg | 2 | |
| <i>miconazole-3 vaginal suppository</i> 200 mg | 2 | |
| <i>nyamyc topical powder 100,000</i> <i>unit/gram</i> (nystatin) | 2 | QL (60 per 30 days) |
| <i>nystatin oral suspension 100,000</i> <i>unit/ml</i> | 2 | |
| <i>nystatin oral tablet 500,000 unit</i> | 2 | |
| <i>nystatin topical cream 100,000</i> <i>unit/gram</i> | 2 | QL (60 per 30 days) |
| <i>nystatin topical ointment 100,000</i> <i>unit/gram</i> | 2 | QL (60 per 30 days) |
| <i>nystatin topical powder 100,000</i> <i>unit/gram</i> (Nyamyc) | 2 | QL (60 per 30 days) |
| <i>nystatin-triamcinolone topical cream</i> <i>100,000-0.1 unit/g-%</i> | 2 | |
| <i>nystatin-triamcinolone topical</i> <i>ointment 100,000-0.1 unit/gram-%</i> | 2 | |
| <i>nystop topical powder 100,000</i> <i>unit/gram</i> (nystatin) | 2 | QL (60 per 30 days) |
| <i>posaconazole oral tablet, delayed</i> <i>release (dr/ec) 100 mg</i> | 5 | PA; NM; NDS |
| <i>terbinafine hcl oral tablet 250 mg</i> | 1 | |
| <i>voriconazole intravenous recon soln</i> 200 mg (Vfend IV) | 5 | PA BvD; NM; NDS |
| <i>voriconazole oral suspension for</i> <i>reconstitution 200 mg/5 ml (40</i> <i>mg/ml)</i> (Vfend) | 5 | PA; NM; NDS |
| <i>voriconazole oral tablet 200 mg, 50</i> <i>mg</i> | 2 | |
| Antihistamínicos | | |
| Antihistamínicos | | |
| <i>hydroxyzine hcl oral tablet 10 mg, 25</i> <i>mg, 50 mg</i> | 2 | |
| <i>levocetirizine oral tablet 5 mg</i> (24HR Allergy Relief) | 1 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|------------------------------|
| Antimicobacteriales | | |
| Antimicobacteriales | | |
| <i>dapsone oral tablet 100 mg, 25 mg</i> | 2 | |
| <i>ethambutol oral tablet 100 mg, 400 mg</i> | 2 | |
| <i>isoniazid oral tablet 100 mg, 300 mg</i> | 1 | |
| PRIFTIN ORAL TABLET 150 MG | 4 | |
| <i>pyrazinamide oral tablet 500 mg</i> | 2 | |
| <i>rifabutin oral capsule 150 mg</i> | 2 | |
| <i>rifampin intravenous recon soln 600 mg</i> (Rifadin) | 2 | |
| <i>rifampin oral capsule 150 mg, 300 mg</i> | 2 | |
| SIRTURO ORAL TABLET 100 MG, 20 MG | 5 | PA; NM; NDS |
| TRECTOR ORAL TABLET 250 MG | 4 | |
| Antivirales (Sitémico) | | |
| Antirretrovirales | | |
| <i>abacavir oral solution 20 mg/ml</i> (Ziagen) | 2 | |
| <i>abacavir oral tablet 300 mg</i> | 2 | |
| <i>abacavir-lamivudine oral tablet 600-300 mg</i> | 2 | |
| APTIVUS ORAL CAPSULE 250 MG | 5 | NM; NDS |
| <i>atazanavir oral capsule 150 mg</i> | 2 | |
| <i>atazanavir oral capsule 200 mg, 300 mg</i> (Reyataz) | 2 | |
| BIKTARVY ORAL TABLET 30-120-15 MG, 50-200-25 MG | 5 | NM; NDS; QL (30 per 30 days) |
| CABENUVA INTRAMUSCULAR SUSPENSION, EXTENDED RELEASE 400 MG/2 ML- 600 MG/2 ML, 600 MG/3 ML- 900 MG/3 ML | 5 | NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>cabotegravir intramuscular suspension, extended release 400 mg/2 ml (200 mg/ml)</i> | 5 | NM; NDS; QL (24 per 365 days) |
| <i>cabotegravir intramuscular suspension, extended release 600 mg/3 ml (200 mg/ml)</i> (Apretude) | 5 | NM; NDS; QL (24 per 365 days) |
| CIMDUO ORAL TABLET 300-300 MG | 5 | NM; NDS |
| <i>darunavir oral tablet 600 mg</i> (Prezista) | 2 | |
| <i>darunavir oral tablet 800 mg</i> (Prezista) | 5 | NM; NDS |
| DELSTRIGO ORAL TABLET 100-300-300 MG | 5 | NM; NDS |
| DESCOVY ORAL TABLET 120-15 MG, 200-25 MG | 5 | NM; NDS |
| <i>didanosine oral capsule, delayed release(dr/ec) 250 mg, 400 mg</i> | 2 | |
| DOVATO ORAL TABLET 50-300 MG | 5 | NM; NDS |
| EDURANT ORAL TABLET 25 MG (rilpivirine hcl) | 5 | NM; NDS |
| EDURANT PED ORAL TABLET FOR SUSPENSION 2.5 MG | 5 | NM; NDS |
| <i>efavirenz oral capsule 200 mg, 50 mg</i> | 2 | |
| <i>efavirenz oral tablet 600 mg</i> | 2 | |
| <i>efavirenz-emtricitabin-tenofovir oral tablet 600-200-300 mg</i> | 2 | |
| <i>efavirenz-lamivudine-tenofovir disoproxil fumarate oral tablet 400-300-300 mg</i> | 5 | NM; NDS |
| <i>efavirenz-lamivudine-tenofovir disoproxil fumarate oral tablet 600-300-300 mg</i> (Symfi) | 5 | NM; NDS |
| <i>emtricitabine oral capsule 200 mg</i> (Emtriva) | 2 | |
| <i>emtricitabine-tenofovir (tdf) oral tablet 100-150 mg, 167-250 mg, 200-300 mg</i> (Truvada) | 2 | |
| <i>emtricitabine-tenofovir (tdf) oral tablet 133-200 mg</i> (Truvada) | 5 | NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>emtricitina-rilpivirina-tenofovir oral tablet 200-25-300 mg</i> (Complera) | 5 | NM; NDS |
| EMTRIVA ORAL SOLUTION 10 MG/ML | 4 | |
| EPIVIR HBV ORAL SOLUTION 25 MG/5 ML (5 MG/ML) | 4 | |
| <i>etravirina oral tablet 100 mg, 200 mg</i> (Intelence) | 5 | NM; NDS |
| EVOTAZ ORAL TABLET 300-150 MG | 5 | NM; NDS |
| <i>fosamprenavir oral tablet 700 mg</i> | 5 | NM; NDS |
| FUZEON SUBCUTANEOUS RECON SOLN 90 MG | 5 | NM; NDS |
| GENVOYA ORAL TABLET 150-150-200-10 MG | 5 | NM; NDS |
| INTELENCE ORAL TABLET 25 MG | 4 | |
| ISENTRESS HD ORAL TABLET 600 MG | 5 | NM; NDS |
| ISENTRESS ORAL POWDER IN PACKET 100 MG | 5 | NM; NDS |
| ISENTRESS ORAL TABLET 400 MG | 5 | NM; NDS |
| ISENTRESS ORAL TABLET, CHEWABLE 100 MG | 5 | NM; NDS |
| ISENTRESS ORAL TABLET, CHEWABLE 25 MG | 3 | |
| JULUCA ORAL TABLET 50-25 MG | 5 | NM; NDS |
| KALETRA ORAL SOLUTION 400-100 MG/5 ML (lopinavir-ritonavir) | 4 | QL (480 per 30 days) |
| <i>lamivudina oral solution 10 mg/ml</i> (Epivir) | 2 | |
| <i>lamivudina oral tablet 100 mg</i> | 2 | |
| <i>lamivudina oral tablet 150 mg, 300 mg</i> (Epivir) | 2 | |
| <i>lamivudina-zidovudina oral tablet 150-300 mg</i> | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| LEXIVA ORAL SUSPENSION 50 MG/ML | 4 | |
| <i>lopinavir-ritonavir oral solution 400-100 mg/5 ml</i> (Kaletra) | 2 | QL (480 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 100-25 mg</i> (Kaletra) | 2 | QL (300 per 30 days) |
| <i>lopinavir-ritonavir oral tablet 200-50 mg</i> (Kaletra) | 2 | QL (120 per 30 days) |
| <i>maraviroc oral tablet 150 mg, 300 mg</i> (Selzentry) | 5 | NM; NDS |
| <i>nevirapine oral suspension 50 mg/5 ml</i> | 2 | QL (1200 per 30 days) |
| <i>nevirapine oral tablet 200 mg</i> | 2 | QL (60 per 30 days) |
| <i>nevirapine oral tablet extended release 24 hr 100 mg</i> | 2 | QL (90 per 30 days) |
| <i>nevirapine oral tablet extended release 24 hr 400 mg</i> | 2 | QL (30 per 30 days) |
| NORVIR ORAL POWDER IN PACKET 100 MG | 4 | |
| NORVIR ORAL SOLUTION 80 MG/ML | 4 | |
| ODEFSEY ORAL TABLET 200-25-25 MG | 5 | NM; NDS |
| PIFELTRO ORAL TABLET 100 MG | 5 | NM; NDS |
| PREZCOBIX ORAL TABLET 675-150 MG, 800-150 MG-MG | 5 | NM; NDS |
| PREZISTA ORAL SUSPENSION 100 MG/ML | 5 | NM; NDS |
| PREZISTA ORAL TABLET 150 MG | 5 | NM; NDS |
| PREZISTA ORAL TABLET 75 MG | 4 | |
| RETROVIR INTRAVENOUS SOLUTION 10 MG/ML | 4 | |
| REYATAZ ORAL POWDER IN PACKET 50 MG | 5 | NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>rilpivirine hcl oral tablet 25 mg</i> (Edurant) | 5 | NM; NDS |
| <i>rilpivirine intramuscular suspension, extended release 600 mg/2 ml (300 mg/ml), 900 mg/3 ml (300 mg/ml)</i> | 5 | NM; NDS |
| <i>ritonavir oral tablet 100 mg</i> (Norvir) | 2 | |
| RUKOBIA ORAL TABLET EXTENDED RELEASE 12 HR 600 MG | 5 | NM; NDS |
| SELZENTRY ORAL SOLUTION 20 MG/ML | 5 | NM; NDS |
| SELZENTRY ORAL TABLET 25 MG | 3 | |
| SELZENTRY ORAL TABLET 75 MG | 5 | NM; NDS |
| <i>stavudine oral capsule 15 mg, 20 mg, 30 mg, 40 mg</i> | 2 | |
| STRIBILD ORAL TABLET 150-150-200-300 MG | 5 | NM; NDS |
| SUNLENCA ORAL TABLET 300 MG, 300 MG (4-TABLET PACK), 300 MG (5-TABLET PACK) | 5 | NM; NDS |
| SUNLENCA SUBCUTANEOUS SOLUTION 309 MG/ML | 5 | PA BvD; NM; NDS |
| SYMTUZA ORAL TABLET 800-150-200-10 MG | 5 | NM; NDS |
| TEMIXYS ORAL TABLET 300-300 MG | 5 | NM; NDS |
| <i>tenofovir disoproxil fumarate oral tablet 300 mg</i> (Viread) | 2 | |
| TIVICAY ORAL TABLET 10 MG | 4 | |
| TIVICAY ORAL TABLET 25 MG, 50 MG | 5 | NM; NDS |
| TIVICAY PD ORAL TABLET FOR SUSPENSION 5 MG | 5 | NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------------|
| TRIUMEQ ORAL TABLET 600-50-300 MG | 5 | NM; NDS; QL (30 per 30 days) |
| TRIUMEQ PD ORAL TABLET FOR SUSPENSION 60-5-30 MG | 4 | |
| TRIZIVIR ORAL TABLET 300-150-300 MG | 5 | NM; NDS |
| TROGARZO INTRAVENOUS SOLUTION 200 MG/1.33 ML (150 MG/ML) | 5 | NM; NDS |
| VEMLIDY ORAL TABLET 25 MG | 5 | NM; NDS; QL (30 per 30 days) |
| VIRACEPT ORAL TABLET 250 MG, 625 MG | 5 | NM; NDS |
| VIREAD ORAL POWDER 40 MG/SCOOP (40 MG/GRAM) | 5 | NM; NDS |
| VIREAD ORAL TABLET 150 MG, 200 MG, 250 MG | 5 | NM; NDS |
| VOCABRIA ORAL TABLET 30 MG | 4 | |
| <i>zidovudine oral capsule 100 mg</i> (Retrovir) | 2 | |
| <i>zidovudine oral syrup 10 mg/ml</i> (Retrovir) | 2 | |
| <i>zidovudine oral tablet 300 mg</i> | 2 | |
| Antivirales Hcv | | |
| EPCLUSA ORAL PELLETS IN PACKET 150-37.5 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| EPCLUSA ORAL PELLETS IN PACKET 200-50 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |
| EPCLUSA ORAL TABLET 200-50 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| EPCLUSA ORAL TABLET 400-100 (sofosbuvir-velpatasvir) MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 33.75-150 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| HARVONI ORAL PELLETS IN PACKET 45-200 MG | 5 | PA; NM; NDS; QL (56 per 28 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------------|
| HARVONI ORAL TABLET 45-200 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| HARVONI ORAL TABLET 90-400 MG (ledipasvir-sofosbuvir) | 5 | PA; NM; NDS; QL (28 per 28 days) |
| VOSEVI ORAL TABLET 400-100-100 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| Antivirales, Varios | | |
| LIVTENCITY ORAL TABLET 200 MG | 5 | PA; NM; NDS |
| <i>oseltamivir oral capsule 30 mg</i> | 2 | QL (84 per 180 days) |
| <i>oseltamivir oral capsule 45 mg</i> (Tamiflu) | 2 | QL (48 per 180 days) |
| <i>oseltamivir oral capsule 75 mg</i> (Tamiflu) | 2 | QL (42 per 180 days) |
| <i>oseltamivir oral suspension for reconstitution 6 mg/ml</i> (Tamiflu) | 2 | QL (540 per 180 days) |
| PAXLOVID ORAL TABLETS,DOSE PACK 150 MG (10)- 100 MG (10) | 2 | QL (20 per 5 days) |
| PAXLOVID ORAL TABLETS,DOSE PACK 150 MG (6)- 100 MG (5) | 2 | QL (11 per 28 days) |
| PAXLOVID ORAL TABLETS,DOSE PACK 300 MG (150 MG X 2)-100 MG | 2 | QL (30 per 5 days) |
| PREVYMIS ORAL TABLET 240 MG, 480 MG | 5 | PA; NM; NDS; QL (28 per 28 days) |
| RELENZA DISKHALER INHALATION BLISTER WITH DEVICE 5 MG/ACTUATION | 4 | QL (60 per 180 days) |
| Interferones | | |
| PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML | 5 | PA; NM; NDS |
| PEGASYS SUBCUTANEOUS SYRINGE 180 MCG/0.5 ML | 5 | PA; NM; NDS |
| Nucleósidos Y Nucleótidos | | |
| <i>acyclovir oral capsule 200 mg</i> | 1 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| <i>acyclovir oral suspension 200 mg/5 ml</i> (Zovirax) | 2 | |
| <i>acyclovir oral tablet 400 mg, 800 mg</i> | 2 | |
| <i>acyclovir sodium intravenous solution 50 mg/ml</i> | 2 | PA BvD |
| <i>adefovir oral tablet 10 mg</i> (Hepsera) | 2 | |
| <i>entecavir oral tablet 0.5 mg, 1 mg</i> (Baraclude) | 2 | |
| <i>famciclovir oral tablet 125 mg, 250 mg, 500 mg</i> | 2 | |
| <i>ribavirin oral tablet 200 mg</i> | 2 | |
| <i>valacyclovir oral tablet 1 gram, 500 mg</i> (Valtrex) | 2 | |
| <i>valganciclovir oral recon soln 50 mg/ml</i> (Valcyte) | 5 | NM; NDS |
| <i>valganciclovir oral tablet 450 mg</i> | 2 | |
| Cofactores Enzimáticos/Otros | | |
| Cofactores Enzimáticos/Otros | | |
| MIPLYFFA ORAL CAPSULE 124 MG, 47 MG, 62 MG, 93 MG | 5 | PA; NM; NDS; QL (90 per 30 days) |
| Dispositivos | | |
| Dispositivos | | |
| 1ST TIER UNIFINE PENTP 5MM 31G 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTIP 4MM 32G 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTIP 6MM 31G 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTIP 8MM 31G STRL,SINGLE-USE,SHRT 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTP 29GX1/2" 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| 1ST TIER UNIFINE PNTP 31GX3/16 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|--|----------------------------|
| 1ST TIER UNIFINE PNTD 32GX5/32 32 GAUGE X 5/32" | (pen needle, diabetic) 2 | PA; ST |
| ABOUTTIME PEN NEEDLE NEEDLE 30 GAUGE X 5/16", 31 GAUGE X 3/16", 31 GAUGE X 5/16", 32 GAUGE X 5/32" | (pen needle, diabetic) 2 | PA; ST |
| ADVOCATE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| ADVOCATE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| ADVOCATE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| ADVOCATE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| ADVOCATE INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) 2 | PA; ST |
| ADVOCATE INS SYR 0.3 ML 29GX1/2 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| ADVOCATE INS SYR 0.5 ML 29GX1/2 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| ADVOCATE INS SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| ADVOCATE INS SYR 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) 2 | PA; ST |
| ADVOCATE PEN NDL 12.7MM 29G 29 GAUGE X 1/2" | (pen needle, diabetic) 2 | PA; ST |
| ADVOCATE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) 2 | PA; ST |
| ADVOCATE PEN NEEDLE 4MM 33G 33 GAUGE X 5/32" | (pen needle, diabetic) 2 | PA; ST |
| ADVOCATE PEN NEEDLES 5MM 31G 31 GAUGE X 3/16" | (pen needle, diabetic) 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| ADVOCATE PEN NEEDLES 8MM (pen needle, diabetic) 31G 31 GAUGE X 5/16" | 2 | PA; ST |
| ALCOHOL PADS TOPICAL PADS, (alcohol swabs) MEDICATED | 1 | PA; ST |
| ALCOHOL PREP SWABS (alcohol swabs) TOPICAL PADS, MEDICATED | 1 | PA; ST |
| ALCOHOL WIPES TOPICAL (alcohol swabs) PADS, MEDICATED | 1 | PA; ST |
| AQINJECT PEN NEEDLE 31G (pen needle, diabetic) 5MM 31 GAUGE X 3/16" | 2 | PA; ST |
| AQINJECT PEN NEEDLE 32G (pen needle, diabetic) 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| ASSURE ID DUO PRO NDL 31G (pen needle, diabetic, 5MM 31 GAUGE X 3/16" safety) | 2 | PA; ST |
| ASSURE ID DUO-SHIELD 30GX3/16" 30 GAUGE X 3/16" | 2 | PA; ST |
| ASSURE ID DUO-SHIELD 30GX5/16" 30 GAUGE X 5/16" | 2 | PA; ST |
| ASSURE ID INSULIN SAFETY SYRINGE 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| ASSURE ID PEN NEEDLE 30GX3/16" 30 GAUGE X 3/16" | 2 | PA; ST |
| ASSURE ID PEN NEEDLE 30GX5/16" 30 GAUGE X 5/16" | 2 | PA; ST |
| ASSURE ID PEN NEEDLE (pen needle, diabetic, 31GX3/16" 31 GAUGE X 3/16" safety) | 2 | PA; ST |
| ASSURE ID PRO PEN NDL 30G 5MM 30 GAUGE X 3/16" | 2 | PA; ST |
| ASSURE ID SYR 0.5 ML 31GX15/64" 0.5 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| ASSURE ID SYR 1 ML 31GX15/64" 1 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| AUTOSHIELD DUO PEN NDL 30G 5MM 30 GAUGE X 3/16" | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites | |
|--|-----------------------------------|------------------------------------|--------|
| BD AUTOSHIELD DUO NDL 5MMX30G 30 GAUGE X 3/16" | 2 | PA; ST | |
| BD ECLIPSE 30GX1/2" SYRINGE 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD ECLIPSE NEEDLE 30GX1/2" (OTC) 30 X 1/2 " | 2 | PA; ST | |
| BD INS SYR 0.3 ML 8MMX31G(1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST | |
| BD INS SYR UF 0.3 ML 12.7MMX30G 0.3 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD INS SYR UF 0.5 ML 12.7MMX30G NOT FOR RETAIL SALE 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD INSULIN SYR 1 ML 27GX12.7MM 1 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD INSULIN SYR 1 ML 27GX5/8" MICRO-FINE 1 ML 27 GAUGE X 5/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD LO-DOSE ULTRA-FINE SYRINGE 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD NANO 2 GEN PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| BD SAFETGLD INS 0.3 ML 29G 13MM 0.3 ML 29 GAUGE X 1/2" | 2 | PA; ST | |
| BD SAFETYGLD INS 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST | |
| BD SAFETYGLD INS 0.5 ML 30G 8MM 0.5 ML 30 GAUGE X 5/16" | 2 | PA; ST | |
| BD SAFETYGLD INS 1 ML 29G 13MM 1 ML 29 GAUGE X 1/2" | 2 | PA; ST | |
| BD SAFETYGLID INS 1 ML 6MMX31G 1 ML 31 GAUGE X 15/64" | 2 | PA; ST | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------------------|------------------------------|------------------------------------|
| BD SAFETYGLIDE SYRINGE 27GX5/8 1 ML 27 GAUGE X 5/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD SAFTYGLD INS 0.3 ML 6MMX31G 0.3 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| BD SAFTYGLD INS 0.5 ML 29G 13MM 0.5 ML 29 GAUGE X 1/2" | | 2 | PA; ST |
| BD SAFTYGLD INS 0.5 ML 6MMX31G 0.5 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| BD SINGLE USE SWAB | (alcohol swabs) | 1 | PA; ST |
| BD UF MICRO PEN NEEDLE 6MMX32G 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| BD UF MINI PEN NEEDLE 5MMX31G 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| BD UF NANO PEN NEEDLE 4MMX32G 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| BD UF ORIG PEN NDL 12.7MMX29G 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| BD UF SHORT PEN NEEDLE 8MMX31G 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| BD VEO INS 0.3 ML 6MMX31G (1/2) 0.3 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| BD VEO INS SYRING 1 ML 6MMX31G 1 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD VEO INS SYRN 0.3 ML 6MMX31G 0.3 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BD VEO INS SYRN 0.5 ML 6MMX31G 1/2 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| BORDERED GAUZE 2"X2" 2 X 2 " | (gauze bandage) | 1 | PA; ST |
| CAREFINE PEN NEEDLE 12.7MM 29G 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| CAREFINE PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLE 5MM 32G 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLE 8MM 30G 30 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| CAREFINE PEN NEEDLES 8MM 31G 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH ALCOHOL 70% PREP PAD (alcohol swabs) | 1 | PA; ST |
| CARETOUCH PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH PEN NEEDLE 32GX3/16" 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| CARETOUCH SYR 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| CARETOUCH SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| CARETOUCH SYR 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| CARETOUCH SYR 1 ML 28GX5/16" 1 ML 28 X 5/16" | 2 | PA; ST |
| CARETOUCH SYR 1 ML 29GX5/16" 1 ML 29 GAUGE X 5/16 | 2 | PA; ST |
| CARETOUCH SYR 1 ML (insulin syringe-needle 30GX5/16" 1 ML 30 GAUGE X 5/16 u-100) | 2 | PA; ST |
| CARETOUCH SYR 1 ML (insulin syringe-needle 31GX5/16" 1 ML 31 GAUGE X 5/16 u-100) | 2 | PA; ST |
| CLICKFINE PEN NEEDLE (pen needle, diabetic) 32GX5/32" 32GX4MM, STERILE 32 GAUGE X 5/32" | 2 | PA; ST |
| COMFORT EZ 0.3 ML 31G 15/64" (insulin syringe-needle 0.3 ML 31 GAUGE X 15/64" u-100) | 2 | PA; ST |
| COMFORT EZ 0.5 ML 31G 15/64" (insulin syringe-needle 1/2 ML 31 GAUGE X 15/64" u-100) | 2 | PA; ST |
| COMFORT EZ INS 0.3 ML (insulin syringe-needle 30GX1/2" 0.3 ML 30 GAUGE X u-100) 1/2" | 2 | PA; ST |
| COMFORT EZ INS 0.3 ML (insulin syringe-needle 30GX5/16" 0.3 ML 30 GAUGE X u-100) 5/16" | 2 | PA; ST |
| COMFORT EZ INS 1 ML 31G (insulin syringe-needle 15/64" 1 ML 31 GAUGE X 15/64" u-100) | 2 | PA; ST |
| COMFORT EZ INS 1 ML (insulin syringe-needle 31GX5/16" 1 ML 31 GAUGE X 5/16 u-100) | 2 | PA; ST |
| COMFORT EZ INSULIN SYR 0.3 (insulin syringe-needle ML 0.3 ML 31 GAUGE X 5/16" u-100) | 2 | PA; ST |
| COMFORT EZ INSULIN SYR 0.5 (insulin syringe-needle ML 0.5 ML 30 GAUGE X 5/16", 0.5 u-100) ML 31 GAUGE X 5/16" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLE (pen needle, diabetic) 12MM 29G 29 GAUGE X 1/2" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES (pen needle, diabetic) 4MM 32G SINGLE USE, MICRO 32 GAUGE X 5/32" | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES (pen needle, diabetic) 4MM 33G 33 GAUGE X 5/32" | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------------------|------------------------------|------------------------------------|
| COMFORT EZ PEN NEEDLES 5MM 31G MINI 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 5MM 32G SINGLE USE,MINI,HRI 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 5MM 33G 33 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 6MM 31G 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 6MM 33G 33 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 8MM 31G SHORT 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 8MM 32G 32 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| COMFORT EZ PEN NEEDLES 8MM 33G 33 GAUGE X 5/16" | | 2 | PA; ST |
| COMFORT EZ PRO PEN NDL 30G 8MM 30 GAUGE X 5/16" | | 2 | PA; ST |
| COMFORT EZ PRO PEN NDL 31G 4MM 31 GAUGE X 5/32" | (pen needle, diabetic, safety) | 2 | PA; ST |
| COMFORT EZ PRO PEN NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic, safety) | 2 | PA; ST |
| COMFORT EZ SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ SYR 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ SYR 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| COMFORT EZ SYR 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ SYR 1 ML 27G 12.7MM 1 ML 27 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT EZ SYR 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| COMFORT POINT PEN NDL 31GX1/3" 31 GAUGE X 1/3" | 2 | PA; ST |
| COMFORT POINT PEN NDL 31GX1/6" 31 GAUGE X 1/6" | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 31G 4MM 31 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 31G 6MM 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 31G 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 32G 5MM 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 32G 6MM 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 32G 8MM 32 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| COMFORT TOUCH PEN NDL 33G 4MM 33 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| COMFORT TOUCH PEN NDL 33G (pen needle, diabetic) 6MM 33 GAUGE X 1/4" | 2 | PA; ST |
| COMFORT TOUCH PEN NDL (pen needle, diabetic) 33GX5MM 33 GAUGE X 3/16" | 2 | PA; ST |
| CURAD GAUZE PADS 2" X 2" 2 X (gauze bandage) 2 " | 1 | PA; ST |
| CURITY ALCOHOL PREPS 2 (alcohol swabs) PLY,MEDIUM | 1 | PA; ST |
| CURITY GAUZE PADS 2 X 2 " (gauze bandage) | 1 | PA; ST |
| CURITY GAUZE SPONGES (12 PLY)-200/BAG 2 X 2 " | 1 | PA; ST |
| DERMACEA 2"X2" GAUZE 12 (gauze bandage) PLY, USP TYPE VII 2 X 2 " | 1 | PA; ST |
| DERMACEA GAUZE 2"X2" SPONGE 8 PLY 2 X 2 " | 1 | PA; ST |
| DERMACEA NON-WOVEN 2"X2" SPNGE 2 X 2 " | 1 | PA; ST |
| DROPLET 0.3 ML 29G 12.7MM(1/2) 0.3 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| DROPLET 0.3 ML 30G 12.7MM(1/2) 0.3 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| DROPLET 0.5 ML 29GX12.5MM(1/2) 0.5 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| DROPLET 0.5 ML 30GX12.5MM(1/2) 0.5 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| DROPLET INS 0.3 ML (insulin syringe-needle 29GX12.5MM 0.3 ML 29 GAUGE u-100) X 1/2" | 2 | PA; ST |
| DROPLET INS 0.3 ML 30G 8MM(1/2) 0.3 ML 30 GAUGE X 5/16" | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| DROPLET INS 0.3 ML 30GX12.5MM 0.3 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS 0.3 ML 31G 6MM(1/2) 0.3 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| DROPLET INS 0.3 ML 31G 8MM(1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| DROPLET INS 0.5 ML 29G 12.7MM 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS 0.5 ML 30G 12.7MM 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS 0.5 ML 30GX6MM(1/2) 0.5ML 30 GAUGE X 15/64" | 2 | PA; ST |
| DROPLET INS 0.5 ML 30GX8MM(1/2) 0.5 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| DROPLET INS 0.5 ML 31GX6MM(1/2) 0.5 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| DROPLET INS 0.5 ML 31GX8MM(1/2) 0.5 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| DROPLET INS SYR 0.3 ML 30GX6MM 0.3 ML 30 GAUGE X 15/64" | 2 | PA; ST |
| DROPLET INS SYR 0.3 ML 30GX8MM 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 0.3 ML 31GX8MM 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------------------|------------------------------|------------------------------------|
| DROPLET INS SYR 0.5 ML 30G 8MM 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 0.5 ML 31G 6MM 1/2 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 0.5 ML 31G 8MM 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 29G 12.7MM 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 30G 8MM 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 30GX12.5MM 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 30GX6MM 1 ML 30 GAUGE X 15/64" | | 2 | PA; ST |
| DROPLET INS SYR 1 ML 31G 6MM 1 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET INS SYR 1 ML 31GX8MM 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| DROPLET MICRON 34G X 9/64" 34 GAUGE X 9/64" | | 2 | PA; ST |
| DROPLET PEN NEEDLE 29G 10MM 29 GAUGE X 3/8" | | 2 | PA; ST |
| DROPLET PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 31G 6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| DROPLET PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 32G 5MM 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| DROPLET PEN NEEDLE 32G 8MM 32 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| DROPSAFE ALCOHOL 70% PREP PADS (alcohol swabs) | 1 | PA; ST |
| DROPSAFE INS SYR 0.3 ML 31G 6MM 0.3 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| DROPSAFE INS SYR 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| DROPSAFE INS SYR 0.5 ML 31G 6MM 0.5 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| DROPSAFE INS SYR 0.5 ML 31G 8MM 0.5 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| DROPSAFE INSUL SYR 1 ML 31G 6MM 1 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| DROPSAFE INSUL SYR 1 ML 31G 8MM 1 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| DROPSAFE INSULN 1 ML 29G 12.5MM 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| DROPSAFE PEN NEEDLE 31G 4MM 31 GAUGE X 5/32" (pen needle, diabetic, safety) | 2 | PA; ST |
| DROPSAFE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic, safety) | 2 | PA; ST |
| DROPSAFE PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | 2 | PA; ST |
| DROPSAFE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-------------------------------------|----------------------------|
| DRUG MART ULTRA COMFORT SYR 0.3 ML 29 GAUGE X 1/2", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) 2 | PA; ST |
| EASY CMFT SFTY PEN NDL 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic, safety) 2 | PA; ST |
| EASY CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| EASY CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| EASY COMFORT 0.3 ML 31G 1/2" 0.3 ML 31 X 1/2" | 2 | PA; ST |
| EASY COMFORT 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| EASY COMFORT 0.3 ML SYRINGE 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| EASY COMFORT 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| EASY COMFORT 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| EASY COMFORT 0.5 ML 32GX5/16" 1/2 ML 32 GAUGE X 5/16" | 2 | PA; ST |
| EASY COMFORT 0.5 ML SYRINGE 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| EASY COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| EASY COMFORT 1 ML 32GX5/16" 1 ML 32 GAUGE X 5/16" | 2 | PA; ST |
| EASY COMFORT ALCOHOL 70% PAD | (alcohol swabs) 1 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| EASY COMFORT INSULIN 1 ML SYR 1 ML 30 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT PEN NDL 29G 4MM 29 GAUGE X 5/32" | 2 | PA; ST |
| EASY COMFORT PEN NDL 29G 5MM 29 GAUGE X 3/16" | 2 | PA; ST |
| EASY COMFORT PEN NDL 31GX1/4" 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 31GX3/16" 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 31GX5/16" 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 32GX5/32" 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 33G 4MM 33 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 33G 5MM 33 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT PEN NDL 33G 6MM 33 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| EASY COMFORT SYR 0.5 ML 29G 8MM 1/2 ML 29 X5/16 " (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY COMFORT SYR 1 ML 29G 8MM 1 ML 29 GAUGE X 5/16 | 2 | PA; ST |
| EASY COMFORT SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY GLIDE INS 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY GLIDE INS 0.5 ML 31GX6MM 1/2 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY GLIDE INS 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" (insulin syringe-needle u-100) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| EASY GLIDE PEN NEEDLE 4MM (pen needle, diabetic) 33G 33 GAUGE X 5/32" | 2 | PA; ST |
| EASY TOUCH 0.3 ML SYR (insulin syringe-needle 30GX1/2" 0.3 ML 30 GAUGE X u-100) 1/2" | 2 | PA; ST |
| EASY TOUCH 0.5 ML SYR (insulin syringe-needle 27GX1/2" 1/2 ML 27 GAUGE X u-100) 1/2" | 2 | PA; ST |
| EASY TOUCH 0.5 ML SYR 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH 0.5 ML SYR (insulin syringe-needle 30GX1/2" 0.5 ML 30 GAUGE X u-100) 1/2" | 2 | PA; ST |
| EASY TOUCH 0.5 ML SYR 30GX5/16 0.5 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| EASY TOUCH 1 ML SYR (insulin syringe-needle 27GX1/2" 1 ML 27 GAUGE X u-100) 1/2" | 2 | PA; ST |
| EASY TOUCH 1 ML SYR 29GX1/2" 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH 1 ML SYR 30GX1/2" 1 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH ALCOHOL 70% (alcohol swabs) PADS GAMMA-STERILIZED | 1 | PA; ST |
| EASY TOUCH FLIPILOK 1 ML 27GX0.5 1 ML 27 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH INSULIN 1 ML 29GX1/2 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH INSULIN 1 ML 30GX1/2 1 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH INSULIN SYR 0.3 (insulin syringe-needle ML 0.3 ML 30 GAUGE X 5/16", 0.3 u-100) ML 31 GAUGE X 5/16" | 2 | PA; ST |
| EASY TOUCH INSULIN SYR 0.5 (insulin syringe-needle ML 0.5 ML 30 GAUGE X 5/16", 0.5 u-100) ML 31 GAUGE X 5/16" | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| EASY TOUCH INSULIN SYR 1 ML 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH INSULIN SYR 1 ML RETRACTABLE 1 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH INSULN 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH INSULN 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| EASY TOUCH INSULN 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| EASY TOUCH INSULN 1 ML 30GX5/16 1 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| EASY TOUCH INSULN 1 ML 31GX5/16 1 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| EASY TOUCH INSULN 1 ML 31GX5/16 1 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| EASY TOUCH LUER LOK INSUL 1 ML (insulin syringe needleless) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 30GX5/16 30 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 31GX3/16 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 31GX5/16 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 32GX3/16 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| EASY TOUCH PEN NEEDLE 32GX5/32 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites | |
|--|-----------------------------------|------------------------------------|--------|
| EASY TOUCH SAF PEN NDL 29G 5MM 29 GAUGE X 3/16" | 2 | PA; ST | |
| EASY TOUCH SAF PEN NDL 29G 8MM 29 GAUGE X 5/16" | 2 | PA; ST | |
| EASY TOUCH SAF PEN NDL 30G 5MM 30 GAUGE X 3/16" | 2 | PA; ST | |
| EASY TOUCH SAF PEN NDL 30G 8MM 30 GAUGE X 5/16" | 2 | PA; ST | |
| EASY TOUCH SYR 0.5 ML 28G 12.7MM 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH SYR 0.5 ML 29G 12.7MM 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH SYR 1 ML 27G 16MM 1 ML 27 GAUGE X 5/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH SYR 1 ML 28G 12.7MM 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH SYR 1 ML 29G 12.7MM 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| EASY TOUCH UNI-SLIP SYR 1 ML | (insulin syringe needleless) | 2 | PA; ST |
| EASYTOUCH SAF PEN NDL 30G 6MM 30 GAUGE X 1/4" | 2 | PA; ST | |
| EMBRACE PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 30G 5MM 30 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 31G 6MM 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| EMBRACE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| EQL INSULIN 0.5 ML SYRINGE 1/2 ML 29 (Ultilet Insulin Syringe) | 2 | PA; ST |
| EQL INSULIN 0.5 ML SYRINGE SHORT NEEDLE 1/2 ML 30 GAUGE (Ultra Comfort Insulin Syringe) | 2 | PA; ST |
| EQL INSULIN 1 ML SYRINGE SHORT NEEDLE 1 ML 30 GAUGE X 7/16" (Ultra Comfort Insulin Syringe) | 2 | PA; ST |
| EXEL U100 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| FP INSULIN 1 ML SYRINGE 1 ML 28 GAUGE | 2 | PA; ST |
| FREESTYLE PREC 0.5 ML 30GX5/16 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| FREESTYLE PREC 0.5 ML 31GX5/16 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| FREESTYLE PREC 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| FREESTYLE PREC 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| GAUZE PAD TOPICAL BANDAGE 2 X 2 " (gauze bandage) | 1 | PA; ST |
| GAUZE PADS 2"X2" STRL 2 X 2 " (Bordered Gauze) | 1 | PA; ST |
| GNP ALCOHOL SWAB STERILE, TWO PLY (Alcohol Pads) | 1 | PA; ST |
| GNP CLICKFINE 31G X 1/4" NDL 6MM, UNIVERSAL 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| GNP CLICKFINE 31G X 5/16" NDL 8MM, UNIVERSAL 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| GNP PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" (1st Tier Unifine Pentips) | 2 | PA; ST |
| GNP PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" (1st Tier Unifine Pentips) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| GNP PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" (CareFine Pen Needle) | 2 | PA; ST |
| GNP SIMPLI PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| GNP ULT C 0.3 ML 29GX1/2" (1/2) 1/2 UNIT 0.3 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| GNP ULT CMFRT 0.5 ML 29GX1/2" 1/2 ML 29 (insulin syringe-needle u-100) | 2 | PA; ST |
| GNP ULTRA COMFORT 0.5 ML SYR 1/2 ML 30 GAUGE (insulin syringe-needle u-100) | 2 | PA; ST |
| GNP ULTRA COMFORT 1 ML SYRINGE 1 ML 29 GAUGE | 2 | PA; ST |
| GNP ULTRA COMFORT 1 ML SYRINGE 1 ML 30 GAUGE X 7/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| GNP ULTRA COMFORT 3/10 ML SYR 0.3 ML 30 (insulin syringe-needle u-100) | 2 | PA; ST |
| GS PEN NEEDLE 31G X 8MM 31 GAUGE X 5/16" (1st Tier Unifine Pentips) | 2 | PA; ST |
| HEALTHWISE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE INS 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| HEALTHWISE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| HEALTHWISE PEN NEEDLE 31G (pen needle, diabetic) 8MM 31 GAUGE X 5/16" | 2 | PA; ST |
| HEALTHWISE PEN NEEDLE 32G (pen needle, diabetic) 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| HEALTHY ACCENTS PENTIP (pen needle, diabetic) 4MM 32G 32 GAUGE X 5/32" | 2 | PA; ST |
| HEALTHY ACCENTS PENTIP (pen needle, diabetic) 5MM 31G 31 GAUGE X 3/16" | 2 | PA; ST |
| HEALTHY ACCENTS PENTIP (pen needle, diabetic) 6MM 31G 31 GAUGE X 1/4" | 2 | PA; ST |
| HEALTHY ACCENTS PENTIP (pen needle, diabetic) 8MM 31G 31 GAUGE X 5/16" | 2 | PA; ST |
| HEALTHY ACCENTS PENTIP 12MM 29G 29 GAUGE X 1/2" | 2 | PA; ST |
| HEB INCONTROL ALCOHOL 70% (alcohol swabs) PADS | 1 | PA; ST |
| INCONTROL PEN NEEDLE 12MM (pen needle, diabetic) 29G 29 GAUGE X 1/2" | 2 | PA; ST |
| INCONTROL PEN NEEDLE 4MM (pen needle, diabetic) 32G 32 GAUGE X 5/32" | 2 | PA; ST |
| INCONTROL PEN NEEDLE 5MM (pen needle, diabetic) 31G 31 GAUGE X 3/16" | 2 | PA; ST |
| INCONTROL PEN NEEDLE 6MM (pen needle, diabetic) 31G 31 GAUGE X 1/4" | 2 | PA; ST |
| INCONTROL PEN NEEDLE 8MM (pen needle, diabetic) 31G 31 GAUGE X 5/16" | 2 | PA; ST |
| INPEN (FOR HUMALOG) BLUE SUBCUTANEOUS INSULIN PEN | 3 | |
| INPEN (NOVOLOG OR FIASP) BLUE SUBCUTANEOUS INSULIN PEN | 3 | |
| INSULIN SYR 0.3 ML (UltiCare Insuln Syr(half 31GX1/4(1/2) 0.3 ML 31 GAUGE X unit)) 1/4" | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| INSULIN SYR 0.5 ML 28G 12.7MM (OTC) 1/2 ML 28 GAUGE X 1/2" (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRIN 0.5 ML 30GX1/2" (RX) 0.5 ML 30 GAUGE X 1/2" (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 0.5 ML 27G 1/2" INNER 1/2 ML 27 GAUGE X 1/2" (Easy Touch Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 0.3 ML 0.3 ML 29 GAUGE (insulin syringe-needle u-100) | 2 | PA; ST |
| INSULIN SYRINGE 0.3 ML 31GX1/4 0.3 ML 31 GAUGE X 1/4" (Sure Comfort Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 0.5 ML 1/2 ML 29 (insulin syringe-needle u-100) | 2 | PA; ST |
| INSULIN SYRINGE 0.5 ML 31GX1/4 1/2 ML 31 GAUGE X 1/4" (Sure Comfort Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 1 ML 29 GAUGE | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 27G 1/2" INNER 1 ML 27 GAUGE X 1/2" (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 27G 16MM 1 ML 27 GAUGE X 5/8" (BD SafetyGlide Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 28G 12.7MM (OTC) 1 ML 28 GAUGE X 1/2" (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 30GX1/2" SHORT NEEDLE (OTC) 1 ML 30 GAUGE X 1/2" (BD Eclipse Luer-Lok) | 2 | PA; ST |
| INSULIN SYRINGE 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" (Sure Comfort Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE NEEDLELESS SYRINGE 1 ML (Easy Touch Luer Lock Insulin) | 2 | PA; ST |
| INSULIN SYRINGE-NEEDLE U- 100 SYRINGE 0.3 ML 29 GAUGE (Ultilet Insulin Syringe) | 2 | PA; ST |
| INSULIN SYRINGE-NEEDLE U- 100 SYRINGE 1 ML 29 GAUGE X 1/2" (Comfort EZ Insulin Syringe) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| INSULIN SYRINGE-NEEDLE U-100 SYRINGE 1/2 ML 28 GAUGE (Monoject Syringe) | 2 | PA; ST |
| INSULIN U-500 SYRINGE-NEEDLE SYRINGE 1/2 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| INSUMED SYRINGE 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| INSUPEN 30G ULTRAFIN NEEDLE 30 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN 31G ULTRAFIN NEEDLE 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN 32G 8MM PEN NEEDLE 32 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN PEN NEEDLE 29GX12MM 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN PEN NEEDLE 32G 6MM (RX) 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN PEN NEEDLE 32GX4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| INSUPEN PEN NEEDLE 33GX4MM 33 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| IV ANTISEPTIC WIPES (alcohol swabs) | 1 | PA; ST |
| KENDALL ALCOHOL 70% PREP PAD (alcohol swabs) | 1 | PA; ST |
| LISCO SPONGES 100/BAG 2 X 2 " | 1 | PA; ST |
| LITE TOUCH 31GX1/4" PEN NEEDLE 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| LITE TOUCH INSULIN 0.5 ML SYR 1/2 ML 28 GAUGE, 1/2 ML 29 , 1/2 ML 30 GAUGE (insulin syringe-needle u-100) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| LITE TOUCH INSULIN 1 ML SYR (insulin syringe-needle 1 ML 28 GAUGE, 1 ML 30 GAUGE u-100) X 7/16" | 2 | PA; ST |
| LITE TOUCH INSULIN 1 ML SYR 1 ML 29 GAUGE | 2 | PA; ST |
| LITE TOUCH INSULIN SYR 1 ML (insulin syringe-needle 1 ML 31 GAUGE X 5/16 u-100) | 2 | PA; ST |
| LITE TOUCH PEN NEEDLE 29G (pen needle, diabetic) 29 GAUGE X 1/2" | 2 | PA; ST |
| LITE TOUCH PEN NEEDLE 31G (pen needle, diabetic) 31 GAUGE X 3/16", 31 GAUGE X 5/16" | 2 | PA; ST |
| LITETOUCH INS 0.3 ML 29GX1/2" (insulin syringe-needle 0.3 ML 29 GAUGE X 1/2" u-100) | 2 | PA; ST |
| LITETOUCH INS 0.3 ML (insulin syringe-needle 30GX5/16" 0.3 ML 30 GAUGE X u-100) 5/16" | 2 | PA; ST |
| LITETOUCH INS 0.3 ML (insulin syringe-needle 31GX5/16" 0.3 ML 31 GAUGE X u-100) 5/16" | 2 | PA; ST |
| LITETOUCH INS 0.5 ML (insulin syringe-needle 31GX5/16" 0.5 ML 31 GAUGE X u-100) 5/16" | 2 | PA; ST |
| LITETOUCH SYR 0.5 ML (insulin syringe-needle 28GX1/2" 1/2 ML 28 GAUGE X u-100) 1/2" | 2 | PA; ST |
| LITETOUCH SYR 0.5 ML (insulin syringe-needle 29GX1/2" 0.5 ML 29 GAUGE X u-100) 1/2" | 2 | PA; ST |
| LITETOUCH SYR 0.5 ML (insulin syringe-needle 30GX5/16" 0.5 ML 30 GAUGE X u-100) 5/16" | 2 | PA; ST |
| LITETOUCH SYRIN 1 ML (insulin syringe-needle 28GX1/2" 1 ML 28 GAUGE X u-100) 1/2" | 2 | PA; ST |
| LITETOUCH SYRIN 1 ML (insulin syringe-needle 29GX1/2" 1 ML 29 GAUGE X u-100) 1/2" | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| LITETOUCH SYRIN 1 ML (insulin syringe-needle 30GX5/16" 1 ML 30 GAUGE X 5/16 u-100) | 2 | PA; ST |
| MAGELLAN INSUL SYRINGE 0.3 ML 0.3 ML 30 X 5/16" | 2 | PA; ST |
| MAGELLAN INSUL SYRINGE 0.5 ML 0.5 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| MAGELLAN INSULIN SYR 0.3 ML 0.3 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| MAGELLAN INSULIN SYR 0.5 ML 0.5 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| MAGELLAN INSULIN SYRINGE 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| MAXICOMFORT II PEN NDL (pen needle, diabetic) 31GX6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| MAXICOMFORT INS 0.5 ML (insulin syringe-needle 27GX1/2" 1/2 ML 27 GAUGE X u-100) 1/2" | 2 | PA; ST |
| MAXI-COMFORT INS 0.5 ML 28G (insulin syringe-needle 1/2 ML 28 GAUGE X 1/2" u-100) | 2 | PA; ST |
| MAXICOMFORT INS 1 ML (insulin syringe-needle 27GX1/2" 1 ML 27 GAUGE X 1/2" u-100) | 2 | PA; ST |
| MAXI-COMFORT INS 1 ML (insulin syringe-needle 28GX1/2" 1 ML 28 GAUGE X 1/2" u-100) | 2 | PA; ST |
| MAXICOMFORT PEN NDL 29G X 5MM 29 GAUGE X 3/16" | 2 | PA; ST |
| MAXICOMFORT PEN NDL 29G X 8MM 29 GAUGE X 5/16" | 2 | PA; ST |
| MICRODOT PEN NEEDLE (pen needle, diabetic) 31GX6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| MICRODOT PEN NEEDLE (pen needle, diabetic) 32GX4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| MICRODOT PEN NEEDLE (pen needle, diabetic) 33GX4MM 33 GAUGE X 5/32" | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|---------------------------------|------------------------------|------------------------------------|
| MICRODOT READYGARD NDL 31G 5MM OUTER 31 GAUGE X 3/16" | (pen needle, diabetic, safety) | 2 | PA; ST |
| MINI PEN NEEDLE 32G 5MM 32 GAUGE X 3/16" | (CareFine Pen Needle) | 2 | PA; ST |
| MINI PEN NEEDLE 32G 8MM 32 GAUGE X 5/16" | (Comfort EZ Pen Needles) | 2 | PA; ST |
| MINI PEN NEEDLE 33G 4MM 33 GAUGE X 5/32" | (Advocate Pen Needle) | 2 | PA; ST |
| MINI PEN NEEDLE 33G 5MM 33 GAUGE X 3/16" | (Comfort EZ Pen Needles) | 2 | PA; ST |
| MINI PEN NEEDLE 33G 6MM 33 GAUGE X 1/4" | (Comfort EZ Pen Needles) | 2 | PA; ST |
| MINI ULTRA-THIN II PEN NDL 31G STERILE 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| MONOJECT 0.5 ML SYRN 28GX1/2" 1/2 ML 28 GAUGE | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT 1 ML SYRN 27X1/2" 1 ML 27 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT 1 ML SYRN 28GX1/2" (OTC) 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 (OTC) 0.3 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 .5ML,29GX1/2" (OTC) 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 0.5 ML CONVERTS TO 29G (OTC) 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 1 ML 1 ML 25 GAUGE X 5/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 1 ML 3'S, 29GX1/2" (OTC) 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSUL SYR U100 1 ML W/O NEEDLE (OTC) | (insulin syringes (disposable)) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| MONOJECT INSULIN SYR 0.3 ML (OTC) 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR 0.3 ML 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR 0.5 ML (OTC) 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR 0.5 ML 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR 1 ML 3'S (OTC) 1 ML 30 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR U-100 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT INSULIN SYR U-100 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| MONOJECT SYRINGE 0.3 ML 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT SYRINGE 0.5 ML 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| MONOJECT SYRINGE 1 ML 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| MS INSULIN SYR 1 ML 31GX5/16" (OTC) 1 ML 31 GAUGE X 5/16 (Advocate Syringes) | 2 | PA; ST |
| MS INSULIN SYRINGE 0.3 ML 0.3 ML 30 (Ultra Comfort Insulin Syringe) | 2 | PA; ST |
| NANO 2 GEN PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| NANO PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| NOVOFINE 30 NEEDLE | 2 | PA; ST |
| NOVOFINE 32G NEEDLES 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| NOVOFINE PLUS PEN NDL 32GX1/6" 32 GAUGE X 1/6" | 2 | PA; ST |
| NOVOTWIST NEEDLE 32 GAUGE X 1/5" | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| OMNIPOD 5 (G6/LIBRE 2 PLUS) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD 5 G6-G7 INTRO KT(GEN5) SUBCUTANEOUS CARTRIDGE | 3 | QL (1 per 365 days) |
| OMNIPOD 5 G6-G7 PODS (GEN 5) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD 5 INTRO(G6/LIBRE2PLUS) SUBCUTANEOUS CARTRIDGE | 3 | QL (1 per 365 days) |
| OMNIPOD CLASSIC PDM KIT(GEN 3) | 3 | QL (1 per 365 days) |
| OMNIPOD CLASSIC PODS (GEN 3) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| OMNIPOD DASH INTRO KIT (GEN 4) SUBCUTANEOUS CARTRIDGE | 3 | QL (1 per 365 days) |
| OMNIPOD DASH PDM KIT (GEN 4) | 3 | QL (1 per 365 days) |
| OMNIPOD DASH PODS (GEN 4) SUBCUTANEOUS CARTRIDGE | 3 | QL (10 per 30 days) |
| PC UNIFINE PENTIPS 8MM NEEDLE SHORT 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| PEN NEEDLE 30G 5MM OUTER 30 GAUGE X 3/16" (Embrace Pen Needle) | 2 | PA; ST |
| PEN NEEDLE 30G 8MM INNER 30 GAUGE X 5/16" (CareFine Pen Needle) | 2 | PA; ST |
| PEN NEEDLE 30G X 5/16" 30 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| PEN NEEDLE 31G X 1/4" HRI 31 GAUGE X 1/4" (1st Tier Unifine Pentips) | 2 | PA; ST |
| PEN NEEDLE 6MM 31G 6MM 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| PEN NEEDLE, DIABETIC NEEDLE 29 GAUGE X 1/2" (1st Tier Unifine Pentips Plus) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| PEN NEEDLES 12MM 29G 29GX12MM,STRL 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| PEN NEEDLES 4MM 32G 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| PEN NEEDLES 5MM 31G 31GX5MM,STRL,MINI (OTC) 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| PEN NEEDLES 8MM 31G 31GX8MM,STRL,SHORT (OTC) 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 29G 1/2" 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 31G 1/4" 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 31GX3/16" MINI, 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 31GX5/16" SHORT, 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 32G 1/4" 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| PENTIPS PEN NEEDLE 32GX5/32" 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| PIP PEN NEEDLE 31G X 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| PIP PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| PREFPLS INS SYR 1 ML 30GX5/16" (OTC) 1 ML 30 GAUGE X 5/16 (Advocate Syringes) | 2 | PA; ST |
| PREVENT PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | 2 | PA; ST |
| PREVENT PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | 2 | PA; ST |
| PRO COMFORT 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| PRO COMFORT 0.5 ML 30GX5/16" (insulin syringe-needle 0.5 ML 30 GAUGE X 5/16" u-100) | 2 | PA; ST |
| PRO COMFORT 0.5 ML 31GX5/16" (insulin syringe-needle 0.5 ML 31 GAUGE X 5/16" u-100) | 2 | PA; ST |
| PRO COMFORT 1 ML 30GX1/2" 1 (insulin syringe-needle ML 30 GAUGE X 1/2" u-100) | 2 | PA; ST |
| PRO COMFORT 1 ML 30GX5/16" 1 (insulin syringe-needle ML 30 GAUGE X 5/16" u-100) | 2 | PA; ST |
| PRO COMFORT 1 ML 31GX5/16" 1 (insulin syringe-needle ML 31 GAUGE X 5/16" u-100) | 2 | PA; ST |
| PRO COMFORT ALCOHOL 70% (alcohol swabs) PADS | 1 | PA; ST |
| PRO COMFORT PEN NDL 32G (pen needle, diabetic) 8MM 32 GAUGE X 5/16" | 2 | PA; ST |
| PRO COMFORT PEN NDL 32G X (pen needle, diabetic) 1/4" 32 GAUGE X 1/4" | 2 | PA; ST |
| PRO COMFORT PEN NDL 4MM (pen needle, diabetic) 32G 32 GAUGE X 5/32" | 2 | PA; ST |
| PRO COMFORT PEN NDL 5MM (pen needle, diabetic) 32G 32 GAUGE X 3/16" | 2 | PA; ST |
| PRODIGY INS SYR 1 ML (insulin syringe-needle 28GX1/2" 1 ML 28 GAUGE X 1/2" u-100) | 2 | PA; ST |
| PRODIGY SYRNG 0.5 ML (insulin syringe-needle 31GX5/16" 0.5 ML 31 GAUGE X u-100) 5/16" | 2 | PA; ST |
| PRODIGY SYRNGE 0.3 ML (insulin syringe-needle 31GX5/16" 0.3 ML 31 GAUGE X u-100) 5/16" | 2 | PA; ST |
| PURE CMFT SFTY PEN NDL 31G (pen needle, diabetic, 5MM 31 GAUGE X 3/16" safety) | 2 | PA; ST |
| PURE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| PURE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| PURE COMFORT ALCOHOL 70% (alcohol swabs) PADS | 1 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| PURE COMFORT PEN NDL 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| PURE COMFORT PEN NDL 32G 5MM 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| PURE COMFORT PEN NDL 32G 6MM 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| PURE COMFORT PEN NDL 32G 8MM 32 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| RAYA SURE PEN NEEDLE 29G 12MM 29 GAUGE X 15/32" | 2 | PA; ST |
| RAYA SURE PEN NEEDLE 31G 4MM 31 GAUGE X 5/32" (Comfort Touch Pen Needle) | 2 | PA; ST |
| RAYA SURE PEN NEEDLE 31G 5MM 31 GAUGE X 13/64" | 2 | PA; ST |
| RAYA SURE PEN NEEDLE 31G 6MM 31 GAUGE X 15/64" | 2 | PA; ST |
| RELION INS SYR 0.3 ML 31GX6MM 0.3 ML 31 GAUGE X 15/64" (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| RELION INS SYR 0.5 ML 31GX6MM 1/2 ML 31 GAUGE X 15/64" (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| RELION INS SYR 1 ML 31GX15/64" 1 ML 31 GAUGE X 15/64" (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| SAFESNAP INS SYR UNITS-100 0.3 ML 30GX5/16",10X10 0.3 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| SAFESNAP INS SYR UNITS-100 0.5 ML 29GX1/2",10X10 0.5 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| SAFESNAP INS SYR UNITS-100 0.5 ML 30GX5/16",10X10 0.5 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| SAFESNAP INS SYR UNITS-100 1 ML 28GX1/2",10X10 1 ML 28 GAUGE X 1/2" | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| SAFESNAP INS SYR UNITS-100 1 ML 29GX1/2",10X10 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| SAFETY PEN NEEDLE 31G 4MM 31 GAUGE X 5/32" (Comfort EZ PRO Safety Pen Ndl) | 2 | PA; ST |
| SAFETY PEN NEEDLE 5MM X 31G 31 GAUGE X 3/16" (pen needle, diabetic, safety) | 2 | PA; ST |
| SAFETY SYRINGE 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| SECURESAFE PEN NDL 30GX5/16" OUTER 30 GAUGE X 5/16" | 2 | PA; ST |
| SECURESAFE SYR 0.5 ML 29G 1/2" OUTER 0.5 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| SECURESAFE SYRNG 1 ML 29G 1/2" OUTER 1 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| SKY SAFETY PEN NEEDLE 30G 5MM 30 GAUGE X 3/16" | 2 | PA; ST |
| SKY SAFETY PEN NEEDLE 30G 8MM 30 GAUGE X 5/16" | 2 | PA; ST |
| SM ULT CFT 0.3 ML 31GX5/16(1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| STERILE PADS 2" X 2" 2 X 2 " (gauze bandage) | 1 | PA; ST |
| SURE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| SURE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| NEEDLES, INSULIN DISP., SAFETY (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE COMFORT 0.5 ML SYRINGE 0.5 ML 30 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1/2 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| SURE COMFORT 1 ML SYRINGE (insulin syringe-needle u-100) 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | 2 | PA; ST |
| SURE COMFORT 3/10 ML SYRINGE (insulin syringe-needle u-100) 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| SURE COMFORT 3/10 ML SYRINGE (insulin syringe-needle u-100) INSULIN SYRINGE 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| SURE COMFORT 30G PEN (pen needle, diabetic) NEEDLE 30 GAUGE X 5/16" | 2 | PA; ST |
| SURE COMFORT ALCOHOL (alcohol swabs) PREP PADS | 1 | PA; ST |
| SURE COMFORT INS 0.3 ML (insulin syringe-needle u-100) 31GX1/4 0.3 ML 31 GAUGE X 1/4" | 2 | PA; ST |
| SURE COMFORT INS 0.5 ML (insulin syringe-needle u-100) 31GX1/4 1/2 ML 31 GAUGE X 1/4" | 2 | PA; ST |
| SURE COMFORT INS 1 ML (insulin syringe-needle u-100) 31GX1/4" 1 ML 31 GAUGE X 1/4" | 2 | PA; ST |
| SURE COMFORT PEN NDL (pen needle, diabetic) 29GX1/2" 12.7MM 29 GAUGE X 1/2" | 2 | PA; ST |
| SURE COMFORT PEN NDL 31G (pen needle, diabetic) 5MM 31 GAUGE X 3/16" | 2 | PA; ST |
| SURE COMFORT PEN NDL 31G (pen needle, diabetic) 8MM 31 GAUGE X 5/16" | 2 | PA; ST |
| SURE COMFORT PEN NDL 32G (pen needle, diabetic) 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| SURE COMFORT PEN NDL 32G (pen needle, diabetic) 6MM 32 GAUGE X 1/4" | 2 | PA; ST |
| SURE-FINE PEN NEEDLES (pen needle, diabetic) 12.7MM 29 GAUGE X 1/2" | 2 | PA; ST |
| SURE-FINE PEN NEEDLES 5MM (pen needle, diabetic) 31 GAUGE X 3/16" | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| SURE-FINE PEN NEEDLES 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| SURE-JECT INSU SYR U100 0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE-JECT INSU SYR U100 0.5 ML 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 1/2 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE-JECT INSU SYR U100 1 ML 1 ML 28 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE-JECT INSUL SYR U100 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE-JECT INSULIN SYRINGE 1 ML 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| SURE-PREP ALCOHOL PREP PADS (alcohol swabs) | 1 | PA; ST |
| TECHLITE 0.3 ML 29GX12MM (1/2) 0.3 ML 29 GAUGE X 1/2" | 2 | PA; ST |
| TECHLITE 0.3 ML 30GX8MM (1/2) 0.3 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| TECHLITE 0.3 ML 31GX6MM (1/2) 0.3 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| TECHLITE 0.3 ML 31GX8MM (1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| TECHLITE 0.5 ML 30GX12MM (1/2) 0.5 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| TECHLITE 0.5 ML 30GX8MM (1/2) 0.5 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| TECHLITE 0.5 ML 31GX6MM (1/2) 0.5 ML 31 GAUGE X 15/64" | 2 | PA; ST |
| TECHLITE 0.5 ML 31GX8MM (1/2) 0.5 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| TECHLITE INS SYR 1 ML 29GX12MM 1 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------------------|------------------------------|------------------------------------|
| TECHLITE INS SYR 1 ML 30GX12MM 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TECHLITE INS SYR 1 ML 31GX6MM 1 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TECHLITE INS SYR 1 ML 31GX8MM 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 29GX3/8" 29 GAUGE X 3/8" | | 2 | PA; ST |
| TECHLITE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 32GX5/16" 32 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| TECHLITE PLUS PEN NDL 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| TERUMO INS SYRINGE U100-1 ML 1 ML 27 GAUGE X 1/2", 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TERUMO INS SYRINGE U100-1 ML 1 ML 30 GAUGE X 3/8" | (Thinpro Insulin Syringe) | 2 | PA; ST |
| TERUMO INS SYRINGE U100-1/2 ML 1/2 ML 30 X 3/8" | (insulin syringe-needle u-100) | 2 | PA; ST |
| TERUMO INS SYRINGE U100-1/3 ML 0.3 ML 30 X 3/8" | (insulin syringe-needle u-100) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-------------------------------------|------------------------------------|
| TERUMO INS SYRNG U100-1/2 ML 0.5 ML 29 GAUGE X 1/2", 1/2 ML 27 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| THINPRO INS SYRIN U100-0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 X 3/8" | (insulin syringe-needle u-100) 2 | PA; ST |
| THINPRO INS SYRIN U100-0.3 ML 0.3 ML 31 X 3/8" | 2 | PA; ST |
| THINPRO INS SYRIN U100-0.5 ML 0.5 ML 29 GAUGE X 1/2", 1/2 ML 28 GAUGE X 1/2", 1/2 ML 30 X 3/8" | (insulin syringe-needle u-100) 2 | PA; ST |
| THINPRO INS SYRIN U100-0.5 ML 0.5 ML 31 X 3/8" | 2 | PA; ST |
| THINPRO INS SYRIN U100-1 ML 1 ML 28 GAUGE X 1/2", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 3/8" | (insulin syringe-needle u-100) 2 | PA; ST |
| THINPRO INS SYRIN U100-1 ML 1 ML 31 X 3/8" | 2 | PA; ST |
| TOPCARE CLICKFINE 31G X 1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) 2 | PA; ST |
| TOPCARE CLICKFINE 31G X 5/16" 31 GAUGE X 5/16" | (pen needle, diabetic) 2 | PA; ST |
| TOPCARE ULTRA COMFORT SYRINGE 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16", 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16", 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) 2 | PA; ST |
| TRUE CMFRT PRO 0.5 ML 30G 5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| TRUE CMFRT PRO 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| TRUE CMFRT PRO 0.5 ML 32G 5/16" 1/2 ML 32 GAUGE X 5/16" | 2 | PA; ST |
| TRUE CMFT SFTY PEN NDL 31G (pen needle, diabetic, 5MM 31 GAUGE X 3/16" safety) | 2 | PA; ST |
| TRUE CMFT SFTY PEN NDL 31G 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| TRUE CMFT SFTY PEN NDL 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| TRUE COMFORT 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| TRUE COMFORT 0.5 ML 30G 5/16" 0.5 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| TRUE COMFORT 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| TRUE COMFORT 0.5 ML (insulin syringe-needle 31GX5/16" 0.5 ML 31 GAUGE X u-100) 5/16" | 2 | PA; ST |
| TRUE COMFORT 1 ML 31GX5/16" (insulin syringe-needle 1 ML 31 GAUGE X 5/16 u-100) | 2 | PA; ST |
| TRUE COMFORT ALCOHOL 70% (alcohol swabs) PADS | 1 | PA; ST |
| TRUE COMFORT PEN NDL 31G (pen needle, diabetic) 8MM 31 GAUGE X 5/16" | 2 | PA; ST |
| TRUE COMFORT PEN NDL (pen needle, diabetic) 31GX5MM 31 GAUGE X 3/16" | 2 | PA; ST |
| TRUE COMFORT PEN NDL (pen needle, diabetic) 31GX6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| TRUE COMFORT PEN NDL (pen needle, diabetic) 5MM 32 GAUGE X 3/16" | 2 | PA; ST |
| TRUE COMFORT PEN NDL (pen needle, diabetic) 6MM 32 GAUGE X 1/4" | 2 | PA; ST |
| TRUE COMFORT PEN NDL (pen needle, diabetic) 32GX4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| TRUE COMFORT PEN NDL (pen needle, diabetic) 4MM 33 GAUGE X 5/32" | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| TRUE COMFORT PEN NDL 33G 5MM 33 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PEN NDL 33G 6MM 33 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| TRUE COMFORT PRO 1 ML 30G 1/2" 1 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE COMFORT PRO 1 ML 30G 5/16" 1 ML 30 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE COMFORT PRO 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE COMFORT PRO 1 ML 32G 5/16" 1 ML 32 GAUGE X 5/16" | 2 | PA; ST |
| TRUE COMFORT PRO ALCOHOL PADS (alcohol swabs) | 1 | PA; ST |
| TRUE COMFORT SFTY 1 ML 30G 1/2" 1 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| TRUE COMFRT PRO 0.5 ML 30G 1/2" 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| TRUE COMFRT SFTY 1 ML 30G 5/16" 1 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| TRUE COMFRT SFTY 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16" | 2 | PA; ST |
| TRUE COMFRT SFTY 1 ML 32G 5/16" 1 ML 32 GAUGE X 5/16" | 2 | PA; ST |
| TRUEPLUS PEN NEEDLE 29GX1/2" 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| TRUEPLUS PEN NEEDLE 31G X 1/4" 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| TRUEPLUS PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| TRUEPLUS PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| TRUEPLUS PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| TRUEPLUS SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-------------------------------------|------------------------------------|
| TRUEPLUS SYR 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 PA; ST |
| TRUEPLUS SYR 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 PA; ST |
| TRUEPLUS SYR 0.5 ML 28GX1/2" 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 PA; ST |
| TRUEPLUS SYR 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 PA; ST |
| TRUEPLUS SYR 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 PA; ST |
| TRUEPLUS SYR 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 PA; ST |
| TRUEPLUS SYR 1 ML 28GX1/2" 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 PA; ST |
| TRUEPLUS SYR 1 ML 29GX1/2" 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 PA; ST |
| TRUEPLUS SYR 1 ML 30GX5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 PA; ST |
| TRUEPLUS SYR 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 PA; ST |
| ULTICAR INS 0.3 ML 31GX1/4(1/2) 0.3 ML 31 GAUGE X 1/4" | (insulin syr/ndl u100 half mark) | 2 PA; ST |
| ULTICARE INS 1 ML 31GX1/4" 1 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 PA; ST |
| ULTICARE INS SYR 0.3 ML 30G 8MM 0.3 ML 30 GAUGE X 5/16" | (Advocate Syringes) | 2 PA; ST |
| ULTICARE INS SYR 0.3 ML 31G 6MM 0.3 ML 31 GAUGE X 1/4" | (insulin syringe-needle u-100) | 2 PA; ST |
| ULTICARE INS SYR 0.3 ML 31G 8MM 0.3 ML 31 GAUGE X 5/16" | (Advocate Syringes) | 2 PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|-----------------------|----------------------------|
| ULTICARE INS SYR 0.5 ML 30G 8MM (OTC) 0.5 ML 30 GAUGE X 5/16" (Advocate Syringes) | 2 | PA; ST |
| ULTICARE INS SYR 0.5 ML 31G 6MM 1/2 ML 31 GAUGE X 1/4" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE INS SYR 0.5 ML 31G 8MM (OTC) 0.5 ML 31 GAUGE X 5/16" (Advocate Syringes) | 2 | PA; ST |
| ULTICARE INS SYR 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| ULTICARE PEN NEEDLE 6MM 31G 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| ULTICARE PEN NEEDLE 8MM 31G 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| ULTICARE PEN NEEDLES 12MM 29G 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| ULTICARE PEN NEEDLES 4MM 32G MICRO, 32GX4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| ULTICARE PEN NEEDLES 6MM 32G 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| ULTICARE SAFE PEN NDL 30G 8MM 30 GAUGE X 5/16" | 2 | PA; ST |
| ULTICARE SAFE PEN NDL 5MM 30G 30 GAUGE X 3/16" | 2 | PA; ST |
| ULTICARE SAFETY 0.5 ML 29GX1/2 (RX) 0.5 ML 29 GAUGE X 1/2" (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| ULTICARE SYR 0.3 ML 29G 12.7MM 0.3 ML 29 GAUGE X 1/2" (Comfort EZ Insulin Syringe) | 2 | PA; ST |
| ULTICARE SYR 0.3 ML 30GX1/2" 0.3 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTICARE SYR 0.3 ML 31GX5/16" SHORT NDL 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| ULTICARE SYR 0.5 ML 30GX1/2" (insulin syringe-needle 0.5 ML 30 GAUGE X 1/2" u-100) | 2 | PA; ST |
| ULTICARE SYR 0.5 ML (insulin syringe-needle 31GX5/16" SHORT NDL 0.5 ML 31 u-100) GAUGE X 5/16" | 2 | PA; ST |
| ULTICARE SYR 1 ML 31GX5/16" (insulin syringe-needle 1 ML 31 GAUGE X 5/16 u-100) | 2 | PA; ST |
| ULTIGUARD SAFE 1 ML 30G 12.7MM 1 ML 30 X 1/2" | 2 | PA; ST |
| ULTIGUARD SAFE0.3 ML 30G 12.7MM 0.3 ML 30 X 1/2" | 2 | PA; ST |
| ULTIGUARD SAFE0.5 ML 30G 12.7MM 1/2 ML 30 X 1/2" | 2 | PA; ST |
| ULTIGUARD SAFEPACK 1 ML 31G 8MM 1 ML 31 X 5/16" | 2 | PA; ST |
| ULTIGUARD SAFEPACK 29G 12.7MM 29 GAUGE X 1/2" | 2 | PA; ST |
| ULTIGUARD SAFEPACK 31G 5MM 31 GAUGE X 3/16" | 2 | PA; ST |
| ULTIGUARD SAFEPACK 31G 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| ULTIGUARD SAFEPACK 31G 8MM 31 GAUGE X 5/16" | 2 | PA; ST |
| ULTIGUARD SAFEPACK 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| ULTIGUARD SAFEPACK 32G 6MM 32 GAUGE X 1/4" | 2 | PA; ST |
| ULTIGUARD SAFEPK 0.3 ML 31G 8MM 0.3 ML 31 X 5/16" | 2 | PA; ST |
| ULTIGUARD SAFEPK 0.5 ML 31G 8MM 1/2 ML 31 X 5/16" | 2 | PA; ST |
| ULTILET ALCOHOL STERL (alcohol swabs) SWAB | 1 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-------------------------------------|----------------------------|
| ULTILET INSULIN SYRINGE 0.3 ML 0.3 ML 29 GAUGE X 1/2", 0.3 ML 30 GAUGE X 5/16", 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| ULTILET INSULIN SYRINGE 0.5 ML 0.5 ML 29 GAUGE X 1/2", 0.5 ML 30 GAUGE X 5/16", 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| ULTILET INSULIN SYRINGE 1 ML 1 ML 29 GAUGE X 1/2", 1 ML 30 GAUGE X 5/16, 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) 2 | PA; ST |
| ULTILET PEN NEEDLE 29 GAUGE | 2 | PA; ST |
| ULTILET PEN NEEDLE 4MM 32G 32 GAUGE X 5/32" | (pen needle, diabetic) 2 | PA; ST |
| ULTRA COMFORT 0.3 ML SYRINGE 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) 2 | PA; ST |
| ULTRA COMFORT 0.5 ML 28GX1/2" CONVERTS TO 29G 1/2 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| ULTRA COMFORT 0.5 ML 29GX1/2" 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| ULTRA COMFORT 0.5 ML SYRINGE 1/2 ML 28 GAUGE | (insulin syringe-needle u-100) 2 | PA; ST |
| ULTRA COMFORT 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) 2 | PA; ST |
| ULTRA COMFORT 1 ML SYRINGE 1 ML 28 GAUGE X 1/2" | (insulin syringe-needle u-100) 2 | PA; ST |
| ULTRA FLO 0.3 ML 30G 1/2" (1/2) 0.3 ML 30 GAUGE X 1/2" | 2 | PA; ST |
| ULTRA FLO 0.3 ML 30G 5/16"(1/2) 0.3 ML 30 GAUGE X 5/16" | 2 | PA; ST |
| ULTRA FLO 0.3 ML 31G 5/16"(1/2) 0.3 ML 31 GAUGE X 5/16" | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|------------------------------|------------------------------------|
| ULTRA FLO PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO PEN NEEDLE 33G 4MM 33 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO PEN NEEDLES 12MM 29G 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |
| ULTRA FLO SYR 0.3 ML 29GX1/2" 0.3 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA FLO SYR 0.3 ML 30G 5/16" 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA FLO SYR 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA FLO SYR 0.5 ML 29G 1/2" 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA THIN PEN NDL 32G X 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE INS 0.3 ML 30GX5/16" 0.3 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 0.3 ML 31GX5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 0.5 ML 30GX1/2" 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 0.5 ML 30GX5/16" 0.5 ML 30 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 0.5 ML 31GX5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|--|--------------------------------|------------------------------|------------------------------------|
| ULTRACARE INS 1 ML 30G X 5/16" 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 1 ML 30GX1/2" 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE INS 1 ML 31G X 5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 31GX1/4" 31 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 31GX3/16" 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 31GX5/16" 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 32GX1/4" 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 32GX3/16" 32 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 32GX5/32" 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRACARE PEN NEEDLE 33GX5/32" 33 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA-FINE 0.3 ML 30G 12.7MM 0.3 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-FINE 0.3 ML 31G 6MM (1/2) 0.3 ML 31 GAUGE X 15/64" | | 2 | PA; ST |
| ULTRA-FINE 0.3 ML 31G 8MM (1/2) 0.3 ML 31 GAUGE X 5/16" | | 2 | PA; ST |
| ULTRA-FINE 0.5 ML 30G 12.7MM 0.5 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-FINE INS SYR 1 ML 31G 6MM 1 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-FINE INS SYR 1 ML 31G 8MM 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-FINE PEN NDL 29G 12.7MM 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA-FINE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------------------|------------------------------|------------------------------------|
| ULTRA-FINE PEN NEEDLE 31G 8MM 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA-FINE PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA-FINE SYR 0.5 ML 31G 6MM 1/2 ML 31 GAUGE X 15/64" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-FINE SYR 0.5 ML 31G 8MM 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-FINE SYR 1 ML 30G 12.7MM 1 ML 30 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II 1 ML 31GX5/16" 1 ML 31 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.3 ML 30G 0.3 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.3 ML 31G 0.3 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.5 ML 29G 0.5 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.5 ML 30G 0.5 ML 30 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II INS 0.5 ML 31G 0.5 ML 31 GAUGE X 5/16" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II INS SYR 1 ML 29G 1 ML 29 GAUGE X 1/2" | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II INS SYR 1 ML 30G 1 ML 30 GAUGE X 5/16 | (insulin syringe-needle u-100) | 2 | PA; ST |
| ULTRA-THIN II PEN NDL 29GX1/2" 29 GAUGE X 1/2" | (pen needle, diabetic) | 2 | PA; ST |
| ULTRA-THIN II PEN NDL 31GX5/16 31 GAUGE X 5/16" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE OTC PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE OTC PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE PEN NEEDLE 32G 4MM 32 GAUGE X 5/32" | (pen needle, diabetic) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| UNIFINE PENTIPS 12MM 29G (pen needle, diabetic) 29GX12MM, STRL 29 GAUGE X 1/2" | 2 | PA; ST |
| UNIFINE PENTIPS 31GX3/16" (pen needle, diabetic) 31GX5MM,STRL,MINI 31 GAUGE X 3/16" | 2 | PA; ST |
| UNIFINE PENTIPS 32G 4MM 32 (pen needle, diabetic) GAUGE X 5/32" | 2 | PA; ST |
| UNIFINE PENTIPS 32GX1/4" 32 (pen needle, diabetic) GAUGE X 1/4" | 2 | PA; ST |
| UNIFINE PENTIPS 33GX5/32" 33 (pen needle, diabetic) GAUGE X 5/32" | 2 | PA; ST |
| UNIFINE PENTIPS 6MM 31G 31 (pen needle, diabetic) GAUGE X 1/4" | 2 | PA; ST |
| UNIFINE PENTIPS MAX (pen needle, diabetic) 30GX3/16" 30 GAUGE X 3/16" | 2 | PA; ST |
| UNIFINE PENTIPS NEEDLES 29G 29 GAUGE | 2 | PA; ST |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 29GX1/2" 12MM 29 GAUGE X 1/2" | 2 | PA; ST |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 30GX3/16" 30 GAUGE X 3/16" | 2 | PA; ST |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 31GX1/4" ULTRA SHORT, 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 31GX3/16" MINI 31 GAUGE X 3/16" | 2 | PA; ST |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 31GX5/16" SHORT 31 GAUGE X 5/16" | 2 | PA; ST |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 32GX5/32" 32 GAUGE X 5/32" | 2 | PA; ST |
| UNIFINE PENTIPS PLUS (pen needle, diabetic) 33GX5/32" 33 GAUGE X 5/32" | 2 | PA; ST |
| UNIFINE PROTECT 30G 5MM 30 GAUGE X 3/16" | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| UNIFINE PROTECT 30G 8MM 30 GAUGE X 5/16" | 2 | PA; ST |
| UNIFINE PROTECT 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| UNIFINE SAFECONTROL 30G 5MM 30 GAUGE X 3/16" | 2 | PA; ST |
| UNIFINE SAFECONTROL 30G 8MM 30 GAUGE X 5/16" | 2 | PA; ST |
| UNIFINE SAFECONTROL 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic, safety) | 2 | PA; ST |
| UNIFINE SAFECONTROL 31G 6MM 31 GAUGE X 1/4" | 2 | PA; ST |
| UNIFINE SAFECONTROL 31G 8MM 31 GAUGE X 5/16" | 2 | PA; ST |
| UNIFINE SAFECONTROL 32G 4MM 32 GAUGE X 5/32" | 2 | PA; ST |
| UNIFINE ULTRA PEN NDL 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE ULTRA PEN NDL 31G 6MM 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE ULTRA PEN NDL 31G 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| UNIFINE ULTRA PEN NDL 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| VANISHPOINT 0.5 ML 30GX1/2" SY OUTER 0.5 ML 30 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| VANISHPOINT INS 1 ML 30GX3/16" 1 ML 30 GAUGE X 3/16" | 2 | PA; ST |
| VANISHPOINT U-100 29X1/2 SYR 1 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| VERIFINE INS SYR 1 ML 29G 1/2" 1 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 29G 12MM 29 GAUGE X 1/2" (pen needle, diabetic) | 2 | PA; ST |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| VERIFINE PEN NEEDLE 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 31G X 6MM 31 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 31G X 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 32G 6MM 32 GAUGE X 1/4" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 32G X 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PEN NEEDLE 32G X 5MM 32 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PLUS PEN NDL 31G 5MM 31 GAUGE X 3/16" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PLUS PEN NDL 31G 8MM 31 GAUGE X 5/16" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PLUS PEN NDL 32G 4MM 32 GAUGE X 5/32" (pen needle, diabetic) | 2 | PA; ST |
| VERIFINE PLUS PEN NDL 32G 4MM-SHARPS CONTAINER 32 GAUGE X 5/32" | 2 | PA; ST |
| VERIFINE SYRING 0.5 ML 29G 1/2" 0.5 ML 29 GAUGE X 1/2" (insulin syringe-needle u-100) | 2 | PA; ST |
| VERIFINE SYRING 1 ML 31G 5/16" 1 ML 31 GAUGE X 5/16 (insulin syringe-needle u-100) | 2 | PA; ST |
| VERIFINE SYRNG 0.3 ML 31G 5/16" 0.3 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| VERIFINE SYRNG 0.5 ML 31G 5/16" 0.5 ML 31 GAUGE X 5/16" (insulin syringe-needle u-100) | 2 | PA; ST |
| VERSALON ALL PURPOSE SPONGE 25'S,N-STERILE,3PLY 2 X 2 " | 1 | PA; ST |
| V-GO 20 DEVICE | 3 | QL (30 per 30 days) |
| V-GO 30 DEVICE | 3 | QL (30 per 30 days) |
| V-GO 40 DEVICE | 3 | QL (30 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | | Nivel del Medicamento | Requerimientos/ Límites |
|--|-------------------------------------|-----------------------|----------------------------|
| WEBCOL ALCOHOL PREPS 20'S,LARGE | (alcohol swabs) | 1 | PA; ST |
| Preparaciones De Reemplazo | | | |
| Preparaciones De Reemplazo | | | |
| <i>d5 % (d-glucose)-0.9 % sodchlr intravenous parenteral solution</i> | (d5 % and 0.9 % sodium chloride) | 2 | |
| <i>d5 % and 0.9 % sodium chloride intravenous parenteral solution</i> | (D5 % (d-glucose)-0.9 % sodchlr) | 2 | |
| <i>d5 %-0.45 % sodium chloride intravenous parenteral solution</i> | | 2 | |
| <i>klor-con m10 oral tablet,er particles/crystals 10 meq</i> | (potassium chloride) | 2 | |
| <i>klor-con m15 oral tablet,er particles/crystals 15 meq</i> | (potassium chloride) | 2 | |
| <i>klor-con m20 oral tablet,er particles/crystals 20 meq</i> | (potassium chloride) | 2 | |
| <i>magnesium sulfate injection solution 500 mg/ml (50 %)</i> | | 4 | |
| <i>magnesium sulfate injection syringe 500 mg/ml (50 %)</i> | | 2 | |
| <i>potassium chloride intravenous solution 2 meq/ml</i> | | 2 | |
| <i>potassium chloride oral capsule, extended release 10 meq, 8 meq</i> | | 2 | |
| <i>potassium chloride oral liquid 20 meq/15 ml, 40 meq/15 ml</i> | | 2 | |
| <i>potassium chloride oral tablet extended release 10 meq</i> | (Klor-Con 10) | 2 | |
| <i>potassium chloride oral tablet extended release 15 meq, 20 meq</i> | | 2 | |
| <i>potassium chloride oral tablet extended release 8 meq</i> | (Klor-Con 8) | 2 | |
| <i>potassium chloride oral tablet,er particles/crystals 10 meq</i> | (Klor-Con M10) | 2 | |
| <i>potassium chloride oral tablet,er particles/crystals 15 meq</i> | (Klor-Con M15) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| <i>potassium chloride oral tablet,er particles/crystals 20 meq</i> (Klor-Con M20) | 2 | |
| <i>potassium citrate oral tablet extended release 10 meq (1,080 mg)</i> (Urocit-K 10) | 2 | |
| <i>potassium citrate oral tablet extended release 15 meq</i> (Urocit-K 15) | 2 | |
| <i>potassium citrate oral tablet extended release 5 meq (540 mg)</i> | 2 | |
| <i>sodium chloride 0.45 % intravenous parenteral solution 0.45 %</i> | 2 | |
| <i>sodium chloride 0.9 % intravenous parenteral solution</i> | 2 | |
| <i>sodium chloride 0.9% solution mini-bag, single use</i> | 2 | |

Productos Para La Tos Y Resfriado

Productos Para La Tos Y Resfriado

| | | |
|--|---|----|
| <i>benzonatate oral capsule 100 mg, 200 mg</i> | 1 | EX |
|--|---|----|

Productos Sanguíneos/Modificadores/Expansores De Volumen

Agentes Hematológicos, Varios

| | | |
|---|---|--|
| <i>anagrelide oral capsule 0.5 mg</i> (Agrylin) | 2 | |
| <i>anagrelide oral capsule 1 mg</i> | 2 | |
| <i>tranexamic acid oral tablet 650 mg</i> | 2 | |

Anticoagulantes

| | | |
|--|---|---------------------|
| <i>dabigatran etexilate oral capsule 110 mg, 150 mg, 75 mg</i> (Pradaxa) | 3 | QL (60 per 30 days) |
| ELIQUIS DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 5 MG (74 TABS) | 3 | |
| ELIQUIS ORAL TABLET 2.5 MG | 3 | QL (60 per 30 days) |
| ELIQUIS ORAL TABLET 5 MG | 3 | QL (74 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| ELIQUIS ORAL TABLET FOR SUSPENSION 0.5 MG, 1.5 MG (0.5 MG X 3), 2 MG (0.5 MG X 4) | 3 | QL (960 per 30 days) |
| ELIQUIS SPRINKLE ORAL CAPSULE, SPRINKLE 0.15 MG | 3 | QL (120 per 30 days) |
| <i>enoxaparin subcutaneous syringe</i> (Lovenox) <i>100 mg/ml, 150 mg/ml</i> | 2 | QL (60 per 30 days) |
| <i>enoxaparin subcutaneous syringe</i> (Lovenox) <i>120 mg/0.8 ml, 80 mg/0.8 ml</i> | 2 | QL (48 per 30 days) |
| <i>enoxaparin subcutaneous syringe 30 mg/0.3 ml</i> (Lovenox) | 2 | QL (18 per 30 days) |
| <i>enoxaparin subcutaneous syringe 40 mg/0.4 ml</i> (Lovenox) | 2 | QL (24 per 30 days) |
| <i>enoxaparin subcutaneous syringe 60 mg/0.6 ml</i> (Lovenox) | 2 | QL (36 per 30 days) |
| <i>fondaparinux subcutaneous syringe 10 mg/0.8 ml</i> (Arixtra) | 5 | NM; NDS; QL (24 per 30 days) |
| <i>fondaparinux subcutaneous syringe 2.5 mg/0.5 ml</i> (Arixtra) | 2 | QL (15 per 30 days) |
| <i>fondaparinux subcutaneous syringe 5 mg/0.4 ml</i> (Arixtra) | 5 | NM; NDS; QL (12 per 30 days) |
| <i>fondaparinux subcutaneous syringe 7.5 mg/0.6 ml</i> (Arixtra) | 5 | NM; NDS; QL (18 per 30 days) |
| <i>heparin (porcine) injection solution 1,000 unit/ml, 10,000 unit/ml, 20,000 unit/ml, 5,000 unit/ml</i> | 2 | |
| <i>jantoven oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> (warfarin) | 1 | |
| <i>rivaroxaban oral suspension for reconstitution 1 mg/ml</i> (Xarelto) | 2 | QL (600 per 30 days) |
| <i>rivaroxaban oral tablet 2.5 mg</i> (Xarelto) | 2 | QL (60 per 30 days) |
| <i>warfarin oral tablet 1 mg, 10 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg</i> (Jantoven) | 1 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|--------------------------------------|
| XARELTO DVT-PE TREAT 30D START ORAL TABLETS,DOSE PACK 15 MG (42)- 20 MG (9) | 3 | |
| XARELTO ORAL SUSPENSION (rivaroxaban) FOR RECONSTITUTION 1 MG/ML | 3 | QL (600 per 30 days) |
| XARELTO ORAL TABLET 10 MG, (rivaroxaban) 20 MG | 3 | QL (30 per 30 days) |
| XARELTO ORAL TABLET 15 MG (rivaroxaban) | 3 | QL (60 per 30 days) |
| XARELTO ORAL TABLET 2.5 MG (rivaroxaban) | 3 | ST; QL (60 per 30 days) |
| Inhibidores De Agregación De Plaquetas | | |
| <i>aspirin-dipyridamole oral capsule, er multiphase 12 hr 25-200 mg</i> | 2 | |
| <i>cilostazol oral tablet 100 mg, 50 mg</i> | 2 | |
| <i>clopidogrel oral tablet 75 mg</i> (Plavix) | 1 | |
| <i>dipyridamole oral tablet 25 mg, 50 mg, 75 mg</i> | 2 | PA-HRM; AGE (Max 64 Years) |
| <i>pentoxifylline oral tablet extended release 400 mg</i> | 2 | |
| <i>prasugrel hcl oral tablet 10 mg, 5 mg</i> (Effient) | 2 | QL (30 per 30 days) |
| <i>ticagrelor oral tablet 60 mg, 90 mg</i> (Brilinta) | 2 | |
| Modificadores De Formación De Sangre | | |
| ALVAIZ ORAL TABLET 18 MG, 36 MG, 54 MG, 9 MG | 5 | PA; NM; NDS; QL (60 per 30 days) |
| <i>eltrombopag olamine oral powder in</i> (Promacta) <i>packet 12.5 mg</i> | 5 | PA; NM; NDS; QL (90 per 30 days) |
| <i>eltrombopag olamine oral powder in</i> (Promacta) <i>packet 25 mg</i> | 5 | PA; NM; NDS; QL (180 per 30 days) |
| <i>eltrombopag olamine oral tablet 12.5</i> (Promacta) <i>mg</i> | 5 | PA; NM; NDS; QL (90 per 30 days) |
| <i>eltrombopag olamine oral tablet 25</i> (Promacta) <i>mg</i> | 5 | PA; NM; NDS; QL (30 per 30 days) |
| <i>eltrombopag olamine oral tablet 50</i> (Promacta) <i>mg, 75 mg</i> | 5 | PA; NM; NDS; QL (60 per 30 days) |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| HAEGARDA SUBCUTANEOUS RECON SOLN 2,000 UNIT | 5 | PA; NM; NDS; QL (30 per 30 days) |
| HAEGARDA SUBCUTANEOUS RECON SOLN 3,000 UNIT | 5 | PA; NM; NDS; QL (20 per 30 days) |
| NIVESTYM INJECTION SOLUTION 300 MCG/ML, 480 MCG/1.6 ML | 5 | PA; NM; NDS |
| NIVESTYM SUBCUTANEOUS SYRINGE 300 MCG/0.5 ML, 480 MCG/0.8 ML | 5 | PA; NM; NDS |
| NYVEPRIA SUBCUTANEOUS SYRINGE 6 MG/0.6 ML | 5 | PA; NM; NDS |
| RETACRIT INJECTION SOLUTION 10,000 UNIT/ML, 2,000 UNIT/ML, 20,000 UNIT/2 ML, 20,000 UNIT/ML, 3,000 UNIT/ML, 4,000 UNIT/ML | 3 | PA; QL (12 per 28 days) |
| RETACRIT INJECTION SOLUTION 40,000 UNIT/ML | 3 | PA; QL (4 per 28 days) |
| UDENYCA ONBODY SUBCUTANEOUS SYRINGE, W/ WEARABLE INJECTOR 6 MG/0.6 ML | 5 | PA; NM; NDS |
| Reemplazo/Modificadores De Enzima | | |
| Reemplazo/Modificadores De Enzima | | |
| CREON ORAL CAPSULE,DELAYED RELEASE(DR/EC) 12,000-38,000 - 60,000 UNIT, 24,000-76,000 - 120,000 UNIT, 3,000-9,500- 15,000 UNIT, 36,000-114,000- 180,000 UNIT, 6,000-19,000 -30,000 UNIT | 3 | |
| <i>javygtor oral tablet,soluble 100 mg</i> (sapropterin) | 5 | PA; NM; NDS |
| <i>nitisinone oral capsule 10 mg, 2 mg, 20 mg, 5 mg</i> (Orfadin) | 5 | PA; NM; NDS |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| ORFADIN ORAL SUSPENSION 4 MG/ML | 5 | PA; NM; NDS |
| PULMOZYME INHALATION SOLUTION 1 MG/ML | 5 | PA BvD; NM; NDS |
| REVCovi INTRAMUSCULAR SOLUTION 2.4 MG/1.5 ML (1.6 MG/ML) | 5 | PA; NM; NDS |
| <i>sapropterin oral tablet, soluble 100 mg</i> (Javygtor) | 5 | PA; NM; NDS |
| STRENSIQ SUBCUTANEOUS SOLUTION 18 MG/0.45 ML, 28 MG/0.7 ML, 40 MG/ML, 80 MG/0.8 ML | 5 | PA; NM; LA; NDS |
| ZENPEP ORAL CAPSULE, DELAYED RELEASE (DR/EC) 10,000-32,000 - 42,000 UNIT, 15,000-47,000 - 63,000 UNIT, 20,000-63,000- 84,000 UNIT, 25,000-79,000- 105,000 UNIT, 3,000-10,000 -14,000-UNIT, 40,000-126,000- 168,000 UNIT, 5,000-17,000- 24,000 UNIT, 60,000-189,600- 252,600 UNIT | 3 | |
| Relajantes Musculares Esqueléticos | | |
| Relajantes Musculares Esqueléticos | | |
| <i>baclofen oral tablet 10 mg, 20 mg, 5 mg</i> | 2 | |
| <i>cyclobenzaprine oral tablet 10 mg, 5 mg</i> | 1 | |
| <i>dantrolene oral capsule 100 mg, 50 mg</i> | 2 | |
| <i>dantrolene oral capsule 25 mg</i> (Dantrium) | 2 | |
| <i>methocarbamol oral tablet 500 mg, 750 mg</i> | 2 | |
| <i>tizanidine oral tablet 2 mg</i> | 2 | |
| <i>tizanidine oral tablet 4 mg</i> (Zanaflex) | 2 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|-----------------------|----------------------------|
| Vitaminas Y Minerales | | |
| Vitaminas Y Minerales | | |
| <i>bal-care dha combo pack 27-1-430 mg</i> | 1 | |
| <i>bal-care dha essential pack 27 mg iron-1 mg -374 mg</i> | 1 | |
| <i>c-nate dha softgel 28 mg iron-1 mg -200 mg</i> | 1 | |
| <i>completenate tablet chew 29 mg iron-1 mg</i> | 1 | |
| <i>cyanocobalamin (vitamin b-12) injection solution</i> (Dodex) | 1 | EX |
| <i>ergocalciferol (vitamin d2) oral capsule 1,250 mcg (50,000 unit)</i> (ergocalciferol (vitamin d2)) | 1 | EX |
| <i>folic acid oral tablet 1 mg</i> | 1 | EX |
| <i>folivane-ob capsule 85-1 mg</i> | 1 | |
| <i>kosher prenatal plus iron tab 30 mg iron- 1 mg</i> | 1 | |
| <i>marnatal-f capsule 60 mg iron-1 mg</i> | 1 | |
| <i>m-natal plus tablet 27 mg iron- 1 mg</i> (pnv,calcium 72-iron-folic acid) | 1 | |
| <i>mynatal advance oral tablet 90-1-50 mg</i> | 1 | |
| <i>mynatal capsule 65 mg iron- 1 mg</i> | 1 | |
| <i>mynatal oral tablet 90-1-50 mg</i> | 1 | |
| <i>mynatal plus captab 65 mg iron- 1 mg</i> | 1 | |
| <i>mynatal-z captab 65 mg iron- 1 mg</i> | 1 | |
| <i>mynate 90 plus oral tablet extended release 90 mg iron-1 mg</i> | 1 | |
| <i>newgen tablet 32-1,000 mg-mcg</i> | 1 | |
| <i>niva-plus tablet 27 mg iron- 1 mg</i> | 1 | |
| <i>obstetrix dha combo pack 29 mg iron- 1,700 mcg dfe</i> | 1 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|---|---------------------------------------|------------------------------------|
| <i>obstetrix dha oral combo pack,tablet and cap,dr 29 mg iron-1 mg -50 mg</i> | 1 | |
| <i>pnv 29-1 oral tablet 29 mg iron- 1 mg</i> | 1 | |
| <i>pnv prenatal plus multivit tab gluten-free (rx) 27 mg iron- 1 mg</i> | (pnv,calcium 72-iron-folic acid) 1 | |
| <i>pnv-dha + docusate oral capsule 27-1.25-55-300 mg</i> | 1 | |
| <i>pnv-omega softgel 28-1-300 mg</i> | 1 | |
| <i>pr natal 400 combo pack 29-1-400 mg</i> | 1 | |
| <i>pr natal 400 ec combo pack 29-1-400 mg</i> | 1 | |
| <i>pr natal 430 combo pack 29 mg iron-1 mg -430 mg</i> | 1 | |
| <i>pr natal 430 ec combo pack 29-1-430 mg</i> | 1 | |
| <i>prena1 true combo pack 30 mg iron-1.4 mg-300 mg</i> | 1 | |
| <i>prenaissance oral capsule 29-1.25-55-325 mg</i> | 1 | |
| <i>prenaissance plus oral capsule 28-1-50-250 mg</i> | 1 | |
| <i>prenatabs fa tablet 29-1 mg</i> | 1 | |
| <i>prenatal 19 (with docusate) oral tablet 29 mg iron- 1 mg-25 mg</i> | 1 | |
| <i>prenatal 19 chewable tablet 29 mg iron- 1 mg</i> | 1 | |
| <i>prenatal plus iron tablet (rx) 29 mg iron- 1 mg</i> | (pnv,calcium 72-iron,carb-folic) 1 | |
| <i>prenatal vitamin plus low iron oral tablet 27 mg iron- 1 mg</i> | (pnv,calcium 72-iron-folic acid) 1 | |
| <i>prenatal-u capsule 106.5-1 mg</i> | 1 | |
| <i>preplus oral tablet 27 mg iron- 1 mg</i> | (pnv,calcium 72-iron-folic acid) 1 | |
| <i>pretab oral tablet 29-1 mg</i> | 1 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

| Nombre del Medicamento | Nivel del Medicamento | Requerimientos/ Límites |
|--|------------------------------|------------------------------------|
| <i>r-natal ob softgel 20 mg iron- 1 mg-320 mg</i> | 1 | |
| <i>select-ob chewable caplet 29 mg iron- 1 mg</i> | 1 | |
| <i>select-ob chewable caplet 29 mg iron- 1 mg</i> | 1 | |
| <i>se-natal 19 chewable tablet 29 mg iron- 1 mg</i> | 1 | |
| <i>taron-c dha capsule 35-1-200 mg</i> | 1 | |
| <i>taron-prex prenatal-dha oral capsule 30 mg iron-1.2 mg-55 mg-265 mg</i> | 1 | |
| <i>virt-c dha oral capsule 35-1-200 mg</i> | 1 | |
| <i>virt-nate dha softgel 28 mg iron-1 mg -200 mg</i> | 1 | |
| <i>virt-pn dha softgel (rx) 27 mg iron-1 mg -300 mg</i> | 1 | |
| <i>virt-pn plus oral capsule 28-1-300 mg</i> | 1 | |
| <i>vitafol gummies 3.33 mg iron- 0.33 mg</i> | 1 | |
| <i>vitafol nano oral tablet 18 mg iron- 1 mg</i> | 1 | |
| <i>vitafol-ob+dha combo pack 65-1-250 mg</i> | 1 | |
| <i>vp-ch-pnv oral capsule 30 mg iron-1 mg -50 mg-260 mg</i> | 1 | |
| <i>vp-pnv-dha oral capsule 28 mg iron-1 mg-200 mg</i> | 1 | |
| <i>zatean-pn dha capsule 27 mg iron-1 mg -300 mg</i> | 1 | |
| <i>zatean-pn plus softgel 28-1-300 mg</i> | 1 | |
| <i>zingiber tablet 1.2 mg-40 mg- 124.1 mg-100 mg</i> | 1 | |

Puede encontrar información sobre qué significan los símbolos y abreviaturas en esta tabla refiriéndose a las páginas de introducción de este documento.

04/01/2026

ÍNDICE

| | | |
|---|---|--|
| 1ST TIER UNIFINE PENTIPS 140 | AIMOVIG AUTOINJECTOR... 32 | <i>ammonium lactate</i>69 |
| 1ST TIER UNIFINE PENTIPS PLUS..... 140, 141 | AIRSUPRA..... 63, 65 | <i>amoxapine</i>127 |
| <i>abacavir</i> 133 | AKEEGA.....3 | <i>amoxicil-clarithromy-lansopraz</i> . 71 |
| <i>abacavir-lamivudine</i> 133 | <i>ala-cort</i> 67 | <i>amoxicillin</i> 110 |
| ABELCET..... 130 | <i>albendazole</i>34 | <i>amoxicillin-pot clavulanate</i> 110 |
| <i>abigale</i> 76 | <i>albuterol sulfate</i>65 | <i>amphotericin b</i> 130 |
| <i>abigale lo</i> 76 | ALCOHOL PADS..... 142 | <i>amphotericin b liposome</i> 130 |
| ABILIFY ASIMTUFII..... 37 | ALCOHOL PREP PADS..... 162 | <i>ampicillin</i> 110 |
| ABILIFY MAINTENA..... 37 | ALCOHOL PREP SWABS..... 142 | <i>ampicillin sodium</i> 110 |
| <i>abiraterone</i> 3 | ALCOHOL SWABS..... 158 | <i>ampicillin-sulbactam</i> 110 |
| <i>abiraterone, submicronized</i>3 | ALCOHOL WIPES..... 142 | <i>anagrelide</i> 189 |
| <i>abirtega</i>3 | ALECENSA..... 3 | <i>anastrozole</i> 3 |
| ABOUTTIME PEN NEEDLE..141 | <i>alendronate</i>56 | ANKTIVA.....3 |
| ABRYSVO (PF).....87 | <i>alfuzosin</i>74 | ANORO ELLIPTA.....65 |
| <i>acamprosate</i>23 | <i>aliskiren</i> 55 | <i>aprepitant</i> 33 |
| <i>acarbose</i>26 | <i>allopurinol</i> 31, 32 | <i>apri</i> 113 |
| <i>acebutolol</i> 45 | <i>alosetron</i> 55, 56 | APTIVUS..... 133 |
| <i>acetaminophen-codeine</i> 102 | <i>alprazolam</i>24 | AQINJECT PEN NEEDLE..... 142 |
| <i>acetazolamide</i> 93 | <i>altavera (28)</i> 113 | ARCALYST..... 80 |
| <i>acetazolamide sodium</i>93 | ALTRENO.....71 | AREXVY (PF)..... 88 |
| <i>acetic acid</i>94 | ALUNBRIG.....3 | ARIKAYCE.....105 |
| <i>acetylcysteine</i>61 | ALVAIZ..... 191 | <i>aripiprazole</i> 37 |
| <i>acitretin</i>69 | <i>alyacen 1/35 (28)</i> 113 | ARISTADA..... 37, 38 |
| ACTHIB (PF)..... 87 | <i>alyacen 7/7/7 (28)</i> 113 | ARISTADA INITIO.....37 |
| ACTIMMUNE.....98 | ALYFTREK..... 61, 62 | <i>armodafinil</i> 57 |
| <i>acyclovir</i> 69, 139, 140 | <i>alyq</i> 100 | ARNUITY ELLIPTA..... 64 |
| <i>acyclovir sodium</i> 140 | <i>amantadine hcl</i> 35 | <i>asenapine maleate</i> 38 |
| ADACEL(TDAP | <i>amethyst (28)</i> 113 | <i>aspirin-dipyridamole</i> 191 |
| ADOLESN/ADULT)(PF)..... 87 | <i>amikacin</i>105 | ASSURE ID DUO PRO SFTY |
| <i>adapalene</i>71 | <i>amikacin</i>105 | PEN NDL..... 142 |
| <i>adefovir</i> 140 | <i>amiloride</i>52 | ASSURE ID DUO-SHIELD.... 142 |
| ADEMPAS..... 100 | <i>amiloride-hydrochlorothiazide</i> ...52 | ASSURE ID INSULIN |
| <i>adrucil</i>3 | <i>amiodarone</i>45 | SAFETY..... 142 |
| ADVAIR HFA.....63 | <i>amitriptyline</i> 127 | ASSURE ID PEN NEEDLE.....142 |
| ADVOCATE PEN NEEDLE | <i>amlodipine</i> 50 | ASSURE ID PRO PEN |
| 141, 142 | <i>amlodipine-atorvastatin</i> 50, 51 | NEEDLE.....142 |
| ADVOCATE SYRINGES.....141 | <i>amlodipine-benazepril</i>50 | ASTAGRAF XL.....80 |
| <i>afirmelle</i> 113 | <i>amlodipine-olmesartan</i>50 | <i>atazanavir</i> 133 |
| | <i>amlodipine-valsartan</i>50 | <i>atenolol</i> 46 |
| | <i>amlodipine-valsartan-hcthiazid</i> ..50 | |

| | | | | | |
|--------------------------------------|-----|--|----------|--|--------|
| <i>atenolol-chlorthalidone</i> | 46 | BALVERSA..... | 4 | BESREMI..... | 80 |
| <i>atomoxetine</i> | 58 | BAQSIMI..... | 98 | <i>betaine</i> | 98 |
| <i>atorvastatin</i> | 51 | BCG VACCINE, LIVE (PF)..... | 88 | <i>betamethasone dipropionate</i> | 67 |
| <i>atovaquone</i> | 34 | BD ALCOHOL SWABS..... | 144 | <i>betamethasone valerate</i> | 67 |
| <i>atovaquone-proguanil</i> | 34 | BD AUTOSHIELD DUO PEN | | <i>betamethasone, augmented</i> | 67 |
| <i>atropine</i> | 98 | NEEDLE..... | 143 | BETASERON..... | 58 |
| ATROVENT HFA..... | 65 | BD ECLIPSE LUER-LOK..... | 143 | <i>betaxolol</i> | 93 |
| ATTRUBY..... | 48 | BD INSULIN SYRINGE..... | 143 | <i>bethanechol chloride</i> | 74 |
| <i>aubra eq</i> | 113 | BD INSULIN SYRINGE | | <i>bexarotene</i> | 4 |
| AUGTYRO..... | 3 | (HALF UNIT)..... | 143 | BEXSERO..... | 88 |
| <i>aurovela 1.5/30 (21)</i> | 113 | BD INSULIN SYRINGE | | <i>bicalutamide</i> | 4 |
| <i>aurovela 1/20 (21)</i> | 113 | ULTRA-FINE..... | 143 | BICILLIN L-A..... | 110 |
| <i>aurovela 24 fe</i> | 113 | BD LO-DOSE ULTRA-FINE.. | 143 | BIKTARVY..... | 133 |
| <i>aurovela fe 1.5/30 (28)</i> | 113 | BD NANO 2ND GEN PEN | | <i>bisoprolol fumarate</i> | 46 |
| <i>aurovela fe 1-20 (28)</i> | 113 | NEEDLE..... | 143 | <i>bisoprolol-hydrochlorothiazide</i> .. | 46 |
| AUSTEDO..... | 58 | BD SAFETYGLIDE INSULIN | | BIZENGRI..... | 4 |
| AUSTEDO XR..... | 58 | SYRINGE..... | 143, 144 | <i>bleomycin</i> | 4 |
| AUSTEDO XR TITRATION | | BD SAFETYGLIDE SYRINGE | | <i>blisovi 24 fe</i> | 114 |
| KT(WK1-4)..... | 58 | | 144 | <i>blisovi fe 1.5/30 (28)</i> | 114 |
| AUTOSHIELD DUO PEN | | BD ULTRA-FINE MICRO | | <i>blisovi fe 1/20 (28)</i> | 114 |
| NEEDLE..... | 142 | PEN NEEDLE..... | 144 | BOOSTRIX TDAP..... | 88 |
| AUVELITY..... | 127 | BD ULTRA-FINE MINI PEN | | BORDERED GAUZE..... | 144 |
| <i>aviane</i> | 114 | NEEDLE..... | 144 | <i>bortezomib</i> | 4 |
| AVMAPKI..... | 3 | BD ULTRA-FINE NANO PEN | | BORUZU..... | 4 |
| AVMAPKI-FAKZYNJA..... | 3 | NEEDLE..... | 144 | <i>bosentan</i> | 100 |
| AVONEX..... | 58 | BD ULTRA-FINE ORIG PEN | | BOSULIF..... | 4, 5 |
| AXTLE..... | 3 | NEEDLE..... | 144 | BRAFTOVI..... | 5 |
| <i>ayuna</i> | 114 | BD ULTRA-FINE SHORT | | BREO ELLIPTA..... | 64 |
| AYVAKIT..... | 4 | PEN NEEDLE..... | 144 | <i>breyna</i> | 64 |
| <i>azacitidine</i> | 4 | BD VEO INSULIN SYR | | BREZTRI AEROSPHERE..... | 65 |
| <i>azathioprine</i> | 80 | (HALF UNIT)..... | 144 | <i>brimonidine</i> | 93 |
| <i>azathioprine sodium</i> | 80 | BD VEO INSULIN SYRINGE | | <i>brimonidine-timolol</i> | 93 |
| <i>azelastine</i> | 98 | UF..... | 144 | <i>brinzolamide</i> | 93 |
| <i>azithromycin</i> | 109 | BELSOMRA..... | 57 | BRIVIACT..... | 121 |
| <i>aztreonam</i> | 107 | <i>benazepril</i> | 54 | <i>bromfenac</i> | 96 |
| <i>azurette (28)</i> | 114 | <i>benazepril-hydrochlorothiazide</i> .. | 54 | <i>bromocriptine</i> | 35 |
| <i>bacitracin</i> | 94 | <i>bendamustine</i> | 4 | BRONCHITOL..... | 62 |
| <i>bacitracin-polymyxin b</i> | 94 | BENDAMUSTINE..... | 4 | BRUKINSA..... | 5 |
| <i>baclofen</i> | 193 | BENDEKA..... | 4 | <i>budesonide</i> | 56, 64 |
| <i>bal-care dha</i> | 194 | BENLYSTA..... | 80 | <i>budesonide-formoterol</i> | 64 |
| <i>bal-care dha essential</i> | 194 | <i>benzonatate</i> | 189 | <i>bumetanide</i> | 53 |
| <i>balsalazide</i> | 56 | <i>benztropine</i> | 35 | <i>buprenorphine</i> | 102 |

| | | | | | |
|--|----------|---|----------|---|---------------|
| <i>buprenorphine hcl</i> | 23 | <i>cefazolin</i> | 108 | CLINIMIX 6%-D5W | |
| <i>buprenorphine-naloxone</i> | 23 | <i>cefdinir</i> | 108 | (SULFITE-FREE)..... | 44 |
| <i>bupropion hcl</i> | 127 | <i>cefepime</i> | 108 | CLINIMIX 8%- | |
| <i>bupropion hcl (smoking deter)</i> ... | 23 | <i>cefixime</i> | 108 | D10W(SULFITE-FREE)..... | 44 |
| <i>bupirone</i> | 98 | <i>cefoxitin</i> | 108 | CLINIMIX 8%- | |
| <i>butalbital-acetaminop-caf-cod</i> .. | 102 | <i>cefpodoxime</i> | 108 | D14W(SULFITE-FREE)..... | 44 |
| <i>butalbital-acetaminophen-caff</i> .. | 102 | <i>cefprozil</i> | 108 | CLINIMIX E 8%-D10W | |
| CABENUVA..... | 133 | <i>ceftaroline fosamil</i> | 108 | SULFITEFREE..... | 44 |
| <i>cabergoline</i> | 35 | <i>ceftazidime</i> | 108 | CLINIMIX E 8%-D14W | |
| CABOMETYX..... | 5 | <i>ceftriaxone</i> | 108 | SULFITEFREE..... | 44 |
| <i>cabotegravir</i> | 134 | <i>cefuroxime axetil</i> | 108 | <i>clobazam</i> | 122 |
| <i>calcipotriene</i> | 69 | <i>cefuroxime sodium</i> | 108, 109 | <i>clobetasol</i> | 67, 68 |
| <i>calcitonin (salmon)</i> | 56 | <i>celecoxib</i> | 100 | <i>clobetasol-emollient</i> | 68 |
| <i>calcitriol</i> | 56 | <i>cephalexin</i> | 109 | <i>clomipramine</i> | 128 |
| <i>calcium acetate(phosphat bind)</i> .. | 73 | <i>cevimeline</i> | 66 | <i>clonazepam</i> | 24 |
| CALQUENCE..... | 5 | <i>chateal eq (28)</i> | 114 | <i>clonidine</i> | 44, 45 |
| CALQUENCE | | <i>chlordiazepoxide hcl</i> | 24 | <i>clonidine hcl</i> | 44 |
| (ACALABRUTINIB MAL)..... | 5 | <i>chlorhexidine gluconate</i> | 66 | <i>clopidogrel</i> | 191 |
| CAMCEVI (6 MONTH)..... | 5 | <i>chloroquine phosphate</i> | 34 | <i>clorazepate dipotassium</i> | 24 |
| <i>camila</i> | 114 | <i>chlorpromazine</i> | 38 | <i>clotrimazole</i> | 131 |
| CAMZYOS..... | 48 | <i>chlorthalidone</i> | 53 | <i>clotrimazole-betamethasone</i> | 131 |
| <i>candesartan</i> | 49 | <i>cholestyramine</i> | 51 | <i>clozapine</i> | 38 |
| <i>candesartan-hydrochlorothiazid</i> | 49 | <i>cholestyramine light</i> | 51 | <i>c-nate dha</i> | 194 |
| CAPLYTA..... | 38 | <i>ciclopirox</i> | 130, 131 | COARTEM..... | 34 |
| CAPRELSA..... | 5 | <i>cilostazol</i> | 191 | COBENFY..... | 38 |
| <i>captopril</i> | 54 | CIMDUO..... | 134 | COBENFY STARTER PACK... | 38 |
| <i>carbamazepine</i> | 122 | <i>cimetidine hcl</i> | 71 | <i>colchicine</i> | 32 |
| <i>carbidopa-levodopa</i> | 35, 36 | CIMZIA..... | 80, 81 | <i>colesevelam</i> | 51 |
| CAREFINE PEN NEEDLE | | CIMZIA POWDER FOR | | <i>colestipol</i> | 51 |
| | 144, 145 | RECONST..... | 81 | <i>colistin (colistimethate na)</i> | 106 |
| CARETOUCH ALCOHOL | | CIMZIA STARTER KIT..... | 81 | COMBIVENT RESPIMAT..... | 65 |
| PREP PAD..... | 145 | <i>cinacalcet</i> | 56 | COMETRIQ..... | 5 |
| CARETOUCH INSULIN | | <i>ciprofloxacin hcl</i> | 94, 111 | COMFORT EZ INSULIN | |
| SYRINGE..... | 145, 146 | <i>ciprofloxacin in 5 % dextrose</i> ... | 111 | SYRINGE..... | 146, 147, 148 |
| CARETOUCH PEN NEEDLE..... | 145 | <i>ciprofloxacin-dexamethasone</i> | 94 | COMFORT EZ PEN | |
| <i>carglumic acid</i> | 72 | <i>citalopram</i> | 127 | NEEDLES..... | 146, 147 |
| <i>carteolol</i> | 93 | <i>clarithromycin</i> | 109 | COMFORT EZ PRO SAFETY | |
| <i>cartia xt</i> | 47 | CLICKFINE PEN NEEDLE | | PEN NDL..... | 147 |
| <i>carvedilol</i> | 46 | | 146, 158 | COMFORT TOUCH PEN | |
| CAYSTON..... | 107 | <i>clindamycin hcl</i> | 106 | NEEDLE..... | 148, 149 |
| <i>cefaclor</i> | 108 | <i>clindamycin phosphate</i> 70, 105, 106 | | <i>completenate</i> | 194 |
| <i>cefadroxil</i> | 108 | <i>clindamycin-benzoyl peroxide</i> | 70 | <i>compro</i> | 33 |

| | | | | | |
|--|------------|---|--------------|--|---------------|
| <i>conjugated estrogens</i> | 76 | <i>dapsone</i> | 133 | <i>dicloxacillin</i> | 111 |
| <i>constulose</i> | 72 | DAPTACEL (DTAP | | <i>dicyclomine</i> | 72 |
| COPIKTRA..... | 5 | PEDIATRIC) (PF)..... | 88 | <i>didanosine</i> | 134 |
| CORLANOR..... | 48 | <i>daptomycin</i> | 106 | <i>difluprednate</i> | 97 |
| CORTROPHIN GEL..... | 78 | <i>darunavir</i> | 134 | <i>digoxin</i> | 48 |
| COSENTYX..... | 81 | <i>dasatinib</i> | 6 | <i>dihydroergotamine</i> | 32 |
| COSENTYX (2 SYRINGES)..... | 81 | <i>dasetta 1/35 (28)</i> | 114 | DILANTIN..... | 122 |
| COSENTYX PEN (2 PENS)..... | 81 | <i>dasetta 7/7/7 (28)</i> | 114 | <i>diltiazem hcl</i> | 47 |
| COSENTYX UNOREADY | | DATROWAY..... | 6 | <i>dilt-xr</i> | 47 |
| PEN..... | 81 | DAURISMO..... | 6 | <i>dimethyl fumarate</i> | 59 |
| COTELLIC..... | 5 | <i>deblitane</i> | 114 | <i>diphenoxylate-atropine</i> | 72 |
| CREON..... | 192 | <i>decitabine</i> | 6 | <i>dipyridamole</i> | 191 |
| CRESEMBA..... | 131 | <i>deferasirox</i> | 105 | <i>disulfiram</i> | 23 |
| <i>cromolyn</i> | 62, 72, 98 | DELSTRIGO..... | 134 | <i>divalproex</i> | 122 |
| <i>cryselle (28)</i> | 114 | <i>demeclocycline</i> | 112 | <i>dofetilide</i> | 45 |
| CURAD GAUZE PAD..... | 149 | DENGVAXIA (PF)..... | 88 | <i>dolishale</i> | 114 |
| CURITY ALCOHOL SWABS | 149 | <i>denta 5000 plus</i> | 66 | <i>donepezil</i> | 25 |
| CURITY GAUZE..... | 149 | <i>dentagel</i> | 66 | <i>dorzolamide</i> | 93 |
| <i>cyanocobalamin (vitamin b-12)</i> | 194 | DEPO-SUBQ PROVERA 104... 79 | | <i>dorzolamide-timolol</i> | 93 |
| <i>cyclobenzaprine</i> | 193 | DERMACEA..... | 149 | DOVATO..... | 134 |
| <i>cyclophosphamide</i> | 6 | DERMACEA NON-WOVEN.. | 149 | <i>doxazosin</i> | 45 |
| <i>cyclosporine</i> | 81, 96 | <i>dermacinrx lidocan</i> | 104 | <i>doxepin</i> | 57, 128 |
| <i>cyclosporine modified</i> | 81 | DESCOVY..... | 134 | <i>doxorubicin, peg-liposomal</i> | 6 |
| CYLTEZO(CF)..... | 82 | <i>desipramine</i> | 128 | <i>doxy-100</i> | 112 |
| CYLTEZO(CF) PEN..... | 82 | <i>desmopressin</i> | 78 | <i>doxycycline hyclate</i> | 112 |
| CYLTEZO(CF) PEN | | <i>desog-e.estradiol/e.estradiol</i> ... 114 | | <i>doxycycline monohydrate</i> .. 112, 113 | |
| CROHN'S-UC-HS..... | 81 | <i>desogestrel-ethinyl estradiol</i> 114 | | DRIZALMA SPRINKLE..... | 128 |
| CYLTEZO(CF) PEN | | <i>desvenlafaxine succinate</i> | 128 | <i>dronabinol</i> | 33 |
| PSORIASIS-UV..... | 82 | <i>dexamethasone</i> | 77 | DROPLET INSULIN | |
| <i>cyred eq</i> | 114 | <i>dexamethasone sodium</i> | | SYR(HALF UNIT)..... | 149, 150 |
| <i>d5 % (d-glucose)-0.9 % sodchlr</i> | | <i>phosphate</i> | 77, 96 | DROPLET INSULIN | |
| | 188 | <i>dextroamphetamine-</i> | | SYRINGE..... | 149, 150, 151 |
| <i>d5 % and 0.9 % sodium</i> | | <i>amphetamine</i> | 59 | DROPLET MICRON PEN | |
| <i>chloride</i> | 188 | <i>dextrose 5 % in water (d5w)</i> | 44 | NEEDLE..... | 151 |
| <i>d5 %-0.45 % sodium chloride</i> .. | 188 | DIACOMIT..... | 122 | DROPLET PEN NEEDLE | |
| <i>dabigatran etexilate</i> | 189 | <i>diazepam</i> | 24, 122 | | 151, 152 |
| <i>dalfampridine</i> | 59 | <i>diazepam intensol</i> | 24 | DROPSAFE ALCOHOL PREP | |
| <i>danazol</i> | 75 | <i>diazoxide</i> | 98 | PADS..... | 152 |
| <i>dantrolene</i> | 193 | <i>diclofenac epolamine</i> | 100 | DROPSAFE INSULIN | |
| DANYELZA..... | 6 | <i>diclofenac potassium</i> | 100 | SYRINGE..... | 152 |
| DANZITEN..... | 6 | <i>diclofenac sodium</i> | 97, 100, 101 | DROPSAFE PEN NEEDLE..... | 152 |
| <i>dapagliflozin propanediol</i> | 26 | <i>diclofenac-misoprostol</i> | 101 | <i>droxidopa</i> | 45 |

| | | | | | |
|--|---------------|--|----------|--|---------|
| <i>duloxetine</i> | 128 | ELEPSIA XR..... | 123 | EPCLUSA..... | 138 |
| DUPIXENT PEN..... | 82 | ELIGARD..... | 7 | EPIDIOLEX..... | 123 |
| DUPIXENT SYRINGE..... | 82 | ELIGARD (3 MONTH)..... | 6 | <i>epinastine</i> | 98 |
| <i>dutasteride</i> | 74 | ELIGARD (4 MONTH)..... | 6 | <i>epinephrine</i> | 48 |
| EASY COMFORT ALCOHOL | | ELIGARD (6 MONTH)..... | 7 | <i>epitol</i> | 123 |
| PAD..... | 153 | <i>elinest</i> | 114 | EPIVIR HBV..... | 135 |
| EASY COMFORT INSULIN | | ELIQUIS..... | 189, 190 | EPKINLY..... | 7 |
| SYRINGE..... | 153, 154 | ELIQUIS DVT-PE TREAT | | <i>eplerenone</i> | 55 |
| EASY COMFORT PEN | | 30D START..... | 189 | ERBITUX..... | 7 |
| NEEDLES..... | 154 | ELIQUIS SPRINKLE..... | 190 | <i>ergocalciferol (vitamin d2)</i> | 194 |
| EASY COMFORT SAFETY | | ELREXFIO..... | 7 | <i>ergoloid</i> | 25 |
| PEN NEEDLE..... | 153 | <i>eltrombopag olamine</i> | 191 | ERIVEDGE..... | 7 |
| EASY GLIDE INSULIN | | <i>eluryng</i> | 114 | ERLEADA..... | 7 |
| SYRINGE..... | 154 | EMBRACE PEN NEEDLE..... | 157 | <i>erlotinib</i> | 7 |
| EASY GLIDE PEN NEEDLE.. | 155 | EMCYT..... | 7 | <i>errin</i> | 115 |
| EASY TOUCH..... | 156 | EMGALITY PEN..... | 32 | <i>ertapenem</i> | 107 |
| EASY TOUCH ALCOHOL | | EMGALITY SYRINGE..... | 32 | <i>erythromycin</i> | 94, 109 |
| PREP PADS..... | 155 | EMRELIS..... | 7 | <i>erythromycin ethylsuccinate</i> | 109 |
| EASY TOUCH FLIPLOCK | | EMSAM..... | 128 | <i>erythromycin with ethanol</i> | 70 |
| INSULIN..... | 156 | <i>emtricitabine</i> | 134 | ERZOFRI..... | 38, 39 |
| EASY TOUCH FLIPLOCK | | <i>emtricitabine-tenofovir (tdf)</i> | 134 | <i>escitalopram oxalate</i> | 128 |
| SYRINGE..... | 155 | <i>emtricitabine-tenofovir df</i> | 135 | <i>eslicarbazepine</i> | 123 |
| EASY TOUCH INSULIN | | EMTRIVA..... | 135 | <i>esomeprazole magnesium</i> | 71 |
| SAFETY SYR..... | 155 | <i>emzahn</i> | 115 | <i>estarylla</i> | 115 |
| EASY TOUCH INSULIN | | <i>enalapril maleate</i> | 54 | <i>estradiol</i> | 76 |
| SYRINGE..... | 155, 156, 157 | <i>enalapril-hydrochlorothiazide</i> | 54 | <i>estradiol-norethindrone acet</i> | 76, 77 |
| EASY TOUCH LUER LOCK | | ENBREL..... | 82 | <i>eszopiclone</i> | 57 |
| INSULIN..... | 156 | ENBREL MINI..... | 82 | <i>ethambutol</i> | 133 |
| EASY TOUCH PEN NEEDLE | 156 | ENBREL SURECLICK..... | 82 | <i>ethosuximide</i> | 123 |
| EASY TOUCH SAFETY PEN | | <i>endocet</i> | 102 | <i>ethynodiol diac-eth estradiol</i> ... | 115 |
| NEEDLE..... | 157 | ENGERIX-B (PF)..... | 88 | <i>etodolac</i> | 101 |
| EASY TOUCH | | ENGERIX-B PEDIATRIC (PF) | 88 | <i>etonogestrel-ethinyl estradiol</i> .. | 115 |
| SHEATHLOCK INSULIN | | <i>enilloring</i> | 115 | ETOPOPHOS..... | 7 |
| | 155, 156 | <i>enoxaparin</i> | 190 | <i>etoposide</i> | 7 |
| EASY TOUCH UNI-SLIP..... | 157 | <i>enpresse</i> | 115 | <i>etravirine</i> | 135 |
| <i>econazole nitrate</i> | 131 | ENSACOVE..... | 7 | EUCRISA..... | 68 |
| EDURANT..... | 134 | <i>enskyce</i> | 115 | EULEXIN..... | 8 |
| EDURANT PED..... | 134 | <i>entacapone</i> | 36 | <i>everolimus (antineoplastic)</i> | 8 |
| <i>efavirenz</i> | 134 | <i>entecavir</i> | 140 | <i>everolimus</i> | |
| <i>efavirenz-emtricitabin-tenofov</i> .. | 134 | ENTRESTO..... | 49 | (<i>immunosuppressive</i>)..... | 82 |
| <i>efavirenz-lamivu-tenofov disop</i> .. | 134 | ENTRESTO SPRINKLE..... | 49 | EVOTAZ..... | 135 |
| ELAHERE..... | 6 | <i>enulose</i> | 72 | EXEL INSULIN..... | 158 |

| | | | | |
|---|----------|---|--|-------------|
| <i>exemestane</i> | 8 | FIRMAGON KIT W | <i>galantamine</i> | 25 |
| EXTENCILLINE..... | 111 | DILUENT SYRINGE..... | <i>gallifrey</i> | 79 |
| EXXUA..... | 128 | <i>flavoxate</i> | GAMUNEX-C..... | 82 |
| EYSUVIS..... | 97 | <i>flecainide</i> | GARDASIL 9 (PF)..... | 88, 89 |
| <i>ezetimibe</i> | 51 | <i>floxuridine</i> | GAUZE BANDAGE..... | 158 |
| <i>ezetimibe-simvastatin</i> | 51 | <i>fluconazole</i> | GAUZE PAD..... | 158 |
| FAKZYNJA..... | 8 | <i>fluconazole in nacl (iso-osm)</i> | <i>gavilyte-c</i> | 74 |
| <i>falmina (28)</i> | 115 | <i>flucytosine</i> | <i>gavilyte-g</i> | 74 |
| <i>famciclovir</i> | 140 | <i>fludrocortisone</i> | <i>gavilyte-n</i> | 74 |
| <i>famotidine</i> | 71 | <i>flunisolide</i> | GAVRETO..... | 9 |
| FANAPT..... | 39 | <i>fluocinolone</i> | <i>gefitinib</i> | 9 |
| FANAPT TITRATION PACK | | <i>fluocinolone acetonide oil</i> | <i>gemfibrozil</i> | 51 |
| A..... | 39 | <i>fluocinonide</i> | <i>generlac</i> | 72 |
| FANAPT TITRATION PACK | | <i>fluoride (sodium)</i> | <i>gengraf</i> | 82, 83 |
| B..... | 39 | <i>fluorometholone</i> | <i>gentak</i> | 95 |
| FANAPT TITRATION PACK | | <i>fluorouracil</i> | <i>gentamicin</i> | 70, 95, 105 |
| C..... | 39 | <i>fluoxetine</i> | <i>gentamicin sulfate (ped) (pf)</i> | 106 |
| FARXIGA..... | 26 | <i>fluphenazine decanoate</i> | <i>gentamicin sulfate (pf)</i> | 106 |
| FASENRA..... | 62 | <i>fluphenazine hcl</i> | GENVOYA..... | 135 |
| FASENRA PEN..... | 62 | <i>flurbiprofen</i> | GILOTRIF..... | 9 |
| <i>febuxostat</i> | 32 | <i>flurbiprofen sodium</i> | <i>glatiramer</i> | 59 |
| <i>feirza</i> | 115 | <i>flutamide</i> | <i>glatopa</i> | 59 |
| <i>felbamate</i> | 123 | <i>fluticasone propionate</i> | <i>glimepiride</i> | 31 |
| <i>felodipine</i> | 50 | <i>fluticasone propion-salmeterol</i> ... | <i>glipizide</i> | 31 |
| <i>femynor</i> | 115 | <i>fluvastatin</i> | <i>glipizide-metformin</i> | 31 |
| <i>fenofibrate</i> | 51 | <i>fluvoxamine</i> | <i>glucagon emergency kit</i> | |
| <i>fenofibrate micronized</i> | 51 | <i>folic acid</i> | (human)..... | 99 |
| <i>fenofibrate nanocrystallized</i> | 51 | <i>folivane-ob</i> | <i>glutamine (sickle cell)</i> | 99 |
| <i>fentanyl</i> | 103 | <i>fondaparinux</i> | <i>glyburide</i> | 31 |
| <i>fentanyl citrate</i> | 102, 103 | <i>fosamprenavir</i> | <i>glyburide micronized</i> | 31 |
| <i>fesoterodine</i> | 74 | <i>fosfomycin tromethamine</i> | <i>glyburide-metformin</i> | 31 |
| FETZIMA..... | 128, 129 | <i>fosinopril</i> | <i>glycopyrrolate</i> | 72 |
| FIASP FLEXTOUCH U-100 | | <i>fosinopril-hydrochlorothiazide</i> ... | <i>glydo</i> | 104 |
| INSULIN..... | 28 | <i>fosphenytoin</i> | GLYXAMBI..... | 26 |
| FIASP PENFILL U-100 | | FOTIVDA..... | GOMEKLI..... | 9 |
| INSULIN..... | 28 | FREESTYLE PRECISION..... | <i>griseofulvin microsize</i> | 131 |
| FIASP PUMPCART..... | 28 | FRUZAQLA..... | <i>griseofulvin ultramicrosize</i> | 131 |
| FIASP U-100 INSULIN..... | 29 | <i>fulvestrant</i> | <i>guanfacine</i> | 45, 59 |
| <i>fidaxomicin</i> | 110 | <i>furosemide</i> | GVOKE..... | 99 |
| <i>finasteride</i> | 74 | FUZEON..... | GVOKE HYPOPEN 2-PACK.... | 99 |
| <i>fingolimod</i> | 59 | FYARRO..... | GVOKE PFS 1-PACK | |
| FINTEPLA..... | 123 | <i>gabapentin</i> | SYRINGE..... | 99 |

| | | | | | |
|-------------------------------------|----------|---|------------|--|-----|
| HAEGARDA..... | 192 | HUMULIN R U-500 (CONC) | | <i>indapamide</i> | 53 |
| <i>hailey 24 fe</i> | 115 | KWIKPEN..... | 29 | <i>indomethacin</i> | 101 |
| <i>hailey fe 1.5/30 (28)</i> | 115 | <i>hydralazine</i> | 48 | INFANRIX (DTAP) (PF)..... | 89 |
| <i>hailey fe 1/20 (28)</i> | 115 | <i>hydrochlorothiazide</i> | 53 | <i>infliximab</i> | 83 |
| <i>halobetasol propionate</i> | 68 | <i>hydrocodone-acetaminophen</i> | 103 | INGREZZA..... | 60 |
| <i>haloette</i> | 115 | <i>hydrocortisone</i> | 56, 68, 77 | INGREZZA INITIATION | |
| <i>haloperidol</i> | 40 | <i>hydrocortisone valerate</i> | 68 | PK(TARDIV)..... | 59 |
| <i>haloperidol decanoate</i> | 39 | <i>hydrocortisone-acetic acid</i> | 95 | INGREZZA SPRINKLE..... | 60 |
| <i>haloperidol lactate</i> | 39 | <i>hydromorphone</i> | 103 | INLEXZO..... | 10 |
| HARVONI..... | 138, 139 | <i>hydroxychloroquine</i> | 34, 35 | INLURIYO..... | 10 |
| HAVRIX (PF)..... | 89 | <i>hydroxyurea</i> | 9 | INLYTA..... | 10 |
| HEALTHWISE INSULIN | | <i>hydroxyzine hcl</i> | 132 | INPEN (FOR HUMALOG) | |
| SYRINGE..... | 159 | <i>hydroxyzine pamoate</i> | 99 | BLUE..... | 160 |
| HEALTHWISE PEN NEEDLE | | HYRNUO..... | 9 | INPEN (NOVOLOG OR | |
| | 159, 160 | <i>ibandronate</i> | 56 | FIASP) BLUE..... | 160 |
| HEALTHY ACCENTS | | IBRANCE..... | 9 | INQOVI..... | 10 |
| UNIFINE PENTIP..... | 160 | IBTROZI..... | 9 | INREBIC..... | 10 |
| <i>heather</i> | 115 | <i>ibu</i> | 101 | <i>insulin asp prt-insulin aspart</i> | 29 |
| <i>heparin (porcine)</i> | 190 | <i>ibuprofen</i> | 101 | <i>insulin aspart u-100</i> | 29 |
| HEPLISAV-B (PF)..... | 89 | <i>icatibant</i> | 48 | <i>insulin glargine-yfgn</i> | 29 |
| HERCEPTIN HYLECTA..... | 9 | <i>iclevia</i> | 116 | <i>insulin lispro</i> | 29 |
| HERNEXEOS..... | 9 | ICLUSIG..... | 9 | INSULIN SYR/NDL U100 | |
| HIBERIX (PF)..... | 89 | <i>icosapent ethyl</i> | 52 | HALF MARK..... | 160 |
| HUMIRA..... | 83 | IDHIFA..... | 9 | INSULIN SYRINGE | |
| HUMIRA PEN..... | 83 | <i>ifosfamide</i> | 9, 10 | MICROFINE..... | 143 |
| HUMIRA PEN CROHNS-UC- | | ILEVRO..... | 97 | INSULIN SYRINGE | |
| HS START..... | 83 | <i>imatinib</i> | 10 | NEEDLELESS..... | 161 |
| HUMIRA PEN PSOR- | | IMBRUVICA..... | 10 | INSULIN SYRINGE-NEEDLE | |
| UVEITS-ADOL HS..... | 83 | IMDELLTRA..... | 10 | U-100 | |
| HUMIRA(CF)..... | 83 | <i>imipenem-cilastatin</i> | 107 | 158, 161, 162, 166, 168, 170, 174, | |
| HUMIRA(CF) PEDI CROHNS | | <i>imipramine hcl</i> | 129 | 178, 179 | |
| STARTER..... | 83 | <i>imiquimod</i> | 70 | INSULIN U-500 SYRINGE- | |
| HUMIRA(CF) PEN..... | 83 | IMJUDO..... | 10 | NEEDLE..... | 162 |
| HUMIRA(CF) PEN CROHNS- | | IMKELDI..... | 10 | INSUMED..... | 162 |
| UC-HS..... | 83 | IMOVAX RABIES VACCINE | | INSUPEN PEN NEEDLE..... | 162 |
| HUMIRA(CF) PEN | | (PF)..... | 89 | INTELENCE..... | 135 |
| PEDIATRIC UC..... | 83 | IMPAVIDO..... | 35 | <i>introvale</i> | 116 |
| HUMIRA(CF) PEN PSOR-UV- | | <i>incassia</i> | 116 | INVEGA HAFYERA..... | 40 |
| ADOL HS..... | 83 | INCONTROL ALCOHOL | | INVEGA SUSTENNA..... | 40 |
| HUMULIN R U-500 (CONC) | | PADS..... | 160 | INVEGA TRINZA..... | 40 |
| INSULIN..... | 29 | INCONTROL PEN NEEDLE.. | 160 | INVELTYS..... | 97 |
| | | INCRELEX..... | 78 | IPOL..... | 89 |

| | | | | | |
|--|--------|--|----------|--|----------|
| <i>ipratropium bromide</i> | 65, 98 | <i>kariva (28)</i> | 116 | <i>larin 24 fe</i> | 117 |
| <i>ipratropium-albuterol</i> | 65 | <i>kelnor 1/35 (28)</i> | 116 | <i>larin fe 1.5/30 (28)</i> | 117 |
| <i>irbesartan</i> | 49 | <i>kelnor 1/50 (28)</i> | 116 | <i>larin fe 1/20 (28)</i> | 117 |
| <i>irbesartan-hydrochlorothiazide</i> .. | 49 | KERENDIA..... | 55 | <i>latanoprost</i> | 93 |
| ISENTRESS..... | 135 | KESIMPTA PEN..... | 60 | LAZCLUZE..... | 12 |
| ISENTRESS HD..... | 135 | <i>ketoconazole</i> | 131 | <i>leflunomide</i> | 84 |
| <i>isibloom</i> | 116 | <i>ketorolac</i> | 97, 101 | <i>lenalidomide</i> | 12 |
| <i>isoniazid</i> | 133 | KEYTRUDA..... | 11 | LENTOCILIN S..... | 111 |
| <i>isosorbide dinitrate</i> | 55 | KEYTRUDA QLEX..... | 11 | LENVIMA..... | 12 |
| <i>isosorbide mononitrate</i> | 55 | KIMMTRAK..... | 11 | <i>lessina</i> | 117 |
| ITOVEBI..... | 10 | KINERET..... | 83 | <i>letrozole</i> | 12 |
| <i>itraconazole</i> | 131 | KINRIX (PF)..... | 89 | <i>leucovorin calcium</i> | 99 |
| IV PREP WIPES..... | 162 | <i>kionex (with sorbitol)</i> | 72 | LEUKERAN..... | 12 |
| <i>ivabradine</i> | 48 | KISQALI..... | 11 | <i>leuprolide</i> | 12 |
| <i>ivermectin</i> | 35 | KISQALI FEMARA CO- PACK..... | 11 | <i>leuprolide acetate (3 month)</i> | 12 |
| IWILFIN..... | 11 | KLISYRI (250 MG)..... | 70 | <i>levetiracetam</i> | 124 |
| IXIARO (PF)..... | 89 | <i>klor-con m10</i> | 188 | <i>levobunolol</i> | 94 |
| JAKAFI..... | 11 | <i>klor-con m15</i> | 188 | <i>levocetirizine</i> | 132 |
| <i>jantoven</i> | 190 | <i>klor-con m20</i> | 188 | <i>levofloxacin</i> | 111, 112 |
| JANUMET..... | 26 | KLOXXADO..... | 23 | <i>levofloxacin in d5w</i> | 111 |
| JANUMET XR..... | 26 | KOMZIFTI..... | 12 | <i>levonest (28)</i> | 117 |
| JANUVIA..... | 26 | KOSELUGO..... | 12 | <i>levonorgest-eth.estradiol-iron</i> .. | 117 |
| JARDIANCE..... | 26 | <i>kosher prenatal plus iron</i> | 194 | <i>levonorgestrel-ethinyl estrad</i> | 117 |
| <i>javygtor</i> | 192 | KRAZATI..... | 12 | <i>levonorg-eth estrad triphasic</i> | 117 |
| JAYPIRCA..... | 11 | <i>kurvelo (28)</i> | 116 | <i>levora-28</i> | 117 |
| JEMPERLI..... | 11 | KYLEENA..... | 116 | <i>levothyroxine</i> | 75 |
| <i>jencycla</i> | 116 | KYNMOBI..... | 36 | LEXIVA..... | 136 |
| JENTADUETO..... | 26 | <i>labetalol</i> | 46 | LIBERVANT..... | 124 |
| JENTADUETO XR..... | 26 | <i>lacosamide</i> | 123 | <i>lidocaine</i> | 104 |
| <i>jolessa</i> | 116 | <i>lactulose</i> | 72 | <i>lidocaine hcl</i> | 104 |
| <i>juleber</i> | 116 | <i>lamivudine</i> | 135 | <i>lidocaine viscous</i> | 104 |
| JULUCA..... | 135 | <i>lamivudine-zidovudine</i> | 135 | <i>lidocaine-prilocaine</i> | 104 |
| <i>junel 1.5/30 (21)</i> | 116 | <i>lamotrigine</i> | 123, 124 | <i>lidocan iii</i> | 104 |
| <i>junel 1/20 (21)</i> | 116 | <i>lanreotide</i> | 78 | LILETTA..... | 117 |
| <i>junel fe 1.5/30 (28)</i> | 116 | <i>lansoprazole</i> | 71 | <i>linezolid</i> | 106 |
| <i>junel fe 1/20 (28)</i> | 116 | LANTUS SOLOSTAR U-100 INSULIN..... | 29 | <i>linezolid in dextrose 5%</i> | 106 |
| <i>junel fe 24</i> | 116 | LANTUS U-100 INSULIN..... | 30 | LINZESS..... | 72 |
| JYLAMVO..... | 11 | <i>lapatinib</i> | 12 | <i>liomny</i> | 75 |
| JYNARQUE..... | 53 | <i>larin 1.5/30 (21)</i> | 117 | <i>liothyronine</i> | 75 |
| JYNNEOS (PF)..... | 89 | <i>larin 1/20 (21)</i> | 117 | LISCO..... | 162 |
| KALETRA..... | 135 | | | <i>lisinopril</i> | 54 |
| KALYDECO..... | 62 | | | <i>lisinopril-hydrochlorothiazide</i> | 54 |

| | | | | |
|---|--------------------------------|-----|--|--------------|
| LITE TOUCH INSULIN PEN | LYBALVI..... | 41 | MAYZENT STARTER(FOR | |
| NEEDLES..... | <i>lyleq</i> | 118 | 1MG MAINT)..... | 61 |
| LITE TOUCH INSULIN | LYNOZYFIC..... | 14 | MAYZENT STARTER(FOR | |
| SYRINGE..... | LYNPARZA..... | 14 | 2MG MAINT)..... | 61 |
| <i>lithium carbonate</i> | LYSODREN..... | 14 | <i>meclizine</i> | 33 |
| <i>lithium citrate</i> | LYTGOBI..... | 14 | <i>medroxyprogesterone</i> | 80 |
| LIVTENCITY..... | <i>lyza</i> | 118 | <i>mefloquine</i> | 35 |
| LOKELMA..... | MAGELLAN INSULIN | | <i>megestrol</i> | 14, 80 |
| <i>lomustine</i> | SAFETY SYRNG..... | 164 | MEKINIST..... | 14 |
| LONSURF..... | MAGELLAN SYRINGE..... | 164 | MEKTOVI..... | 14 |
| <i>loperamide</i> | <i>magnesium sulfate</i> | 188 | <i>meleya</i> | 118 |
| <i>lopinavir-ritonavir</i> | <i>malathion</i> | 71 | <i>meloxicam</i> | 101 |
| LOQTORZI..... | <i>maraviroc</i> | 136 | <i>memantine</i> | 25 |
| <i>lorazepam</i> | MARGENZA..... | 14 | MENACTRA (PF)..... | 89 |
| <i>lorazepam intensol</i> | <i>marlissa (28)</i> | 118 | MENQUADFI (PF)..... | 89 |
| LORBRENA..... | <i>marnatal-f</i> | 194 | MENVEO A-C-Y-W-135-DIP | |
| <i>losartan</i> | MARPLAN..... | 129 | (PF)..... | 89 |
| <i>losartan-hydrochlorothiazide</i> | MATULANE..... | 14 | <i>mercaptopurine</i> | 14 |
| LOTEMAX..... | MAVENCLAD (10 TABLET | | <i>meropenem</i> | 107 |
| LOTEMAX SM..... | PACK)..... | 60 | <i>mesalamine</i> | 56 |
| <i>loteprednol etabonate</i> | MAVENCLAD (4 TABLET | | <i>mesna</i> | 99 |
| <i>lovastatin</i> | PACK)..... | 60 | <i>metformin</i> | 26, 27 |
| <i>low-ogestrel (28)</i> | MAVENCLAD (5 TABLET | | <i>methadone</i> | 103 |
| <i>loxapine succinate</i> | PACK)..... | 60 | <i>methazolamide</i> | 94 |
| <i>lubiprostone</i> | MAVENCLAD (6 TABLET | | <i>methenamine hippurate</i> | 106 |
| <i>luizza</i> | PACK)..... | 60 | <i>methimazole</i> | 75 |
| LUMAKRAS..... | MAVENCLAD (7 TABLET | | <i>methocarbamol</i> | 193 |
| LUMIGAN..... | PACK)..... | 60 | <i>methotrexate sodium</i> | 15 |
| LUNSUMIO..... | MAVENCLAD (8 TABLET | | <i>methotrexate sodium (pf)</i> | 14 |
| LUNSUMIO VELO..... | PACK)..... | 60 | <i>methoxsalen</i> | 70 |
| LUPRON DEPOT..... | MAVENCLAD (9 TABLET | | <i>methsuximide</i> | 124 |
| LUPRON DEPOT (3 MONTH) | PACK)..... | 60 | <i>methylphenidate hcl</i> | 61 |
| | MAXICOMFORT II PEN | | <i>methylprednisolone</i> | 77 |
| | NEEDLE..... | 164 | <i>methylprednisolone acetate</i> | 77 |
| LUPRON DEPOT (4 MONTH). | MAXICOMFORT INSULIN | | <i>metoclopramide hcl</i> | 73 |
| LUPRON DEPOT (6 MONTH). | SYRINGE..... | 164 | <i>metolazone</i> | 53 |
| LUPRON DEPOT-PED..... | MAXI-COMFORT INSULIN | | <i>metoprolol succinate</i> | 46 |
| LUPRON DEPOT-PED (3 | SYRINGE..... | 164 | <i>metoprolol ta-hydrochlorothiaz</i> .. | 46 |
| MONTH)..... | MAXICOMFORT SAFETY | | <i>metoprolol tartrate</i> | 46 |
| | PEN NEEDLE..... | 164 | <i>metronidazole</i> | 70, 105, 107 |
| <i>lurasidone</i> | MAYZENT..... | 60 | <i>metronidazole in nacl (iso-os)</i> .. | 107 |
| <i>lutea (28)</i> | | | <i>metyrosine</i> | 48 |
| LUTRATE DEPOT (3 | | | | |
| MONTH)..... | | | | |

| | | | | | |
|---|----------|--|----------|--|----------|
| <i>micafungin</i> | 132 | <i>morphine concentrate</i> | 103 | NERLYNX..... | 15 |
| <i>miconazole-3</i> | 132 | MOUNJARO..... | 27 | <i>nevirapine</i> | 136 |
| MICRODOT INSULIN PEN | | MOVANTIK..... | 73 | <i>newgen</i> | 194 |
| NEEDLE..... | 164 | <i>moxifloxacin</i> | 95, 112 | NEXLETOL..... | 52 |
| MICRODOT READYGARD | | <i>moxifloxacin-sod.ace,sul-water</i> | 112 | NEXLIZET..... | 52 |
| PEN NEEDLE..... | 165 | <i>moxifloxacin-sod.chloride(iso)</i> | 112 | NEXPLANON..... | 118 |
| <i>microgestin 1.5/30 (21)</i> | 118 | MRESVIA (PF)..... | 90 | <i>niacin</i> | 52 |
| <i>microgestin 1/20 (21)</i> | 118 | MULTAQ..... | 45 | NICOTROL NS..... | 23 |
| <i>microgestin 24 fe</i> | 118 | <i>mupirocin</i> | 70 | <i>nifedipine</i> | 50 |
| <i>microgestin fe 1.5/30 (28)</i> | 118 | <i>mycophenolate mofetil</i> | 84 | NIKTIMVO..... | 84 |
| <i>microgestin fe 1/20 (28)</i> | 118 | <i>mycophenolate mofetil (hcl)</i> | 84 | <i>nilutamide</i> | 15 |
| <i>midodrine</i> | 45 | <i>mycophenolate sodium</i> | 84 | NINLARO..... | 15 |
| MIEBO (PF)..... | 98 | <i>mynatal</i> | 194 | <i>nitazoxanide</i> | 35 |
| <i>mifepristone</i> | 27 | <i>mynatal advance</i> | 194 | <i>nitisinone</i> | 192 |
| <i>mili</i> | 118 | <i>mynatal plus</i> | 194 | <i>nitrofurantoin macrocrystal</i> | 107 |
| <i>mimvey</i> | 77 | <i>mynatal-z</i> | 194 | <i>nitrofurantoin monohyd/m-cryst</i> | 107 |
| MINI ULTRA-THIN II..... | 165 | <i>mynate 90 plus</i> | 194 | | 107 |
| <i>minocycline</i> | 113 | MYRBETRIQ..... | 74 | <i>nitroglycerin</i> | 55, 99 |
| <i>minoxidil</i> | 55 | <i>nabumetone</i> | 101 | <i>niva-plus</i> | 194 |
| MIPLYFFA..... | 140 | <i>nafcellin</i> | 111 | NIVESTYM..... | 192 |
| MIRENA..... | 118 | <i>naloxone</i> | 23 | NORDITROPIN FLEXPRO..... | 79 |
| <i>mirtazapine</i> | 129 | <i>naltrexone</i> | 23 | <i>norelgestromin-ethin.estradiol</i> | 118 |
| <i>misoprostol</i> | 71 | NANO 2ND GEN PEN | | <i>norethindrone (contraceptive)</i> .. | 118 |
| <i>mitoxantrone</i> | 15 | NEEDLE..... | 166 | <i>norethindrone acetate</i> | 80 |
| M-M-R II (PF)..... | 90 | NANO PEN NEEDLE..... | 166 | <i>norethindrone-e.estradiol-iron</i> | 118, 119 |
| <i>m-natal plus</i> | 194 | <i>naproxen</i> | 101, 102 | | 118, 119 |
| <i>modafinil</i> | 57 | <i>naratriptan</i> | 32 | <i>norgestimate-ethinyl estradiol</i> .. | 119 |
| MODEYSO..... | 15 | NATACYN..... | 95 | <i>nortrel 1/35 (21)</i> | 119 |
| <i>moexipril</i> | 54 | <i>nateglinide</i> | 27 | <i>nortrel 1/35 (28)</i> | 119 |
| <i>molindone</i> | 41 | NATPARA..... | 57 | <i>nortrel 7/7/7 (28)</i> | 119 |
| <i>mometasone</i> | 69, 97 | NAYZILAM..... | 124 | <i>nortriptyline</i> | 129 |
| MONOJECT INSULIN | | <i>nebivolol</i> | 46 | NORVIR..... | 136 |
| SAFETY SYRINGE..... | 166 | <i>nefazodone</i> | 129 | NOVOFINE 30..... | 166 |
| MONOJECT INSULIN | | <i>neomycin</i> | 106 | NOVOFINE 32..... | 166 |
| SYRINGE..... | 165, 166 | <i>neomycin-bacitracin-poly-hc</i> | 95 | NOVOFINE PLUS..... | 166 |
| MONOJECT SYRINGE..... | 165 | <i>neomycin-bacitracin-polymyxin</i> | 95 | NOVOLIN 70/30 U-100 | |
| MONOJECT ULTRA | | <i>neomycin-polymyxin b-</i> | | INSULIN..... | 30 |
| COMFORT INSULIN..... | 181 | <i>dexameth</i> | 95 | NOVOLIN 70-30 FLEXPEN | |
| <i>mono-linyah</i> | 118 | <i>neomycin-polymyxin-gramicidin</i> | 95 | U-100..... | 30 |
| <i>montelukast</i> | 64 | <i>neomycin-polymyxin-hc</i> | 95 | NOVOLIN N FLEXPEN..... | 30 |
| <i>morphine</i> | 103 | <i>neo-polycin</i> | 95 | NOVOLIN N NPH U-100 | |
| MORPHINE..... | 103 | <i>neo-polycin hc</i> | 95 | INSULIN..... | 30 |

| | | | | | |
|---|-----|--|-----|---------------------------------------|------------------------------|
| NOVOLIN R FLEXPEN..... | 30 | <i>olopatadine</i> | 98 | OTEZLA STARTER..... | 84 |
| NOVOLIN R REGULAR U100 | | <i>omega-3 acid ethyl esters</i> | 52 | OTEZLA XR..... | 85 |
| INSULIN..... | 30 | <i>omeprazole</i> | 72 | OTEZLA XR INITIATION..... | 84 |
| NOVOLOG FLEXPEN U-100 | | OMNIPOD 5 (G6/LIBRE 2 | | <i>oxandrolone</i> | 75 |
| INSULIN..... | 30 | PLUS)..... | 167 | <i>oxcarbazepine</i> | 124 |
| NOVOLOG MIX 70-30 U-100 | | OMNIPOD 5 G6-G7 INTRO | | <i>oxybutynin chloride</i> | 75 |
| INSULN..... | 30 | KT(GEN5)..... | 167 | <i>oxycodone</i> | 104 |
| NOVOLOG MIX 70- | | OMNIPOD 5 G6-G7 PODS | | <i>oxycodone-acetaminophen</i> | 104 |
| 30FLEXPEN U-100..... | 30 | (GEN 5)..... | 167 | OZEMPIC..... | 27 |
| NOVOLOG PENFILL U-100 | | OMNIPOD 5 | | <i>pacerone</i> | 45 |
| INSULIN..... | 30 | INTRO(G6/LIBRE2PLUS)..... | 167 | <i>paclitaxel protein-bound</i> | 16 |
| NOVOLOG U-100 INSULIN | | OMNIPOD CLASSIC PDM | | <i>paliperidone</i> | 41 |
| ASPART..... | 30 | KIT(GEN 3)..... | 167 | PANRETIN..... | 70 |
| NOVOTWIST..... | 166 | OMNIPOD CLASSIC PODS | | <i>pantoprazole</i> | 72 |
| NUBEQA..... | 15 | (GEN 3)..... | 167 | <i>paricalcitol</i> | 57 |
| NUCALA..... | 62 | OMNIPOD DASH INTRO KIT | | <i>paroxetine hcl</i> | 129 |
| NULOJIX..... | 84 | (GEN 4)..... | 167 | PAXLOVID..... | 139 |
| NUPLAZID..... | 41 | OMNIPOD DASH PDM KIT | | <i>pazopanib</i> | 16 |
| NURTEC ODT..... | 32 | (GEN 4)..... | 167 | PEDIARIX (PF)..... | 90 |
| <i>nyamyc</i> | 132 | OMNIPOD DASH PODS | | PEDVAX HIB (PF)..... | 90 |
| <i>nylia 1/35 (28)</i> | 119 | (GEN 4)..... | 167 | <i>peg 3350-electrolytes</i> | 74 |
| <i>nylia 7/7/7 (28)</i> | 119 | ONAPGO..... | 36 | PEGASYS..... | 139 |
| <i>nymyo</i> | 119 | <i>ondansetron</i> | 34 | <i>peg-electrolyte soln</i> | 74 |
| <i>nystatin</i> | 132 | <i>ondansetron hcl</i> | 33 | PEMAZYRE..... | 16 |
| <i>nystatin-triamcinolone</i> | 132 | ONUREG..... | 15 | <i>pemetrexed disodium</i> | 16 |
| <i>nystop</i> | 132 | OPDIVO..... | 16 | PEMRYDI RTU..... | 16 |
| NYVEPRIA..... | 192 | OPDIVO QVANTIG..... | 16 | PEN NEEDLE..... | 167, 168 |
| <i>obstetrix dha</i> | 195 | OPDUALAG..... | 16 | PEN NEEDLE, DIABETIC | |
| <i>obstetrix dha prenatal duo</i> | 194 | OPIPZA..... | 41 | | 148, 158, 159, 165, 167, 170 |
| <i>octreotide acetate</i> | 79 | OPSUMIT..... | 100 | PEN NEEDLE, DIABETIC, | |
| ODEFSEY..... | 136 | ORENCIA..... | 84 | SAFETY..... | 171 |
| ODOMZO..... | 15 | ORENCIA (WITH MALTOSE) | 84 | PENBRAYA (PF)..... | 90 |
| OFEV..... | 62 | ORENCIA CLICKJECT..... | 84 | PENBRAYA MENACWY | |
| <i>ofloxacin</i> | 96 | ORFADIN..... | 193 | COMPONENT(PF)..... | 90 |
| OGIVRI..... | 15 | ORGOVYX..... | 79 | PENBRAYA MENB | |
| OGSIVEO..... | 15 | ORLISSA..... | 79 | COMPONENT (PF)..... | 90 |
| OJEMDA..... | 15 | ORKAMBI..... | 62 | <i>penicillamine</i> | 105 |
| OJJAARA..... | 15 | <i>orquidea</i> | 119 | <i>penicillin g potassium</i> | 111 |
| <i>olanzapine</i> | 41 | ORSERDU..... | 16 | <i>penicillin g procaine</i> | 111 |
| <i>olmesartan</i> | 49 | <i>oseltamivir</i> | 139 | <i>penicillin v potassium</i> | 111 |
| <i>olmesartan-amlodipin-hcthiazyd</i> | 49 | OSENVELT..... | 57 | PENMENVY MEN A-B-C-W- | |
| <i>olmesartan-hydrochlorothiazide</i> | 49 | OTEZLA..... | 84 | Y (PF)..... | 90 |

| | | | | | |
|---|----------|--|----------|--|----------|
| PENMENVY MENACWY COMPONENT(PF)..... | 90 | <i>portia 28</i> | 119 | <i>primidone</i> | 125 |
| PENMENVY MENB COMPONENT (PF)..... | 90 | <i>posaconazole</i> | 132 | PRIORIX (PF)..... | 91 |
| PENTACEL (PF)..... | 90 | <i>potassium chloride</i> | 188, 189 | PRO COMFORT ALCOHOL PADS..... | 169 |
| <i>pentamidine</i> | 35 | <i>potassium citrate</i> | 189 | PRO COMFORT INSULIN SYRINGE..... | 168, 169 |
| PENTIPS PEN NEEDLE..... | 168 | <i>pr natal 400</i> | 195 | PRO COMFORT PEN NEEDLE..... | 169 |
| <i>pentoxifylline</i> | 191 | <i>pr natal 400 ec</i> | 195 | <i>probenecid</i> | 32 |
| <i>perampanel</i> | 124 | <i>pr natal 430</i> | 195 | <i>probenecid-colchicine</i> | 32 |
| <i>perindopril erbumine</i> | 54 | <i>pr natal 430 ec</i> | 195 | <i>prochlorperazine</i> | 34 |
| <i>periogard</i> | 67 | <i>pramipexole</i> | 36 | <i>prochlorperazine edisylate</i> ... 34, 42 | |
| <i>permethrin</i> | 71 | <i>prasugrel hcl</i> | 191 | <i>prochlorperazine maleate</i> | 34 |
| <i>perphenazine</i> | 41 | <i>pravastatin</i> | 52 | <i>procto-med hc</i> | 69 |
| <i>perphenazine-amitriptyline</i> | 129 | <i>praziquantel</i> | 35 | <i>proctosol hc</i> | 69 |
| PERSERIS..... | 41 | <i>prazosin</i> | 45 | <i>proctozone-hc</i> | 69 |
| <i>phenelzine</i> | 129 | <i>prednisolone</i> | 77 | PRODIGY INSULIN SYRINGE..... | 169 |
| <i>phenobarbital</i> | 124, 125 | <i>prednisolone acetate</i> | 97 | <i>progesterone micronized</i> | 80 |
| <i>phenytek</i> | 125 | <i>prednisolone sodium phosphate</i> | 77, 78 | PROGRAF..... | 85 |
| <i>phenytoin</i> | 125 | <i>prednisone</i> | 78 | PROLASTIN-C..... | 63 |
| <i>phenytoin sodium</i> | 125 | <i>pregabalin</i> | 125 | <i>promethazine</i> | 34 |
| <i>phenytoin sodium extended</i> | 125 | PREMARIN..... | 77 | <i>promethegan</i> | 34 |
| PIFELTRO..... | 136 | PREMPHASE..... | 77 | <i>propafenone</i> | 45 |
| <i>pilocarpine hcl</i> | 67, 94 | PREMPRO..... | 77 | <i>propranolol</i> | 46 |
| <i>pimecrolimus</i> | 69 | <i>prenal true</i> | 195 | <i>propylthiouracil</i> | 75 |
| <i>pimozide</i> | 41 | <i>prenaissance</i> | 195 | PROQUAD (PF)..... | 91 |
| <i>pimtree (28)</i> | 119 | <i>prenaissance plus</i> | 195 | <i>protriptyline</i> | 129 |
| <i>pioglitazone</i> | 27 | <i>prenatabs fa</i> | 195 | PULMOZYME..... | 193 |
| <i>pioglitazone-metformin</i> | 27 | <i>prenatal 19</i> | 195 | PURE COMFORT ALCOHOL PADS..... | 169 |
| PIP PEN NEEDLE..... | 168 | <i>prenatal 19 (with docusate)</i> | 195 | PURE COMFORT PEN NEEDLE..... | 170 |
| <i>piperacillin-tazobactam</i> | 111 | <i>prenatal plus</i> | 195 | PURE COMFORT SAFETY PEN NEEDLE..... | 169 |
| PIQRAY..... | 16 | <i>prenatal plus (calcium carb)</i> | 195 | <i>pyrazinamide</i> | 133 |
| <i>pirfenidone</i> | 62, 63 | <i>prenatal vitamin plus low iron</i> .. | 195 | <i>pyridostigmine bromide</i> | 99 |
| <i>pitavastatin calcium</i> | 52 | <i>prenatal-u</i> | 195 | <i>pyrimethamine</i> | 35 |
| PLEGRIDY..... | 61 | <i>preplus</i> | 195 | QINLOCK..... | 17 |
| <i>pnv 29-1</i> | 195 | <i>pretab</i> | 195 | QUADRACEL (PF)..... | 91 |
| <i>pnv-dha + docusate</i> | 195 | <i>prevalite</i> | 52 | <i>quetiapine</i> | 42 |
| <i>pnv-omega</i> | 195 | PREVENT DROPSAFE PEN NEEDLE..... | 168 | <i>quinapril</i> | 54 |
| <i>podofilox</i> | 70 | PREVYMIS..... | 139 | | |
| <i>polycin</i> | 96 | PREZCOBIX..... | 136 | | |
| <i>polymyxin b sulf-trimethoprim</i> | 96 | PREZISTA..... | 136 | | |
| <i>pomalidomide</i> | 16 | PRIFTIN..... | 133 | | |
| POMALYST..... | 17 | PRIMAQUINE..... | 35 | | |

| | | | | | |
|--|-----|-------------------------------------|----------|---|--------|
| <i>quinapril-hydrochlorothiazide</i> ... | 55 | RITUXAN HYCELA..... | 17 | <i>se-natal 19 chewable</i> | 196 |
| <i>quinidine sulfate</i> | 45 | <i>rivaroxaban</i> | 190 | SEREVENT DISKUS..... | 66 |
| <i>quinine sulfate</i> | 35 | <i>rivastigmine</i> | 25 | SEROSTIM..... | 79 |
| QULIPTA..... | 32 | <i>rivastigmine tartrate</i> | 25 | <i>sertraline</i> | 130 |
| RABAVERT (PF)..... | 91 | <i>rizatriptan</i> | 32 | <i>setlakin</i> | 119 |
| <i>rabeprazole</i> | 72 | <i>r-natal ob</i> | 196 | <i>sevelamer carbonate</i> | 73 |
| RALDESY..... | 130 | ROCKLATAN..... | 94 | <i>sevelamer hcl</i> | 74 |
| <i>raloxifene</i> | 77 | <i>roflumilast</i> | 63 | SEZABY..... | 125 |
| <i>ramipril</i> | 55 | ROMVIMZA..... | 17 | <i>sf 5000 plus</i> | 67 |
| <i>ranolazine</i> | 48 | <i>ropinirole</i> | 36 | <i>sharobel</i> | 119 |
| <i>rasagiline</i> | 36 | <i>rosadan</i> | 70 | SHINGRIX (PF)..... | 91 |
| RASUVO (PF)..... | 85 | <i>rosuvastatin</i> | 52 | SIGNIFOR..... | 79 |
| RAYALDEE..... | 57 | ROTARIX..... | 91 | <i>sildenafil</i> | 100 |
| <i>reclipsen (28)</i> | 119 | ROTATEQ VACCINE..... | 91 | <i>sildenafil (pulm.hypertension)</i> .. | 100 |
| RECOMBIVAX HB (PF)..... | 91 | ROZLYTREK..... | 17 | <i>silver sulfadiazine</i> | 70 |
| RELENZA DISKHALER..... | 139 | RUBRACA..... | 17 | SIMBRINZA..... | 94 |
| <i>repaglinide</i> | 27 | <i>rufinamide</i> | 125 | <i>simliya (28)</i> | 120 |
| REPATHA PUSHTRONEX..... | 52 | RUKOBIA..... | 137 | SIMPLI PEN NEEDLE..... | 159 |
| REPATHA SURECLICK..... | 52 | RYBELSUS..... | 27 | <i>simvastatin</i> | 52 |
| REPATHA SYRINGE..... | 52 | RYBREVANT..... | 18 | <i>sirolimus</i> | 85 |
| RETACRIT..... | 192 | RYBREVANT FASPRO..... | 18 | SIRTURO..... | 133 |
| RETEVMO..... | 17 | RYDAPT..... | 18 | SKY SAFETY PEN NEEDLE..... | 171 |
| RETROVIR..... | 136 | RYKINDO..... | 42 | SKYLA..... | 120 |
| REVCOVI..... | 193 | RYTELO..... | 18 | SKYRIZI..... | 85, 86 |
| REVUFORJ..... | 17 | <i>sacubitril-valsartan</i> | 49 | <i>sodium chloride 0.45 %</i> | 189 |
| REXULTI..... | 42 | SAFESNAP INSULIN | | <i>sodium chloride 0.9 %</i> | 189 |
| REYATAZ..... | 136 | SYRINGE..... | 170, 171 | <i>sodium fluoride-pot nitrate</i> | 67 |
| REZDIFFRA..... | 75 | SAFETY PEN NEEDLE..... | 171 | <i>sodium oxybate</i> | 57 |
| REZLIDHIA..... | 17 | SANTYL..... | 70 | <i>sodium polystyrene sulfonate</i> | 73 |
| REZUROCK..... | 85 | <i>sapropterin</i> | 193 | <i>sodium,potassium,mag sulfates</i> .. | 74 |
| RHOPRESSA..... | 94 | SCSEMBLIX..... | 18 | <i>solifenacin</i> | 75 |
| <i>ribavirin</i> | 140 | <i>scopolamine base</i> | 34 | SOLIQUEA 100/33..... | 31 |
| <i>rifabutin</i> | 133 | SECUADO..... | 42 | SOLTAMOX..... | 18 |
| <i>rifampin</i> | 133 | SECURES SAFE INSULIN | | SOMATULINE DEPOT..... | 79 |
| <i>rilpivirine</i> | 137 | SYRINGE..... | 171 | SOMAVERT..... | 79 |
| <i>rilpivirine hcl</i> | 137 | SECURES SAFE PEN NEEDLE..... | 171 | <i>sorafenib</i> | 18 |
| <i>riluzole</i> | 61 | SELARSDI..... | 85 | <i>sorine</i> | 46 |
| RINVOQ..... | 85 | <i>select-ob</i> | 196 | <i>sotalol</i> | 47 |
| RINVOQ LQ..... | 85 | <i>select-ob (folic acid)</i> | 196 | <i>sotalol af</i> | 46 |
| <i>risperidone</i> | 42 | <i>selegiline hcl</i> | 36 | SPIRIVA RESPIMAT..... | 66 |
| <i>risperidone microspheres</i> | 42 | <i>selenium sulfide</i> | 70 | <i>spironolactone</i> | 53 |
| <i>ritonavir</i> | 137 | SELZENTRY..... | 137 | <i>spironolacton-hydrochlorothiaz</i> | 53 |

| | | | | |
|---|----------|--|--|----------|
| SPRAVATO..... | 130 | SURE-PREP ALCOHOL PREP | TEMIXYS..... | 137 |
| <i>sprintec (28)</i> | 120 | PADS..... | TENIVAC (PF)..... | 92 |
| SPRITAM..... | 125 | SYMPAZAN..... | <i>tenofovir disoproxil fumarate</i> ... | 137 |
| <i>sps (with sorbitol)</i> | 73 | SYMTUZA..... | TEPMETKO..... | 19 |
| <i>sronyx</i> | 120 | SYNJARDY..... | <i>terazosin</i> | 74 |
| <i>ssd</i> | 70 | SYNJARDY XR..... | <i>terbinafine hcl</i> | 132 |
| <i>stavudine</i> | 137 | SYNRIBO..... | <i>terconazole</i> | 105 |
| STERILE PADS..... | 171 | SYRINGE WITH NEEDLE, | <i>teriparatide</i> | 57 |
| STIOLTO RESPIMAT..... | 66 | SAFETY..... | TERUMO INSULIN | |
| STIVARGA..... | 18 | TABLOID..... | SYRINGE..... | 174, 175 |
| STOBOCLO..... | 57 | TABRECTA..... | <i>testosterone</i> | 76 |
| STRENSIQ..... | 193 | <i>tacrolimus</i> | <i>testosterone cypionate</i> | 75, 76 |
| <i>streptomycin</i> | 106 | <i>tadalafil</i> | <i>testosterone enanthate</i> | 76 |
| STRIBILD..... | 137 | TAFINLAR..... | <i>tetrabenazine</i> | 61 |
| STRIVERDI RESPIMAT..... | 66 | TAGRISSE..... | <i>tetracycline</i> | 113 |
| SUBVENITE..... | 125 | TALVEY..... | TEVIMBRA..... | 19 |
| <i>subvenite</i> | 125 | TALZENNA..... | THALOMID..... | 99 |
| <i>sucralfate</i> | 72 | <i>tamoxifen</i> | <i>theophylline</i> | 66 |
| <i>sulfacetamide sodium</i> | 96 | <i>tamsulosin</i> | THINPRO INSULIN | |
| <i>sulfacetamide-prednisolone</i> | 96 | <i>tarina 24 fe</i> | SYRINGE..... | 175 |
| <i>sulfadiazine</i> | 112 | <i>tarina fe 1-20 eq (28)</i> | <i>thioridazine</i> | 42 |
| <i>sulfamethoxazole-trimethoprim</i> | 112 | <i>taron-c dha</i> | <i>thiothixene</i> | 43 |
| <i>sulfasalazine</i> | 56 | <i>taron-prex prenatal-dha</i> | <i>tiadylt er</i> | 47 |
| <i>sulindac</i> | 102 | TASIGNA..... | <i>tiagabine</i> | 126 |
| <i>sumatriptan</i> | 33 | TAVNEOS..... | TIBSOVO..... | 19 |
| <i>sumatriptan succinate</i> | 33 | <i>tazarotene</i> | <i>ticagrelor</i> | 191 |
| <i>sunitinib malate</i> | 18 | <i>tazicef</i> | TICE BCG..... | 19 |
| SUNLENCA..... | 137 | <i>taztia xt</i> | TICOVAC..... | 92 |
| SURE COMFORT ALCOHOL | | TAZVERIK..... | <i>tigecycline</i> | 113 |
| PREP PADS..... | 172 | TDVAX..... | <i>tilia fe</i> | 120 |
| SURE COMFORT INS. SYR. | | TECHLITE INSULIN | <i>timolol</i> | 94 |
| U-100..... | 171 | SYRINGE..... | <i>timolol maleate</i> | 47, 94 |
| SURE COMFORT INSULIN | | TECHLITE INSULN | <i>tinidazole</i> | 35 |
| SYRINGE..... | 171, 172 | SYR(HALF UNIT)..... | <i>tiotropium bromide</i> | 66 |
| SURE COMFORT PEN | | TECHLITE PEN NEEDLE..... | TIVDAK..... | 19 |
| NEEDLE..... | 172 | TECHLITE PLUS PEN | TIVICAY..... | 137 |
| SURE COMFORT SAFETY | | NEEDLE..... | TIVICAY PD..... | 137 |
| PEN NEEDLE..... | 171 | TECVAYLI..... | <i>tizanidine</i> | 193 |
| SURE-FINE PEN NEEDLES | | TEFLARO..... | TOBI PODHALER..... | 106 |
| | 172, 173 | <i>telmisartan</i> | <i>tobramycin</i> | 96 |
| SURE-JECT INSULIN | | <i>telmisartan-hydrochlorothiazid</i> .. | <i>tobramycin in 0.225 % nacl</i> | 106 |
| SYRINGE..... | 173 | <i>temazepam</i> | <i>tobramycin sulfate</i> | 106 |

| | | | | | |
|--|------------|--------------------------------|---------------|----------------------------|---------------|
| <i>tobramycin-dexamethasone</i> | 96 | TRIJARDY XR..... | 28 | TRUXIMA..... | 20 |
| <i>tolterodine</i> | 75 | TRIKAFTA..... | 63 | TUKYSA..... | 20 |
| <i>tolvaptan (polycys kidney dis)</i> | 53 | <i>tri-legest fe</i> | 120 | TURALIO..... | 20 |
| TOPCARE CLICKFINE..... | 175 | <i>tri-linyah</i> | 120 | <i>turqoz (28)</i> | 121 |
| TOPCARE ULTRA | | <i>tri-lo-estarylla</i> | 120 | TWINRIX (PF)..... | 92 |
| COMFORT..... | 175 | <i>tri-lo-marzia</i> | 120 | TYBOST..... | 99 |
| <i>topiramate</i> | 126 | <i>tri-lo-mili</i> | 120 | TYENNE..... | 86 |
| <i>toposar</i> | 19 | <i>tri-lo-sprintec</i> | 120 | TYENNE AUTOINJECTOR..... | 86 |
| <i>toremifene</i> | 19 | <i>trimethoprim</i> | 107 | TYMLOS..... | 57 |
| <i>torpenz</i> | 19 | <i>tri-mili</i> | 120 | TYPHIM VI..... | 92 |
| <i>torse mide</i> | 53 | <i>trimipramine</i> | 130 | UBRELVY..... | 33 |
| TOUJEO MAX U-300 | | TRINTELLIX..... | 130 | UDENYCA ONBODY..... | 192 |
| SOLOSTAR..... | 31 | <i>tri-nymyo</i> | 120 | ULTICARE..... | 179, 180 |
| TOUJEO SOLOSTAR U-300 | | <i>tri-sprintec (28)</i> | 120 | ULTICARE INSULIN | |
| INSULIN..... | 31 | TRIUMEQ..... | 138 | SYRINGE..... | 178, 179 |
| TRADJENTA..... | 28 | TRIUMEQ PD..... | 138 | ULTICARE INSULN | |
| <i>tramadol</i> | 104 | <i>trivora (28)</i> | 121 | SYR(HALF UNIT)..... | 178 |
| <i>tramadol-acetaminophen</i> | 104 | <i>tri-vylibra</i> | 121 | ULTICARE PEN NEEDLE..... | 179 |
| <i>trandolapril</i> | 55 | <i>tri-vylibra lo</i> | 121 | ULTICARE SAFETY PEN | |
| <i>tranexamic acid</i> | 189 | TRIZIVIR..... | 138 | NEEDLE..... | 179 |
| <i>tranylcypromine</i> | 130 | TROGARZO..... | 138 | ULTIGUARD SAFEPACK- | |
| <i>travoprost</i> | 94 | <i>trosipium</i> | 75 | INSULIN SYR..... | 180 |
| <i>trazodone</i> | 130 | TRUE COMFORT ALCOHOL | | ULTIGUARD SAFEPACK- | |
| TRECATOR..... | 133 | PADS..... | 176 | PEN NEEDLE..... | 180 |
| TRELEGY ELLIPTA..... | 66 | TRUE COMFORT INSULIN | | ULTILET ALCOHOL SWAB..... | 180 |
| TRELSTAR..... | 20 | SYRINGE..... | 176 | ULTILET INSULIN SYRINGE | |
| TREMFYA..... | 86 | TRUE COMFORT PEN | | | 161, 181 |
| TREMFYA ONE-PRESS..... | 86 | NEEDLE..... | 176, 177 | ULTILET PEN NEEDLE..... | 181 |
| TREMFYA PEN..... | 86 | TRUE COMFORT PRO | | ULTRA CMFT INS SYR | |
| TREMFYA PEN INDUCTION | | ALCOHOL PADS..... | 177 | (HALF UNIT)..... | 159, 171 |
| PK(2PEN)..... | 86 | TRUE COMFORT PRO INS | | ULTRA COMFORT INSULIN | |
| <i>tretinoin</i> | 71 | SYRINGE..... | 175, 176, 177 | SYRINGE..... | 153, 159, 181 |
| <i>tretinoin (antineoplastic)</i> | 20 | TRUE COMFORT SAFE | | ULTRA FLO INSUL | |
| <i>triamcinolone acetonide</i> | 67, 69, 78 | INSULIN SYRG..... | 176, 177 | SYR(HALF UNIT)..... | 181 |
| <i>triamterene-hydrochlorothiazid</i> | | TRUE COMFORT SAFETY | | ULTRA FLO INSULIN | |
| | 53, 54 | PEN NEEDLE..... | 176 | SYRINGE..... | 182 |
| <i>tridacaine ii</i> | 105 | TRUEPLUS INSULIN..... | 177, 178 | ULTRA FLO PEN NEEDLE... .. | 182 |
| <i>trientine</i> | 105 | TRUEPLUS PEN NEEDLE..... | 177 | ULTRA THIN PEN NEEDLE..... | 182 |
| <i>tri-estarylla</i> | 120 | TRULANCE..... | 73 | ULTRACARE INSULIN | |
| <i>trifluoperazine</i> | 43 | TRULICITY..... | 28 | SYRINGE..... | 182, 183 |
| <i>trifluridine</i> | 96 | TRUMENBA..... | 92 | ULTRACARE PEN NEEDLE..... | 183 |
| <i>trihexyphenidyl</i> | 36 | TRUQAP..... | 20 | | |

| | | | | | |
|--|----------|--|----------|--|--------|
| ULTRA-FINE INS SYR (HALF UNIT)..... | 183 | VANFLYTA..... | 20 | <i>virt-nate dha</i> | 196 |
| ULTRA-FINE INSULIN SYRINGE..... | 183, 184 | VANISHPOINT INSULIN SYRINGE..... | 186 | <i>virt-pn dha</i> | 196 |
| ULTRA-FINE PEN NEEDLE | 183, 184 | VANISHPOINT SYRINGE..... | 186 | <i>virt-pn plus</i> | 196 |
| ULTRA-THIN II (SHORT) INS SYR..... | 184 | VAQTA (PF)..... | 92 | <i>vitafol gummies</i> | 196 |
| ULTRA-THIN II (SHORT) PEN NDL..... | 184 | <i>varenicline tartrate</i> | 23, 24 | <i>vitafol nano</i> | 196 |
| ULTRA-THIN II INS PEN NEEDLES..... | 184 | VARIVAX (PF)..... | 92 | <i>vitafol-ob+dha</i> | 196 |
| ULTRA-THIN II INSULIN SYRINGE..... | 184 | VAXCHORA VACCINE..... | 92 | VITRAKVI..... | 20, 21 |
| UNIFINE OTC PEN NEEDLE | 184 | VELTASSA..... | 73 | VIVIMUSTA..... | 21 |
| UNIFINE PEN NEEDLE..... | 184 | VEMLIDY..... | 138 | VIVOTIF..... | 93 |
| UNIFINE PENTIPS..... | 167, 185 | VENCLEXTA..... | 20 | VIZIMPRO..... | 21 |
| UNIFINE PENTIPS MAXFLOW..... | 185 | VENCLEXTA STARTING PACK..... | 20 | VOCABRIA..... | 138 |
| UNIFINE PENTIPS PLUS..... | 185 | <i>venlafaxine</i> | 130 | <i>volnea (28)</i> | 121 |
| UNIFINE PENTIPS PLUS MAXFLOW..... | 185 | VEOZAH..... | 99 | VONJO..... | 21 |
| UNIFINE PROTECT..... | 185, 186 | <i>verapamil</i> | 47, 48 | VOQUEZNA..... | 72 |
| UNIFINE SAFECONTROL PEN NEEDLE..... | 186 | VERIFINE INSULIN SYRINGE..... | 186, 187 | VORANIGO..... | 21 |
| UNIFINE ULTRA PEN NEEDLE..... | 186 | VERIFINE PEN NEEDLE | 186, 187 | <i>voriconazole</i> | 132 |
| UPTRAVI..... | 100 | VERIFINE PLUS PEN NEEDLE..... | 187 | VOSEVI..... | 139 |
| <i>ursodiol</i> | 73 | VERIFINE PLUS PEN NEEDLE-SHARP..... | 187 | VOWST..... | 99 |
| <i>ustekinumab-aauz</i> | 86 | VERQUOVO..... | 48 | <i>vp-ch-pnv</i> | 196 |
| UZEDY..... | 43 | VERSACLOZ..... | 43 | <i>vp-pnv-dha</i> | 196 |
| <i>valacyclovir</i> | 140 | VERSALON..... | 187 | VRAYLAR..... | 43 |
| VALCHLOR..... | 70 | VERZENIO..... | 20 | VUMERITY..... | 61 |
| <i>valganciclovir</i> | 140 | V-GO 20..... | 187 | VYALEV..... | 36 |
| <i>valproate sodium</i> | 126 | V-GO 30..... | 187 | <i>vylibra</i> | 121 |
| <i>valproic acid</i> | 126 | V-GO 40..... | 187 | VYLOY..... | 21 |
| <i>valproic acid (as sodium salt)</i> .. | 126 | <i>vienna</i> | 121 | VYNDAMAX..... | 49 |
| <i>valsartan</i> | 50 | <i>vigabatrin</i> | 126 | VYZULTA..... | 94 |
| <i>valsartan-hydrochlorothiazide</i> ... | 50 | <i>vigadron</i> | 126 | <i>warfarin</i> | 190 |
| VALTOCO..... | 126 | <i>vigpoder</i> | 126 | WEBCOL..... | 188 |
| <i>valtya</i> | 121 | <i>vilazodone</i> | 130 | WELIREG..... | 21 |
| <i>vancomycin</i> | 107 | VIMKUNYA..... | 93 | WINREVAIR..... | 63 |
| | | <i>vinorelbine</i> | 20 | <i>wixela inhub</i> | 64 |
| | | <i>viorele (28)</i> | 121 | XALKORI..... | 21 |
| | | VIRACEPT..... | 138 | <i>xarah fe</i> | 121 |
| | | VIREAD..... | 138 | XARELTO..... | 191 |
| | | <i>virt-c dha</i> | 196 | XARELTO DVT-PE TREAT 30D START..... | 191 |
| | | | | XATMEP..... | 21 |
| | | | | XCOPRI..... | 127 |
| | | | | XCOPRI MAINTENANCE PACK..... | 126 |
| | | | | XCOPRI TITRATION PACK.. | 127 |

| | | | |
|----------------------------------|--------|-------------------------|-----|
| XDEMVI | 96 | ZONISADE | 127 |
| XELJANZ | 86, 87 | <i>zonisamide</i> | 127 |
| XELJANZ XR | 87 | <i>zovia 1/35e (28)</i> | 121 |
| XERMELO | 73 | <i>zovia 1-35 (28)</i> | 121 |
| XIFAXAN | 107 | ZTALMY | 127 |
| XIGDUO XR | 28 | ZTLIDO | 105 |
| XIIDRA | 98 | ZURZUVAE | 130 |
| XOLAIR | 63 | ZYDELIG | 22 |
| XOSPATA | 21 | ZYKADIA | 22 |
| XPOVIO | 21, 22 | ZYLET | 96 |
| XTANDI | 22 | ZYNLONTA | 22 |
| <i>xulane</i> | 121 | ZYNYZ | 23 |
| XULTOPHY 100/3.6 | 31 | ZYPREXA RELPREVV | 44 |
| YERVOY | 22 | | |
| YESINTEK | 87 | | |
| YF-VAX (PF) | 93 | | |
| YONSA | 22 | | |
| YUFLYMA(CF) | 87 | | |
| YUFLYMA(CF) AI CROHN'S- UC-HS | 87 | | |
| YUFLYMA(CF) AUTOINJECTOR | 87 | | |
| <i>yuvafem</i> | 77 | | |
| <i>zafemy</i> | 121 | | |
| <i>zafirlukast</i> | 65 | | |
| <i>zaleplon</i> | 57 | | |
| <i>zatean-pn dha</i> | 196 | | |
| <i>zatean-pn plus</i> | 196 | | |
| ZEJULA | 22 | | |
| ZELBORAF | 22 | | |
| <i>zenatane</i> | 70 | | |
| ZENPEP | 193 | | |
| <i>zidovudine</i> | 138 | | |
| ZIIHERA | 22 | | |
| <i>zingiber</i> | 196 | | |
| <i>ziprasidone hcl</i> | 43 | | |
| <i>ziprasidone mesylate</i> | 43 | | |
| ZIRABEV | 22 | | |
| ZIRGAN | 96 | | |
| ZOLADEX | 22 | | |
| ZOLINZA | 22 | | |
| <i>zolpidem</i> | 58 | | |